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This is the fourth Special Issue in Pharmaceuticals within the last six years dealing with aspects
of radiopharmaceutical sciences. It demonstrates the significant interest and increasing relevance to
ameliorate nuclear medicine imaging with PET or SPECT, and also radiotherapeutical procedures.
Numerous targets and mechanisms have been identified and have been under investigation over
the previous years, covering many fields of medical and clinical research. This development is well
illustrated by the articles in the present issue, including 13 original research papers and one review,
covering a broad range of actual research topics in the field of radiopharmaceutical sciences.
Imaging in oncology still is the most important area, demonstrated by five papers, dealing with
the identification of a target of interest, development of a radiopharmaceutical (tracer) to image the
target, followed by first evaluations in vitro (cell experiments) or in vivo in small animals. Hypoxia is a
characteristic property that can be found in various tumor tissues and therefore has been an interesting
target for imaging for many years. Maier et al. linked deoxyribose to 2-nitroimidazole a common
hypoxia pharmacophore, thereby mimicking a nucleoside, labeled the molecule with 18F (PET) and
investigated the uptake pattern in a tumor mouse model. They found a faster uptake of the tracer
compared to the well-known [18F]FMISO, which was attributed to the involvement of active transport
mechanisms by nucleoside transporters. More recently, various receptors specifically expressed by
tumor cells, became targets for molecular imaging. Here, Kaloudi et al. chose the gastrin-releasing
peptide receptor (GRPR) as target and developed two ligands, labeled with 99mTc for SPECT and
evaluated their biological behavior in prostate cancer cells and in mice. Uptake in GRPR-expressing
lesions could be drastically enhanced by neprilysin inhibition. The cholecystokinin-2 receptor (CCK2R)
was the target in the study by Klingler et al. Their HYNIC-conjugated minigastrin analogs, also labeled
with 99mTc, showed a high biostability and a high tumor uptake in tumor bearing mice, which make
the derivatives promising SPECT ligands. To generally accelerate and enhance tumor uptake of tracers
two concepts have been in discussion for some time. Pretargeting may be advantageous for tracers
that show slow biokinetics, like antibodies. The antibody is injected first, after the time necessary to
bind to its target, in a second injection a radiolabeled ligand that shall selectively bind to the antibody
(e.g., via click chemistry) is administered. With this rationale, long uptake times of radiolabeled
antibodies (long-lived isotopes necessary) may be overcome, also reducing radioactive doses for
patients. To improve binding of a 68Ga-labeled ligand to the pretargeted antibody, Summer et al.
synthesized ligands with one to three 1,2,4,5-tetrazines for binding to the antibody. They could show
in vitro and in vivo that the binding capability was improved with an increasing number of tetrazines
at the ligand. Another concept with the intention to improve tumor uptake of tracers is the design of
bivalent/bispecific ligands, in the case when two different receptors are present in a certain tumor type.
Vall-Sagarra et al. could demonstrate the value of this concept by developing 68Ga-labeled peptidic
ligands to address two different receptors in breast cancer (neuropeptide Y receptor and GRPR). Tumor
uptake was considerably higher compared to the corresponding monovalent tracers.
In neuro imaging, for more than two decades numerous tracers have been developed to image
various brain receptors. Challenges in these efforts have been the in vivo stability of compounds,
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their ability to cross the blood-brain-barrier and especially their specificity versus the different types
and subtypes of receptors. Receptor binding of tracers may also be influenced by, e.g., the presence of
the endogenous receptor ligands. Müller Herde et al. investigated the receptor binding of [18F]PSS232,
a derivative of the longer known [11C]ABP688, a ligand for the metabotropic glutamate receptor 5
(mGluR5), in dependence of glutamate levels. Both in vitro autoradiography on rat brain slices and
in vivo PET showed no change of tracer binding upon drug-induced altering of glutamate levels.
They concluded that in contrast to [11C]ABP688, [18F]PSS232 cannot be used to measure fluctuations of
glutamate levels, but is useful to image mGluR5 occupancy. In another study by Tanzey et al. a novel
PET tracer was synthesized and in vivo evaluated for targeting the colony stimulating factor 1 receptor
(CSF1R), which is involved in both neuroinflammation (microglia) and inflammation in the periphery
(macrophages). Although it turned out that in rodent and non-human primate PET brain uptake was
very low, the tracer may still be useful for imaging of peripheral inflammation. Further, imaging in
immunology, whether it is inflammation or infection, has gained increasing interest over the last years.
The above described studies within this special issue consistently demonstrate that besides the
radiochemical aspects the in vitro and in vivo evaluations are an integrative part already at an early
stage in the development of a new tracer. This trend within the last decade was strongly supported by
a rapidly increasing availability of a large variety of animal and in vitro models and on the other hand
by the broad dissemination of small animal imaging using dedicated PET but also SPECT scanners.
Besides 18F and 11C, 68Ga has made its way to the clinics and is regularly used in different tracers.
Other longer-lived PET isotopes like 64Cu or 89Zr are still more research focused. However, as shown
by the contributions in this issue research regarding development of SPECT tracers, labeled with
99mTc or iodine isotopes (131I, 123I) is also substantial, not least due to the possibility of quantification
with modern SPECT/CT systems or regarding the application of 99mTc tracers in radio-guided surgery
(see Klingler et al.).
Development and optimization of labeling strategies for SPECT tracers was the aim of three
other studies, presented in this issue. Durante et al. could show systematically that for 131I-labeling
Chloramine T has advantages over Iodo-Gen®, due to shorter reaction times and solubility in aqueous
medium. For the first time, two tirapazamine derivatives were 131I-radioiodinated by Elsaidi et al.
Tirapazamine is known as radiosensitizer of hypoxic tissue. Reaction parameters were optimized and
could be controlled in a way to obtain either the one or the other product, which are now available
to be evaluated for hypoxia imaging. For imaging of mannose receptors expressed by lymph node
macrophages, Boschi et al. successfully developed a strategy for 99mTc-labeling of mannose-dextran
derivatives, using the highly stable 99mTcN synthon.
Radiopharmaceutical sciences and nuclear medicine are not limited to high-specific molecular
imaging but are also fields of expertise in therapy and as a consequence ideal for theranostic approaches.
The prostate-specific-membrane-antigen (PSMA) in prostate cancer has been a major focus in nuclear
medicine over the last years, numerous tracers have been developed for imaging and therapy. For this
indication, the most commonly used therapeutic isotope today is 177Lu, but also alpha-emitters
gain increasing interest. For a better mechanistic understanding Tönnesmann et al. systematically
investigated the uptake characteristics in salivary glands of the most prominent endoradiotherapy
tracer [177Lu]Lu-PSMA-617 in vitro. Accumulation in salivary glands could be attributed to both
specific and non-specific uptake mechanisms. These results are of high value for a future design of
radiopharmaceuticals targeting PSMA. Basaco et al. developed 177Lu-labeled girentuximab, an antibody
targeting carbonic anhydrase IX, expressed on most renal cancer cells. The authors optimized labeling
conditions and found increasing in vitro antigen affinity and immunoreactivity with a decreasing
number of 177Lu binding chelators DOTA per antibody.
Typically, radiopharmaceutical sciences are embedded in a clinical environment. All basic research
in radiochemistry or preclinical radiopharmaceutical development finds its justification and needs
the perspective of a consequent translation of the results into clinical application in nuclear medicine.
The statement “a mouse is not a man” is trivial and translation “from bench to bedside” must be the
2
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driving force. Regulatory requirements and especially GMP have become a challenge to be faced
and handled, but nevertheless cannot be showstoppers. A tracer that already made its way into
clinical application for cardiac imaging is [11C]meta-hydroxyephedrine ([11C]mHED). On the other
hand, this is a good example that translation “from bench to bedside” is not a uni-directional process.
As production is challenging and specific activity and impurities from the precursor obviously affect
image quality, Vraka et al. describe in their study their way back “from bedside to bench” to investigate
the various influences. After optimization of the synthesis, the improved product was again evaluated
with PET imaging in rats and later in humans, proving little effect of specific activity on image quality.
In a review, Schirrmacher et al. summarized the current status in development of PET tracers to
image tropomyosin receptor kinases (Trk), which are involved in neurological disorders, but also in
tumorigenesis in a variety of human cancers. Trk inhibitors have been developed as PET probes and
some were already translated to human application.
The present special issue on radiopharmaceutical developments of course can only reflect a limited
overview of the actual broad spectrum of trends in this field. In general, possible contributions of
radiopharmaceutical sciences and nuclear medicine imaging to a personalized medicine have been
shown in the past and even seem to be broader in the future. Imaging sciences today are regarded as
an integral part of clinical research. With new therapies becoming more complex and specific, imaging
together with, e.g., metabolomics procedures, histology and advanced data analysis is a most valuable
tool in such multi-modal approaches, providing molecular and functional profiles for therapy planning
and monitoring.
Funding: This research received no external funding.
Conflicts of Interest: The author declares no conflict of interest.
© 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
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Abstract: The benefits of PET imaging of tumor hypoxia in patient management has been demonstrated
in many examples and with various tracers over the last years. Although, the optimal hypoxia
imaging agent has yet to be found, 2-nitroimidazole (azomycin) sugar derivatives—mimicking
nucleosides—have proven their potential with [18F]FAZA ([18F]fluoro-azomycin-α-arabinoside) as
a prominent representative in clinical use. Still, for all of these tracers, cellular uptake by passive
diffusion is postulated with the disadvantage of slow kinetics and low tumor-to-background ratios.
We recently evaluated [18F]fluoro-azomycin-β-deoxyriboside (β-[18F]FAZDR), with a structure more
similar to nucleosides than [18F]FAZA and possible interaction with nucleoside transporters. For a
deeper insight, we comparatively studied the interaction of FAZA, β-FAZA, α-FAZDR and β-FAZDR
with nucleoside transporters (SLC29A1/2 and SLC28A1/2/3) in vitro, showing variable interactions
of the compounds. The highest interactions being for β-FAZDR (IC50 124 ± 33 μM for SLC28A3),
but also for FAZA with the non-nucleosidic α-configuration, the interactions were remarkable
(290 ± 44 μM {SLC28A1}; 640 ± 10 μM {SLC28A2}). An improved synthesis was developed for
β-FAZA. For a PET study in tumor-bearing mice, α-[18F]FAZDR was synthesized (radiochemical yield:
15.9 ± 9.0% (n = 3), max. 10.3 GBq, molar activity > 50 GBq/μmol) and compared to β-[18F]FAZDR
and [18F]FMISO, the hypoxia imaging gold standard. We observed highest tumor-to-muscle ratios
(TMR) for β-[18F]FAZDR already at 1 h p.i. (2.52 ± 0.94, n = 4) in comparison to [18F]FMISO
(1.37 ± 0.11, n = 5) and α-[18F]FAZDR (1.93 ± 0.39, n = 4), with possible mediation by the involvement
of nucleoside transporters. After 3 h p.i., TMR were not significantly different for all 3 tracers
(2.5–3.0). Highest clearance from tumor tissue was observed for β-[18F]FAZDR (56.6 ± 6.8%, 2 h p.i.),
followed by α-[18F]FAZDR (34.2 ± 7.5%) and [18F]FMISO (11.8 ± 6.5%). In conclusion, both isomers
of [18F]FAZDR showed their potential as PET hypoxia tracers. Differences in uptake behavior may be
attributed to a potential variable involvement of transport mechanisms.
Keywords: tumor hypoxia; PET; small animal imaging; azomycin nucleosides; [18F]FMISO
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1. Introduction
Nowadays, the value of tumor hypoxia imaging for patient stratification, targeted and
individualized therapy, and the monitoring thereof is undeniable [1–6]. The presence of tumor
hypoxia is associated with increased tumor-aggressiveness, invasiveness, and therapy resistance [1,7,8].
While considerable effort has been made in the past decades, the full potential of hypoxia imaging,
especially using specific tracers for positron emission tomography (PET) still has to be unraveled,
as detection sensitivity, PET tracer target specificity, and the underlying molecular mechanisms by
which these can be achieved are not entirely clear. Thus, there is still the need for optimization
of hypoxia tracers; the mechanistic questions of the underlying principles of PET hypoxia tracer
uptake and image contrast need to be answered as well. Of the numerous hypoxia tracer classes
that have evolved, we investigated the class of 2-nitroimidazoles in the past, with a specific focus on
18F-labeled 1-(5′-deoxy-5′-fluoro-α-D-arabinofuranosyl)-2-nitroimidazole ([18F]FAZA) [9–13]. To date,
the uptake mechanism of e.g. [18F]FAZA has not been identified in detail, yet it is assumed to be via
passive diffusion, as an alpha-configurated nucleoside derivative should not be transported actively.
It has been conceptualized in the past [13–16] that uptake and retention of 2-nitroimidazole-sugars in
hypoxic tumor tissue can be altered by permutation of both, sugar moiety and stereochemistry at the
anomeric carbon atom (2-nitroimidazole linked)—with the rationale to take advantage of transport
mechanisms involving nucleoside transporters. Involvement of nucleoside transporters in the tissue
uptake-process of 2-nitroimidazole-sugars was only investigated recently with β-allofuranose as
C6-sugar [15]. Transport of nucleosides and nucleoside analog drugs is mediated by two unrelated
protein families in humans, the SLC28 family of concentrative nucleoside transporters (hCNTs)
and the SLC29 family of equilibrative nucleoside transporters (hENTs) [17]. The SLC28 family
has three concentrative (hCNT1/2/3) members and the SLC29 family four equilibrative members
(hENT1/2/3/4), respectively. The roles of human nucleoside transporters (hNTs) in transport of
nucleosides and nucleoside drugs are summarized in recent reviews [18,19].
Here, we aimed at a systematic investigation of the interaction of selected 2-nitroimidazole-
furanoses, resembling nucleoside analogs, with each of the five recombinant hNTs produced in a
yeast model system (hENT1/2 and hCNT1/2/3). Transporters that may play a role in uptake of
these nitroimidazoles into hypoxic tumor cells or normoxic control tissue like e.g. the muscle should be
identified. The four compounds chosen for evaluation of their interaction with nucleoside transporters are
found in Table 1, together with references to published data and the work list for the actual study. Besides
the transporter interaction investigation, for β-FAZA, a novel synthesis route should be developed and
for 1′-α-[2′,5′-dideoxy-5′-[18F]fluoro-D-ribofuranosyl]-2-nitroimidazole (α-[18F]FAZDR) 18F-radiolabeling
should be established. In subsequent small animal PET imaging in a well-established tumor hypoxia
model (colon carcinoma mouse model), α-[18F]FAZDR should be compared with [18F]FMISO, the
gold standard in PET imaging of hypoxia [20,21] and β-[18F]FAZDR, of which positive PET imaging
results have been recently obtained [13]. The mouse colon carcinoma model could be chosen, as mouse
transporters exhibit close similarity to human nucleoside transporters [22]. With this comparative study,
we sought to gain further insight into the importance and influence of the sugar moiety and configuration
of 2-nitroimidazole at the anomeric carbon atom on tracer uptake and image contrast.
Table 1. 2-Nitroimidazole arabinose (FAZA) or deoxyribose (FAZDR) α-, β-derivatives with
references to published data or to be investigated in this study (*), regarding transporter interaction,
18F-radiolabeling and small animal PET imaging.
Compound Transporter Interaction 18F-Radiolabeling
PET In Vivo Data
(18F-Labeled; Small Animal Studies)
FAZA * [12] [9–13]
β-FAZA * [14] [14]
α-FAZDR * * *
β-FAZDR * [13] [13] and *
5
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2. Results
2.1. Organic Chemistry
FAZA [23,24], α-FAZDR and β-FAZDR [13] were prepared by known procedures; for β-FAZA,
a novel synthesis route was developed, although β-FAZA is a known compound [14]. Figure 1 gives
the structures of the non-radioactive fluorinated 2-nitroimidazole sugars that were synthesized and
evaluated for their interaction with human nucleoside transporters (see Section 2.3).
 
Figure 1. Chemical structures of the fluorinated 2-nitroimidazole C5-sugars FAZA, β-FAZA
and α-, β-FAZDR, synthesized and used in the investigation of their interaction with human
nucleoside transporters.
An improved synthesis of the β-arabinose-derived nucleoside analog β-FAZA from the
known starting material β-1 (prepared as described by Kumar et al. [25]) was developed
(Scheme 1). Selective silylation of the primary hydroxyl group at C-5′ with TBDMSCl/imidazole
in pyridine, followed by acetylation, furnished crystalline and fully protected nucleoside β-2 (80%).
Bis(2-methoxyethyl)aminosulfur trifluoride [26] (Deoxo-Fluor®) converted it to 5′-fluoro nucleoside
β-3 in 80% yield. Deprotection with MeONa in MeOH gave the desired arabinose-derived nucleoside
β-FAZA in 75%. β-FAZA was recently prepared by a different approach [14]. Here, we were able to
improve the overall process compared to [14] by a reduction of synthetic steps (for initial reaction steps
from the commercially available 1-β-D-(ribofuranosyl)-2-nitroimidazole, see [14,25]), overall reaction
times, and an increase in yield to 48% for the three steps shown in Scheme 1, compared to 21% for
the last three steps in [14]. The improvement was obviously due to the utilization of the commercial
fluorination agent, Deoxo-Fluor®, in the penultimate step.
 
Scheme 1. Three-step synthesis of the 5′-fluoro nucleoside analog β-FAZA, starting from 1-(2′-O-acetyl-
β-D-arabinofuranosyl)-2-nitroimidazole (β-1; [25]). Reagents for and yields of the individual steps are
given in the scheme.
6
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2.2. Radiochemistry
For a direct comparison with gold standard hypoxia PET imaging agent [18F]FMISO
and the recently evaluated beta-isomer β-[18F]FAZDR [13] in a small-animal imaging study,
alpha-ribofuranoside α-[18F]FAZDR was synthesized.
Radiolabeling, hydrolysis, and purification were carried out similar to the synthesis of
β-[18F]FAZDR (Scheme 2). Radiochemistry was performed on the same automated synthesis module
(TRACERlab FXF-N, GE, non-cassette based) as for the other two PET tracers. Radiochemical yields
were 15.9 ± 9.0% (n = 3) with higher variations compared to β-[18F]FAZDR (10.9 ± 2.4%, n = 4,
uncorrected for decay [13]). Maximum yield obtained was 10.3 GBq at the end of the synthesis. As
these amounts were sufficient for the planned mouse experiments and quality of the product was also
satisfactory, the process and reaction parameters were not optimized further.
Scheme 2. Radiosynthesis of α-[18F]FAZDR by nucleophilic substitution from the tosyl precursor α-1
and subsequent hydrolysis with NH4OH.
Radiochemical (RCP) and chemical purity (CP) were determined using HPLC and TLC. The latter
method showed RCP of α-[18F]FAZDR of > 97%; in HPLC radiochromatograms, only the product
peak was visible, corresponding to > 98% of RCP. With UV detection at 220 nm, only matrix peaks
were visible (< 5 min retention time), with no other chemical impurities above the detection limit. The
product solutions were always clear, colorless, and free of visible particles with a pH of 6.7 and a molar
activity > 50 GBq/μmol.
2.3. Transporter Studies in Saccharomyces cerevisiae
The interaction of 2-nitroimidazole sugars with nucleoside transporters was determined by ability
of the 2-nitroimidazole sugars to inhibit [3H]uridine uptake in yeast cells producing recombinant
human nucleoside transporters and results expressed as IC50 values. Among the four compounds
tested, only the β-sugar compounds inhibited hENT1 and hENT2 (SLC29A1/2), but at high
concentrations. For FAZA and α-FAZDR, no interaction was detected. β-FAZDR inhibited hCNT1
(SLC28A1) and hCNT3 (SLC28A3) potently with IC50 values of 269 ± 4 μM and 124 ± 33 μM,
respectively. FAZA inhibited hCNT1 with an IC50 value of 290 ± 44 μM and FAZA was the only
compound to show considerable inhibitory activity against hCNT2 (SLC28A2) with an IC50 value of
640 ± 10 μM. Individual IC50 values for all compounds and investigated transporters are summarized
in Table 2.
In summary, FAZA inhibited [3H]uridine transport by hCNT1 and hCNT2, in contrast to the
commonly accepted theory of FAZA entering cells by passive diffusion. Although some of the
compounds inhibited [3H]uridine uptake by nucleoside transporters, transporter interaction does not
necessarily imply transport through the cell membrane. To confirm this uptake, experiments with the
corresponding radioactive compounds needed to be undertaken, which was not possible here, due to
their lack of availability. Keeping this in mind, it is nevertheless possible that our results challenge the
current understanding of FAZA image contrast, as tumor-type dependent transporter expression might
especially alter the early-phase uptake in tumor tissue and contribute to PET signal heterogeneity.
This should be clarified in additional studies in the future. In contrast to FAZA, β-FAZA with the
nucleosidic β-configuration showed weak interaction with the nucleoside transporters. Among the
tested compounds, β-FAZDR showed best inhibition of uridine uptake by hCNT1 and hCNT3, while
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α-FAZDR showed no interaction with any transporter. Thus, both the deoxyribose sugar moiety and
the β-configuration of the 2-nitroimidazole at the anomeric carbon atom are important molecular
properties, if nucleoside transporter mediated uptake is envisaged in order to obtain higher TMR at
early imaging time-points.
Table 2. Inhibition of [3H]uridine transport by the 2-nitroimidazole sugar compounds in yeast cells
producing each of the five recombinant hNTs in concentration-effect experiments, as described in
Methods. IC50 values (calculated from dose-response curves) are presented as the mean ± SE for
n = 2–3 experiments. (NI = no interaction).
Compound
hENT1 hENT2 hCNT1 hCNT2 hCNT3
(SLC29A1) (SLC29A2) (SLC28A1) (SLC28A2) (SLC28A3)
IC50 (μM)
FAZA NI NI 290 ± 44 640 ± 10 1385 ± 100
β-FAZA 2070 ± 50 >3000 >3000 >3000 2309 ± 352
β-FAZDR NI >3000 269 ± 4 NI 124 ± 33
α-FAZDR NI NI NI NI NI
2.4. PET Hypoxia Imaging of CT26 Colon Carcinoma Bearing Mice
To build upon both, the obtained results from transporter studies in Saccharomyces cerevisiae and
our recently published data on β-[18F]FAZDR PET imaging, we subsequently performed small animal
hypoxia imaging with α-[18F]FAZDR and β-[18F]FAZDR in comparison with the clinical gold standard
[18F]FMISO in CT26 colon carcinoma bearing BALB/c mice, a well-characterized tumor model for
imaging hypoxia ([9,11,13], Figure 2A). Here, we were especially interested in the direct comparison
of α-[18F]FAZDR and β-[18F]FAZDR, as the 2-nitroimidazole position at the anomeric carbon atom of
2-deoxyribofuranoside proved to be of importance for nucleoside transporter interaction.
First, we quantified [18F]FMISO uptake in hypoxic tumor tissue and in normoxic muscle tissue.
While [18F]FMISO uptake was not significantly different at 1 h p.i. between tumor and muscle tissue
(tumor: 2.49 ± 0.88 %ID/cc, muscle: 1.81 ± 0.58 %ID/cc), also reflected by the low TMR at 1 h p.i.
(1.37 ± 0.11, n = 5), we obtained significantly higher uptake in tumors at 2 h and 3 h p.i. (Figure 2B,C).
In direct comparison, we then investigated α-[18F]FAZDR (Figure 2A), where we expected hypoxia
targeting in tumor tissue, but no major involvement of nucleoside transporters regarding tissue uptake.
α-[18F]FAZDR-TMR at 1 h p.i. were higher (however, not significantly different) compared to TMR of
[18F]FMISO at 1 h p.i. (α-[18F]FAZDR: 1.93 ± 0.39, n = 4; [18F]FMISO: 1.37 ± 0.11, n = 5; Figure 2B).
Furthermore, α-[18F]FAZDR showed a significantly higher uptake in tumor tissue at 1 h, 2 h and at 3 h
p.i. (1 h p.i. tumor: *1.90 ± 0.48 %ID/cc, muscle: *1.01 ± 0.32 %ID/cc; 3 h p.i. tumor: *0.88 ± 0.42
%ID/cc, muscle: *0.31 ± 0.15 %ID/cc; n = 4, * p < 0.05, Figure 2D). While the washout from both, tumor
and muscle tissue of [18F]FMISO was limited, we observed an increased washout for α-[18F]FAZDR
from both, tumor and muscle tissue (Figure 2D).
Next, we investigated β-[18F]FAZDR uptake and TMR. In good accordance with data recently
published by us [13], we could again show a substantial washout of β-[18F]FAZDR from both, tumor
and muscle tissue (Figure 2E). Furthermore, β-[18F]FAZDR was characterized by a significantly higher
TMR in comparison to [18F]FMISO at 1 h p.i. (Figure 2B). From 0.40 ± 0.07 %ID/cc at 1 h p.i., the tumor
uptake decreased to 0.18 ± 0.06 %ID/cc at 2 h p.i. and to 0.12 ± 0.05 %ID/cc at 3 h p.i., while normoxic
muscle uptake decreased from the initially measured 0.17 ± 0.03 %ID/cc at 1 h p.i. to 0.07 ± 0.01
%ID/cc at 2 h p.i. and to 0.04 ± 0.01 %ID/cc at 3 h p.i. (n = 4, Figure 2E). This reproduced the results
obtained in [13], also with regards to the TMR, which were 2.52 ± 0.94 at 1 h p.i., 2.65 ± 0.87 at 2 h p.i.
and 2.91 ± 1.01 at 3 h p.i. (n = 4).
8
Pharmaceuticals 2019, 12, 31
 
Figure 2. Exemplary structures and PET images of [18F]FMISO, α-[18F]FAZDR and β-[18F]FAZDR in
carcinoma tissue 1 h p.i. (A), calculated tumor-to-muscle ratios (TMR) are shown in B. β-[18F]FAZDR
(n = 4) displayed significantly higher TMR in comparison to [18F]FMISO (n = 5) 1 h p.i. (B), while
α-[18F]FAZDR-TMR (n = 4) were not significantly different at any time-point. [18F]FMISO displayed
significantly higher uptake in carcinomas vs. muscles only at 2 h and 3 h p.i. (C), while α-[18F]FAZDR
and β-[18F]FAZDR at all measured time-points (1 h, 2 h and 3 h p.i.). * p < 0.05, ** p < 0.01 (D,E).
To get a deeper understanding of this body of data, we also calculated tumor and muscle clearance
for [18F]FMISO, α-[18F]FAZDR and β-[18F]FAZDR at 2 h and 3 h p.i. relative to 1 h p.i. Tumor clearance
for [18F]FMISO was calculated to 11.8 ± 6.5% at 2 h p.i. (muscle clearance at 2 h p.i. 37.2 ± 4.3%)
and to 26.9 ± 10.1% at 3 h p.i. (muscle clearance at 3 h p.i. 58.6 ± 3.3%, n = 5, Figure 3A); tumor
clearance was significantly lower than muscle clearance for [18F]FMISO (p < 0.01). In direct comparison
to [18F]FMISO, we observed higher tumor and muscle clearance rates for α-[18F]FAZDR (Figure 3B).
Tumor clearance for α-[18F]FAZDR amounted to 34.2 ± 7.5% at 2 h p.i. (muscle clearance at 2 h p.i.
53.3 ± 8.3%) and to 55.3 ± 8.3% at 3 h p.i. (muscle clearance at 3 h p.i. 70.3 ± 5.5%, n = 4, Figure 3B)
with significantly higher clearance rates from normoxic muscle tissue (p < 0.05). Finally, we quantified
clearance rates for β-[18F]FAZDR, which turned out to be not significantly different between tumor
and muscle tissue, reproducing our previously published results [13]. Overall, β-[18F]FAZDR tumor
clearance was 56.6 ± 6.8% at 2 h p.i. (muscle clearance at 2 h p.i. 58.4 ± 8.2%) and 71.5 ± 7.0% at 3 h
p.i. (muscle clearance at 3 h p.i. 75.3 ± 6.4%, n = 4, Figure 3C).
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Figure 3. [18F]FMISO clearance was significantly different from carcinoma and muscle tissue (n = 5,
A), however lower in comparison to clearance rates from both tissues for α-[18F]FAZDR (n = 4, B)
and β-[18F]FAZDR (n = 4, C). Tumor/muscle-clearance ratios were significantly lower for [18F]FMISO
in comparison to β-[18F]FAZDR at 2 h p.i. and to both, α-[18F]FAZDR and β-[18F]FAZDR at 3 h p.i.
* p < 0.05, ** p < 0.01 (D).
Next, we calculated clearance ratios for tumor relative to muscle tissue at 2 h and 3 h p.i. for
a direct comparison between [18F]FMISO, α-[18F]FAZDR and β-[18F]FAZDR. Here, clearance ratios
well below unity indicate higher clearance from muscle tissue, unity indicates equal clearance rates
for both tumor and muscle tissue, and clearance ratios bigger than unity indicate higher clearance
rates from tumor tissue. The latter case was not expected, as this would likely be the case for a rather
hypoxia-unspecific tracer. Fitting the results of tracer-specific uptake behavior, TMR and clearance
rates, [18F]FMISO showed the lowest clearance ratios (*, **0.45 ± 0.17, n = 5, 3 h p.i.), followed
by α-[18F]FAZDR (*0.79 ± 0.12, n = 4, 3 h p.i.) and β-[18F]FAZDR with unitary clearance ratios
(**0.95 ± 0.02, n = 4, 3 h p.i., * p < 0.05, ** p < 0.01, Figure 3D).
Conclusively, we observed the highest TMR for β-[18F]FAZDR at 1 h p.i. in comparison to
[18F]FMISO and α-[18F]FAZDR, most probably mediated by the involvement of nucleoside transporters
(Figure 2B). However, β-[18F]FAZDR was also characterized by the lowest net uptake in both tumor
and muscle tissue in direct comparison with [18F]FMISO and α-[18F]FAZDR (Figure 2C–E), while
[18F]FMISO- and α-[18F]FAZDR-uptake were comparable. Further confirming these findings, clearance
rates from tumor tissue (and tumor-to-muscle clearance ratios) were lowest for [18F]FMISO, followed
by α-[18F]FAZDR and β-[18F]FAZDR.
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3. Discussion
While a lot of effort has been put in the development of hypoxia specific PET tracers (based on
2-nitroimidazole as hypoxia-selective moiety), and a wealth of studies indicate both hypoxia specificity
and added value for patient stratification and treatment monitoring [1–6]; the exact image contrast
generating mechanisms are still poorly understood. While the commonly accepted underlying theory
assumes trapping of 2-nitroimidazole-based PET tracers in hypoxic tissue and washout from normoxic
control tissue [12,23,27], a plethora of studies (both clinical and preclinical) have demonstrated that
this is most probably not the only mechanism explaining the obtained image contrast for various
2-nitroimidazole-based PET tracers in diverse tumor-entities [9,13,28–31]. Especially, the fact that
PET tracer kinetics of 2-nitroimidazole-based compounds can indicate both reversible or irreversible
uptake in patients with the selfsame tumor type, e.g. head and neck cancer, challenges the concept of
hypoxia-selective trapping [31]. This ambiguous behavior was also observed by others in both mouse
and man [28,32,33]. Substantial tumor and muscle washout could recently be observed by us for both
[18F]FAZA [9] and β-[18F]FAZDR [13]. While rapid washout from normoxic control tissue (in this
case muscle tissue) was anticipated, we were again struck by the high washout rates from hypoxic
tumor tissue, especially for β-[18F]FAZDR, and also, to a lesser extent, α-[18F]FAZDR. However, for
both α-[18F]FAZDR and [18F]FMISO, the clearance ratios indicate lower tumor clearance, fitting the
common theory of the underlying principle of a hypoxia-detecting PET tracer. But, although the
unitary clearance ratios imply it, this does not conclude that β-[18F]FAZDR is not a valid hypoxia
marker. In fact, we could recently prove the tumor hypoxia specificity of β-[18F]FAZDR [13]. Thus, one
could conclude from this body of data that hypoxia tracer image contrast consists of three different
components, which are theoretically influenced by the contribution of nucleoside transporters (detailed
analysis of hypoxia tracer kinetic modeling complexity can be found in [30]): (i) Free tracer in tissue
or in the fractional blood volume of target and reference tissue, (ii) non-specifically bound in target
and reference tissue, and (iii) specifically bound or trapped in target tissue. Looking at all examined
time-points (1 h, 2 h and 3 h p.i.), the in vivo behavior of the 2-nitroimidazole tracers we used in
this study, ([18F]FMISO, α-[18F]FAZDR and β-[18F]FAZDR), could be explained by reversible kinetics.
However, theoretically, if the sum of free and non-specifically bound tracer in target tissue is higher
than the actual specific binding in target tissue, the observed clearance could be dominated by the
washout of the non-specific or free tracer, while the specific fraction of the PET signal does not
necessarily need to be reversible to generate the observed contrast; this could also be caused by a
smaller fraction of irreversible binding. In addition, nucleoside transporters actively contribute to early
and, thus also to late PET image contrast. While we cannot draw conclusions on the dominance of free,
non-specific or specific fractions, we can conclude that nucleoside transporters definitely influence
image contrast, especially early image contrast, here at 1 h p.i. Furthermore, the hypoxia specificity
of α-[18F]FAZDR could be indirectly proven in this manuscript, as α-[18F]FAZDR-uptake perfectly
resembled β-[18F]FAZDR-uptake in the same tumor, imaged on consecutive days (Figure 2A).
We additionally validated this finding by an exemplary scan of one CT26 colon carcinoma
bearing mouse with [18F]FAZA, α-[18F]FAZDR and β-[18F]FAZDR on three consecutive days (Figure 4),
displaying very similar uptake patterns. This can be concluded as the hypoxia selectivity of
β-[18F]FAZDR, as recently shown by us [13], while [18F]FAZA hypoxia selectivity was shown by
us and others in a plethora of publications [1,5,7,9,10,12,13,28,29,31]. In perfect concordance with the
transporter data from this study, TMR at 1 h p.i. were highest for β-[18F]FAZDR, probably due to the
involvement of nucleoside transporters.
Conclusively, the exact mechanism generating 2-nitroimidazole PET hypoxia tracer image contrast
is still elusive, while we add knowledge on stereochemistry-dependent involvement of nucleoside
transporters regarding both early and late PET signals of 2-nitroimidazole-sugars. For the first time, we
could show an interaction of FAZA with nucleoside transporters, thus cellular FAZA-uptake may not
solely be attributable to passive diffusion—although our results still need to be taken with caution, as
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interaction might not necessarily be related to active transport. These findings open up novel avenues
for hypoxia imaging and might help clarifying the underlying principles of hypoxia imaging.
 
Figure 4. Exemplary scan of one CT26 colon carcinoma-bearing mouse with [18F]FAZA, α-[18F]FAZDR
and β-[18F]FAZDR on three consecutive days, along with structures of used hypoxia tracers.
4. Materials and Methods
4.1. General
Acetonitrile for azeotropic drying before 18F-radiolabeling was from Merck (DNA synthesis grade,
Darmstadt, Germany). Dimethylsulfoxide (DMSO, dried over molecular sieves) as solvent for labeling
was used from Fluka (Germany). Kryptofix 2.2.2. was purchased from Merck.
FAZA [23,24], the precursor [13] for radiosynthesis of α-[18F]FAZDR (1-(3′-O-acetyl-2′-deoxy-5′-
O-p-toluenesulfonyl-α-D-ribofuranosyl)-2-nitroimidazole (α-1)), α-FAZDR and β-FAZDR [13] were
prepared by known procedures. All other chemicals and solvents (either Fluka or Merck) were of
the highest purity available and used as received. Deuterated solvents were ordered from Eurisotop
GmbH (Saarbrücken, Germany).
1H and 13C NMR spectra (J-modulated except for 2-nitroimidazole derivatives) were obtained
from compounds dissolved in CDCl3, acetone-d6, and MeOH-d4 at 300 K using a Bruker AV 400
(1H: 400.13 MHz and 13C: 100.61 MHz) spectrometer. Chemical shifts were referenced to residual
CHCl3 (δH = 7.24), CDCl3 (δC = 77.00), residual CHD2C(O)CD3 (δH = 2.05), CD3C(O)CD3 (δC = 30.50),
residual CHD2OD (δH = 3.31) and CD3OD (δC = 49.00). IR spectra were measured of films on a silicon
disk [34] or in ATR mode on a Bruker VERTEX 70 IR spectrometer. Optical rotations were measured
at 20 ◦C on a PerkinElmer 351 polarimeter in a 1 dm cell. TLC was carried out on 0.25 mm thick
precoated Merck plates; silica gel 60 F254. Flash (column) chromatography was performed with Merck
silica gel 60 (230–400 mesh). Spots were visualized by UV and/or dipping the plate into a solution of
(NH4)6Mo7O24.4H2O (23.0 g) and of Ce(SO4)2.4H2O (1.0 g) in 10% aqueous H2SO4 (500 mL), followed
by heating with a heat gun. Melting points were determined on a Reichert Thermovar instrument and
were uncorrected.
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4.2. Synthesis of 1-(5′-Deoxy-5′-fluoro-β-D-arabinofuranosyl)-2-nitroimidazole (β-FAZA)
1-(5′-tert.-Butyldimethylsilyl-2′,3′-di-O-acetyl-β-D-arabinofuranosyl)-2-nitroimidazole (β-2): A
solution of TBDMSCl (0.068 g, 0.45 mmol, 1.1 equiv.) in dry pyridine (1.43 mL) was added to a
mixture of 1-(2′-O-acetyl-β-D-arabinofuranosyl)-2-nitroimidazole (β−1; [25]) (0.118 g, 0.41 mmol) and
imidazole (0.056 g, 0.82 mmol, 2 equiv.) at –20 ◦C under argon atmosphere. The mixture was stirred and
allowed to warm to room temperature in the cooling bath within 18 h before Ac2O (0.27 mL) was added.
After 1 h and addition of water (10 mL) and stirring for 15 min, the reaction mixture was extracted with
EtOAc (3 × 7 mL). The combined organic layers were dried (MgSO4) and concentrated under reduced
pressure. The residue was dried at 0.5 mbar and flash chromatographed (hexanes/EtOAc = 2:1,
Rf = 0.56) to yield silylated and acetylated nucleoside β-2 (0.145 g, 80%) as colorless crystals; mp.
93–94 ◦C (iPr2O, cooling from +50 ◦C to +4 ◦C); [α]D20 = +77.8 (c = 1.07, acetone). IR (Si): ν = 2931, 2858,
1754, 1542, 1482, 1370, 1239, 1098 cm−1; 1H NMR (400.13 MHz, CDCl3): δ = 7.79 (d, J = 1.1 Hz, 1H), 7.13
(d, J = 1.1 Hz, 1H), 6.79 (d, J = 5.3 Hz, 1H), 5.73 (dd, J = 5.3, 4.3 Hz, 1H), 5.36 (dd, J = 5.8, 4.3 Hz, 1H),
4.11 (td, J = 5.8, 3.4 Hz, 1H), 3.92 (AB part of ABX system, JAB = 11.4 Hz, JAX = JBX = 3.4 Hz, 2H), 2.08 (s,
3H), 1.79 (s, 3H), 0.92 (s, 9 H), 0.11 (s, 3H), 0.106 (s, 3H) ppm; 13C NMR (100.61 MHz, CDCl3): δ = 169.6,
168.6, 144.4, 128.1, 123.2, 86.7, 82.3, 75.0, 73.9, 61.3, 25.8 (3C), 20.6, 20.0, 18.3, −5.5, −5.6 ppm. Analysis
calcd for C18H29N3O8Si (443.53): C, 48.75%; H, 6.59%; N, 9.47%: Found: C, 48.73%, H, 6.49%; N, 9.42%.
1-(2′,3′-Di-O-acetyl-5′-O-deoxy-5′-fluoro-β-D-arabinofuranosyl)-2-nitroimidazole (β-3): A solution
of 1-(5′-tert.-butyldimethylsilyl-2′,3′-di-O-acetyl-β-D-arabinofuranosyl)-2-nitroimidazole (β-2) (0.117 g,
0.264 mmol) and Deoxo-Fluor® (0.22 mL, 0.528 mmol, 2 equiv., 50% in toluene) in dry
1,2-dichloroethane (0.23 mL) was stirred and heated at 75–80 ◦C under argon for 2 h. The mixture
was cooled at 0 ◦C, diluted with a saturated aqueous solution of NaHCO3 (10 mL) and extracted
with EtOAc (3 × 10 mL). The combined organic layers were dried (Na2SO4) and concentrated under
reduced pressure. The residue was flash chromatographed (hexanes/EtOAc = 2:1, Rf = 0.23) to give
5′-fluoro nucleoside β-3 (0.070 g, 80%) as colorless needles; mp. 113–114 ◦C (CHCl3/iPr2O, +50 ◦C to
−27 ◦C) (lit.: 112–114 ◦C [14]); [α]D20 = +62.4 (c = 0.75, acetone). IR (Si): ν = 3163, 2992, 1758, 1542, 1483,
1369, 1232, 1055 cm−1. The NMR spectroscopic data are in agreement with those in the literature [14].
Analysis calculated for C12H14FN3O7 (331.26): C, 43.51%; H, 4.26%; N, 12.69. Found: C, 43.59%, H,
4.13%; N, 12.60%.
1-(5′-Deoxy-5′-fluoro-β-D-arabinofuranosyl)-2-nitroimidazole (β-FAZA): A solution of MeONa in
MeOH (1.7 mL, 0.2 M) was added to a solution of protected fluoro arabino nucleoside β-3 (0.061 g, 0.184
mmol) in dry MeOH (2.7 mL) under argon at –20 ◦C. After stirring for 45 min at that temperature, the
solution was neutralized with AcOH and concentrated under reduced pressure. The residue was flash
chromatographed (hexanes/EtOAc = 1:2, Rf = 0.34) to furnish fluoro nucleoside β-FAZA (0.034 g, 75%)
as yellowish crystals; mp. 148 ◦C decomp. (MeOH/iPr2O, cooling to −18 ◦C); [α]D20 = +142.2 (c = 0.69,
MeOH). IR (ATR): ν = 3175, 1536, 1482, 1352, 1250, 1158, 1098, 1075, 1043, 1021 cm−1. The NMR
spectroscopic data are in agreement with those in the literature [14]. Analysis calcd for C8H10FN3O5
(247.18): C, 38.87%; H, 4.08%; N, 17.00%. Found: C, 38.89%, H, 3.95%; N, 16.94%.
4.3. Radiosynthetic Procedures
[18F]FMISO was synthesized according to [35] and [18F]FAZA, β-[18F]FAZDR following [13].
For synthesis of α-[18F]FAZDR, a TRACERlab FXF-N automated system (GE Healthcare, Münster,
Germany) was used. [18F]Fluoride was produced at a PETtrace cyclotron (GE Healthcare, Uppsala,
Sweden) in a niobium target body from [18O]water (Rotem, Israel) via the 18O(p,n)18F nuclear reaction
and beam currents of 35 μA. The [18F]fluoride was trapped on a Sep-Pak Light Accell Plus QMA anion
exchange cartridge (Waters, USA, preconditioning: 10 mL 1 N aqueous NaHCO3, 10 mL H2O, 5 mL
acetonitrile, 10 mL air). Subsequently, radioactivity was eluted with a mixture of 900 μL of acetonitrile
and 100 μL of water containing 3.5 mg (25 μmol) of potassium carbonate and 15 mg (40 μmol) of
Kryptofix 2.2.2. The solvent was evaporated (vacuum ca. 12 mbar) at 70 ◦C for 7 min and then at
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120 ◦C for another 7 min. Labeling was carried out after addition of 5 mg of precursor (α-1) in 1 mL of
DMSO at 70 ◦C for 5 min. After cooling to ca. 40 ◦C, 1 mL of 0.2 N NH4OH was added for hydrolysis
(10 min). The reaction mixture was neutralized using 0.5 mL of 0.2 N NaH2PO4 and injected onto the
semi-preparative HPLC column for purification. A Luna C18(2) 250 × 10 mm, 5 μm (Phenomenex,
Aschaffenburg, Germany) and a mixture of 8% ethanol in 10 mM Na2HPO4 (v/v) as eluent were used.
The product was eluted with a retention time of 24 min (k’ = 9.8; flow rate 5 mL/min), detected by UV
(220 nm) and a radio detector. Product volume was ca. 5–7 mL. Finally, the product was sterile filtered
through a 0.22 μm filter (Millex-GS, Millipore, USA). Overall synthesis time was 65 min. Activity was
determined and a sample taken for quality control.
Identity, radiochemical and chemical purity of α-[18F]FAZDR were determined using an analytical
HPLC system with a Phenomenex Luna C18(2) column (250 × 4.6 mm, 5 μm); eluent was 5%
acetonitrile in water (v/v) and flow rate 2 mL/min. HPLC eluate was monitored by radio- and
UV detector (220 nm) in series. In this system, the product eluted with a retention time of 27 min
(k’ = 26). Radio-TLC was performed on silica gel plates (POLYGRAM SIL G/UV254, 40 × 80 mm,
Macherey&Nagel, Düren, Germany) with ethylacetate as eluent. For analysis, a phosphor imager
(Cyclone Plus, PerkinElmer, Rodgau, Germany) was used, showing an Rf-value between 0.57–0.64 for
the product.
4.4. Transporter Studies in Saccharomyces cerevisiae
Saccharomyces cerevisiae yeast was separately transformed with plasmids (pYPhENT1, pYPhENT2,
pYPhCNT1, pYPhCNT2, or pYPhCNT3) encoding hNTs (hENT1, hENT2, hCNT1, hCNT2, or hCNT3,
respectively) as described elsewhere [36,37]. Uptake of 1 μmol/L [3H]uridine (Moravek Biochemicals)
into yeast was measured as previously described [37,38] using a semi-automated cell harvester (Micro96
HARVESTER; Skatron Instruments, Tranby, Norway). Yeast was incubated at room temperature with
1 μmol/L [3H]uridine in yeast growth media (pH 7.4) in the presence or absence (uninhibited controls)
of graded concentrations (0-3 mM) of test compounds. The following compounds were used for
transporter experiments: FAZA, β-FAZA, α-FAZDR, β-FAZDR. Uridine self-inhibition was used to
determine maximum inhibition of mediated transport. Concentration–effect curves were subjected to
nonlinear regression analysis using Prism software (version 4.03; GraphPad Software Inc.) to obtain
the concentration of test compound that inhibited uridine uptake by 50%, relative to that of untreated
cells (IC50 values). Each IC50 value determination was conducted with nine concentrations and four
replicates per concentration and experiments were repeated two to three times.
4.5. Cell Culture
CT26 mouse colon carcinoma cells were cultured as previously described [9], and mycoplasma
infections were checked once a month. The cells were a kind gift of Prof. Dr. med. Ralph
Mocicat (Institute of Molecular Immunology, German Research Center for Environmental Health,
Munich, Germany).
4.6. Animals
The above-described CT26 mouse colon carcinoma cells were subcutaneously inoculated in the
right shoulder of female BALB/c mice (1 × 106 cells in phosphate-buffered saline, PBS). Subsequently,
the carcinomas were allowed to grow for a period of 13 days, reaching approximately 0.3 cm3. PET
imaging experiments were conducted within day 14-16 post tumor inoculation. All animal experiments
were conducted according to guidelines for the use and care of laboratory research animals under the
German Animal Protection Law, and approved by local authorities (Regierungspräsidium Tübingen).
4.7. PET Imaging
[18F]FMISO (11.8 ± 1.2 MBq, n = 5), α-[18F]FAZDR (12.6 ± 1.3 MBq, n = 4) and β-[18F]FAZDR
(11.7 ± 0.9 MBq, n = 4) were intravenously injected (via the tail vein) in female CT26 colon carcinoma
14
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bearing BALB/c mice 14–16 days post tumor inoculation. One animal was scanned on three consecutive
days with [18F]FAZA, α-[18F]FAZDR and β-[18F]FAZDR; all other animals were scanned with only
one PET tracer (either [18F]FMISO, α-[18F]FAZDR or β-[18F]FAZDR). All experiments were done
using medical air as carrier gas for isoflurane anesthesia (1.5% isoflurane during PET scans, flow rate
0.4 L/min), including tracer injections, with a specialized vaporizer (Vetland, Louisville, KY, USA).
Subsequent to the tracer injections, the animals were allowed to freely move in their home cages for
an uptake period of 55 min, thus, breathing room air. After the uptake period, static 10 min PET
scans were acquired at 1 h post injection (p.i.), 2 h p.i. and 3 h p.i. PET scans were performed with a
Siemens Inveon dedicated PET (DPET, Siemens Healthcare, Knoxville, TN, USA). PET scans were then
reconstructed with a two-dimensional ordered subset expectation maximization algorithm (OSEM2D
with 16 subsets and 4 iterations). Image zoom was set to 1 and matrix size to 128 × 128 yielding a
final PET image spatial resolution of 0.79 × 0.79 × 0.80 mm3. PET data were manually corrected for
radioactive decay of 18F.
PET image analysis was performed using the PMOD 3.2_base 64 image viewing tool (PMOD
Technologies, Zürich, Switzerland). Standardized volumes-of-interest (VOI, spheres with a diameter
of 2 mm) were placed over the maximal activity in the carcinoma tissue (hypoxic target tissue), while
the VOI placement in the shoulder muscle tissue (contralateral to carcinomas, normoxic control tissue)
was done according to studies previously performed by our group [11,13]. Finally, PET data were
expressed as percent injected dose per cubic-centimeter (%ID/cc) or tumor-to-muscle ratio (TMR).
4.8. Statistical Analysis
All statistical data analysis was preceded by tests for homoscedasticity and normality of PET
data. These tests were performed using the Brown-Forsythe and the Shapiro-Wilk test with the
Origin 8.0 Pro Software Package (OriginLab, Northhampton, USA). Normally distributed data were
analyzed for statistically significant differences with the two-sample Student’s t-test, done with the
JMP 11.1.1 software package (SAS Institute GmbH, Böblingen, Germany). Multi-group comparisons
were performed with p-values adjusted according to the number of groups (Tukey Kramer correction).
Data are shown as the arithmetic mean ± one standard deviation (SD), unless otherwise mentioned;
box plots contain all individual data points, the 25th, 50th and 75th percentile, as well as the arithmetic
mean and one standard deviation (indicated by whiskers). For all tests, except for multi-group
comparisons, p-values below 0.05 were considered as statistically relevant.
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Abstract: The overexpression of gastrin-releasing peptide receptors (GRPRs) in frequently occurring
human tumors has provided the opportunity to use bombesin (BBN) analogs as radionuclide
carriers to cancer sites for diagnostic and therapeutic purposes. We have been alternatively exploring
human GRP motifs of higher GRPR selectivity compared to frog BBN sequences aiming to improve
pharmacokinetic profiles. In the present study, we compared two differently truncated human
endogenous GRP motifs: GRP(14–27) and GRP(18–27). An acyclic tetraamine was coupled at the
N-terminus to allow for stable binding of the SPECT radionuclide 99mTc. Their biological profiles
were compared in PC-3 cells and in mice without or with coinjection of phosphoramidon (PA) to
induce transient neprilysin (NEP) inhibition in vivo. The two 99mTc-N4-GRP(14/18–27) radioligands
displayed similar biological behavior in mice. Coinjection of PA exerted a profound effect on in vivo
stability and translated into notably improved radiolabel localization in PC-3 experimental tumors.
Hence, this study has shown that promising 99mTc-radiotracers for SPECT imaging may indeed
derive from human GRP sequences. Radiotracer bioavailability was found to be of major significance.
It could be improved during in situ NEP inhibition resulting in drastically enhanced uptake in
GRPR-expressing lesions.
Keywords: bombesin; gastrin-releasing peptide; gastrin-releasing peptide receptor; tumor targeting;
99mTc-radioligand; metabolic stability; neprilysin-inhibition; phosphoramidon
1. Introduction
Gastrin-releasing peptide receptors (GRPRs) are overexpressed in several human malignancies
such as prostate cancer, mammary carcinoma, and lung cancer [1–10]. Consequently, they have
attracted considerable attention as potential biomolecular targets for diagnosis and therapy
with radionuclide carriers directed to GRPR-positive cancer lesions [11,12]. Originally, the frog
tetradecapeptide bombesin (BBN, Pyr-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2)
and its truncated C-terminal octapeptide fragment BBN(7–14) have served as motifs for the
development of GRPR-targeting radioligands. However, BBN-like analogs bind with comparable
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affinity not only to GRPR (BB2R), but also to the neuromedin B (NMBR, BB1R), another
member of the three mammalian bombesin receptor subtypes [1,2]. The above two subtypes
are pharmacologically distinguished by their selectivity for different endogenous human
homologs of amphibian BBN. Thus, the 27-mer GRP (H-Val-Pro-Leu-Pro-Ala-Gly-Gly-Gly-Thr-
Val-Leu-Thr-Lys-Met-Tyr-Pro-Arg-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2), the 14-mer
GRP(14–27), and the C-terminal decapeptide GRP(18–27) fragments strongly bind to the GRPR,
whereas neuromedin B (NMB, H-Gly-Asn-Leu-Trp-Ala-Thr-Gly-His-Phe-Met-NH2) exhibits high
affinity for the NMBR [13]. The two GRPR and NMBR subtypes are physiologically expressed in the
human brain and the gut, especially in stomach, pancreas, and gastrointestinal tract, and they are
also implicated in cancer [14–16]. It is reasonable to assume, that radiolabeled BBN agonists of poor
GRPR selectivity will show increased levels of background radioactivity by virtue of their binding to
both GRPR and NMBR populations distributed in the body, especially in the abdomen. Furthermore,
additive GRPR- and NMBR-mediated effects in the gastrointestinal tract, such as abdominal smooth
muscle contraction and stimulation of gastrointestinal hormone secretion, are to be expected after
intravenous injection of BBN-like agonist radioligands [17–22].
In contrast to amphibian BBN-like motifs, the respective human homologs have surprisingly
remained unexploited as radionuclide carriers for targeting GRPR-positive cancer [13]. Motivated by
this gap in the inventory of GRPR-directed radioligands we have expanded our research efforts to
native human GRP sequences in order to explore their applicability in GRPR-targeted tumor diagnosis
and therapy. First, we introduced a small library of tetraamine derivatized GRP(18–27) analogs labeled
with the SPECT radionuclide 99mTc [23,24]. Compared to previously reported 99mTc-radiopeptides,
which are based on the full-length BBN or its truncated BBN(7–14) octapeptide fragment [25],
the 99mTc-N4-GRP(18–27) showed high GRPR selectivity and superior in vivo characteristics in
tumor-bearing mice, such as faster renal clearance and improved tumor to background ratios.
On the other hand, single or double amino acid substitutions in the decapeptide backbone exerted
pronounced effects on several biological properties, eventually affecting tumor targeting capabilities
and pharmacokinetics. In a following study, a series of differently truncated GRP sequences were
coupled to the universal chelator DOTA (1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid) and
labeled with 111In. Receptor affinity, internalization efficiency and tumor uptake of these analogs were
favored both by longer peptide chain and by the presence of basic amino acids Lys13 and Arg17 in the
native GRP sequence [26].
Following this line of research, we herein introduced 99mTc-N4-GRP(14–27) and compared its
biological profile in PC-3 cells and mice models with 99mTc-N4-GRP(18–27) (Figure 1). It should
be noted that basic positions Lys13 and Arg17 in the native GRP sequence are now occupied by
the positively charged N4+x/[99mTc(O)2(N4)]+1-moiety and not by the negatively charged DOTA.
This arrangement allows for comparisons with the DOTA-derivatized analogs and further studying
the influence of positive/negative charges in 13 and 17 positions of the GRP chain [26]. Next,
the selectivity of N4-GRP(14–27) for each of the three mammalian bombesin receptor subtypes was
investigated applying receptor autoradiography in human excised biopsy samples, expressing one of
the GRPR, NMBR, and bombesin subtype 3 (BB3R) receptors. Finally, the impact of in vivo stability
of 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27) on tumor targeting and pharmacokinetics was
compared in mice. The role of neprilysin (NEP) [27] on the in vivo degradation of the two human
GRP-based sequences was monitored by HPLC analysis of blood samples collected without or with
coinjection of the NEP-inhibitor phosphoramidon (PA) [28,29], as previously described for BBN-like
radioligands [30–34]. The enhancement of radiotracer localization in experimental GRPR-positive
PC-3 tumors in mice during transient NEP inhibition induced by PA was assessed.
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Figure 1. Chemical structure of (a) 99mTc-N4-GRP(14–27) (red) and (b) 99mTc-N4-GRP(18–27) (blue).
2. Results
2.1. Peptides and Radioligands
The bifunctional acyclic tetraamine chelator (6-(carboxy)-1,4,8,11-tetraazaundecane) was
covalently coupled by its carboxy functionality at the N-terminal Met14 of GRP(14–27) or the Gly18
of GRP(18–27) via an amide bond [24], generating two different length GRP analogs amenable
for labeling with the preeminent SPECT radionuclide 99mTc. Labeling was typically proceeded by
a brief incubation with 99mTcO4− generator eluate, SnCl2 as reducing agent, and citrate anions as
transfer ligand in alkaline pH at ambient temperature at molar activities of 20 to 40 MBq 99mTc/nmol
peptide. Quality control of the radiolabeled products combined HPLC and ITLC analysis. The total
radiochemical impurities, comprising 99mTcO4−, [99mTc] citrate, and 99mTcO2 × H2O, did not exceed
2%, while a single radiopeptide species was detected by RP-HPLC. In view of labeling yields >98%
and >99% radiochemical purity of the resultant 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27),
the radioligands were used without further purification in all subsequent experiments. Representative
radiochromatograms of HPLC analysis of 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27) are included
in Figure 2a,b, respectively.
Figure 2. Representative radiochromatograms of the radiolabeling reaction mixture of
(a) 99mTc-N4-GRP(14–27) (red) and (b) 99mTc-N4-GRP(18–27) (blue), confirming the quantitative
formation of high purity radioligands at tR = 14.9 min and tR = 13.3 min, respectively (HPLC system 1).
21
Pharmaceuticals 2019, 12, 42
2.2. In Vitro Assays
2.2.1. Receptor Autoradiography in Human Tumor Samples
The selective affinities of N4-GRP(14–27) for each of the three bombesin receptor subtypes
found in mammals were studied during in vitro competition binding assays against the universal
radioligand 125I-[DTyr6,βAla11,Phe13,Nle14]BBN(6–14) [6]. Receptor autoradiography was applied
in cryostat sections of well characterized human cancers, preferentially expressing one of the
subtypes. As summarized in Table 1, N4-GRP(14–27) showed high affinity for the GRPR expressed
in resected prostate carcinoma specimens (IC50 = 4.2 ± 1.0 nM, n = 3, vs. IC50 = 2.4 ± 1.0 nM,
n = 3 for N4-GRP(18–27) [23]), very low affinity for NMBR present in ileal carcinoid biopsy samples
(IC50 = 72 ± 7.6 nM, n = 3, vs. IC50 = 106 ± 13 nM; n = 2 for N4-GRP(18–27) [23]), and no affinity for the
BB3R expressed in bronchial carcinoid samples (IC50 > 1000 nM, n = 3, identical to N4-GRP(18–27) [23]).
Thus, N4-GRP(14–27) similarly to N4-GRP(18–27), displayed good selectivity for the GRPR. Hence,
the GRP-based analogs turned out to be more GRPR-preferring compared to BBN-based radioligands,
like Demobesin 3 (N4-[Pro1,Tyr4]BBN) [25] or [DTyr6,βAla11,Phe13,Nle14]BBN(6–14) (Table 1).
Table 1. Affinities for the three human bombesin receptor subtypes.
Peptide Conjugate
IC50s in nM
GRPR 1 NMBR 2 BB3R
3
Universal ligand 4 1.5 ± 0.1 (3) 1.5 ± 0.2 (3) 3.5 ± 0.7 (3)
N4-GRP(14–27) 4.2 ± 1.0 (3) 72 ± 7.6 (3) >1000 (3)
N4-GRP(18–27) 2.4 ± 1.0 (3) 106 ± 13 (2) >1000 (3)
Demobesin 3 0.5 (2) 1.6 (2) >100 (3)
The data represents the mean (±SEM; n = 3) for the cold universal ligand and for the two N4-GRP(14/18–27) analogs
and the mean (n = 2) for Demobesin 3. 125I[DTyr6,βAla11, Phe13,Nle14]BBN(6–14) was used as radioligand in all
experiments; 1 expressed in human prostate cancer, 2 in human ileal carcinoids and 3 in human lung carcinoids,
4[DTyr6,βAla11,Phe13,Nle14]BBN(6–14) was used as cold universal ligand.
2.2.2. Binding Affinity for the Human GRPR
As shown in Figure 3a, N4-GRP(14–27) and N4-GRP(18–27) as well as the respective GRP(14–27)
and GRP(18–27) parent peptide references displaced [125I-Tyr4]BBN from GRPR-sites on PC-3 cell
membranes in a monophasic and dose-dependent manner. The respective half-maximal inhibitory
concentration (IC50) values differed, yielding the following rank of decreasing receptor affinity:
N4-GRP(14–27) (IC50 0.32 ± 0.03 nM) > GRP(14–27) (IC50 0.45 ± 0.02 nM) > N4-GRP(18–27)
(IC50 0.63 ± 0.06 nM) > GRP(18–27) (IC50 1.66 ± 0.20 nM). We observe that the longer-chain peptides
consistently showed higher binding affinity to GRPR than their shorter chain counterparts. Moreover,
coupling of the positively charged acyclic tetraamine unit in the N-terminus of parent GRP(14/18–27)
references improved the affinity of resulting analogs to the GRPR, as previously reported for similarly
modified peptide analogs [35].
2.2.3. Internalization of 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27) in PC-3 Cells
During incubation at 37 ◦C in PC-3 cells, both 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27)
were taken up by the cells via a GRPR-mediated process, as demonstrated by the lack of internalization
observed in the presence of excess [Tyr4]BBN. In both cases the bulk of cell-associated radioactivity
was found in the cells with 99mTc-N4-GRP(14–27) internalizing much faster in PC-3 cells compared to
99mTc-N4-GRP(18–27) at all time intervals (Figure 3b). For example, at 1 h, 12.7 ± 0.7% of total added
99mTc-N4-GRP(14–27) specifically internalized in the cells vs. 5.0 ± 0.3% of 99mTc-N4-GRP(18–27),
whereas at 2 h these values increased to 19.5 ± 1.4% and 6.9 ± 1.5%, respectively.
22
Pharmaceuticals 2019, 12, 42
Figure 3. (a) [125I-Tyr4]BBN displacement curves from gastrin-releasing peptide receptor (GRPR)-sites
on PC-3 cells after 1-h incubation at 22 ◦C by N4-GRP(14–27) (red solid line—IC50 0.32±0.03 nM),
GRP(14–27) (red dashed line—IC50 0.45 ± 0.02 nM), N4-GRP(18–27) (blue solid line—IC50 0.63±0.06
nM) and GRP(18–27) (blue dashed line—IC50 1.66 ± 0.20 nM). (b) GRPR-specific internalization of
99mTc-N4-GRP(14–27) (red solid line) and 99mTc-N4-GRP(18–27) (blue solid line) in PC-3 cells during
incubation at 37 ◦C at 15, 30, 60, and 120 min. Results represent average of cell internalized activity ± sd,
n = 3; data is corrected for nonspecific internalization in the presence of 1 μM [Tyr4]BBN.
2.3. In Vivo Comparison of 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27)
2.3.1. Stability of 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27) in Mice
The two 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27) radiotracers exhibited distinct resistance
to degrading proteases after injection in mice. As revealed by HPLC analysis of blood samples collected
at 5 min postinjection (pi), 99mTc-N4-GRP(14–27) was found less stable (20.1 ± 4.5% intact, n = 3) than
the shorter chain 99mTc-N4-GRP(18–27) (31.0 ± 0.9% intact, n = 3). Representative radiochromatograms
are shown in Figure 4a,b, respectively.
Figure 4. Representative radiochromatograms of HPLC analysis of mouse blood samples collected 5 min
pi of (a) 99mTc-N4-GRP(14–27) (25.2% intact radiotracer; red dashed line) or (b) 99mTc-N4-GRP(18–27)
(31.8% intact radiotracer; blue dashed line) without PA coinjection; the respective radiochromatograms of
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(c) 99mTc-N4-GRP(14–27) (63.1% intact radiotracer; tR = 29.6 min; red solid line) or (d) 99mTc-N4-GRP(18–27)
(68.1% intact radiotracer; tR = 25.1 min; blue solid line) with PA coinjection are also included; the tR of
parent radiopeptide was determined by coinjection with the respective radioligand sample in the column
(HPLC system 2) and is indicated here by the arrow.
It should be noted that coinjection of the NEP-inhibitor PA remarkably enhanced the in vivo
stability of 99mTc-N4-GRP(14–27) (66.5 ± 4.8% intact, n = 3) and 99mTc-N4-GRP(18–27) (70.8 ± 5.4%
intact, n = 3) in the circulation, revealing NEP as a major degrading protease for both radiotracers in
mice. Representative radiochromatograms are included in Figure 4c,d, respectively.
2.3.2. Biodistribution in PC-3 Xenograft-Bearing Mice
The biodistribution of 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27) was studied in severe
combined immune deficiency (SCID) mice bearing human PC-3 xenografts expressing the human
GRPR. Subcutaneous tumors of suitable size developed in the flanks of mice about four weeks after
inoculation of a suspension of prostate adenocarcinoma PC-3 cells and biodistribution was conducted.
Cumulative biodistribution results for 99mTc-N4-GRP(14–27) at the 1-, 4-, and 24-h pi intervals are
summarized in Table 2, and are expressed as mean % injected dose per gram (%ID/g) values ± sd,
n = 4. The radiotracer washed rapidly from the blood and the background tissues predominantly
via the kidneys and the urinary system. High uptake was observed in the PC-3 tumor at 1-h pi
(10.20 ± 0.72%ID/g) that remained at comparably high levels at 4-h pi (8.41 ± 4.16%ID/g; p > 0.05),
declining by ~50% at 24-h pi (4.50 ± 0.69%ID/g). Tumor uptake at 4-h pi was significantly lower in the
animals treated with excess [Tyr4]BBN (0.62 ± 0.24%ID/g; p < 0.001), suggestive of a GRPR-mediated
process. Likewise, 99mTc-N4-GRP(14–27) highly localized in the GRPR-rich mouse pancreas via
a GRPR-specific process, as demonstrated by the lack of pancreatic uptake during GRPR-blockade by
coinjection of excess [Tyr4]BBN (35.24 ± 4.70%ID/g vs. 0.83 ± 0.24%ID/g in block; p < 0.001).
Table 2. Biodistribution data for 99mTc-N4-GRP(14–27), expressed as %ID/g mean ± sd, n = 4, in PC-3
xenograft-bearing SCID mice at 1-h, 4-h block, 4-h, and 24-h pi.
Tissue 1 h 1 4 h 1 24 h 1 4 h block 2
Blood 1.54 ± 0.17 0.10 ± 0.03 0.07 ± 0.01 0.08 ± 0.02
Liver 5.02 ± 0.46 3.75 ± 1.11 3.23 ± 0.78 6.12 ± 2.89
Heart 0.70 ± 0.07 0.11 ± 0.04 0.07 ± 0.01 0.28 ± 0.13
Kidneys 14.82 ± 2.22 4.83 ± 2.12 3.10 ± 0.73 4.85 ± 2.66
Stomach 1.02 ± 0.29 1.42 ± 0.93 0.78 ± 0.33 0.43 ± 0.18
Intestines 7.21 ± 0.52 7.61 ± 2.23 1.73 ± 0.23 1.45 ± 0.44
Muscle 0.29 ± 0.02 0.03 ± 0.01 0.06 ± 0.01 0.05 ± 0.02
Lungs 1.96 ± 0.33 0.49 ± 0.30 0.18 ± 0.04 0.65 ± 0.22
Pancreas 37.85 ± 1.95 35.24 ± 4.70 13.41 ± 0.77 0.83 ± 0.24
Tumor 10.20 ± 0.72 8.41 ± 4.16 4.50 ± 0.69 0.62 ± 0.24
1 Animal groups injected with 180–370 kBq/10 pmol peptide; 2 block mice group coinjected with 40 nmol [Tyr4]
BBN for in vivo GRPR blockade.
Comparative biodistribution results for 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27) at the
4-h pi interval are included in Table 3. Data from additional 4-h pi animal groups coinjected with
the NEP-inhibitor PA (300 μg) is also included in the Table. The radiotracers displayed similar tissue
distribution patterns. The observed higher tumor and pancreatic uptake of 99mTc-N4-GRP(14–27)
did not however differ significantly to that of 99mTc-N4-GRP(18–27) (p > 0.05) [24]. Treatment with
PA induced a drastic increase in tumor values for both radiotracers with 99mTc-N4-GRP(14–27)
showing superior tumor values than the shorter chain 99mTc-N4-GRP(18–27) (38.19 ± 4.79%ID/g vs.
28.37 ± 8.05%ID/g, respectively; p < 0.01). Pancreatic values increased by >3-fold for both radiotracers
as well. Thus, in agreement with previous studies on BBN-based analogs [31–34], NEP inhibition
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likewise resulted in significant stabilization of GRP(14/18–27)-based radioligands in peripheral mouse
blood and notable improvement of localization in GRPR-expressing lesions in mice.
Table 3. Comparative biodistribution data for 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27),
expressed as %ID/g mean ± sd, n = 4, in PC-3 xenograft-bearing SCID mice at 4-h pi (controls)




4 h 1 4 h PA 1,2 4 h1 4 h PA 1,2
Blood 0.10 ± 0.03 0.23 ± 0.08 0.13 ± 0.04 0.21 ± 0.04
Liver 3.75 ± 1.11 4.99 ± 1.53 1.02 ± 0.17 2.13 ± 0.37
Heart 0.11 ± 0.04 0.89 ± 0.06 0.14 ± 0.10 0.47 ± 0.27
Kidneys 4.83 ± 2.12 11.68 ± 1.61 6.01 ± 1.38 7.66 ± 1.39
Stomach 1.42 ± 0.93 3.82 ± 1.10 1.12 ± 0.75 4.02 ± 0.66
Intestines 7.61 ± 2.23 21.35 ± 1.68 7.28 ± 0.60 16.23 ± 3.90
Muscle 0.03 ± 0.01 0.06 ± 0.02 0.03 ± 0.01 0.06 ± 0.01
Lungs 0.49 ± 0.30 1.06 ± 0.19 0.28 ± 0.09 0.84 ± 0.26
Pancreas 35.24 ± 4.70 110.32 ± 8.76 32.18 ± 5.91 95.39 ± 20.34
Tumor 8.41 ± 4.16 38.19 ± 4.79 7.08 ± 1.29 28.37 ± 8.05
1 Animal groups injected with 180–370 kBq/10 pmol peptide; 2 PA mice groups with animals coinjected with 300 μg
PA to in situ inhibit NEP.
3. Discussion
A considerable number of radiolabeled analogs of frog BBN have been developed for potential
application in the diagnosis and therapy of GRPR-expressing tumors in Homo sapiens [11,12].
This pursuit is based on the overexpression of GRPRs on the surface of malignant cells serving as
easily accessible biomolecular targets on cancer lesions [3–10]. Joining this effort, we have previously
introduced a series of BBN-like analogs, generated by covalently coupling of an acyclic tetraamine at the
N-terminus, Demobesin 3–6 [25]. Like native BBN, these peptide ligands displayed indistinguishable
binding affinities for the human bombesin receptor subtypes GRPR and NMBR, but no affinity for the
BB3R. The respective radiotracers [99mTc] Demobesin 3–6 specifically localized in GRPR-expressing
human PC-3 xenografts in mice. Moreover, one of the analogs, [99mTc] Demobesin 4, was able to
visualize malignant lesions in a small number of prostate cancer patients with SPECT/CT [36].
We have recently expanded our search toward radioligands based on human endogenous GRP
sequences [23,24,26]. The latter are reported for higher GRPR selectivity compared to their frog
homolog BBN [13]. This approach has surprisingly remained unexplored up to now, although it
offers two major advantages. First, radioactivity levels in abdominal tissues physiologically
expressing both GRPR and NMBR subtypes would favorably decrease when GRPR-selective
radioligands are used [14–16]. Second, injection of GRPR-selective agonists will not activate the
NMBR subtype populations in the gut and is hence associated with less adverse effects [17–22].
Promising GRPR-selective radioligands based on receptor antagonists have been developed and
evaluated in animals and in human, showing excellent tumor targeting and pharmacokinetic
profiles [37,38]. Yet, the suitability and efficacy of noninternalizing GRPR antagonists for therapy
with low-range beta, alpha, or Auger emitters of high LET has not been established thus far [39,40].
Therefore, the study of radiolabeled GRPR-selective agonists is warranted and may provide
an alternative platform for the development of radioligands exhibiting new combinations of biological
features particularly suited for cancer theranostics.
As a part of this effort we herein introduced two analogs of endogenous truncated fragments
of human GRP carrying an acyclic tetraamine at their terminus, one based on the tetradecapeptide
GRP(14–27), and the other on a shorter decapeptide GRP(18–27) chain identical to human neuromedin
C (NMC) (Figure 1). As revealed during receptor autoradiography studies in excised biopsy samples
of well characterized human tumors expressing each of the GRPR, NMBR, and BB3R subtypes
25
Pharmaceuticals 2019, 12, 42
using the universal 125I-[DTyr6,βAla11,Phe13,Nle14]BBN(6–14) radioligand, both N4-GRP(14–27) and
N4-GRP(18–27) analogs showed good selectivity for the GRPR subtype (Table 1). This finding is
in agreement with previous reports documenting the preference of human GRP and its C-terminal
native fragments for GRPR [13]. In contrast, the tetraamine derivatized BBN-like analogs Demobesin
3–6 do not distinguish between GRPR and NMBR, instead behaving like the native frog BBN [25].
The His20 of GRP corresponding to Gln7 of BBN seems to have significant impact on subtype
selectivity, followed by the Met14-Tyr13-Pro12-Arg11-tetrapeptide in GRP(14–27) corresponding to
the Pyr1-Gln2-Arg3-Leu4-counterpart in native BBN.
Both N4-GRP(14–27) and N4-GRP(18–27) analogs displayed sub-nM affinities for the GRPR during
competition assays against [125I-Tyr4]BBN in PC-3 cell membranes, which were found to be increased
compared to unmodified GRP(14/18–27) lead structures (Figure 3a). It is interesting to note that the
presence of the positively charged N4+x-moiety at positions 13 and 17 of the native GRP chain occupy
the two basic amino acids Lys13 and Arg17. When these positions were taken up by negatively charged
DOTA instead, a drastic drop in binding affinity was observed (IC50 DOTA-GRP(14–27) = 6.6 ± 0.9 nM
and IC50 DOTA-GRP(18–27) = 112 ± 16 nM) [26]. In all cases, longer chain GRP(14–27) analogs
consistently displayed higher GRPR-affinity compared to their C-terminal decapeptide counterparts.
In agreement with this observation, the internalization rate of 99mTc-N4-GRP(14–27) in PC-3 cells was
clearly superior to that of 99mTc-N4-GRP(18–27) (Figure 3b).
A crucial feature for efficient tumor targeting is metabolic stability that will ensure sufficient
radioligand supply to tumor sites after injection in the living organism [31]. Recent studies have revealed
the significance of in vivo stability assessment of BBN-like radiotracers vs. in vitro determinations in
serum or tissue homogenate incubates to more accurately predict the actual protease(s) encountered
by the radioligand after entering the circulation. These studies have demonstrated NEP as a major
degrading protease of BBN and its radiolabeled analogs [41,42]. In a recently proposed approach,
NEP-inhibitors, like PA [28,29], coinjected with the BBN-based radioligand drastically increased
metabolic stability leading to notable enhancement of tumor uptake in animal models [31–34].
Following this rationale, we have tested the in vivo stability of the two 99mTc-N4-GRP(14–27) and
99mTc-N4-GRP(18–27) radiotracers in peripheral mouse blood collected 5 min pi by radioanalytical
HPLC (Figure 4). The longer chain 99mTc-N4-GRP(14–27) displayed somewhat poorer stability
(20.1 ± 4.5% intact, n = 3) compared to shorter chain 99mTc-N4-GRP(18–27) (31.0 ± 0.9% intact, n = 3).
Thus, the presence of additional amide bonds in the longer peptide chain offered further degradation
sites for attacking proteases. It is interesting to note, that coinjection of PA drastically increased the
stability of both analogs in the circulation, indicating NEP as a major protease in the catabolism of
GRP sequences as well.
Aiming to explore the effects of peptide chain as well as NEP inhibition on the pharmacokinetics
and tumor targeting capabilities of the two tracers, we have conducted biodistribution experiments in
immunosuppressed mice bearing human GRPR-expressing xenografts. Interestingly, the biodistribution
patterns of the two radiotracers did not clearly differ (Table 3). Compared to the previously reported
111In-DOTA analogs [26], 99mTc-N4-GRP(14–27) showed higher tumor uptake. Comparable in vivo
tumor targeting was obtained only by 111In-DOTA-GRP(13–27), carrying basic Lys at position 13.
However, kidney clearance was notably faster for the 99mTc-radiotracer (4.83 ± 2.12%/g at 4 h pi)
than for the 111In-DOTA-Lys13-analog (46.02 ± 3.73%/g at 4 h pi) [26]. Treatment of mice with PA
exerted a profound effect on the in vivo profile of both 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27)
(Table 2), is in agreement with previous findings for other BBN-like radioligands. The longer chain
99mTc-N4-GRP(14–27) exhibited the highest uptake in the experimental tumor, as a combined result of
higher internalization rate and pronounced in vivo stabilization induced by PA.
The present study has shown that GRP motifs of different chain length may provide new
opportunities for the development of promising GRPR-selective radioligands. The latter may prove to
be a useful asset in the arsenal of anti-GRPR radioactive drugs, by internalizing in cancer cells while
evading binding to and activation of bombesin receptor subtypes other than the GRPR in the gut.
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Furthermore, it has shown the impact of in vivo metabolic stability in maximizing tumor localization.
Structural modifications in peptide lead-structures to improve the stability of radiopeptides, such as
amino acid replacements, cyclization, or changes of cleavable peptide bonds, may deteriorate other
important biological features, as for example receptor affinity, cell uptake, tumor targeting, and overall
pharmacokinetics. On the other hand, transient in situ inhibition of NEP represents a smart method
to accomplish this goal and warrants further efforts for translation in the clinic. Despite challenges
related to biosafety, regulatory and financial hurdles, once established in a proof-of-principal study,
this strategy is expected to boost the development and clinical application of other NEP-catabolized
radioligands, considerably saving costs and resources [31–34].
4. Materials and Methods
4.1. Peptides and Reagents
The N4-GRP(14–27) and N4-GRP(18–27) peptide conjugates were synthesized on the solid
support following a published method [24] and were provided by PiChem (Graz, Austria).
The [Tyr4]BBN (Tyr4-bombesin, Pyr-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2)
and GRP(14–27) (H-Met-Tyr-Pro-Arg-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2) references
were purchased from PSL GmbH (Heidelberg, Germany), whereas GRP(18–27) (H-Gly-Asn-His-Trp-Ala-
Val-Gly-His-Leu-Met-NH2) was provided by PeptaNova GmbH (Sandhousen, Germany). Phosphoramidon
disodium dehydrate (N-(α-rhamnopyranosyloxyhydro xyphosphinyl) -L-leucyl-L-tryptophan × 2Na ×
2H2O; PA) was purchased from PeptaNova GmbH (Sandhousen, Germany).
Preparation and Quality Control of 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27)
Lyophilized N4-GRP(14–27) and N4-GRP(18–27) were dissolved in bidistilled water to a final
1 mM concentration and bulk solutions were distributed in 50 μL aliquots in Eppendorf vials (Protein
LoBind Tube 1.5 mL; Eppendorf AG, Hamburg, Germany) and stored at −20 ◦C. For 99mTc labeling,
the following solutions were added into an Eppendorf tube containing 0.5 M phosphate buffer pH 11.5
(25 μL): 0.1 M sodium citrate (3 μL), [99mTc]NaTcO4 (210 μL, 150–300 MBq) eluted from a commercial
99Mo/99mTc generator (Ultratechnekow, Tyco Healthcare, Petten, The Netherlands), N4-GRP(14–27) or
N4-GRP(18–27) stock solution (7.5 μL, 7.5 nmol), and finally, fresh SnCl2 solution in EtOH (5 μg, 5 μL).
After 30 min incubation at ambient temperature the reaction mixture was neutralized by addition of
1 M HCl (4 μL) and EtOH was added (25 μL).
Quality control of the radiolabeled products comprised radioanalytical HPLC and instant
thin-layer chromatography (ITLC). HPLC analyses were performed on a Waters Chromatograph
coupled to a 2998 photodiode array UV detector (Waters, Vienna, Austria) and a Gabi gamma
detector (Raytest RSM Analytische Instrumente GmbH, Germany). For analysis, a Waters Symmetry
Shield RP-18 cartridge column (5 μm, 3.9 mm × 20 mm) was eluted at a 1.0 mL/min flow rate with
the following gradient, 0% B to 40% B in 20 min, where A = 0.1% aq. trifluoroacetic acid (TFA),
B = MeCN (System 1). Under these conditions 99mTcO4− eluted at 1.8 min and 99mTc-N4-GRP(14–27)
and 99mTc-N4-GRP(18–27) with a tR > 12 min. For the detection of reduced hydrolyzed technetium
(99mTcO2·× H2O) ITLC was conducted on ITLC-SG strips (Pall Corporation, New York, NY, USA),
as previously described. The resultant 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27) radioligands
were used without further purification in all subsequent experiments.
Radioiodination of [Tyr4]BBN was performed using 125I ([125I]NaI in 0.1 N NaOH (pH 12–14)
provided by MDS Nordion, Ottawa, ON, Canada) according to the chloramine-T methodology,
as previously described [34]. Methionine was added to the purified radioligand solution to prevent
reoxidation of Met14 to the corresponding sulfoxide and the resulting stock solution in 0.1% BSA-PBS
was kept at −20 ◦C; aliquots thereof were used in competition binding assays (molar activity of
81.4 GBq/μmol).
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4.2. In Vitro Assays
4.2.1. Cell Lines and Culture
Human androgen-independent prostate adenocarcinoma PC-3 cells endogenously expressing
the human GRPR (LGC Promochem, Teddington, UK) were used in the present study [43]. Cells
were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium, supplemented with 10%
heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin, and kept
in a controlled humidified atmosphere containing 5% CO2 at 37 ◦C. Passages were performed weekly
using a trypsin/EDTA (0.05%/0.02% w/v) solution. All culture media were purchased from Gibco
BRL, Life Technologies and supplements were provided by Biochrom KG Seromed.
4.2.2. Receptor Autoradiography
Binding affinities of N4-GRP(14–27) were determined by in vitro receptor autoradiography
performed on cryostat sections of well characterized human tumor tissues, prostate carcinomas
for GRPR, ileal carcinoids for NMBR and bronchial carcinoids for BB3R, as previously described [23].
The universal radioligand 125I-[DTyr6,βAla11,Phe13,Nle14]BBN(6–14) (2 Ci/mol; ANAWA, Wangen
Switzerland) was used as tracer known to identify all three bombesin receptor subtypes [6]. IC50 values
are given in nM ± SEM.
4.2.3. Competition Binding in PC-3 Cell-Membranes
Competition binding experiments against [125I-Tyr4] BBN were performed with N4-GRP(14–27)
and N4-GRP(18–27), or with the unmodified parent peptide references GRP(14–27) and GRP(18–27)
in PC-3 cell membranes. For the assay, triplicates per concentration point (concentration range:
10−13–10−6 M) of each test peptide were incubated together with the radioligand (~40,000 cpm per
assay tube at a 50 pM concentration) in PC-3 cell-membrane homogenates in a total volume of 300 μL
binding buffer (BB, 50 mM HEPES pH 7.4, 1% BSA, 5.5 mM MgCl2, 35 μM bacitracin) for 1 h at
22 ◦C in an Incubator-Orbital Shaker (MPM Instr. SrI, Bernareggio, Italy). Binding was interrupted by
ice-cold washing buffer (WB, 10 mM HEPES pH 7.4, 150 mM NaCl) and rapid filtration (Whatman
GF/B filters presoaked in BB) on a Brandel Cell Harvester (Adi Hassel Ing. Büro, Munich, Germany).
Filters were washed with ice-cold WB and counted in an automatic well-type gamma counter (NaI(Tl)
3′-crystal, Cobra Packard Auto-Gamma 5000 series instrument). The IC50 values were calculated
using nonlinear regression according to a one-site model applying the PRISM 2 program (Graph Pad
Software, San Diego, CA, USA).
4.2.4. Internalization Assay in PC-3 Cells
The internalization rates of 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27) were compared in
PC-3 cells. Briefly, PC-3 cells were seeded in six-well plates (~1 × 106 cells per well) 24 h before
the experiment. Approximately 50,000 cpm of either 99mTc-N4-GRP(14–27) or 99mTc-N4-GRP(18–27)
(corresponding to 250 fmol total peptide in 150 μL of 0.5% BSA/PBS) was added alone (total) or in the
presence of 1 μM [Tyr4]BBN (nonspecific). Cells were incubated at 37 ◦C for 15, 30, 60, and 120 min
and incubation was interrupted each time by placing the plates on ice, removing the supernatants and
rapid rinsing with ice-cold 0.5% BSA/PBS. Cells were then treated 2 × 5 min with acid wash buffer
(2 × 0.6 mL, 50 mM glycine buffer pH 2.8, 0.1 M NaCl) at room temperature and supernatants were
collected (membrane-bound fraction). After rinsing with 1 mL chilled 0.5% BSA/PBS, cells were lysed
by treatment with 1 N NaOH (2 × 0.6 mL) and lysates were collected (internalized fraction). Sample
radioactivity was measured in the γ-counter and percent internalized radioactivity was determined
vs. total added activity. Results represent the average values ± sd of three experiments performed
in triplicate.
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4.3. Animal Studies
4.3.1. In Vivo Stability Tests
For stability experiments, healthy male Swiss albino mice (30 ± 5 g, NCSR “Demokritos” Animal
House Facility) were used. Test radioligand—99mTc-N4-GRP(14–27) or 99mTc-N4-GRP(18–27)—was
injected as a 100 μL bolus (37–74 MBq, 3 nmol total peptide) in the tail vein together with injection
solution (100 μL; control) or with a PA-solution (100 μL injection solution containing 300 μg PA).
Animals were euthanized and blood (0.5–1 mL) was directly withdrawn from the heart in an ice-cold
syringe and transferred in a prechilled EDTA and methionine-containing Eppendorf tube on ice.
Blood samples were centrifuged for 10 min at 2000 g/4 ◦C and plasma was collected. After addition
of an equal volume of ice-cold MeCN the mixture was centrifuged for 10 min at 15,000 g/4 ◦C.
The supernatant was concentrated under a N2-flux at 60 ◦C to 0.05–0.1 mL, diluted with saline (0.4 mL),
filtered through a 0.22 μm Millex GV filter (Millipore, Milford, CT, USA), and analyzed by RP-HPLC.
The Symmetry Shield RP18 (5 μm, 3.9 mm × 20 mm) column was eluted at a flow rate of 1.0 mL/min
with the following linear gradient (system 2): 0% B at 0 min to 10% B in 10 min and then in 40 min
to 30% B; A = 0.1% aq. TFA and B = MeCN. The tR of the intact radiopeptide was determined by
coinjection with the 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27) reference in the HPLC.
4.3.2. Induction of PC-3 Xenografts in SCID Mice
A suspension containing freshly harvested human PC-3 cells (≈150 μL of a ≈1.2 × 107 cells) was
subcutaneously injected in the flanks of female SCID mice (15 ± 3 g, six weeks of age at the day of
arrival, NCSR “Demokritos” Animal House Facility). The animals were kept under aseptic conditions
and 4 weeks later developed well-palpable tumors (80–200 mg) at the inoculation sites.
4.3.3. Biodistribution in PC-3 Xenograft-Bearing SCID Mice
For the biodistribution study, animals in groups of 4 received via the tail vein a 100 μL bolus
of 99mTc-N4-GRP(14–27) (180–370 kBq, corresponding to 10 pmol total peptide) coinjected either
with injection solution (100 μL; control) or PA-solution (300 μg PA dissolved in 100 μL injection
solution; 4 h + PA), or with excess [Tyr4]BBN (100 μL injection solution containing 50 μg [Tyr4]BBN
for in vivo GRPR-blockade; 4 h block). Animals were euthanized at 1-, 4-, and 24-h pi; in the case of
99mTc-N4-GRP(18–27) two animal groups were included at the 4-h pi interval, namely the control and
PA groups described above. Mice were dissected; samples of blood, tumors, and organs of interest were
collected, weighed, and measured for radioactivity in the gamma counter. Intestines and stomach were
not emptied of their contents. Data was calculated as percent injected dose per gram tissue (%ID/g)
with the aid of standard solutions and represent mean values ± sd, n = 4. All animal experiments were
performed in compliance with national and European guidelines and approved by national authorities
(Prefecture of Athens, EL 25 BIO 021; #1609 and #1610).
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Abstract: The high overexpression of cholecystokinin-2 receptors (CCK2R) in tumors, such as
medullary thyroid carcinoma, allows for highly specific diagnostic and therapeutic targeting with
radiolabeled peptide probes derived from natural ligands for the receptor. Based on the ideal imaging
characteristics, high availability and low cost of technetium-99m (99mTc)-labeled radiopharmaceuticals
we have developed two hydrazinonicotinic acid (HYNIC) conjugated minigastrin analogs allowing
labeling at high specific activity. The CCK2R targeting peptide conjugates show specific amino acid
substitutions in the C-terminal receptor-specific sequence with the aim to increase stability and tumor
targeting. The CCK2R affinity and the cell uptake of the new radioligands were analyzed using A431
human epidermoid carcinoma cells stably transfected with human CCK2R and mock transfected
cells. Metabolic studies in BALB/c mice revealed a high resistance against enzymatic degradation
for both radioligands. Biodistribution studies in tumor-xenografted athymic BALB/c nude mice at
1 h and 4 h p.i. showed that the two 99mTc-labeled compounds showed varying uptake in receptor
expressing organs, stomach and pancreas (1.3–10.4% IA/g), as well as kidneys, the main route of
excretion (7.8–19.9% IA/g). The tumor uptake in A431-CCK2R xenografts was 24.75 ± 4.38% IA/g for
[99mTc]Tc-HYNIC-MGS5 and 42.48 ± 6.99% IA/g for [99mTc]Tc-HYNIC-MGS11 at 4 h p.i., whereas the
tumor-to-kidney ratio was comparable (2.6–3.3). On demand availability and potential application
for radioguided surgery of a 99mTc-labeled minigastrin analog support the further evaluation of these
highly promising new compounds.
Keywords: cholecystokinin-2 receptor; minigastrin; molecular imaging; radiometals; technetium-99m;
hydrazinonicotinic acid (HYNIC)
1. Introduction
Regulatory peptides exhibiting high target specificity are suitable lead structures, particularly
in the field of oncology, for the development of analogs for radionuclide imaging and therapy [1,2].
Such peptide analogs have the advantage of an easy production via well-established solid phase
peptide synthesis (SPPS) allowing the conjugation of a chelator for radiolabeling and the introduction
of different modifications into the peptide sequence to optimize pharmacokinetics. Additionally,
peptide analogs show low immunogenicity and toxicity and are therefore preferable candidates as new
targeting agents [3,4]. A highly promising molecular target to develop radiopeptides for diagnostic
imaging and targeted radiotherapy (TRT) of medullary thyroid carcinoma (MTC), small cell lung cancer
(SCLC), astrocytoma, stromal ovarian cancer, as well as carcinoids and other tumors of neuroendocrine
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origin is the cholecystokinin-2 receptor (CCK2R) as an increased level of expression is observed in
these malignancies [5,6].
The most promising CCK2R targeting radiopeptides developed so far, are based on the peptide
sequence of minigastrin (MG), a naturally occurring ligand for this receptor [7]. MG and its analogs
bind to CCK2R with their bioactive C-terminal region (Trp-Met-Asp-Phe-NH2). In the last 20 years
a variety of MG analogs conjugated to different chelators for nuclear medicine procedures have been
reported [7–9]. Most of the preclinically [10–16] and clinically [17,18] investigated MG analogs have
been conjugated to the bifunctional chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
(DOTA) allowing stable radiolabeling with trivalent radiometals such as Gallium-68, Indium-111 or
Lutetium-177 suitable for positron emission tomography (PET), single photon emission computed
tomography (SPECT) and TRT. Due to radioprotection issues and regulatory requirements for the
in-house production of radiopharmaceuticals, such as the need of hot cells, automated synthesis
modules, aseptic processing and trained personnel, the availability of these radiopeptides seems to be
restricted to a limited number of clinics.
A cost-effective and broadly available alternative for CCK2R imaging in hospitals without
PET would be a kit-based MG analog suitable for 99mTc-labeling. Such a kit is already available for
somatostatin receptor targeting using [99mTc]Tc-EDDA/HYNIC-Tyr3-octreotide (Tektrotyd, Polatom,
Otwock, Poland). Technetium-99m can be easily eluted from a licensed 99Mo/99mTc-generator and is
used in the major part of nuclear medicine procedures. Due to its ideal physical properties (half-life of
6 h, monoenergetic gamma photons of 140 keV, low radiation burden) Technetium-99m remains the
most attractive radionuclide for SPECT applications as well as for gamma probe detection during
radioguided surgery [19,20].
Different attempts have been made to develop MG analogs with high tumor accumulation and
a biodistribution profile suitable for gastrin receptor scintigraphy [19,21,22]. However, only two
99mTc-labeled MG analogs have been investigated in clinical studies. [99mTc]Tc-Demogastrin
2 ([99mTc]Tc-N4-Gly-dGlu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) contains an open chain
tetraamine chelator forming a monocationic complex [23,24]. [99mTc]Tc-EDDA/HYNIC-MG11
([99mTc]Tc-EDDA/HYNIC-dGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) conjugated to the monodentate
ligand hydrazinonicotinic acid (HYNIC) needs additional coligands such as tris(hydroxymethyl)-
methylglycine (tricine) or ethylenediamine-N,N’-diacetic acid (EDDA) to complete the coordination
sphere [25]. The administration of these two 99mTc-labeled MG analogs to patients was well tolerated
showing no to only mild side effects. With [99mTc]Tc-Demogastrin 2 all known lesions in nine MTC
patients could be visualized. In a comparative study with [99mTc]Tc-EDDA/HYNIC-MG11 and
[99mTc]Tc-EDDA/HYNIC-TOC the potential additional information which can be obtained in MTC
patients using gastrin receptor scintigraphy was pointed out. The same MG analogs conjugated to
DOTA showed drawbacks related to high kidney uptake or low in vivo stability, requiring further
improvement to develop a CCK2R targeting peptide analog with optimal tumor targeting and
biodistribution profile [8].
Various research groups have worked on the development of metabolically stable MG analogs.
Different strategies such as cyclization, dimerization and substitutions of amino acids mainly
in the N-terminal part of the peptide sequence were investigated [8]. However, due to rapid
C-terminal enzymatic degradation the need of alternative stabilization strategies was suggested [26].
Recently we could present different amino acid substitutions introduced into the C-terminal
receptorspecific sequence of MG analogs improving the stability against enzymatic degradation
and the biodistribution profile [15,16]. After an intense preclinical evaluation of different
substitutions, we discovered that most promising results in terms of improved in vivo stability
and enhanced tumor targeting could be achieved when substituting methionine (Met) with
N-methyl-norleucine ((N-Me)-Nle) and phenylalanine (Phe) with 1-naphtyl-alanine (1-Nal). With the
new MG analog DOTA-dGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-NH2 (DOTA-MGS5) radiolabeled
with Gallium-68, Indium-111 and Lutetium-177 a very promising targeting profile was achieved [16].
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In the present study we have conjugated the clinically well-established HYNIC ligand to MGS5 to
develop a 99mTc-labeled MG analog, suitable for SPECT and radioguided surgery. Furthermore the
HYNIC-conjugate dGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-(N-Me)1-Nal-NH2 (HYNIC-MGS11) with
additional N-methylation of the peptide bond between Asp and 1-Nal was synthesized to evaluate
if a further stabilizing effect can be achieved. The two 99mTc-labeled MG analogs were characterized
in vitro and in vivo, including receptor affinity and cell uptake assays, as well as metabolic and
biodistribution studies in tumor-xenografted BALB/c nude mice.
2. Results and Discussion
2.1. Peptide Synthesis and Radiolabeling
Following straightforward SPPS HYNIC-MGS5 and HYNIC-MGS11 were synthesized using
30 μmol of resin, 150 μmol of each Fmoc-protected amino acid and 90 μmol of HYNIC.
After purification by RP-HPLC and lyophilization the peptide conjugates were obtained in ~10%
yield with a chemical purity ≥95% as confirmed by RP-HPLC and MALDI-TOF MS. The amino acid
sequences and chemical structures of both MG analogs are presented in Figure 1.
Figure 1. Amino acid sequence and chemical structure of (a) HYNIC-MGS5 and (b) HYNIC-MGS11.
Radiolabeling with technetium-99m using the exchange labeling approach from tricine, used as an
intermediate coligand, to EDDA yielded in [99mTc]Tc-HYNIC-MGS5 and [99mTc]Tc-HYNIC-MGS11 at
high molar activity of 35–40 GBq/μmol comparable to previously published results [22,27]. The main
peak occurring in the radio-HPLC chromatogram after labeling indicates complete conversion
of the initial tricine complex into the EDDA complex, as already described previously [28,29].
Minor hydrophilic impurities, related to free pertechnetate and 99mTc-coligands, could be efficiently
removed by solid phase extraction (SPE) resulting in labeling with radiochemical purity >95%.
Peptide related side products with relative retention of 0.9–1.1 were below 5%. Representative
radiochromatograms are displayed in Figure 2.
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Figure 2. Radiochromatograms of (a) [99mTc]Tc-HYNIC-MGS5 and (b) [99mTc]Tc-HYNIC-MGS11.
2.2. Characterization in Vitro
The stability of the two radiopeptides was analyzed in PBS, confirming a high complex stability
obtained by exchange labeling. After 24 h incubation, still a high percentage of intact radiopeptide was
present ([99mTc]Tc-HYNIC-MGS5: 95.1%; [99mTc]Tc-HYNIC-MGS11: 94.4%). MG analogs missing the
penta-Glu motif are generally known for their low in vitro serum stability regardless of whether they
are conjugated to DOTA [26] or HYNIC [30]. This can be changed by introducing site-specific amino
acid substitutions into their C-terminal peptide sequence [15,16]. For [99mTc]Tc-HYNIC-MGS5 and
[99mTc]Tc-HYNIC-MGS11 showing such substitutions, a high stability with no evidence of enzymatic
degradation was found in human serum (>95% intact radiopeptide after 24 h incubation). These results
are in accordance with previous results reported for 111In-, 68Ga- or 177Lu-labeled DOTA-MGS5
(96–98% intact radiopeptide) incubated under the same conditions [16]. From the octanol/PBS
distribution a log D value of −2.91 ± 0.06 was calculated for [99mTc]Tc-HYNIC-MGS5. The additional
methyl group in [99mTc]Tc-HYNIC-MGS11 did not change the hydrophobicity (log D value of
−2.84 ± 0.08; p = 0.07). Protein binding with values of 36.8 ± 0.1% for [99mTc]Tc-HYNIC-MGS5 and
34.5 ± 2.2% for [99mTc]Tc-HYNIC-MGS11 after 24 h incubation was in the same range. The results of
serum stability and protein binding observed over the incubation period of up to 24 h are summarized
in Figure 3.
Figure 3. In vitro properties of [99mTc]Tc-HYNIC-MGS5 (red) and [99mTc]Tc-HYNIC-MGS11 (blue):
(a) stability in human serum (n = 2), (b) protein binding (n = 2).
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2.3. Receptor Binding and Cell Internalization Studies
Saturation binding experiments on A431-CCK2R cells revealed a high affinity to the human
CCK2R. The mean values for the dissociation constant (Kd) calculated by fitting the data from two
experiments to a one-site binding model (r2 ≥ 0.99) were 13.7 ± 1.1 nM for [99mTc]Tc-HYNIC-MGS5
and 14.7 ± 1.2 nM for [99mTc]Tc-HYNIC-MGS11. In Figure 4 a representative saturation binding curve
is displayed for both radioligands.
Figure 4. Representative saturation binding curve obtained on A431-CCK2R cells with [99mTc]Tc-
HYNIC-MGS5 (red) and [99mTc]Tc-HYNIC-MGS11 (blue).
In the internalization assays performed on A431-CCK2R cells a high receptor mediated cell
uptake was observed. With [99mTc]Tc-HYNIC-MGS5 13.1 ± 0.4% of the totally added radioactivity
was internalized already after 15 min and this value increased over time reaching 62.0 ± 1.6% after 2 h
incubation. Even though [99mTc]Tc-HYNIC-MGS5 and [99mTc]Tc-HYNIC-MGS11 showed very similar
Kd values, the cell uptake of [99mTc]Tc-HYNIC-MGS11 was distinctly lower. After 15 min 4.0 ± 0.7%
of the radioactivity was internalized and this value increased to 24.4 ± 1.9% after 2 h incubation.
These unexpected differences between the two MG analogs indicate a possible different binding mode
to human CCK2R of MGS5. Also for DOTA-conjugated MGS5 labeled with different radiometals
a similarly enhanced cell uptake was found [16]. The results of the internalization experiments are
displayed in Figure 5.
Figure 5. Cell uptake of [99mTc]Tc-HYNIC-MGS5 (red) and [99mTc]Tc-HYNIC-MGS11 (blue) into
A431-CCK2R (solid line) and A431-mock (dashed line) cells for up to 2 h incubation.
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In A431-mock cells lacking CCK2R expression a low and comparable non-specific uptake of
radioactivity (≤0.1%) was observed for both radiopeptides at each time point. The receptor specificity
of the uptake in A431-CCK2R cells could be confirmed by additional blocking studies with 1 μM
pentagastrin showing a clear blockage of the CCK2R mediated uptake to values ≤1.0% after 2 h
incubation for both radiopeptides (data not shown).
2.4. In Vivo Stability in BALB/c Mice
Metabolic studies in BALB/c mice were performed to further evaluate the enzymatic stability of
the radiopeptides. In these studies differences in the stability against enzymatic degradation could
be observed between the two radiopeptides. For [99mTc]Tc-HYNIC-MGS5 >65% intact radiopeptide
was found in the blood and liver of BALB/c mice at 10 min after injection. Interestingly, the stability
against metabolic degradation was further increased for [99mTc]Tc-HYNIC-MGS11. The values of
intact radiopeptide at 10 min p.i. were 96.0 ± 1.4% in blood and 95.2 ± 0.7% in liver. A faster
degradation was observed in the excretory system. Much lower levels of intact radiopeptide were
detectable in kidneys ([99mTc]Tc-HYNIC-MGS5: 13.9 ± 0.5%; [99mTc]Tc-HYNIC-MGS11: 40.0 ± 2.0%)
and urine ([99mTc]Tc-HYNIC-MGS5: 3.0 ± 1.6%; [99mTc]Tc-HYNIC-MGS11: 9.8 ± 2.2%). Peptide related
impurities already present after radiolabeling and with a relative retention of 0.9–1.1 were not
considered as metabolites formed during digestion. Representative radio-HPLC profiles of the different
analyzed samples are presented in Figure 6. For [99mTc]Tc-HYNIC-MGS5 two main metabolites were
observed in blood and liver, an early eluting hydrophilic metabolite with retention time (tR) of ~3.5 min
and a second more hydrophobic metabolite eluting at tR ~15.7 min. For [99mTc]Tc-HYNIC-MGS11 only
the metabolite with tR ~3.5 min was detected whereas the second metabolite was missing. This indicates
that additional methylation of the peptide bond between Asp and 1-Nal prevents the formation of
this metabolite during systemic circulation. No further investigations have been performed yet to
identify the metabolite found for [99mTc]Tc-HYNIC-MGS5. From the shift in retention time between
[99mTc]Tc-HYNIC-MGS5 (tR = ~17.5 min) and the formed metabolite (tR = ~15.7 min) as well as from
data available on the literature cleavage at two different positions, namely between (N-Me)Nle-Asp or
Asp-1-Nal, seems possible.
Figure 6. Radiochromatograms for blood, liver, kidney and urine from metabolite studies in BALB/c
mice injected with (a) [99mTc]Tc-HYNIC-MGS5 (red) and (b) [99mTc]Tc-HYNIC-MGS11 (blue) as
analyzed 10 min p.i.; dashed line showing the radiochromatogram of the radiopeptide before injection.
Ocak et al. have suggested a common enzymatic cleavage site of different MG analogs between
Asp and Phe-NH2 when incubated in human serum [26]. Recently, Sauter et al. studied the stability of
three 177Lu-labeled MG analogs in different human proteases finding that substitution of Met with
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Nle had a stabilizing effect and only cleavage between Nle and Asp occured [18]. In kidney and
urine a much higher degree of enzymatic degradation was observed for [99mTc]Tc-HYNIC-MGS5
and [99mTc]Tc-HYNIC-MGS11. In kidneys mainly the hydrophilic metabolite with tR ~3.5 min not
corresponding to pertechnetate eluting at tR 2.6 min was observed, whereas in urine a variety of
additional metabolites with tR < 15 min was detected.
2.5. Biodistribution in Tumor-xenografted BALB/c Nude Mice
The results of the biodistribution studies in the A431-CCK2R/A431-mock tumor-xenograft model
at 1 h and 4 h p.i. evaluating the tumor targeting and tissue uptake are displayed in Figure 7a.
For selected organs additional autoradiography studies were performed at 1 h p.i. (see Figure 7b).
The uptake values calculated for the tumors and different dissected tissues are summarized in the
supplementary material (Table S1). Rapid clearance from the body mainly through the kidneys
resulted in low non-specific uptake in most tissues and organs for [99mTc]Tc-HYNIC-MGS5 as well as
for [99mTc]Tc-HYNIC-MGS11. The uptake of both radiopeptides significantly decreased in most tissues
from 1 h to 4 h p.i. (p < 0.05) except for stomach (p = 0.07), intestine (p = 0.14) and bone (p = 0.18) in
mice injected with [99mTc]Tc-HYNIC-MGS5 as well as pancreas (p = 0.12) and kidneys (p = 0.18) in mice
injected with [99mTc]Tc-HYNIC-MGS11. [99mTc]Tc-HYNIC-MGS5 showed a significantly lower uptake
in blood at 1 h in comparison with [99mTc]Tc-HYNIC-MGS11 (p < 0.01), however both radiopeptides
showed a similar hydrophobicity and protein binding. At 4 h p.i. a similar trend was observed in
blood, but this was not significant (p = 0.06). Also the non-specific uptake in lung, heart, spleen
and liver was higher for [99mTc]Tc-HYNIC-MGS11 at 1 h and 4 h p.i. (p < 0.05). In mouse CCK2R
are primarily localized in brain and stomach and at lower expression levels also in colon, pancreas,
kidney and ovary [31]. Due to the overall negative charge the two radioligands are unable to cross
the blood-brain barrier, but we found a considerable uptake in stomach and pancreas, which was
significantly higher for [99mTc]Tc-HYNIC-MGS5 at both time points. For [99mTc]Tc-HYNIC-MGS5
at 4 h p.i. a stomach uptake of 12.89 ± 2.91% IA/g and a pancreas uptake of 6.64 ± 2.21% IA/g
was found, whereas [99mTc]Tc-HYNIC-MGS11 displayed much lower values of 3.95 ± 0.15% IA/g in
stomach (p = 0.0009) and 1.30 ± 0.42% IA/g in pancreas (p = 0.003) at the same time point. Also the
intestinal uptake of [99mTc]Tc-HYNIC-MGS11 with values of 0.82 ± 0.14% IA/g versus 1.39 ± 0.34%
IA/g for [99mTc]Tc-HYNIC-MGS5 at 4 h p.i. was significantly lower (p = 0.02). In line with the high
CCK2R expression level confirmed for A431-CCK2R cells [32], an impressively high CCK2R mediated
tumor uptake was observed in A431-CCK2R xenografts, whereas the uptake in A431-mock xenografts
remained at very low levels (<1% IA/g). Tumor weights as determined after sacrifice were 0.17 ± 0.06 g
for A431-CCK2R xenografts (n = 16) and 0.16 ± 0.12 g for A431-mock xenografts (n = 15). One mouse
did not develop the A431-mock tumor. In A431-CCK2R xenografts, [99mTc]Tc-HYNIC-MGS5 showed
a high and persistent uptake with values of 25.09 ± 2.39% IA/g at 1 h and 24.75 ± 4.38% IA/g at
4 h p.i. The uptake values of [99mTc]Tc-HYNIC-MGS11 were almost doubled (39.87 ± 7.12% IA/g
at 1 h and 42.48 ± 6.99% IA/g at 4 h p.i.; p < 0.01). This improvement was rather surprising given
the lower cell uptake observed in vitro (24.4 ± 1.9% for [99mTc]Tc-HYNIC-MGS11 versus 62.0 ± 1.6%
for [99mTc]Tc-HYNIC-MGS5 after 2 h incubation). Receptor specificity was only tested by blocking
studies in vitro, however, the very low uptake values observed in A431-mock tumor-xenografts
(0.17–0.93% IA/g) for both radioligands confirmed that the tumor uptake was highly receptor specific.
A very low and similar peptide amount of ~15 pmol was injected to the animals studied with both
radiopeptides to avoid possible receptor saturating effects. The divergent uptake values observed
for mouse stomach and pancreas in comparison with A431-CCK2R tumor-xenografts observed with
both radioligands are therefore rather related to interspecies receptor differences between mouse
and human CCK2R, than varying receptor expression levels. Even though the mouse and human
CCK2R share an amino acid identity of ~90% [31], methylation of the peptide bond between Asp and
1-Nal in [99mTc]Tc-HYNIC-MGS11 seems to affect the uptake into CCK2R-expressing organs in mouse.
Interspecies differences between human and rat CCK2R have been reported also for other radiolabeled
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MG analogs [15,33]. The observed differences in stomach and pancreas need to be interpreted with
caution as a different physiological uptake may occur in humans. However, no further experiments
were carried out to investigate the affinity of the two MG analogs for mouse CCK2R.
Figure 7. Biodistribution of [99mTc]Tc-HYNIC-MGS5 (red) and [99mTc]Tc-HYNIC-MGS11 (blue) in the
A431-CCK2R/A431-mock xenograft model: (a) tissue distribution and tumor uptake at 1 h and 4 h
p.i. with values expressed as % IA/g (mean ± SD, n = 4); (b) autoradiography performed for selected
organs at 1 h p.i. (color scale, pixel intensity: min 9 (blue), max 100 (red)).
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The structural difference of the two radioligands also had a strong impact on the kidney uptake.
The kidney uptake of [99mTc]Tc-HYNIC-MGS11 (19.90 ± 2.09% IA/g at 1 h and 17.17 ± 2.93% IA/g
at 4 h p.i.) was two times higher in comparison with [99mTc]Tc-HYNIC-MGS5 (10.56 ± 1.15% IA/g
at 1 h and 7.80 ± 1.47% IA/g at 4 h p.i.). Despite CCK2R-related uptake, reabsorption and retention
of radiolabeled peptides in kidneys is mainly driven by multiple transport mechanisms, involving
megalin and cubulin [34]. In megalin-deficient mice a significantly reduced renal reabsorption was
confirmed for a radiolabeled minigastrin analog, with renal uptake values reduced to 37–49% when
compared to wild-type mice [35]. It has been shown for different radiolabeled MG analogs that the
uptake in stomach and CCK2R-expressing tumor-xenografts can be efficiently blocked by co-injection
of a 1000-fold molar excess of unlabeled peptide, whereas no considerable effect occurs in kidneys [36].
In this study no additional blocking studies were performed in vivo to confirm the receptor-specific
uptake in the different organs.
The tumor targeting profile of [99mTc]Tc-HYNIC-MGS5 well compares with previous results
obtained with [111In]In-DOTA-MGS5, showing a similar tumor uptake of 19.53 ± 5.42% IA/g and
23.49 ± 1.25% IA/g at 1 h and 4 h p.i., respectively [15]. This high and persistent tumor uptake
is clearly superior when compared to other 99mTc-labeled MG analogs previously studied [37].
For [99mTc]Tc-Demogastrin-2 evaluated in A431-CCK2R xenografted SCID mice at a similar
injected peptide amount of 10 pmol a tumor uptake of 12.89 ± 4.69% ID/g at 4 h p.i. was
reported, which was however, connected with a very high kidney uptake (58.62 ± 8.98% ID/g).
The metabolic stability of this compound (60% intact radiopeptide at 5 min p.i.) was comparable
to [99mTc]Tc-HYNIC-MGS5 [37]. In our previous studies with radiolabeled DOTA-MGS5 we
concluded that a combination of increased protein binding and stabilization against enzymatic
degradation might be responsible for the highly improved targeting profile. The enhanced
protection against metabolic degradation of [99mTc]Tc-HYNIC-MGS11 led to a further doubling
in tumor uptake. Such an improvement could not be achieved by enzymatic stabilization alone,
as exemplified by the co-injection of protease inhibitors [37]. [99mTc]Tc-Demogastrin-2 coinjected
with 300 μg phosphoramidon showed a similar enzymatic stability in vivo (85% intact radiopeptide
at 5 min p.i.) as compared to [99mTc]Tc-HYNIC-MGS11, but the tumor uptake was clearly
inferior (18.21 ± 5.97% ID/g at 4 h p.i.). When comparing the tumor-to-organ activity ratios of
[99mTc]Tc-HYNIC-MGS5 and [99mTc]Tc-HYNIC-MGS11, somewhat lower tumor-to-blood ratios were
observed for [99mTc]Tc-HYNIC-MGS11. Thus, [99mTc]Tc-HYNIC-MGS11 also showed increased
non-specific uptake in most organs at both investigated time points. Due to the concomitant increase
of the uptake in A431-CCK2R xenografts and kidneys observed for [99mTc]Tc-HYNIC-MGS11, a similar
tumor-to-kidney ratio was found for both radiopeptides (2.4–3.3 for [99mTc]Tc-HYNIC-MGS5 and
2.0–2.6 for [99mTc]Tc-HYNIC-MGS11). The respective tumor-to-organ activity ratios calculated for
blood, kidney, intestine, pancreas and stomach for both radioligands at different time points are
displayed in Table 1.
Table 1. Tumor-to-organ activity ratios for A431-CCK2R tumor-xenografts of [99mTc]Tc-HYNIC-MGS5
and [99mTc]Tc-HYNIC-MGS11 (mean ± SD, n = 4).
[99mTc]Tc-HYNIC-MGS5 [99mTc]Tc-HYNIC-MGS11
1 h p.i. 4 h p.i. 1 h p.i. 4 h p.i.
Tumor/blood 21.6 ± 5.1 273 ± 151 15.6 ± 4.5 177 ± 55
Tumor/kidney 2.4 ± 0.3 3.3 ± 1.1 2.0 ± 0.6 2.6 ± 0.8
Tumor/stomach 1.5 ± 0.2 2.0 ± 0.4 6.5 ± 1.9 10.7 ± 1.4
Tumor/pancreas 2.4 ± 0.3 4.2 ± 2.0 20.6 ± 11.7 34.8 ± 9.7
Tumor/intestine 14.2 ± 1.7 19.2 ± 7.5 32.3 ± 5.0 61.1 ± 14.3
To our knowledge this is the first report on 99mTc-labeled CCK2R targeting peptide analogs
showing such an astonishingly improved tumor uptake along with clearly reduced kidney uptake.
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[99mTc]Tc-HYNIC-MGS5 showed a very similar targeting profile when compared to DOTA-MGS5
radiolabeled with different radiometals suitable for SPECT, PET and TRT [15]. The tumor uptake of
[99mTc]Tc-HYNIC-MGS11 was further improved, however, connected with a concomitant increase in
kidney uptake. Recently, two 99mTc-labeled non-peptidic radioligands have been described showing
high tumor uptake in a mouse tumor model based on human epithelial cells transfected with CCK2R,
however, tumor-to-kidney ratio was clearly inferior [38,39].
These developments give high promise that in the near future a kit for 99mTc-labeling will
be available allowing the localization and staging of CCK2R expressing tumors. Gastrin receptor
scintigraphy might show a lower sensitivity when compared to PET imaging with a 68Ga-labeled
CCK2R targeting MG analog, but additionally allows for radioguided surgery. The concept of surgical
guidance with conventional gamma probes for intraoperative identification and removal of metastatic
lesions has already been successfully introduced into clinical practice by the use of 99mTc-labeled
somatostatin analogs in patients with neuroendocrine tumors [40] as well as 99mTc-labeled ligands
targeting prostate specific membrane antigen in patients with prostate cancer [41]. Due to its high tumor
uptake and tumor retention combined with high clearance from other tissues [99mTc]Tc-HYNIC-MGS11
might be favorable for imaging and radioguided surgery. [99mTc]Tc-HYNIC-MGS5 well compares
with DOTA-MGS5 and shows the advantage of using the same peptide for different applications,
[68Ga]Ga-DOTA-MGS5 for PET, [99mTc]Tc-HYNIC-MGS5 for SPECT and radioguided surgery, as well
as [177Lu]Lu-DOTA-MGS5 for TRT.
3. Materials and Methods
3.1. Materials
All commercially obtained chemicals were of analytical grade and used without further
purification. Na[99mTc]TcO4 was obtained from a commercial 99Mo/99mTc-generator (Ultratechnekow,
Mallinckrodt, Petten, The Netherlands) eluted with physiological saline. The A431 human epidermoid
carcinoma cell line stably transfected with the plasmid pCR3.1 containing the full coding sequence
for the human CCK2R (A431-CCK2R) as well as the same cell line transfected with the empty vector
alone (A431-mock) were kindly provided by Dr. Luigi Aloj [42]. Both cell lines were cultured in
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum and
5 mL of a 100× penicillin-streptomycin-glutamine mixture at 37 ◦C in a humidified 95% air/5% CO2
atmosphere. Media and supplements were purchased from Invitrogen Corporation (Lofer, Austria).
3.2. Peptide Synthesis
HYNIC-dGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-NH2 (HYNIC-MGS5) and HYNIC-dGlu-
Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-(N-Me)1-Nal-NH2 (HYNIC-MGS11) were synthesized using
9-fluorenylmethoxycarbonyl (Fmoc) chemistry. The peptides were assembled on 60 mg Rink Amide
MBHA resin with capacity 0.5 mmol/g resin (Novabiochem, Hohenbrunn, Germany). The reactive side
chains of the amino acids were masked with the following protection groups: tert-butyl ester for Asp
and dGlu, tert-butyl ether for Tyr, and tertbutyloxycarbonyl (BOC) for Trp. All coupling reactions were
performed using a 5-fold excess of Fmoc-protected amino acids, 1-hydroxy-7-aza-benzotriazole (HOAt)
and O-(7-Azabenzotriazole-1-yl)-N, N,N’N’-tetramethyluronium hexa-fluorophosphate (HATU) in
N-Methyl-2-pyrrolidone (NMP) pH adjusted to 8-9 with N,N’-diisopropylethylamine. Coupling of
the Fmoc-protected amino acids following (N-Me)Nle or (N-Me)1-Nal was repeated twice. For the
coupling of HYNIC a 3-fold molar excess of BOC-HYNIC, HOAt and HATU was used. The introduction
of an additional methyl group into the peptide bound between Asp and 1-Nal in HYNIC-MGS11
was performed by direct N-methylation of 1-Nal during the peptide synthesis on the solid resin as
described by Chatterjee et al. [43]. Cleavage of the peptides from the resin with concomitant removal
of acid-labile protecting groups was achieved by treatment with a mixture of trifluoroacetic acid (TFA),
triisopropylsilane, and water in a ratio 95/2.5/2.5 v/v/v. The crude peptides were precipitated and
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washed with ether before HPLC purification and characterized by analytical HPLC and MALDI-TOF
MS. The lyophilized peptide derivatives were stored at −20 ◦C.
3.3. Analytical Systems and Methods
For preparative HPLC purification a Gilson 322 chromatography system (Gilson International,
Limburg, Germany) with Gilson UV/VIS-155 multi-wavelength detector, equipped with an Eurosil
Bioselect Vertex Plus C18A precolumn (300 Å, 5 μm, 30 × 8 mm) and a Eurosil Bioselect Vertex Plus
C18A column (300 Å 5 μm 300 × 8 mm) (Knauer, Berlin, Germany) was used with a gradient system
starting from 80% solvent A (water containing 0.1% TFA) and increasing concentrations of solvent B
(acetonitrile (ACN) containing 0.1% TFA) with a flow rate 2 mL/min: 0–4 min 20% B, 4–24 min 20–60%
B, 24–26 min 60% B, 26–27 min 60–80% B, 27–28 min 80% B, 28–29 min 80–20% B, 29–37 min 20% B.
Analytical HPLC was performed using an UltiMate 3000 chromatography system (Dionex, Germering,
Germany) consisting of a HPLC pump, a variable UV-detector (UV-VIS at λ = 280 nm), an autosampler,
a radiodetector (GabiStar, Raytest, Straubenhardt, Germany), equipped with a Phenomenex Jupiter
4 μm Proteo C12 90 Å 250 × 4.6 mm column (Phenomenex Ltd., Aschaffenburg, Germany) using a flow
rate of 1 mL/min together with the following gradient system: 0–3 min 10% B, 3–18 min 10–55% B,
18–20 min 80% B, 20–21 min 80–10% B, 21–25 min 10% B.
For Matrix Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF
MS) a Bruker microflex benchtop MALDI-TOF MS (Bruker Daltonics, Bremen, Germany) was used
in reflector acquisition mode with a positive ion source and 200 shots per spot. MALDI samples
were prepared on a α-cyano-4-hydroxycinnamic acid (HCCA) matrix using dried droplet procedure.
Flex Analysis 2.4 software was used to analyze the recorded data.
3.4. 99mTc-Radiolabeling Using the Tricine/EDDA Exchange Method
99mTc-labeling was performed using a previously described exchange labeling approach with
tricine and EDDA [27]. For this purpose 10–20 μg of the corresponding HYNIC-conjugated peptide
analog (dissolved in EtOH/H2O 30/70 v/v at a concentration of 0.5 μg/μL) together with 250 μL of
EDDA solution (20 mg/mL in 0.1 M NaOH), 250 μL tricine solution (40 mg/mL in 0.2 M PBS pH 6),
500 μL of Na[99mTc]TcO4 (≤750 MBq) and 20 μl of tin(II) chloride solution (20 mg of SnCl2 * 2 H2O
in 10 mL 0.1 N HCl), were incubated in a sealed glass vial at 100 ◦C for 15–20 min. Radiochemical
purity of [99mTc]Tc-HYNIC-MGS5 and [99mTc]Tc-HYNIC-MGS11 was determined by analytical HPLC.
For in vivo assays the radiolabeled peptides were purified by SPE. For this purpose, the labeling
mixture was passed through a C18-SepPak-Light cartridge (Waters, Milford, MA, USA), followed
by 5 mL saline, and the radiolabeled peptide was eluted with EtOH/H2O 65/35 v/v and diluted
with PBS.
3.5. Evaluation of the in Vitro Properties
The resistance against degradation of [99mTc]Tc-HYNIC-MGS5 and [99mTc]Tc-HYNIC-MGS11
(1000 pmol/mL, n = 2) in human serum was studied for up to 24 h. Furthermore, the radiopeptides
were incubated in PBS (1000 pmol/mL, n = 1). At each time point of 1, 2, 4 and 24 h after incubation
the intact radiopeptide was assessed by analytical HPLC. Serum samples were precipitated with
ACN and centrifuged to collect the supernatant and diluted with water prior to radio-HPLC. For the
determination of the distribution coefficient (log D), 500 μL of the radiopeptide solutions (50 pmol/mL
in PBS) were added to 500 μL octanol (1:1) vigorously vortexed (n = 8) for 15 min and centrifuged
to separate the two phases. From each phase a 75 μL sample was taken, the radioactivity measured
in a 2480 Wizard2 automatic gamma-counter (PerkinElmer Life Sciences and Analytical Sciences,
Wallac Oy, Turku, Finland) and the distribution of the radiopeptides calculated. The protein binding in
human serum (500 pmol/mL, n = 2) was assessed by Sephadex G-50 size-exclusion chromatography
(GE Healthcare Illustra, Little Chalfont, UK) for up to 24 h.
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3.6. Receptor Binding and Cell Internalization Studies
The receptor affinity of the radioligands prepared using the above described labeling protocol
was evaluated in saturation studies on A431-CCK2R cells. For the assay, 96-well filter plates
(MultiScreenHTS-FB, Merck Group, Darmstadt, Germany) were pretreated with 10 mM TRIS/139 mM
NaCl buffer, pH 7.4 (TRIS-buffer) (2 × 250 μL) and 400,000 A431-CCK2R cells per well were added in
35 mM HEPES buffer, pH 7.4, containing 10 mM MgCl2, 14 μM bacitracin, and 0.5% bovine serum
albumin (BSA), a hypotonic solution disturbing the integrity of the cell membranes. Thereafter,
increasing concentrations of the radiolabeled peptide conjugates (0.1–112 nM) were added in triplicate
reaching a total volume of 200 μL. In parallel, non-specific binding was determined by co-incubation
with 1 μM pentagastrin. After 1 h incubation at room temperature, the medium was removed by
filtration followed by two rapid rinses with ice-cold TRIS buffer (200 μL). The filters were collected
and counted in a gamma-counter. The Kd value was calculated fitting the data with Origin software
(Origin 6.1, OriginLab Corporation, Northampton, MA, USA) to a one-site binding model using the
formula y = Bmax × x/(Kd + x).
For internalization experiments, A431-CCK2R and A431-mock cells were seeded at a density of
1.0 × 106 cells per well in 6-well plates and grown to confluence for 48 h. At the day of the experiment,
cells were washed twice with ice-cold internalization medium supplemented with 1% (v/v) fetal
bovine serum and supplied with fresh medium before incubation with [99mTc]Tc-HYNIC-MGS5 and
[99mTc]Tc-HYNIC-MGS11 at a final peptide concentration of 0.4 nM in a total volume of 1.5 mL in
triplicates. At different time points for up to 2 h incubation the cell uptake was interrupted by removal
of the medium and rapid rinsing with ice-cold internalization medium (two times). Thereafter, the cells
were incubated twice at ambient temperature in acid wash buffer (50 mM glycine buffer pH 2.8,
0.1 M NaCl) for 5 min, to remove the membrane-bound radioligand. Finally, the cells were lyzed
by treatment in 1 M NaOH and collected (internalized radioligand fraction). All collected fractions
(supernatant, surface wash, lyzed cells) were measured together with a standard in the gamma counter.
The radioactivity of the lyzed cells was expressed as percentage of the total radioactivity added (% of
internalized radioactivity). Non-specific binding was evaluated in A431-mock cells and in additional
blocking studies with 1 μM pentagastrin.
3.7. Evaluation of the in Vivo Stability and Biodistribution
All animal experiments were conducted in compliance with the Austrian animal protection laws
and with the approval of the Austrian Ministry of Science (BMWFW-66.011/0075-WF/V/3b/2016).
3.7.1. Metabolic Stability in BALB/c Mice
Metabolic stability studies in vivo with [99mTc]Tc-HYNIC-MGS5 and [99mTc]Tc-HYNIC-MGS11
were performed in 5–6 week-old female BALB/c mice (Charles River, Sulzfeld, Germany; n = 2).
Mice were injected intravenously via a lateral tail vain with 37–74 MBq of the 99mTc-labeled
HYNIC-analogs (corresponding to 2 nmol total peptide). Ten minutes post injection (p.i.) mice
were euthanized and a sample of blood and urine was collected together with the liver and kidneys.
Liver and kidneys were rapidly homogenized in 0.5 mL of a 20 mM HEPES buffer pH 7.3 with
an Ultra-Turrax T8 homogenator (IKA-Werke, Staufen, Germany) for 1 min at RT. Before determining
the percentage of intact radiopeptide by analytical radio-HPLC samples were precipitated with ACN,
centrifuged and diluted with H2O (1:1).
3.7.2. Biodistribution in Tumor-xenografted BALB/c Nude Mice
Biodistribution studies evaluating the tumor uptake of [99mTc]Tc-HYNIC-MGS5 and
[99mTc]Tc-HYNIC-MGS11 were performed in 7 week-old female athymic BALB/c nude mice
(Charles River, Sulzfeld, Germany). To induce tumor-xenografts, mice were injected subcutaneously
with 2 × 106 A431-CCK2R (right flank) and A431-mock cells (left flank). The tumor-xenografts were
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allowed to grow for 11–12 days reaching medium tumor weights of ~0.2 g. Mice were randomly
divided into groups of four and injected intravenously via a lateral tail vein with 0.3 MBq of the
99mTc-labeled HYNIC-analogs (corresponding to ~15 pmol total peptide). The groups of animals
were sacrificed at 1 h and 4 h p.i., tumors and other tissues (blood, lung, heart, muscle, bone, spleen,
intestine, liver, kidney, stomach and pancreas) were removed, weighed, and the radioactivity measured
together with a standard in the gamma counter. Results were expressed as percentage of injected
activity per gram tissue (% IA/g) and tumor-to-organ activity ratios were calculated for selected
tissues. Statistical analysis was performed using independent two population t-test (significance level
p = 0.05) with Origin software. The radioactivity in selected organs (stomach, pancreas, liver, kidneys,
A431-CCK2R and A431-mock xenograft) was additionally visualized by autoradiography using
a phosphorimager (Cyclone Plus, PerkinElmer Life Sciences and Analytical Sciences, Downers Grove,
Il, USA). After dissection, the organs were exposed to a multisensitive storage phosphor screen for
40 min and image analysis was performed using OptiQuantTM software (OptiQuant 5.0, PerkinElmer
Life Sciences and Analytical Sciences, Downers Grove, Il, USA).
Supplementary Materials: The following are available online at http://www.mdpi.com/1424-8247/12/1/13/
s1, Table S1: Biodistribution of [99mTc]Tc-HYNIC-MGS5 and [99mTc]Tc-HYNIC-MGS11 in BALB/c nude mice
tumor-xenografted with A431-CCK2R and A431-mock tumors (mean ± SD, n = 4).
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Abstract: The inverse electron-demand Diels-Alder reaction between 1,2,4,5-tetrazine (Tz) and
trans-cyclooct-2-ene (TCO) has gained increasing attraction among extensive studies on click
chemistry due to its exceptionally fast reaction kinetics and high selectivity for in vivo pretargeting
applications including PET imaging. The facile two-step approach utilizing TCO-modified antibodies
as targeting structures has not made it into clinics yet. An increase in the blood volume of humans
in comparison to mice seems to be the major limitation. This study aims to show if the design of
multimeric Tz-ligands by chelator scaffolding can improve the binding capacity and may lead to
enhanced PET imaging with gallium-68. We utilized for this purpose the macrocyclic siderophore
Fusarinine C (FSC) which allows conjugation of up to three Tz-residues due to three primary
amines available for site specific modification. The resulting mono- di- and trimeric conjugates
were radiolabelled with gallium-68 and characterized in vitro (logD, protein binding, stability,
binding towards TCO modified rituximab (RTX)) and in vivo (biodistribution- and imaging studies in
normal BALB/c mice using a simplified RTX-TCO tumour surrogate). The 68Ga-labelled FSC-based
Tz-ligands showed suitable hydrophilicity, high stability and high targeting specificity. The binding
capacity to RTX-TCO was increased according to the grade of multimerization. Corresponding
in vivo studies showed a multimerization typical profile but generally suitable pharmacokinetics
with low accumulation in non-targeted tissue. Imaging studies in RTX-TCO tumour surrogate bearing
BALB/c mice confirmed this trend and revealed improved targeting by multimerization as increased
accumulation in RTX-TCO positive tissue was observed.
Keywords: pretargeting; Fusarinine C; rituximab; click chemistry; multimerization; PET; gallium-68
1. Introduction
Immunoglobulins, in particular monoclonal antibodies (mAbs) are highly attractive targeting
structures due to their extraordinary specificity and selectivity and are well established for therapeutic
applications, particularly in the field of oncology [1,2]. Because of their favorable targeting abilities and
therefore an ever increasing clinical importance, mAbs have regained interest also as imaging agents,
Pharmaceuticals 2018, 11, 102; doi:10.3390/ph11040102 www.mdpi.com/journal/pharmaceuticals48
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in particular for positron emission tomography (PET) applications [3–5]. In principle mAbs can be
directly radiolabelled either by direct incorporation of radiohalogens or by attaching a chelator to the
protein in case of radiometals. Prolonged circulation time and slow distribution within the organism,
however, restricts its use to long-lived radionuclides e.g., zirconium-89 (3.26 d) and iodine-124 (4.18 d).
This multiday circulation paired with slow radioactive decay provides unfavorable radiation to healthy
tissue and adds significantly to the overall radiation burden of patients.
In order to overcome this problem, various pretargeting methodologies have been reported
and reviewed recently [6–8], enabling a straight forward two-step approach. Thereby the modified
antibody is administered, allowed to accumulate at the target site and be eliminated from the
bloodstream followed by injection of the radioactive payload to form the radioimmunoconjugate
in vivo. This provides certain advantages as it facilitates the use of short-lived radioisotopes for PET
applications e.g., gallium-68 (1.13 h), fluorine-18 (1.83 h) and copper-64 (12.7 h) and significantly
reduces the radiation dose to healthy tissue, since the radioligand either finds its binding partner to
form stable conjugates or is rapidly eliminated due to its small size. Furthermore, it allows to apply
radiolabelling at high temperatures using high concentrations of organic solvents if necessary—harsh
conditions, where the structural integrity of antibodies would be severely in danger when direct
labelling was performed.
Among these pretargeting strategies the inverse electron-demand Diels-Alder reaction (IEDDA)
between 1,2,4,5-tetrazines (Tz) and trans-cyclooct-2-enes (TCO) has gained enormous attention
mainly due to the exceptionally fast reaction kinetics and high selectivity between the reaction
partners even in complex biological systems as encountered in vivo [9,10]. Various preclinical studies
demonstrated the feasibility of this approach for molecular imaging using PET-radioisotopes with
promising results [11–14]. The application on humans, however, remains unsuccessful due to the
increased blood volume in humans and may therefore lead to insufficient accumulation due to
accelerated elimination of the small-sized radioligand.
Related to this, recent study investigated whether an increase of Tz motifs by chelator scaffolding,
i.e., multimerization, can improve the binding efficiency and thereby improve imaging contrast.
This could contribute in particular to the application of gallium-68 for pretargeted immuno-PET
imaging. For this purpose we utilized the macrocyclic chelator Fusarinine C for the design
of mono- and multimeric Tz-conjugates as presented in Scheme 1 for a proof-of-concept study,
on potentially improved pretargeting for imaging with gallium-68 by applying multimerization.
We chose non-internalizing anti-CD20 antibody rituximab (RTX) modified with TCO as targeting
vector. Radiolabelling was conducted at room temperature within minutes and the 68Ga-labelled
conjugates showed reasonable hydrophilicity and excellent stability in human serum. Protein
binding, however, remained comparable within the conjugates but was generally high. The
68Ga-labelled multimeric conjugates showed a higher binding capacity towards TCO-motif bearing
RTX. Furthermore, cell-binding studies revealed highly specific targeting properties and the binding
of [68Ga]Ga-FSC-Tz multimers to CD20-expressing Raji cells increased with the number of Tz-motifs
attached to the chelator. Imaging studies in a simplified pretargeting mouse model proved the trend
for improved targeting. We therefore conclude, that multimerization bears a great potential to improve
IEDDA related pretargeting when short-lived PET-radioisotopes, particularly gallium-68, are used.
Further investigations in established tumor models are warranted to confirm these promising findings.
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Scheme 1. Synthetic strategy for FSC-based tetrazine (Tz) conjugates [a: methanol and acetic anhydride
(MetOH/Ac2O); b: Tz-PEG5-NHS/DMF/DIPEA; c: EDTA] radiolabelled with gallium-68.
2. Results
2.1. (Radio) Chemistry
FSC-based mono- and multimeric Tz-conjugates were accessible in a three-step synthesis to give
the corresponding conjugates in good yields and high chemical purity (>95%; analytical RP-HPLC,
UV absorption at λ = 220 nm). The results from mass analysis were in good agreement with the
calculated values. The structure of the Tz-conjugates was further confirmed by 1H-NMR spectroscopy.
The singlets at 6.30 and 1.86 ppm which can be assigned to the -C=O-CH=C(CH3)C-substructure
were used as the marker signals of the FSC subunit. The singlet at 1.83 ppm corresponds to the
methyl protons of the acetyl group(s). The singlet at 10.56 ppm is highly characteristic for the tetrazine
moiety. The doublets at 8.44 and 7.53 ppm with coupling constants of 8.4 Hz are characteristic for the
para-substituted phenyl ring, and the triplet at 8.50 ppm as well as the doublet at 4.40 ppm with a
coupling constant of 6.0 Hz can be assigned to the -NH-CH2 group of the PEG5-Tz subunit(s). The ratio
of the integrals of these marker signals is summarized in Table 1 and corresponding 1H-NMR spectra
are presented in Figures S1–S3. Radiolabelling with gallium-68 was quantitative within minutes at RT,
thus exhibiting fast labelling kinetics. Corresponding (radio-)RP-HPLC chromatograms are presented
in Figure S4.
Table 1. 1H-NMR data (chemical shifts and integrals) of characteristic signals of FSC-based
Tz-conjugates and N,N′,N′ ′-triacetylfusarinine (TAFC) as a reference.
FSC Subunit Acetyl PEG5-Tz Subunit
3× CH 3× CH3 CH3 Tetrazine p-Phenylen NH-CH2 NH-CH2
6.3 ppm 1.86 ppm 1.83 ppm 10.56 ppm 8.44 ppm 7.53 ppm 8.50 ppm 4.40 ppm
Tz-monomer 3 H 9 H 6 H 1 H 2 H 2 H 1 H 2 H
Tz-dimer 3 H 9 H 3 H 2 H 4 H 4 H 2 H 4 H
Tz-trimer 3 H 9 H none 3 H 6 H 6 H 3 H 6 H
TAFC 3 H 9 H 9 H none none none none none
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2.2. In Vitro Evaluation
Stability studies of 68Ga-labelled conjugates in fresh human serum and PBS as control revealed
high stability as no major degradation was observed over a period of 4 h. Corresponding radio-RP-
HPLC chromatograms are presented in Figure S5. The results of logD studies and the ability to bind
to serum proteins of 68Ga-labelled conjugates are summarized in Table 2. They revealed suitable
hydrophilicity with minor decrease when increasing the number of Tz residues. All conjugates showed
very high protein binding with minor differences between mono- and multimeric [68Ga]Ga-Tz-ligands.






1 h 2 h 4 h
Tz-monomer −1.64 ± 0.02 61.8 ± 0.2 63.8 ± 2.1 64.0 ± 1.4
Tz-dimer −1.35 ± 0.01 67.0 ± 2.4 65.9 ± 1.3 68.4 ± 0.3
Tz-trimer −1.00 ± 0.06 70.5 ± 0.7 69.5 ± 0.4 67.8 ± 0.4
Data are presented as mean ± SD (n = 3)
The non-internalizing anti-CD20 monoclonal antibody rituximab was modified with the TCO
motif similar to a previously published procedure [15] and corresponding FACS analysis of
CD20-expressing Raji cells incubated with both, TCO-modified and non-modified RTX showed high
target specificity (Figure S6), thus demonstrating that the binding ability was not altered by the
TCO modification.
The binding capacity of 68Ga-labelled mono- and multimeric Tz-ligands was assessed via
competitive binding on immobilized RTX-TCO using the non-labelled conjugates as competitor
and is presented in Figure 1. The binding of the [68Ga]Ga-Tz-monomer was reduced by 50% at a
competitor concentration of 486 ± 52 nM when challenged with the non-labelled monomer, whereas
the non-labelled dimer (112 ± 6 nM) and trimer (100 ± 10 nM) reduced the binding at significantly
lower concentrations. The binding of the [68Ga]Ga-Tz-dimer was reduced by half at 95 ± 25 nM in
competition with its non-labelled counterpart and at a comparable concentration with the non-labelled
trimer (92 ± 15 nM), whereas a decrease to 50% was only achieved at a much higher concentration in
competition with non-labelled monomer (865 ± 263 nM). Binding studies of the [68Ga]Ga-Tz-trimer
showed a comparable trend as the non-labelled trimer reduced the binding by 50% at 147 ± 49 nM and
the dimer at 258 ± 60 nM; whereby a significantly higher amount of the monomer (2987 ± 1664 nM)
was needed for a 50% binding reduction. Overall in all assays improved binding of di- and trimer over
monomer was observed.
The results of cell-binding studies on CD20-expressing Raji cells pre-treated with RTX or
RTX-TCO prior to incubation with 68Ga-labelled Tz-ligands are presented in Figure 2. All
68Ga-labelled conjugates showed highly specific targeting properties as the amount of unspecific
bound radioligand to RTX pre-treated Raji cells was negligible low (<1%). The binding of 68Ga-labelled
Tz-ligands on RTX-TCO bound Raji cells increased with the grade of multimerization and was
4.01 ± 0.24% for [68Ga]Ga-Tz-monomer, 7.35 ± 0.77% for [68Ga]Ga-Tz-dimer and 15.93 ± 0.88 for
[68Ga]Ga-Tz-trimer, respectively.
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Figure 1. Competitive binding studies of [68Ga]Ga-Tz-monomer (A), [68Ga]Ga-Tz-dimer (B) and
[68Ga]Ga-Tz-trimer (C) on immobilized RTX-TCO using the non-labelled counterparts as competitor.
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Figure 2. Cell-binding studies of 68Ga-labelled FSC-based Tz-ligands on CD20-expressing Raji
cells pre-treated with anti-CD20 antibody RTX (negative control, black bars) and its TCO modified
counterpart (white bars).
2.3. In Vivo Evaluation
Biodistribution studies in non-tumour xenografted BALB/c mice 1 h after administration of
the 68Ga-labelled Tz-ligands are shown in Figure 3. In general, accumulation in non-targeted tissue
was significantly lower for the [68Ga]Ga-Tz-monomer compared to the [68Ga]Ga-Tz-trimer, whereby
the difference between the multimers was less pronounced. In particular, the multimeric Tz-ligands
showed slower blood clearance and higher accumulation in renal tissue compared to the monomeric
conjugate. The conjugates generally showed low accumulation in non-targeted tissue and low retention
in critical organs (e.g., muscle, bone).
Figure 3. Biodistribution studies of 68Ga-labelled mono- and multimeric FSC-based pretargeting agents
in normal BALB/c mice 1 h p.i. presented as percentage of total injected activity per gram tissue (n = 3).
Imaging studies using BALB/c mice i.m. injected with RTX and RTX-TCO as tumour surrogate
5 h prior to r.o. administration of the radioligand and imaging performed 90 min p.i. are presented
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in Figure 4. The results mainly confirmed the suitable in vivo distribution profile of FSC-based
Tz-ligands radiolabelled with gallium-68 with main activity in kidneys and bladder and some blood
pool activity for the 68Ga-labelled multimers. Moreover, the accumulation in RTX-TCO positive muscle
tissue increased with ascending numbers of Tz motifs and was ~1% for the [68Ga]Ga-Tz-monomer,
~2% for the [68Ga]Ga-Tz-dimer and ~3% for the [68Ga]Ga-Tz-trimer. Surprisingly, the accumulation
in TCO negative tissue was also approximately 1% showing negligible differences between the
different radioligands.
 
Figure 4. Static μPET/CT image of i.m. RTX(-TCO) pre-treated normal BALB/c mice 5 h after treatment
and 90 min p.i. of the 68Ga-labelled Tz-monomer (a), Tz-dimer (b) and Tz-trimer (c). (1 = coronal slice;
2 = 3D volume rendered projections; both prone position).
3. Discussion
IEDDA-based pretargeting has become increasingly popular for molecular imaging as well
as radioimmunotherapy over the past few years [16–21]. Despite recent advancements towards
structural improvement of cyclen- and TACN-based Tz-probes [22,23] or the synthesis of TCO-bearing
dendrimers [24], the design of targeting probes bearing multiple Tz-motifs for potentially improved
pretargeting has scarcely been investigated. Devaraj and co-workers reported on polymer modified
tetrazines (PMT) radiolabelled with fluorine-18 [25] and gallium-68 [26] for PET applications while
Zlatni et al. recently demonstrated the targeting applicability for microbubbles bearing multiple
Tz-motifs towards prostate specific membrane antigen for ultrasound related diagnostic purposes [15].
However, investigations on the use of small-sized multimeric Tz-ligands have not been reported yet.
FSC is a suitable chelating scaffold for PET radiometals, particularly gallium-68 and
zirconium-89 [27,28]. Its unique structural properties enable straight forward mono- and multimeric
tracer design [29–32]. This novel chelator, therefore, represented a very suitable scaffold for the
synthesis of mono- and multimeric small-sized Tz-bearing probes for radiolabelling with gallium-68 to
evaluate potential benefits for IEDDA-based pretargeting by increasing the number of Tz-residues.
The resulting conjugates showed reasonable hydrophilicity and increasing the number of Tz-residues
from one to three did not alter the water solubility too much, although being somewhat lower in
comparison to linker modified monomeric conjugates [23]. Unexpectedly, all FSC-based Tz-conjugates
showed high protein binding with negligible differences between the compounds. This can be related
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to the introduction of the pegylated Tz residue, since non-modified 68Ga-labelled FSC-based precursors
showed a protein binding of <3% (Kaepookum et al. unpublished results). This phenomenon has not
been reported in the case of monomeric DOTA- and TACN-based derivatives [22,23] and might
be disadvantageous by slowing down the distribution of the tracer to the TCO-interaction site.
In vivo results, however, did not really reveal a major problem with too slow pharmacokinetics,
since the washout from non-targeted tissue was still sufficiently rapid. Competitive binding
assessments showed significantly reduced binding of [68Ga]Ga-Tz-monomer by a factor of five
when challenged with the multimeric conjugates in comparison with the non-labelled monomer.
This corresponded with the significantly higher amounts of Tz-monomer needed, 8 to 20 fold
respectively, to reduce the binding of the 68Ga-labelled multimers by 50%, thus indicating that
the binding capacity increased with the number of Tz residues. This was substantiated by the
results of the cell binding studies, since the binding to CD20-expressing Raji cells increased by a
factor of 1.8 for the [68Ga]Ga-Tz-dimer and 3.9 for the [68Ga]Ga-Tz-trimer in comparison to the
[68Ga]Ga-Tz-monomer. Biodistribution studies in non-tumour xenografted healthy BALB/c mice
indicated suitable pharmacokinetics and showed a multimerization typical profile exhibiting slower
blood clearance and increased kidney retention, similar to prior findings with the FSC-scaffold [31,32].
Imaging studies using a tumour surrogate model confirmed this trend and demonstrated increased
binding of the 68Ga-labelled multimeric Tz-conjugates. The accumulation in RTX-TCO pretreated
muscle tissue doubled for the [68Ga]Ga-Tz-dimer and was 3-fold higher for the [68Ga]Ga-Tz-trimer
compared to the [68Ga]Ga-Tz-monomer.
In regard to imaging in living mice there was a clear improvement of target specific accumulation
when switching from mono- to multimers. The use of our simplified tumour surrogate animal model,
however, requires further investigations in established animal models to address the limitations of
this study:
(1) The accumulation in non-targeted tissue, i.e., i.m. injection of RTX resulted to be ~1%.
This effect was even more pronounced when choosing a shorter time interval of 2 h between i.m.
administration of the mAb and radioligand injection (data not shown) and was only seen at the
injection site but generally not in other tissue. We speculate that this is related to the injection of the
antibody leading to tissue damage with increased tissue permeability and unspecific accumulation of
the radioligand.
(2) Intravenously injected mAb stimulates accumulation at the target interaction site, but a
non-negligible amount remains in circulation, thereby increasing the background signal when
administering the radioligand. In order to reduce this amount, high molecular weight TCO-scavenger
molecules exhibiting low vascular permeability (clearing agents) have been established with great
success, significantly improving target-to-background (TTB) ratios [33,34]. The need for clearing agents
was completely neglected in this study and we are fully aware that our animal model does not reflect
the real situation regarding TTB ratios.
In summary, we have been able to show that FSC is a suitable scaffold for the design of multimeric
Tz-conjugates for radiolabelling with gallium-68. Although multimeric Tz-ligands exhibited significant
improvements towards IEDDA-based pretargeting additional studies in tumour models are warranted
to explore the full potential of this promising concept. Furthermore, a highly interesting therapeutic
approach is the release of drugs directly at the interaction site from antibody-drug conjugates (ADCs)
mediated via IEDDA reaction between Tz and TCO [35–37]. It might be of interest for future
perspectives if multimeric Tz-conjugates can boost the release of drugs improving this highly promising
“click-to-release” strategy.
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4. Materials and Methods
4.1. Instrumentation
4.1.1. Analytical [radio]-RP-HPLC
Reversed-phase high-performance liquid chromatography analysis was performed with the
following instrumentation: UltiMate 3000 RS UHPLC pump, UltiMate 3000 autosampler, UltiMate
3000 column compartment (25 ◦C oven temperature), UltiMate 3000 Variable Wavelength Detector
(Dionex, Germering, Germany; UV detection at λ = 220 nm) a radio detector (GabiStar, Raytest;
Straubenhardt, Germany), Jupiter 5 μm C18 300 Å 150 × 4.6 mm (Phenomenex Ltd. Aschaffenburg,
Germany) column with acetonitrile (ACN)/H2O/0.1% trifluoroacetic acid (TFA) as mobile phase; flow
rate of 1 mL/min; gradient: 0.0–1.0 min 10% ACN, 1.0–12.0 min 10–60% ACN, 13.0–15.0 min 60–80%
ACN, 15.0–16.0 min 80–10% ACN, 16.0–20.0 min 10% ACN.
4.1.2. Preparative RP-HPLC
Sample purification via RP-HPLC was carried out as follows: Gilson 322 Pump with a Gilson
UV/VIS-155 detector (UV detection at λ = 220 nm) using a PrepFC™ automatic fraction collector
(Gilson, Middleton, WI, USA), Eurosil Bioselect Vertex Plus 30 × 8 mm 5 μm C18A 300 Å pre-column
and Eurosil Bioselect Vertex Plus 300 × 8 mm 5 μm C18A 300 Å column (Knauer, Berlin, Germany)
and following ACN/H2O/0.1% TFA gradients with a flow rate of 2 mL/min: gradient A: 0.0–5.0 min
0% ACN, 5.0–35.0 min 0–50% ACN, 35.0–38.0 min 50% ACN, 38.0–40.0 min 50–0% ACN. Gradient B:
0.0–5.0 min 10% ACN, 5.0–40.0 min 10–60% ACN, 41.0–45.0 min 60% ACN, 46.0–50.0 min. 60–80%
ACN, 51.0–55.0 min 80–10% ACN.
4.1.3. MALDI-TOF MS
Mass spectrometry was conducted on a Bruker microflexTM bench-top MALDI-TOF MS (Bruker
Daltonics, Bremen, Germany) with a 20 Hz laser source. Sample preparation was performed according
to dried-droplet method on a micro scout target (MSP96 target ground steel BC, Bruker Daltonics)
using α-cyano-4-hydroxycinnamic acid (HCCA, Sigma-Aldrich, Handels GmbH, Vienna, Austria) as
matrix. Flex Analysis 2.4 software was used for processing of the recorded data.
4.1.4. 1H-NMR Spectroscopy
1H-NMR spectra of the FSC-based Tz-conjugates were recorded on a “Saturn” 600 MHz Avance
II+ spectrometer and the NMR of the reference compound (TAFC) was recorded on a “Mars” 400 MHz
Avance 4 Neo spectrometer, both from Bruker Corporation (Billerica, MA, USA). The centre of the
solvent multiplet (DMSO-d6) was used as internal standard (chemical shifts in δ ppm), which was
related to TMS with δ 2.49 ppm. TopSpin 3.5 pl7 software (Bruker) was used for data processing.
4.2. Synthesis
4.2.1. General Information
All chemicals and solvents were purchased as reagent grade from commercial sources unless
otherwise stated. trans-Cyclooctene-NHS ester and tetrazine-PEG5-NHS ester were bought from Click
Chemistry Tools (Scottsdale, AZ, USA). Rituximab (MabThera®, Roche Pharma AG, Grenzach-Wyhlen,
Germany) was of pharmaceutical grade and was a kind gift from the University Hospital of Innsbruck.
4.2.2. [Fe]Fusarinine C ([Fe]FSC)
The cyclic siderophore Fusarinine C (FSC) was obtained from iron deficient fungal culture and
the extraction of FSC was conducted with a slightly modified method as described before [38]. Briefly,
1 L of iron saturated culture media was flushed through a C18-Reveleris flash cartridge (40 μm, 12 g;
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Grace, MD, USA) by using a REGLO tubing pump (Type ISM795, Ismatec SA, Glattbrugg-Zurich,
Switzerland) with a flow rate of 10 mL/min. [Fe]FSC fixed on the cartridge was washed with 50 mL
of water and eluted afterwards with 50 mL H2O/ACN (20/80% v/v). After evaporation to dryness
~300 mg [Fe]FSC were obtained as red−brown coloured solid in high purity (>90%). Analytical
data: RP-HPLC tR = 6.95 min; MALDI TOF-MS: m/z [M + H]+ = 779.93 [C33H51FeN6O12; exact mass:
779.63 (calculated)].
4.2.3. Acetylation of [Fe]FSC
[Fe]FSC was dissolved in methanol to a final concentration of 30 mg/mL (38.5 mM). An aliquot
of 300 μL was reacted with 10 μL of acetic anhydride for 5 min at room temperature (RT) under
vigorous shaking followed by subsequent purification of the resulting mixture of mono-, di- and
triacetylfusarinine C via preparative RP-HPLC using gradient A to obtain N-monoacetylfusarinine C
([Fe]MAFC, tR = 20.1 min) and N,N’-diacetylfusarinine C ([Fe]DAFC, tR = 24.5 min). Analytical data:
[Fe]MAFC: RP-HPLC tR = 7.67 min; MALDI TOF-MS: m/z [M + H]+ = 822.04 [C35H53FeN6O13; exact
mass: 821.67 (calculated)]. [Fe]DAFC: RP-HPLC tR = 8.49 min; MALDI TOF-MS: m/z [M + H]+ = 864.02
[C37H55FeN6O14; exact mass: 863.71 (calculated)].
4.2.4. Conjugation of Tetrazine-PEG5 Motif
Iron protected FSC (1.0 mg, 1.28 μmol), MAFC (2.0 mg, 2.43 μmol) or DAFC (2.0 mg,
2.32 μmol) were dissolved in 500 μL anhydrous DMF and after addition of Tetrazine-PEG5-NHS
ester, 1.5 equivalents (2.10 mg, 3.48 μmol) in case of DAFC, 2.5 equivalents (3.67 mg, 6.08 μmol) in case
of MAFC and 3.5 equivalents (2.71 mg, 4.48 μmol) in case of FSC, pH was adjusted to 9.0 using DIPEA
and the reaction mixtures were maintained for 4 h at RT. Finally the organic solvent was evaporated
and the crude mixture was used without further purification.
4.2.5. Demetallation
For the purpose of iron removal, corresponding conjugates were dissolved in 1 mL H2O/ACN
solvent 50% (v/v) and 1 mL of aqueous Na2EDTA solution (200 mM) was added. The resulting
mixtures were stirred for 4 h at ambient temperature followed by preparative RP-HPLC purification to
give slightly to intensively pink coloured, iron free FSC-based Tz-conjugates after lyophilisation.
• DAFC-PEG5-Tz (=Tz-monomer): 2.35 mg [1.81 μmol, 78%], gradient B (tR = 31.1 min); Analytical
data: RP-HPLC tR = 11.5 min; MALDI TOF-MS: m/z [M + H]+ = 1303.95 [C60H89N11O21; exact
mass: 1300.41 (calculated)]
• MAFC-(PEG5-Tz)2 (=Tz-dimer): 3.65 mg [2.09 μmol, 86%], gradient B (tR = 35.3 min); Analytical
data: RP-HPLC tR = 12.5 min; MALDI TOF-MS: m/z [M + H]+ = 1748.25 [C81H118N16O27; exact
mass: 1747.89 (calculated)]
• FSC-(PEG5-Tz)3 (=Tz-trimer): 1.68 mg [0.77 μmol, 60%], gradient B (tR = 37.9 min); Analytical
data: RP-HPLC tR = 13.2 min; MALDI TOF-MS: m/z [M + H]+ = 2200.20 [C102H147N21O33; exact
mass: 2195.38 (calculated)]
4.2.6. Modification of Rituximab (RTX)
Rituximab was obtained in solution (Mabthera®, 10 mg/mL, Roche Pharma AG, Grenzach-Wyhlen,
Germany) and a PD-10 (GE Healthcare, Vienna, Austria) size exclusion column was used for buffer
exchange according to manufacturer’s protocol to give RTX in 0.1 M NaHCO3 solution (7 mg/mL).
For the conjugation of trans-cyclooctene (TCO), 2 mL of the RTX solution were mixed with 20 molar
equivalent of TCO-NHS ester dissolved in DMSO and the reaction was stirred for 30 min at ambient
temperature followed by incubation overnight at 4 ◦C under light exclusion. Subsequently, the
modified antibody (RTX-TCO) was purified using size exclusion chromatography (PD-10) to give
10 mg of RTX-TCO dissolved in PBS. The antibody was treated following the same procedure as
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described above without adding TCO-NHS ester, in order to obtain a non-modified RTX counterpart
as negative control.
4.3. Fluorescence Activated Cell-Sorting (FACS)
The humanoid lymphoblast-like CD20-expressing B-lymphocyte cells (Raji cells) were purchased
from American Type Culture Collection (ATCC, Manassas, VA, USA). Flow cytometric analysis of CD20
expression was evaluated on (Raji cells) adjusted to 5 × 105 cells/sample in DMEM (including 10%
FCS, 1% Pen/Strep). Cells were incubated with FC-Block (containing CD16/CD32 (1:200), e-Bioscience,
Thermo Fisher Scientific, Vienna, Austria) for 15 min at 4 ◦C in order to avoid signals from non-specific
binding. The following antibodies were used: RTX-TCO and RTX, both at 20 μM (f. c.). As secondary
antibody a APC-labelled anti-human IgG Fc (clone: HP6017; BioLedgend, San Diego, CA, USA) at a
dilution of 1:100 was used. Antibodies were incubated for at least 15 min at 4 ◦C. FACS analysis was
performed on BD LSRFortessa™ (Cell Analyzer, BD Bioscience, San Jose, CA, USA). As internal control
samples unstained or stained with either primary or secondary antibodies were analyzed. FACS-data
was analyzed by FlowJo v10 software.
4.4. Radiolabelling of FSC-Based Tz-Conjugates with Gallium-68
Gallium-68 was obtained as [68Ga]GaCl3 (gallium chloride) by fractioned elution of a 68Ge/68Ga-
generator (IGG100, nominal activity 1100 MBq, Eckert & Ziegler, Berlin, Germany) with 0.1 M
hydrochloric acid (HCl, Rotem Industries Ltd., Beer-Sheva, Israel). Hereafter, 500 μL of eluate (100 MBq)
were mixed with 100 μL sodium acetate solution (1.14 M) to give a pH of 4.5 followed by addition
of 10 μg (4.55–7.68 nmol) of corresponding FSC-Tz conjugate. After 5 min incubation at RT the
radiolabelling solution was analyzed using radio-RP-HPLC.
4.5. In Vitro Characterization.
4.5.1. Distribution Coefficient (LogD)
To determine the distribution of the 68Ga-labelled conjugates between an organic (octanol) and
aqueous (PBS) layer, aliquots (50 μL) of the tracers (~5 μM) were diluted in 1 mL of octanol/PBS (1:1,
v/v). The mixture was vortexed at 1400 rpm (MS 3 basic vortexer, IKA, Staufen, Germany) for 15 min
at RT followed by centrifugation for 2 min at 4500 rpm. Subsequently, aliquots (50 μL) of both layers
were collected and measured in the gamma counter (Wizard2 3”, Perkin Elmer, Waltham, MA, USA)
followed by logD calculation (n = 3, six replicates).
4.5.2. Protein Binding
Serum protein binding was determined using Sephadex G-50 (GE Healthcare Vienna, Austria)
size exclusion chromatography [38]. Aliquots (50 μL, n = 3) of the radioligand solution (~10 μM)
were incubated in 450 μL freshly prepared human serum or 450 μL PBS (controls) and were kept at
37 ◦C. After 1, 2, and 4 h aliquots (25 μL) were directly transferred to the column (MicroSpin G-50,
GE Healthcare) and after centrifugation (2 min, 2000 rcf) the column containing the free conjugate and
the eluate containing the protein-bound conjugate were measured in the gamma counter. The percent
of activity in both fractions was calculated thereafter.
4.5.3. Stability Studies in Human Serum
Stability of the radioligands was evaluated in human serum as described in [38]. Briefly, 50 μL
of the radioligand solution (~10 μM, n = 2) were mixed with 950 μL freshly prepared serum or
950 μL PBS (controls). The mixtures were then maintained at 37 ◦C. At designated time points, 1, 2
and 4 h respectively, aliquots (100 μL) were mixed with 0.1% TFA/ACN, centrifuged for 2 min at
14 × 103 rcf. The supernatant was diluted with H2O (1:1, v/v) and analyzed by analytical RP-HPLC
for decomposition without filtration prior to injection.
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4.5.4. Competitive Binding Assay
Binding on immobilized RTX-TCO was conducted using high protein-binding capacity Nunc
MaxiSorp™ 96-well plates (Thermo Fisher Scientific, Vienna, Austria). Coating was performed by
adding 20 μg of antibody (RTX or RTX-TCO) dissolved in 100 μL coating buffer (0.1 M NaHCO3,
pH 8.5) to each well and after 2 h incubation at RT the plate was left at 4 ◦C overnight both under
the exclusion of light. After removal of the coating solution 200 μL of blocking buffer (1% BSA in
PBS) was added, left for 1 h at room temperature and subsequently each well was washed twice
with 200 μL binding buffer (0.1% BSA in PBS). Hereafter, the radioligand was mixed with increasing
concentrations of the competitor (=non-labelled conjugate), diluted in binding buffer and 100 μL of
the mixture was added to each well. After 30 min at RT the supernatant was removed, each well
was washed three times with 150 μL binding buffer and the coating film was finally detached with
2 × 150 μL of hot (80 ◦C) 2 N sodium hydroxide (NaOH). The NaOH fraction was taken for gamma
counter measurement to determine the percentage of binding in contrast to the standard followed by
non-liner curve fitting using Origin 6.1 software (Origin Inc., Northampton, MA, USA) to calculate the
apparent half maximum inhibitory concentration of the competitor (n = 3, 4 replicates).
4.5.5. Cell Binding
Raji-cells were seeded in tissue culture flasks (Cellstar; Greiner Bio-One, Kremsmuenster, Austria)
using RPMI-1640 medium supplemented with fetal bovine serum (FBS) to a final concentration of
10% (v/v). In order to do studies on cell binding 10 × 106 cells were washed twice with fresh media,
diluted with PBS to a final concentration of 1 × 106 cells per mL and 500 μL of cell suspension was
transferred to Eppendorf tubes. Hereafter, 50 μL of RTX-TCO or non-modified RTX as negative control
(both 0.5 μM) were added and the cell suspension was maintained at 37 ◦C under gentle shaking.
After 1 h the suspension was centrifuged (2 min, 11 × 103 rcf), the supernatant was discarded, the cells
were washed twice and finally resuspended with 450 μL PBS. Subsequently, 50 μL of the radioligand
solution (22 nM in PBS) was added and the suspension was incubated for 30 min at 37 ◦C. After
centrifugation and two washing steps with 600 μL PBS, the cells were resuspended in 500 μL PBS and
transferred to polypropylene vials for gamma counter measurement followed by calculation from
cell-associated activity in comparison to the standard (n = 3, six replicates).
4.6. In Vivo Characterization
4.6.1. Ethics Statement
All animal experiments were performed in accordance with regulations and guidelines of the
Austrian animal protection laws and the Czech Animal Protection Act (No. 246/1992), with approval
of the Austrian Ministry of Science (BMWF-66.011/0161-WF/V/3b/2016), the Czech Ministry of
Education, Youth, and Sports (MSMT-18724/2016-2), and the institutional Animal Welfare Committee
of the Faculty of Medicine and Dentistry of Palacky University in Olomouc.
4.6.2. Biodistribution Studies
Biodistribution of 68Ga-labelled conjugates was conducted in healthy 5-week-old female BALB/c
mice (Charles River Laboratories, Sulzfeld, Germany). Animals (n = 3) were injected via lateral tail
vain with 1 nmol of conjugate and a total activity of approximately 6 MBq. Mice were sacrificed by
cervical dislocation 1 h p.i. followed by collection of the main organs and tissue, subsequent gamma
counter measurement and calculation of the percentage of injected activity per gram tissue (% IA/g).
4.6.3. Imaging Studies
MicroPET/CT images were acquired with an Albira PET/SPECT/CT small animal imaging
system (Bruker Biospin Corporation, Woodbridge, CT, USA). Mice were pre-treated by intramuscular
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(i.m.) injection of 50 μL of RTX-TCO to the left hind muscle and 50 μL of RTX to the right hind muscle.
Pre-treated mice were retro-orbitally (r.o.) injected with radiolabelled tracer in a dose of 5–10 MBq
corresponding to 1–2 μg of conjugate per animal 5 h after the pre-treatment. Anaesthetized (2%
isoflurane (FORANE, Abbott Laboratories, Abbott Park, IL, USA)) animals were placed in a prone
position in the Albira system before the start of imaging. Static PET/CT images were acquired over
30 min starting 90 min p.i. A 10-min PET scan (axial FOV 148 mm) was performed, followed by a
double CT scan (axial FOV 65 mm, 45 kVp, 400 μA, at 400 projections). Scans were reconstructed
with the Albira software (Bruker Biospin Corporation) using the maximum likelihood expectation
maximization (MLEM) and filtered backprojection (FBP) algorithms. After reconstruction, acquired
data was viewed and analyzed with PMOD software (PMOD Technologies Ltd., Zurich, Switzerland).
3D volume rendered images were obtained using VolView software (Kitware, Clifton Park, NY, USA).
Supplementary Materials: The following are available online at http://www.mdpi.com/1424-8247/11/4/
102/s1, Figure S1: 1H-NMR spectrum of DAFC-PEG5-Tz (Tz-monomer), Figure S2: 1H-NMR spectrum of
of MAFC-(PEG5-Tz)2 (Tz-dimer), Figure S3: 1H-NMR spectrum of FSC-(PEG5-Tz)3 (Tz-trimer), Figure S4:
Representative RP-HPLC chromatograms of mono- and multimeric FSC-Tz conjugates (A, UV/vis chromatograms)
and their 68Ga-labelled counterparts (B, radio-chromatograms), Figure S5: Representative radio-RP-HPLC
chromatograms of the stability assessment of 68Ga-labelled mono- and multimeric FSC-Tz conjugates incubated
with fresh human serum (A) and PBS (B), Figure S6: Fluorescence-activated cell sorting of unstained Raji cells,
RTX, RTX-TCO, secondary antibody (APC), RTX + APC and RTX-TCO + APC (order from left to right).
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Abstract: Heterobivalent peptidic ligands (HBPLs), designed to address two different receptors
independently, are highly promising tumor imaging agents. For example, breast cancer has been
shown to concomitantly and complementarily overexpress the neuropeptide Y receptor subtype 1
(NPY(Y1)R) as well as the gastrin-releasing peptide receptor (GRPR). Thus, radiolabeled HBPLs being
able to bind these two receptors should exhibit an improved tumor targeting efficiency compared to
monospecific ligands. We developed here such bispecific HBPLs and radiolabeled them with 68Ga,
achieving high radiochemical yields, purities, and molar activities. We evaluated the HBPLs and their
monospecific reference peptides in vitro regarding stability and uptake into different breast cancer
cell lines and found that the 68Ga-HBPLs were efficiently taken up via the GRPR. We also performed
in vivo PET/CT imaging and ex vivo biodistribution studies in T-47D tumor-bearing mice for the
most promising 68Ga-HBPL and compared the results to those obtained for its scrambled analogs.
The tumors could easily be visualized by the newly developed 68Ga-HBPL and considerably higher
tumor uptakes and tumor-to-background ratios were obtained compared to the scrambled analogs
in and ex vivo. These results demonstrate the general feasibility of the approach to use bispecific
radioligands for in vivo imaging of breast cancer.
Keywords: breast cancer; 68Ga; GRPR; NPY(Y1)R; peptide heterodimers; PET/CT imaging
1. Introduction
Radiolabeled peptides, being able to specifically bind certain receptors overexpressed on many
malignancies, have become standard radiotracers for tumor-specific imaging by positron emission
tomography (PET) in a clinical routine. However, these radiolabeled peptides are able to address only
one target receptor type, being thus only able to visualize tumors expressing this particular receptor.
Pharmaceuticals 2018, 11, 65; doi:10.3390/ph11030065 www.mdpi.com/journal/pharmaceuticals64
Pharmaceuticals 2018, 11, 65
As different tumor lesions can however overexpress different receptor types and receptor expression
can change upon metastasis and disease progression, a monovalent peptidic radioligand is often not
able to visualize all tumor cells with the same efficiency and some lesions might be completely missed
by the applied radiopeptide.
Radiolabeled heterobivalent peptide ligands (HBPLs) on the other hand—by their ability to
specifically target more than one receptor type—have been proposed to be better-suited agents for
tumor imaging as they enable the visualization of the tumor by different receptor types potentially
overexpressed by the target cells [1,2].
HBPLs furthermore can have favorable effects for in vivo tumor imaging compared to monovalent
ligands such as improved in vivo biodistribution and enhanced avidity caused by simultaneous
binding if both receptors are present on the tumor cell surface. In this case, also a higher probability of
rebinding is achieved for a heterobivalent binder in case of dissociation from the receptor compared
to a monovalent peptide due to “forced proximity” of the second potential binder to the second
target receptor.
Furthermore, by being able to target different receptor types on the tumor cell surface, an
overall higher number of receptors can be addressed by a heterobivalent ligand, increasing the
probability of binding and thus tumor visualization. Thus, HBPLs are also of special interest not
only for the imaging of such tumors that express both receptor types concomitantly, but also for
tumors exhibiting a heterogeneous target expression with varying receptor densities between different
individuals or lesions and for differential target expression during disease progression. A non-uniform
distribution of target receptors between lesions results—if using monomeric peptidic radioligands—in
the visualization of only some of the lesions whereas others are not depicted. Applying a HBPL for
imaging, such lesions can nevertheless be addressed as long as one of the target receptors is present
(Figure 1).
 
Figure 1. Schematic depiction of the functional principle of radiolabeled NPY(Y1)R- and
gastrin-releasing peptide receptor (GRPR)-binding heterobivalent peptidic ligands (HBPLs) for tumor
imaging: Monomeric peptide radiotracers can only bind to one receptor type and thus miss tumor
tissues or lesions that do not express the respective receptor due to tumor heterogeneity or disease
progression whereas the use of radiolabeled HBPLs, which can bind to more than one target receptor
type, results in a higher probability of target visualization.
Recently, a radiolabeled HBPL, being able to address the gastrin-releasing peptide receptor as well
as integrin αvβ3 was successfully translated into the clinics for imaging of prostate cancer with PET/CT,
showing a much higher tumor visualization sensitivity compared to the respective GRPR-targeting
peptide monomer. This proves the clinical relevance of the heterobivalent peptide targeting concept [3].
To be able to develop a HBPL being able to more efficiently target tumor tissues than the respective
peptide monomers, it is necessary to know the receptor expression profile on the target tumor type.
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Regarding this point, some excellent systematical work has been carried out, determining the presence
of certain receptor types and their densities on different human malignancies [2,4–6].
Human breast cancer, for example, overexpresses in about 75% of all cases the gastrin-releasing
peptide receptor (GRPR) [7] and in 66–85% the neuropeptide Y receptor subtype 1 (NPY(Y1)R) [8].
Both receptors are expressed to an insignificant amount on healthy breast tissue, thus rendering
both receptor types well-suited target structures for sensitive and specific breast cancer imaging.
Furthermore, Reubi and co-workers could show on 68 human breast cancer samples that 63/68 (93%)
overexpressed one or both receptor types. Of these, 32 (51%) expressed both receptors concomitantly,
whereas 18 (29%) expressed only the GRPR, and a further 13 (21%) expressed only the NPY(Y1)R [5].
Thus, the combination of two peptidic ligands being able to specifically bind the NPY(Y1)R and the
GRPR to one radioligand should enable a considerably higher breast cancer visualization efficiency and
sensitivity and thus give less false-negative results compared to the respective monovalent radioligands
(Figure 1).
To obtain a highly potent bispecific HBPL, it is mandatory that both peptide parts of the
construct are still able to bind to their respective target receptor type despite the considerable chemical
modifications necessary for peptide heterodimerization. Thus, a suitable molecular design has to be
found that enables the binding of both peptides to their respective target receptor.
So far, only one example of a heterobivalent NPY(Y1)R- and GRPR-targeting ligand has been
described [9,10] and for this substance, no descriptions of radiolabeling with a PET isotope, in vitro
cell uptake or in vivo imaging data are available. Thus, the general feasibility of the approach has not
been demonstrated so far.
Thus, the aims of this study were to: (i) Develop a synthesis strategy yielding different HBPLs
varying in molecular design and consisting of a NPY(Y1)- and a GRPR-affine peptide as well as a
chelating agent (for radiolabeling with the positron-emitting radiometal nuclide 68Ga); (ii) Establish
the 68Ga-radiolabeling and determine the logD and in vitro stability of the resulting 68Ga-HBPLs in
human serum; (iii) Evaluate the uptake of the 68Ga-HBPLs into human breast cancer cell lines in vitro
to determine if the substances can still interact with both target receptors and are taken up by the tumor
cells; (iv) Determine if the particular molecular design used has a measurable influence on tumor cell
uptake; and (v) Show the general feasibility of the approach by investigating the tumor uptake of the
most potent HBPL in vivo by PET/CT imaging and ex vivo biodistribution in a proof-of-concept study
and determine if the tumor uptake profits from the heterodimerization of the receptor-specific peptides.
2. Results and Discussion
2.1. Synthesis of GRPR- and NPY(Y1)R-Binding HBPLs 22–26, Scrambled HBPL Analogs 24a–c, Blocking
Agents 3 and 4 as well as Monomeric Reference Peptides 27 and 28
At first, a suitable synthesis strategy towards the GRPR- and NPY(Y1)R-binding HBPLs was
developed. The target molecular design of the substances is depicted in Figure 2 and was based
on the following considerations: (i) The structure was to be based on a symmetrically branched
scaffold to obtain homogenous products and the scaffold should comprise the chelator NODA-GA
((1,4,7-triazacyclononane-4,7-diyl)diacetic acid-1-glutaric acid), which is able to stably and efficiently
complex 68Ga [11]; (ii) The chelator should be spatially separated from the receptor-affine peptides by
a short PEG linker to prevent an interference of the radiometal complex with receptor binding [12];
(iii) As we and others were able to show before for peptide di- and multimers, the distance between
the peptides within the same molecule can have a significant influence on the achievable receptor
interaction [13–16], thus different distances between both peptidic receptor ligands should be
investigated for the target HBPLs by introducing linkers of different length; (iv) Furthermore, as it was
proposed that also the rigidity of the molecules might influence cellular uptakes by a conformational
stabilization of the spatial orientation of the receptor ligands, the used linker structures did not only
differ in length, but also in rigidity.
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Figure 2. Schematic depiction of the general molecular design of the target HBPLs consisting of
a chelating agent (NODA-GA), a short PEG4-linker between radiometal complex and peptides,
the symmetrical branching unit, the linkers of different length and rigidity (green) and the GRPR- and
NPY(Y1)R-binding peptides BBN7–14 (cyan) and [Lys4,Trp5,Nle7]BVD15 (magenta).
2.1.1. Synthesis of the Peptide Monomers 1−6
Aiming at the synthesis of GRPR-and NPY(Y1)R-binding HBPLs and their following in vitro and
in vivo evaluation in human breast cancer tumor cells, we first synthesized the respective peptide
monomers for subsequent heterodimerization on symmetrically branched scaffolds. As GRPR-affine
peptide monomer, we chose the receptor agonist PESIN (PEG4-BBN7–14), which exhibits a favorably high
stability, significant tumor uptake, as well as high tumor to background ratios in vivo [17,18], and can
be modified at its N-terminal end without considerably changing its receptor binding affinity [13].
As NPY(Y1)R-affine peptide monomer, we chose [Lys4,Trp5,Nle7]BVD15 as this peptide was shown to
exhibit good affinities to the NPY(Y1)R even when further modified in position four [9,19,20].
The peptides were to be conjugated to the symmetrically branched scaffolds by a click chemistry
approach to be able to obtain the desired rather complex target HBPLs efficiently. Furthermore,
the coupling products have to be stable under physiological conditions. Different click chemistry
reactions fulfill these requirements; of these, we chose the oxime formation between aminooxy
functionalities and aldehydes.
Both peptides were synthesized by standard solid phase peptide synthesis (SPPS)
methods [13,21] by successive conjugation of the respective Nα-Fmoc-amino acids after HBTU
activation to the respective rink amide resin and finally modified on resin with bis-Boc-aminooxy acetic
acid, giving aminooxy-PESIN (1) and [Lys4(aminooxy),Trp5,Nle7]BVD15 (2) (Figure 3). In case of PESIN,
the aminooxy functionality was introduced at the N-terminal end as the peptide can be modified in
this position without considerable alterations in binding affinity. In case of [Lys4,Trp5,Nle7]BVD15,
the aminooxy functionality was introduced in position 4 (Nε amine of lysine) as modifications in this
position interfere least with receptor binding.
Figure 3. Depiction of the chemical structures of aminooxy-PESIN (1) and [Lys4(aminooxy),Trp5,
Nle7]BVD15 (2) used for the assembly of the HBPLs.
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As the target HBPLs should be evaluated in vitro regarding their ability to be taken up by human
breast cancer cell lines and the contribution of both parts of the HBPLs on tumor cell uptake should be
assessed, we further synthesized the peptide monomers bombesin (3) and [Lys4,Trp5,Nle7]BVD15 (4)
as blocking substances for the GRPR and the NPY(Y1)R during these experiments (Figure 4).
 
Figure 4. Depiction of the chemical structures of bombesin (3) and [Lys4,Trp5,Nle7]BVD15 (4) used as
receptor blocking substances during the in vitro tumor cell uptake studies.
Regarding the in vivo evaluation of the HBPLs in tumor-bearing animals and the verification of
the receptor specificity of the observed tumor uptakes and the contribution of both peptides of the
HBPLs to overall tumor uptakes, two different approaches can be followed. The first one is to block
the respective target receptor analogous to the in vitro assays by adding blocking substances 3 or 4
and the other one is to use scrambled HBPL analogs. To compare the in vivo tumor uptake of an HBPL
to that of its scrambled analogs instead of performing blocking studies however eliminates possible
difficulties that might arise from the low stability of the monomeric receptor ligands.
Thus, three different scrambled HBPL analogs were synthesized: PESIN combined with
scrambled [Lys4(aminooxy),Trp5,Nle7]BVD15, scrambled PESIN combined with [Lys4(aminooxy),
Trp5,Nle7]BVD15 and both peptides of the HBPL scrambled. For this purpose, the two scrambled
aminooxy-modified peptide monomers aminooxy-PESINscrambled (5) and [Lys4(aminooxy),Trp5,Nle7]
BVD15,scrambled (6) (Figure 5) were synthesized and analogously to 1 and 2 used during the following
HBPL syntheses.
 
Figure 5. Depiction of the chemical structures of aminooxy-PESINscrambled (5) and [Lys4(aminooxy),
Trp5,Nle7]BVD15,scrambled (6) which were used to synthesize partly or fully scrambled HBPL analogs.
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2.1.2. Synthesis of the Heterobivalent Ligands 22–26, 24a–c and Monomeric Reference Peptides
27 and 28
The branched bis-amines 7−11 and bis-aldehydes 12−16 (Scheme 1) were synthesized following
a published procedure [22] with minor modifications (see Supplementary Materials for detailed
description). In the following, these NODA-GA-modified branched bis-aldehyde scaffolds 12−16
were efficiently reacted with aminooxy-PESIN (1) and aminooxy-PESINscrambled (5) to the monovalent
intermediates 17−21 and 19a. These were further reacted with [Lys4(aminooxy),Trp5,Nle7]BVD15 (2)
and its scrambled analog 6 to the final heterobivalent peptidic target structures 22−26 and their partly
or fully scrambled analogs 24a–c (Scheme 1).
 
Scheme 1. Schematic depiction of the syntheses of the GRPR- and NPY(Y1)R-affine HBPLs 22−26 and
the scrambled analogs 24a–c. Conditions: (A) 1, H2O + 0.1% TFA, phosphate buffer, pH 4.0−4.6, RT,
5 min, yields: 47% for 17, 51% for 18, 43% for 19, 44% for 19a, 58% for 20, 55% for 21; (B) 2, H2O + 0.1%
TFA, phosphate buffer, pH 4.0−4.6, RT, 5 min, yields: 82% for 22, 79% for 23, 66% for 24, 49% for 24a,
63% for 24b, 61% for 24c, 75% for 25, 73% for 26.
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1 as well as its scrambled analog 5 reacted efficiently within minutes with the branched
bis-aldehydes 12−16, giving the respective monovalent conjugation products 17−21 and 19a in
satisfactory yields of 47% to 58%. Higher yields could not be obtained as 1 and 5 had to be applied in a
lower amount than the bis-aldehydes 12−16 to minimize the formation of the respective homobivalent
PESIN-dimers, being the only observed side products in this reaction. These monovalent intermediates
were in the following reacted with 2 or 6, proceeding equally efficient than the first reaction step within
minutes, giving the target HBPLs 22−26 as well as the scrambled analogs 24a–c in good yields of 49%
to 82%.
The HBPLs exhibited—depending on the linker structure used—distances between both peptidic
receptor ligands of 46 (no additional linker units used), 64 (PEG2 linkers), 78 (PEG4 linkers), 60 (ACMP
linkers), and 74 (two successive ACMP linkers) bond lengths.
Besides the target HBPLs and the scrambled analogs, also the monomeric reference
compounds DOTA-PESIN (27) [18] and [Lys4(DOTA),Trp5,Nle7]BVD15 (28) [19] (Figure 6) (DOTA =
(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid), having been described before to be
potent agents efficiently targeting the GRPR and NPY(Y1)R, were synthesized in yields of 7% and 45%,
respectively. These ligands, addressing only one of the target receptors types, served as monomeric
reference compounds for the following in vitro evaluations.
 
Figure 6. Depiction of the structures of DOTA-PESIN (27) and [Lys4(DOTA),Trp5,Nle7]BVD15 (28),
serving as mono-specific reference substances for the HBPLs in the following in vitro tumor cell
uptake studies.
2.2. 68Ga-Radiolabeling, logD and Stability Determination of Peptide Heterodimers [68Ga]22−[68Ga]26 and
Monomeric Reference Peptides [68Ga]27 and [68Ga]28
The heterobivalent ligands 22−26 and the reference substances 27 and 28 were in the
following radiolabeled with 68Ga3+. The 68Ga3+ was obtained via elution of an itG or Eckert
& Ziegler IGG100 68Ge/68Ga generator system. After adjusting the pH of the solution to
3.5 to 4.0, the NODA-GA-comprising HBPLs 22−26 were incubated at 40–45 ◦C for 10 min.
The DOTA-comprising reference compounds 27 and 28 were reacted at 99 ◦C under otherwise identical
conditions. The 68Ga-labeled products [68Ga]22−[68Ga]26, [68Ga]27 and [68Ga]28 were obtained in
radiochemical yields and purities of 95−99% (Figure S1A) as well as non-optimized molar activities
of 10−15 GBq/μmol (used for in vitro assays and obtained by using an itG generator system) or
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40−46 GBq/μmol (used for in vivo evaluations, obtained by using an Eckert & Ziegler IGG100
generator system), starting from 110−150 or 420–460 MBq of 68Ga3+, respectively.
Regarding a favorable in vivo biodistribution of the radioligands, the logD of the HBPLs should
be in a comparable range as that of the lead peptide monomers as we and others were able
to show before that a high lipophilicity negatively influences tumor uptake, organ distribution,
and unspecific background accumulation, resulting in a limited usefulness of the radiopeptides
for tumor visualization [23–25]. Consequently, we determined the logD of the developed HBPLs
[68Ga]22−[68Ga]26 in comparison to the monomeric reference peptides [68Ga]27 and [68Ga]28 via
the distribution coefficient of the respective radiotracer between phosphate buffer and 1-octanol.
The results of these evaluations are depicted in Figure S2. The results showed a comparatively high
hydrophilicity for all of the tested substances (−1.857 ± 0.054 for [68Ga]27, −1.982 ± 0.162 for [68Ga]28,
−1.569 ± 0.111 for [68Ga]22, −1.527 ± 0.109 for [68Ga]23, −1.672 ± 0.086 for [68Ga]24, −1.550 ± 0.114
for [68Ga]25 and −1.518 ± 0.089 for [68Ga]26). This indicates that the in vivo pharmacokinetics of the
developed HBPLs [68Ga]22−[68Ga]26 should, in terms of hydrophilicity, be similar to that of the parent
monomeric radiopeptides [68Ga]27 and [68Ga]28.
Besides lipophilicity, the stability of peptidic radioligands is an important parameter regarding
their applicability for in vivo imaging. Thus, the stability of the 68Ga-labeled HBPLs [68Ga]22−[68Ga]26
and the reference compounds [68Ga]27 and [68Ga]28 was determined in human serum. Typical
radio-HPLC chromatograms for each substance (obtained after 90 min incubation with human serum)
are depicted in Figure S1B. All of the tested compounds were stable over the testing period of 90 min,
showing only a negligible degradation after this time: 3 ± 0.2% for [68Ga]27, 4 ± 0.8% for [68Ga]28,
2 ± 1.6% for [68Ga]22, 1 ± 0.5% for [68Ga]23, no observable fragmentation for [68Ga]24, 2 ± 0.3% for
[68Ga]25 and 2 ± 0.5% for [68Ga]26. From the serum stability point of view—which can however only
give a rough estimation of stability under in vivo conditions [26]—all of the radioligands are applicable
for in vivo tumor imaging with PET/computed tomography (CT).
2.3. In Vitro Cell Uptake Studies: Tumor Cell Uptake of [68Ga]22−[68Ga]26 in Comparison to the Reference
Peptides [68Ga]27 and [68Ga]28 in Different Human Breast Cancer Cell Lines
In the following, we intended to determine if we could observe an independent binding of both
peptide parts of the HBPLs to both target receptor types, being the prerequisite for improved/more
likely tumor uptake (→ Figure 1). This can be achieved by tumor cell uptake studies of the radiotracers
as it was shown before for radiolabeled somatostatin analogs that the in vitro cell uptake directly
correlates to in vivo tumor uptakes [27], demonstrating the relevance of such in vitro tumor cell
uptake studies.
The human breast cancer cell line T-47D was described to express both the GRPR [9,28] as well
as the NPY(Y1)R [29,30] (where β-estradiol in the medium increases NPY(Y1)R-expression) and thus
should be the ideal cell line to determine if both parts of the developed HBPLs bind to their respective
receptor and if a synergistic effect of peptide heterodimerization on tumor cell uptake can be achieved.
Of course, it would also have been feasible to use different cells lines expressing either the GRPR or
the NPY(Y1)R to demonstrate that both peptides of the HBPLs are still able to address their respective
target receptor, but a cell line expressing both receptors concomitantly is far more advantageous to
showcase the potential beneficial effects of heterodimerization and to determine the part each of the
peptides contributes to tumor cell uptake in case of a concomitant receptor expression.
Thus, we first determined the uptake of the HBPLs [68Ga]22−[68Ga]26 in comparison to the
peptide monomers [68Ga]27 and [68Ga]28 in T-47D cells. The results of the cell uptake studies of
the radioligands are shown in Figure 7a (overall specific cell uptake of [68Ga]22−[68Ga]26, [68Ga]27
and [68Ga]28) and Figure 7b (uptake of [68Ga]24, differentiated by overall uptake, internalization and
surface binding; the results for the other tested radioligands were comparable and can be found in the
Supplementary Materials in Figures S3–S7).
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Figure 7. (a) Specific cell uptake of [68Ga]22−[68Ga]26, [68Ga]27 and [68Ga]28 in T-47D cells over 4 h of
incubation; (b) Uptake of [68Ga]24 in the same cells, differentiated by overall uptake, internalization,
and surface binding.
As expected, a high and constant specific uptake of the monovalent GRPR-specific peptide
[68Ga]27 of 51.0 ± 5.2% was observed into the T-47D cells after 4 h. Also, the HBPLs [68Ga]22−[68Ga]26
demonstrated a comparably high specific uptake into these cells of 47.8 ± 6.5%, 45.8 ± 2.9%,
50.1 ± 2.4%, 48.2 ± 2.8% and 46.4 ± 2.4%, respectively, after the same time. Interestingly,
the monovalent, NPY(Y1)-binding peptide [68Ga]28 showed no specific uptake (0.2 ± 0.03%). This
means that the uptake of the HBPLs [68Ga]22−[68Ga]26 into the T-47D cells is exclusively mediated by
the GRPR.
These results indicate that the heterodimerization and the resulting significant chemical
modification of the peptides as well as the compounds’ complexity and size do not affect the
GRPR-specific tumor cell uptake of the HBPLs compared to the monomeric reference [68Ga]27. Also,
the molecular design of the heterobivalent ligands comprising linkers of different length and rigidity
does not seem to have a significant effect on the GRPR-mediated cellular uptake of the respective
HBPL radiotracer.
In the following, we tested the uptake of the peptide monomers [68Ga]27 and [68Ga]28 in three
further standard cell lines of breast cancer: BT-474, MCF-7 and MDA-MB-231 cells. Of these, the
BT-474 cells were also described to express both the GRPR [31] and the NPY(Y1)R [31], whereas MCF-7
cells were described to be NPY(Y1)R positive [30,32] but expressing the GRPR only to a low extent [9]
and MDA-MB-231 cells were described to be GRPR positive [33] but expressing the NPY(Y1)R to a
low extent [29,30]. The results of these experiments can be found in the Supplementary Materials
(Figures S8–S10) and demonstrated contrary to the expectations only negligible uptakes of both peptide
monomers in all cell lines.
As the HBPLs [68Ga]22−[68Ga]26 and the respective monomer [68Ga]27 were however shown to
be efficiently taken up by GRPR-positive T-47D cells, these results indicate that the GRPR is present to
an only low amount on BT-474, MCF-7, and MDA-MB-231 cells. Concerning the missing uptake of
[68Ga]28 into all tested cell lines, three explanations are possible: (i) The NPY(Y1)R is present on at
least some of the cells but the peptide sequence [Lys4,Trp5,Nle7]BVD15, being the NPY(Y1)R-targeting
sequence in monomer [68Ga]28 as well as the HBPLs [68Ga]22−[68Ga]26, is not able to efficiently
address the NPY(Y1)R; (ii) The NPY(Y1)R is expressed in such low amounts that the tested radioligands
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cannot be efficiently taken up by the cells by this receptor; or (iii) The molar activities of the tested
radioligands were too low and a significant self-blocking of the NPY(Y1)R-mediated uptake took place,
preventing the cell uptake.
In order to determine if the NPY(Y1)R is actually present on T-47D, MCF-7 and BT-474 cells
and if the molar activity of monomer [68Ga]28 and the HBPLs [68Ga]22−[68Ga]26 prevented their
cellular uptake via the NPY(Y1)R, the cell uptake studies were repeated using commercially available
125I-PYY, binding the NPY(Y1)R [29] and exhibiting a high molar activity of 81.4 GBq/μmol. In these
experiments, an about 100-fold lower amount of substance was used for the cell uptake studies
compared to the 68Ga-labeled ligands ([68Ga]22−[68Ga]26, [68Ga]27 and [68Ga]28: 0.37−0.40 pmol per
1.5 × 106 cells; 125I-PYY: 0.003−0.005 pmol per 1.5 × 106 cells) in order to exclude the eventuality of
self-blocking. In all of the three tested cell lines, the specific uptake of 125I-PYY showed to be negligibly
low (between 0.2 and 2.5% of the total activity applied), confirming that the target NPY(Y1) receptor
might be present on the cells but if so, then only to a very low amount, being too low to give useful
results in the cell uptake studies.
Furthermore, this low receptor density prevents a successful determination of the receptor affinity
of the developed radioligands. This is in contrast to other studies, using identically treated MCF-7 cells
to determine NPY(Y1)R affinities of newly developed NPY(Y1)R-affine radioligands [9,19]. We could
however not reproduce these results using MCF-7 cells of different suppliers due to the observed low
expression of NPY(Y1)R on the cells.
As it was described that MCF-7 cells can express the target NPY(Y1)R to a much higher extent
in vivo than under in vitro conditions [34], this might also be the case for the T-47D cell line,
expressing besides the NPY(Y1)R also the for our scientific question important GRPR. Thus, we in
the following performed initial in vivo evaluations of HBPL [68Ga]24, showing highly promising
results in the preceding evaluations. Of the developed HBPLs, [68Ga]24 showed the highest stability
and hydrophilicity as well as a slightly higher tumor cell uptake than the other analogs in vitro and
thus represents a potent representative of the developed HBPLs for a following proof-of-concept
in vivo evaluation.
2.4. Proof-of-Concept: Evaluation of HBPL [68Ga]24 and Its Scrambled Analogs [68Ga]24a and [68Ga]24b via
In Vivo PET/CT Imaging in T-47D-Bearing Nude Mice and Ex Vivo Biodistribution
To investigate the in vivo pharmacokinetic properties of the most potent HBPL
[68Ga]24, we performed small animal PET/CT imaging studies in T-47D tumor-bearing
immunodeficient mice. Likewise, also the scrambled variants of [68Ga]24, [68Ga]24a
(PESINscrambled combined with [Lys4(aminooxy),Trp5,Nle7]BVD15) and [68Ga]24b (PESIN combined
with [Lys4(aminooxy),Trp5,Nle7]BVD15,scrambled), were evaluated under the same conditions
for comparison.
By evaluating these radioligands under the same conditions, the proportion of both peptide
binders on the uptake of [68Ga]24 and also the receptor-specificity of the uptake of the radioligand
via both receptors should be determined. The evaluation of the partly scrambled monovalent analogs
instead of the monomeric peptides, which would also have been possible, exhibits the advantage that
all evaluated radioligands show a similar pharmacokinetic distribution and also a similar possible
degradation pattern. Using the monovalent peptides bombesin or NPY/BVD for receptor blocking
(to show the receptor specificity of both peptide parts of [68Ga]24 and to determine the contribution of
both peptide parts of the HBPL to overall tumor uptake) might have resulted in an incomplete blocking
of the respective receptor as the GRPR-affine bombesin as well as the NPY(Y1)R-affine peptides NPY
and BVD are known for their limited in vivo stability.
For the PET/CT imaging studies, 5.5–8.0 MBq of the respective 68Ga-radioligand were
administered via the lateral tail vein under isoflurane anesthesia to the tumor-bearing animals. Directly
after completion of the diagnostic scans, the animals were sacrificed, the organs were collected and
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measured in a gamma-counter. The results of these in vivo PET/CT imaging studies and the ex vivo








Figure 8. Representative small animal positron emission tomography/computed tomography
(PET/CT) imaging results for [68Ga]24 (a); [68Ga]24a (b) and [68Ga]24b (c). The images show coronal
(upper row) and transaxial (lower row) slices for all tracers at 37.5 min p.i. The same scaling was used
for all images and 4 animals were examined per radioligand. The tumor is encircled in each image.
As can easily be seen from the in vivo PET/CT imaging as well as the ex vivo biodistribution data,
all developed ligands showed a rather high kidney and liver uptake. Thus, further improvements in
ligand design must be carried out to result in clinically relevant imaging agents for improved breast
cancer visualization with PET/CT.
Compared to the bispecific ligand [68Ga]24 with which the tumor can easily be delineated via
PET/CT, the scrambled analogs [68Ga]24a and [68Ga]24b showed a considerably less efficient tumor
visualization ability (Figure 8).
This results from a lower absolute tumor uptake for [68Ga]24a and [68Ga]24b compared to [68Ga]24
over the course of PET imaging (Figure 9a, SUVs(85min) of 122.03 ± 16.27 kBq/cm3 for [68Ga]24,
42.95 ± 26.38 kBq/cm3 for [68Ga]24a and 70.29 ± 16.09 kBq/cm3 for [68Ga]24b were observed), which
was also confirmed in the ex vivo biodistribution experiments (Figure 9b).
Figure 9. Absolute tumor uptakes as determined by in vivo PET imaging as well as ex vivo
biodistribution experiments (n = 4). (a) Time-activity-curves are depicted, showing tumor uptakes over
the course of PET imaging for [68Ga]24 (black), [68Ga]24a (purple) and [68Ga]24b (green); (b) Tumor
uptakes (% injected dose per gram) are shown for [68Ga]24 (black), [68Ga]24a (purple) and [68Ga]24b
(green) as determined by ex vivo biodistribution directly after the completed diagnostic scans.
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This indicates that both parts of HBPL [68Ga]24 contributed to in vivo tumor uptake and that its
uptake into the tumor was GRPR- and also NPY(Y1)R-specific.
As can be observed from the time-activity-curves obtained by PET imaging (Figure 9a), those
ligands comprising an intact variant of the GRPR-targeting ligand BBN7–14 showed a stable plateau
phase in tumor accumulation ([68Ga]24b) or only a slight decrease ([68Ga]24) whereas [68Ga]24a,
comprising a scrambled variant of BBN7–14, shows a surge in tumor uptake followed by a decline of
activity in the tumor. This might be attributable to the limited stability of BVD analogs under in vivo
conditions, which has been described before [35] and might result in radioligand metabolization during
imaging. If then the GRPR-binding peptide is still able to bind to its target receptor, the tumor uptake
nevertheless remains largely stable due to a GRPR-mediated uptake. However, if only a scrambled
variant of BBN7–14 is present, no receptor-affine peptide binder remains for continuous radiotracer
uptake into the tumor, resulting in an overall decrease in tumor accumulation.
Further, high and considerably improved tumor-to-background ratios could be achieved
for [68Ga]24 (tumor-to-muscle: 11.81 ± 1.83, tumor-to-blood: 2.72 ± 0.43) compared to [68Ga]24a
(tumor-to-muscle: 1.07 ± 1.14, tumor-to-blood: 0.50 ± 0.47) and [68Ga]24b (tumor-to-muscle: 3.83 ± 0.80,
tumor-to-blood: 0.91 ± 0.24) as determined by ex vivo biodistribution at 130 min p.i. This indicates
that both peptide parts of the HBPL contributed to tumor uptake and thus tumor visualization.
In summary, we were able to show here for the first time that the general concept to assemble a
GRPR- and a NPY(Y1)R-affine peptide to one combined radioligand is in general feasible regarding a
contribution of both peptides of the HBPL to in vivo tumor uptake and thus is beneficial with regard
to overall tumor uptake and tumor visualization probability compared to the monospecific agents.
3. Materials and Methods
General. All commercially available chemicals were of analytical grade and were used without
further purification. Resins for solid phase-based syntheses, PyBOP (Benzotriazole-1-yl-oxy-tris-
pyrrolidino-phosphonium hexafluorophosphate), Fmoc-protected standard amino acids as well
as bis-Boc-aminooxy acetic acid were purchased from NovaBiochem (Darmstadt, Germany). SFB
(Succinimidyl-p-formyl-benzoate) was synthesized according to a published procedure [36]. Fmoc-
ACMP-OH (Fmoc-4-amino-1-carboxymethyl-piperidine) was obtained from Iris Biotech (Marktredwitz,
Germany), respectively. Fmoc-L-Lys(Boc2-Aoa)-OH, mono-Fmoc ethylene diamine hydrochloride,
HBTU (O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate), Tracepur water
and N,N-bis(N′-Fmoc-3-aminopropyl)-glycine potassium hemisulfate ((Fmoc-NH-Propyl)2-Gly-OH)
were purchased from Iris Biotech, SigmaAldrich (Schnelldorf, Germany), Carl Roth (Karlsruhe,
Germany), VWR (Bruchsal, Germany) and PolyPeptide (Strasbourg, France), respectively.
NODA-GA-(tBu)3 and DOTA-(tBu)3 were obtained from CheMatech (Dijon, France).
Bis-amines 7–11 and bis-aldehydes 12–16 were synthesized according to published procedures [22]
with minor modifications of the synthesis protocols. Details of these syntheses can be found in the
supplementary information.
Unless otherwise stated, the coupling reactions during solid phase-based syntheses were usually
carried out in DMF for 30 min using 4 eq. of acid, 3.9 eq. of HBTU as coupling reagent and 4 eq. of
DIPEA (N,N-Diisopropylethylamine) as base. Fmoc protecting groups were removed using 50% (v/v)
piperidine in DMF.
For analytical and semipreparative HPLC chromatography, Dionex UltiMate 3000 systems
equipped with a Chromolith Performance (RP-18e, 100-4.6 mm, Merck, Darmstadt, Germany) and
a Chromolith SemiPrep (RP-18e, 100-10 mm, Merck) column were used, operated with a flow rate
of 4 mL/min and H2O + 0.1% TFA and MeCN + 0.1% TFA as eluents. For radio-analytical HPLC
chromatography, a Dionex UltiMate 3000 system equipped with a Chromolith Performance (RP-18e,
100-4.6 mm, Merck) column and a GabiStar radioactivity detector (Raytest, Straubenhardt, Germany)
or an Agilent 1200 system equipped with a Chromolith Performance (RP-18e, 100-4.6 mm, Merck)
column and a GabiStar radioactivity detector (Raytest) were used and operated with a flow rate
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of 4 mL/min and H2O + 0.1% TFA and MeCN + 0.1% TFA as eluents. MALDI (Matrix-Assisted
Laser Desorption/Ionization) spectra were obtained with a Bruker Daltonics Microflex spectrometer
(Bremen, Germany).
The human breast cancer cell lines T-47D, MDA-MB-231 and MCF-7 were purchased from
SigmaAldrich (Schnelldorf, Germany), whereas the cell line BT-474 was obtained from the
Leibniz-Institute DSMZ (Braunschweig, Germany). Dulbecco’s Modified Eagle Medium (DMEM),
RPMI-1640 medium, 200 mM L-glutamine, 0.05% trypsin/EDTA and 0.25% trypsin/EDTA were
purchased from Life Technologies. Fetal calf serum (FCS) was obtained from GE Healthcare Life
Sciences and phosphate buffered saline (PBS) as well as β-estradiol were purchased from Sigma
Aldrich. Bovine serum albumin (BSA) was purchased from CarlRoth (Karlsruhe, Germany).
The human 125I-labeled NPY(Y1)-binding peptide [125I]-Peptide-YY was obtained from
PerkinElmer in a molar activity of 81.4 GBq/μmol. The γ-counter used was a 2480 WIZARD2 system
(PerkinElmer, Rodgau, Germany).
For the in vivo evaluations, five week old female Fox Chase SCID mice were obtained from Janvier
and implanted with estradiol pellets (0.36 mg/60 days; obtained from Innovative Research of America)
one week prior to tumor cell inoculation. Tumor cells were inoculated using Matrigel basal membrane
matrix with reduced growth factor (obtained from VWR). For PET/CT measurements, a small animal
Albira II PET/SPECT/CT system (Bruker, Eggenstein-Leopoldshafen, Germany) was used.
Synthesis of aminooxy-PESIN (1) and aminooxy-PESINscrambled (5). The peptides were
synthesized on solid support by standard Fmoc solid-phase peptide synthesis using a commercially
available standard Rink amide MBHA resin, HBTU as coupling reagent, standard Nα-Fmoc-amino
acids, Nω-Fmoc-PEG4-OH and bis-Boc-aminooxy acetic acid. All amino acids (apart from
bis-Boc-aminooxy acetic acid which was reacted for 60 min) were coupled within 30 min. The crude
aminooxy-modified peptides were cleaved from the solid support using a mixture of TFA:TIS:H2O of
95:2.5:2.5 (v/v) for 60 min, suspended in diethyl ether and purified by semipreparative HPLC.
1 was purified using a gradient of 15–30% MeCN + 0.1% TFA in 8 min (Rt = 6.35 min) and
isolated as white solid after lyophilization in yields of 27% (85.0 mg; 67.4 μmol). MALDI-MS (m/z)
using 2,5-dihydroxybenzoic acid as matrix substance for [M + H+]+ (calculated): 1260.23 (1260.46);
[M + Na+]+ (calculated): 1282.21 (1282.62); [M + K+]+ (calculated): 1298.16 (1298.60). MALDI-MS
(m/z) using α-cyano-4-hydroxycinnamic acid as matrix substance for [M + H+]+ (calculated): 1260.63
(1260.46); [M + Na+]+ (calculated): 1282.56 (1282.62); [M + K+]+ (calculated): 1298.54 (1298.60).
5 was purified using a gradient of 10–60% MeCN + 0.1% TFA in 8 min (Rt = 5.42 min) and isolated
as white solid after lyophilization in yields of 22% (28.1 mg, 22.2 μmol). MALDI-MS (m/z) using
α-cyano-4-hydroxycinnamic acid as matrix substance for [M + H+]+ (calculated): 1260.81 (1260.46);
[M + Na+]+ (calculated): 1282.84 (1282.62); [M + K+]+ (calculated): 1298.78 (1298.60).
Synthesis of [Lys4(aminooxy),Trp5,Nle7]BVD15 (2) and [Lys4(aminooxy),Trp5,Nle7]BVD15scrambled
(6). The peptides were synthesized on solid support by standard Fmoc solid-phase peptide synthesis
using a commercially available Rink amide MBHA resin, HBTU as coupling reagent, standard
Nα-Fmoc-amino acids and Nα-Fmoc-L-Lys(Boc2-Aoa)-OH. The crude aminooxy-modified peptides
were cleaved from the solid support using a mixture of TFA:TIS:H2O of 95:2.5:2.5 (v/v) for 90 min,
suspended in diethyl ether and purified by semipreparative HPLC.
2 was purified using a gradient of 10–60% MeCN + 0.1% TFA in 8 min (Rt = 3.71 min) and
isolated as white solid after lyophilization in yields of 35% (114.2 mg; 86.7 μmol). MALDI-MS (m/z)
using 2,5-dihydroxybenzoic acid as matrix substance for [M + H+]+ (calculated): 1317.02 (1317.54);
[M + Na+]+ (calculated): 1339.13 (1339.74); [M + K+]+ (calculated): 1355.03 (1355.71). MALDI-MS
(m/z) using α-cyano-4-hydroxycinnamic acid as matrix substance for [M + H+]+ (calculated): 1317.89
(1317.54); [M + Na+]+ (calculated): 1339.89 (1339.74); [M + K+]+ (calculated): 1355.86 (1355.71).
6 was purified using a gradient of 10–50% MeCN + 0.1% TFA in 8 min (Rt = 4.31 min) and isolated
as white solid after lyophilization in yields of 20% (26.0 mg; 19.7 μmol). MALDI-MS (m/z) using
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α-cyano-4-hydroxycinnamic acid as matrix substance for [M + H+]+ (calculated): 1317.37 (1317.54);
[M + Na+]+ (calculated): 1339.38 (1339.74).
Synthesis of bombesin (3). The peptide was synthesized on solid support by standard Fmoc
solid-phase peptide synthesis using a commercially available standard Rink amide resin, HBTU as
coupling reagent and standard Nα-Fmoc-amino acids. All amino acids were coupled within 35 min.
The crude peptide was cleaved from the solid support using a mixture of TFA:TIS:H2O of 95:2.5:2.5
(v/v) for 90 min, suspended in diethyl ether and purified by semipreparative HPLC using a gradient of
15–60% MeCN + 0.1% TFA in 5.5 min (Rt = 3.40 min) and isolated as white solid after lyophilization in
yields of 22% (35.2 mg, 21.6 μmol). MALDI-MS (m/z) using α-cyano-4-hydroxycinnamic acid as matrix
substance for [M + H+]+ (calculated): 1618.56 (1618.82); [M + Na+]+ (calculated): 1640.55 (1640.81);
[M + K+]+ (calculated): 1656.57 (1656.78).
Synthesis of [Lys4,Trp5,Nle7]BVD15 (4). The peptide was synthesized on solid support by
standard Fmoc solid-phase peptide synthesis using a commercially available standard Rink amide
resin, HBTU as coupling reagent and standard Nα-Fmoc-amino acids. All amino acids were
coupled within 30 min. The crude peptide was cleaved from the solid support using a mixture of
TFA:TIS:H2O of 95:2.5:2.5 (v/v) for 120 min, suspended in diethyl ether and purified by semipreparative
HPLC using a gradient of 10–60% MeCN + 0.1% TFA in 5.5 min (Rt = 3.05 min) and isolated as
white solid after lyophilization in yields of 40% (49.2 mg; 39.5 μmol). MALDI-MS (m/z) using
α-cyano-4-hydroxycinnamic acid as matrix substance for [M + H+]+ (calculated): 1244.63 (1244.73);
[M + Na+]+ (calculated): 1266.65 (1266.72); [M + K+]+ (calculated): 1282.60 (1282.69).
General synthesis of NODA-GA-PESIN-aldehydes (17−21) and NODA-GA-PESINscrambled-
aldehyde (19a). To a solution of the respective branched NODA-GA-bis-aldehyde (12−16) in H2O + 0.1%
TFA (250−500 μL) was added a solution of aminooxy-PESIN (1) or aminooxy-PESINscrambled (5)
(0.7 eq.) in H2O + 0.1% TFA (250−500 μL). The pH of the solutions was adjusted to 4.0–4.6 by addition
of phosphate buffer (0.1 M, pH 7.2, ~150 μL) and the reaction progress was monitored by analytical
HPLC. The reactions were found to be finished within 5 min and the products were purified by
semipreparative HPLC. The products were isolated as white solids after lyophilization. Gradients
used for HPLC purification and synthesis yields for each compound are given below.
17: gradient: 20–45% MeCN + 0.1% TFA in 5 min (Rt = 4.45 min), yield: 47%. MALDI-MS
(m/z) using α-cyano-4-hydroxycinnamic acid as matrix substance for [M + H+]+ (calculated): 2427.33
(2427.22); [M + Na+]+ (calculated): 2449.30 (2449.21); [M + K+]+ (calculated): 2465.49 (2465.18).
MALDI-MS (m/z) using 2,5-dihydroxybenzoic acid as matrix substance for [M + H+]+ (calculated):
2426.69 (2427.22); [M + Na+]+ (calculated): 2448.99 (2449.21); [M + K+]+ (calculated): 2464.93 (2465.18).
MALDI-MS (m/z) using sinapic acid as matrix substance for [M + H+]+ (calculated): 2427.38 (2427.22);
[M + Na+]+ (calculated): 2449.25 (2449.21).
18: gradient: 25–45% MeCN + 0.1% TFA in 5 min (Rt = 3.76 min), yield: 51%. MALDI-MS
(m/z) using α-cyano-4-hydroxycinnamic acid as matrix substance for [M + H+]+ (calculated): 2717.48
(2717.37); [M + Na+]+ (calculated): 2739.21 (2739.36); [M + K+]+ (calculated): 2755.49 (2755.33).
MALDI-MS (m/z) using 2,5-dihydroxybenzoic acid as matrix substance for [M + H+]+ (calculated):
2717.18 (2717.37); [M + Na+]+ (calculated): 2739.60 (2739.36); [M + K+]+ (calculated): 2755.13 (2755.33).
19: gradient: 25–45% MeCN + 0.1% TFA in 5 min (Rt = 4.26 min), yield: 43%. MALDI-MS
(m/z) using α-cyano-4-hydroxycinnamic acid as matrix substance for [M + H+]+ (calculated): 2921.63
(2921.50); [M + Na+]+ (calculated): 2943.64 (2943.49); [M + K+]+ (calculated): 2959.46 (2959.47).
MALDI-MS (m/z) using 2,5-dihydroxybenzoic acid as matrix substance for [M + H+]+ (calculated):
2921.63 (2921.50); [M + Na+]+ (calculated): 2943.34 (2943.49); [M + K+]+ (calculated): 2959.57 (2959.47).
19a (PESIN scrambled): gradient: 25–45% MeCN + 0.1% TFA in 5.5 min (Rt = 4.18 min), yield:
44%. MALDI-MS (m/z) using α-cyano-4-hydroxycinnamic acid as matrix substance for [M + H+]+
(calculated): 2921.59 (2921.50); [M + Na+]+ (calculated): 2943.56 (2943.49); [M + K+]+ (calculated):
2959.52 (2959.47).
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20: gradient: 20–45% MeCN + 0.1% TFA in 5 min (Rt = 3.93 min), yield: 58%. MALDI-MS
(m/z) using α-cyano-4-hydroxycinnamic acid as matrix substance for [M + H+]+ (calculated): 2707.24
(2707.41); [M + Na+]+ (calculated): 2729.30 (2729.40); [M + K+]+ (calculated): 2745.58 (2745.37).
MALDI-MS (m/z) using 2,5-dihydroxybenzoic acid as matrix substance for [M + H+]+ (calculated):
2706.98 (2707.41); [M + Na+]+ (calculated): 2728.88 (2729.40); [M + K+]+ (calculated): 2744.78 (2745.37).
21: gradient: 25–45% MeCN + 0.1% TFA in 5 min (Rt = 2.85 min), yield: 55%. MALDI-MS
(m/z) using α-cyano-4-hydroxycinnamic acid as matrix substance for [M + H+]+ (calculated): 2987.39
(2987.60); [M + Na+]+ (calculated): 3009.40 (3009.59); [M + K+]+ (calculated): 3025.80 (3025.56).
MALDI-MS (m/z) using 2,5-dihydroxybenzoic acid as matrix substance for [M + H+]+ (calculated):
2987.03 (2987.60). MALDI-MS (m/z) using sinapic acid as matrix substance for [M + H+]+ (calculated):
2987.81 (2987.60).
General synthesis of heterobivalent ligands 22−26 and scrambled analogs 24a–c. To a solution
of the respective NODA-GA-PESIN-aldehyde (17−21 or 19a) in H2O + 0.1% TFA (250−500 μL) was
added a solution of 2 or 6 (3 eq.) in H2O + 0.1% TFA (250−500 μL). The pH of the solutions was
adjusted to 4.0–4.6 by addition of phosphate buffer (0.1 M, pH 7.2, ~150 μL) and the reaction progress
was monitored by analytical HPLC. The reactions were found to be finished within 5 min and the
products were purified by semipreparative HPLC. The products were isolated as white solids after
lyophilization. Gradients used for HPLC purification and synthesis yields for each compound are
given below.
22: gradient: 25–50% MeCN + 0.1% TFA in 5 min (Rt = 3.19 min), yield: 82%. MALDI-MS
(m/z) using α-cyano-4-hydroxycinnamic acid as matrix substance for [M + H+]+ (calculated): 3728.21
(3728.29); [M + Na+]+ (calculated): 3750.49 (3750.28). MALDI-MS (m/z) using 2,5-dihydroxybenzoic
acid as matrix substance for [M + H+]+ (calculated): 3728.71 (3728.29); [M + Na+]+ (calculated):
3750.76 (3750.28).
23: gradient: 25–45% MeCN + 0.1% TFA in 5 min (Rt = 3.65 min), yield: 79%. MALDI-MS
(m/z) using α-cyano-4-hydroxycinnamic acid as matrix substance for [M + H+]+ (calculated): 4018.99
(4018.61); [M + Na+]+ (calculated): 4040.69 (4040.60). MALDI-MS (m/z) using 2,5-dihydroxybenzoic
acid as matrix substance for [M + H+]+ (calculated): 4018.95 (4018.61); [M + Na+]+ (calculated):
4040.02 (4040.60).
24: gradient: 25–45% MeCN + 0.1% TFA in 6 min (Rt = 3.86 min), yield: 66%. MALDI-MS
(m/z) using α-cyano-4-hydroxycinnamic acid as matrix substance for [M + H+]+ (calculated): 4222.98
(4222.87). MALDI-MS (m/z) using 2,5-dihydroxybenzoic acid as matrix substance for [M + H+]+
(calculated): 4222.48 (4222.87); [M + Na+]+ (calculated): 4244.96 (4244.86); [M + K+]+ (calculated):
4260.51 (4260.97). MALDI-MS (m/z) using sinapic acid as matrix substance for [M + H+]+ (calculated):
4222.87 (4222.87).
24a (PESIN scrambled): gradient: 25–45% MeCN + 0.1% TFA in 6 min (Rt = 3.55 min), yield:
49%. MALDI-MS (m/z) using α-cyano-4-hydroxycinnamic acid as matrix substance for [M + H+]+
(calculated): 4222.54 (4222.87). MALDI-MS (m/z) using 2,5-dihydroxybenzoic acid as matrix substance
for [M + H+]+ (calculated): 4222.17 (4222.87); [M + Na+]+ (calculated): 4244.94 (4244.86).
24b ([Lys4,Trp5,Nle7]BVD15 scrambled): gradient: 25–40% MeCN + 0.1% TFA in 5.5 min
(Rt = 4.58 min), yield: 63%. MALDI-MS (m/z) using α-cyano-4-hydroxycinnamic acid as matrix
substance for [M + H+]+ (calculated): 4222.35 (4222.87). MALDI-MS (m/z) using 2,5-dihydroxybenzoic
acid as matrix substance for [M + H+]+ (calculated): 4222.29 (4222.87); [M + Na+]+ (calculated): 4244.99
(4244.86); [M + K+]+ (calculated): 4260.49 (4260.97).
24c (PESIN and [Lys4,Trp5,Nle7]BVD15 scrambled): gradient: 25–45% MeCN + 0.1% TFA in
5.5 min (Rt = 4.36 min), yield: 61%. MALDI-MS (m/z) using α-cyano-4-hydroxycinnamic acid as
matrix substance for [M + H+]+ (calculated): 4222.67 (4222.87); [M + K+]+ (calculated): 4260.98 (4260.97).
MALDI-MS (m/z) using 2,5-dihydroxybenzoic acid as matrix substance for [M + H+]+ (calculated):
4222.48 (4222.87); [M + Na+]+ (calculated): 4244.90 (4244.86).
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25: gradient: 25–50% MeCN + 0.1% TFA in 6 min (Rt = 2.76 min), yield: 75%. MALDI-MS
(m/z) using α-cyano-4-hydroxycinnamic acid as matrix substance for [M + H+]+ (calculated): 4008.53
(4008.66); [M + Na+]+ (calculated): 4030.76 (4030.65); [M + K+]+ (calculated): 4046.33 (4046.76).
MALDI-MS (m/z) using 2,5-dihydroxybenzoic acid as matrix substance for [M + H+]+ (calculated):
4009.12 (4008.66).
26: gradient: 25–45% MeCN + 0.1% TFA in 6 min (Rt = 2.83 min), yield: 73%. MALDI-MS (m/z)
using 2,5-dihydroxybenzoic acid as matrix substance for [M + H+]+ (calculated): 4288.72 (4289.03).
MALDI-MS (m/z) using sinapic acid as matrix substance for [M + H+]+ (calculated): 4289.59 (4289.03).
Synthesis of DOTA-PESIN (27). The peptide was synthesized on solid support by standard
Fmoc solid-phase peptide synthesis using a commercially available standard Rink amide MBHA
resin, HBTU as coupling reagent, standard Nα-Fmoc-amino acids, and Nω-Fmoc-PEG4-OH. After the
conjugation of the PEG4 linker to the peptide sequence, DOTA-(tBu)3 was coupled within 120 min
using an excess of the synthon of 2.7 eq. together with 2.6 eq. HBTU and 4 eq. DIPEA. The crude
product was cleaved from the solid support using a mixture of TFA:TIS:H2O of 95:2.5:2.5 (v/v) for
3 h, suspended in diethyl ether and purified by semipreparative HPLC using a gradient of 20–35%
MeCN + 0.1% TFA in 8 min (Rt = 4.34 min) and isolated as white solid after lyophilization in yields
of 7% (10.7 mg; 6.8 μmol). MALDI-MS (m/z) using 2,5-dihydroxybenzoic acid as matrix substance
for [M + H+]+ (calculated): 1573.02 (1573.80); [M + Na+]+ (calculated): 1595.06 (1595.79); [M + K+]+
(calculated): 1610.94 (1611.76). MALDI-MS (m/z) using α-cyano-4-hydroxycinnamic acid as matrix
substance for [M + H+]+ (calculated): 1573.75 (1573.80); [M + Na+]+ (calculated): 1595.85 (1595.79).
Synthesis of [Lys4(DOTA),Trp5,Nle7]BVD15 (28). The peptide was synthesized on solid support
by standard Fmoc solid-phase peptide synthesis using a commercially available standard Rink amide
MBHA resin, HBTU as coupling reagent, standard Nα-Fmoc-amino acids and Fmoc-Lys(Mtt)-OH.
After conjugation of the last amino acid, the lysine side chain Mtt-protecting group was removed
with diluted TFA (TFA:DCM 1:99 (v/v)) within 2 h and DOTA-(tBu)3 was coupled in this position
within 120 min using an excess of the synthon of 2.7 eq. together with 2.6 eq. HBTU and 4 eq.
DIPEA. The crude DOTA-modified peptide was cleaved from the solid support using a mixture of
TFA:TIS:H2O of 95:2.5:2.5 (v/v) for 3 h, suspended in diethyl ether and purified by semipreparative
HPLC using a gradient of 20–25% MeCN + 0.1% TFA in 8 min (Rt = 2.58 min) and isolated as
white solid after lyophilization in yields of 45% (73.4 mg; 45.0 μmol). MALDI-MS (m/z) using
2,5-dihydroxybenzoic acid as matrix substance for [M + H+]+ (calculated): 1630.38 (1630.91); [M + Na+]+
(calculated): 1652.59 (1652.90); [M + K+]+ (calculated): 1668.39 (1668.87). MALDI-MS (m/z) using
α-cyano-4-hydroxycinnamic acid as matrix substance for [M + H+]+ (calculated): 1630.54 (1630.91).
MALDI-MS (m/z) using sinapic acid as matrix substance for [M + H+]+ (calculated): 1630.53 (1630.91).
68Ga-radiolabeling of NODAGA-modified peptide heterodimers (22−26) and peptide
monomers 27 and 28 for in vitro evaluations. The respective labeling precursor (10 nmol, dissolved
in 10 μL of Tracepur water) was reacted with 110–150 MBq of 68Ga3+ obtained by an itG 68Ge/68Ga
generator system (Garching, Germany). The generator was eluted with HCl (0.05 M, 3 mL) and the
eluate was trapped on a cation exchange cartridge (Macherey-Nagel, Chromafix PS-H+). The 68Ga3+
was eluted from the cartridge using a NaCl solution (5 M, 1.5 mL) and the pH was adjusted to 3.5–4.0 by
addition of sodium acetate solution (1.25 M, ~50 μL). After reaction for 10 min at 45 ◦C (22−26) or 99 ◦C
(27 and 28), the reaction mixtures were analyzed by analytical radio-HPLC. The radiolabeled products
were found to be 95–99% pure and obtained in molar activities of 10–15 GBq/μmol (non-optimized).
68Ga-radiolabeling of NODAGA-modified peptide heterodimers (24 and 24a–c) for in vivo
evaluations. The respective labeling precursor (10 nmol, dissolved in 10 μL of Tracepur water) was
reacted with 420–460 MBq of 68Ga3+ obtained by fractioned elution of an Eckert & Ziegler 68Ge/68Ga
generator system (IGG100, Eckert & Ziegler, Berlin, Germany). The generator was eluted with HCl
(0.1 M, 1.4 mL) and the pH was adjusted to 3.5–4.0 by addition of sodium acetate solution (1.25 M,
90–95 μL). After reaction for 10 min at 45 ◦C, the reaction mixtures were analyzed by analytical
radio-HPLC. The radiolabeled products were found to be 95–99% pure and obtained in molar activities
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of 40–46 GBq/μmol (non-optimized). The pH of the radiotracer solution was adjusted to 6.0–7.0 using
HEPES buffer (2.0 M, pH 8.0, 200 μL) and used for the in vivo studies.
Determination of radiotracer lipophilicity. The heterobivalent ligands (22–26) as well as the
monomeric reference compounds (27 and 28) were radiolabeled with 68Ga as described before and
2 μL of the product solution (~65 pmol of the respective radioligand) were added to a mixture of
phosphate buffer (0.05 M, pH 7.4, 800 μL) and 1-octanol (800 μL) and incubated for 5 min at ambient
temperature under vigorous shaking. Both phases were separated by centrifugation and 100 μL of
each phase were measured for radioactivity in a gamma-counter. From these data, the distribution
coefficient logD was calculated from the following equation: logDo/w = log(cpmo/cpmw), where: cpmo
= activity in the 1-octanol phase [cpm] (cpm = counts per minute), cpmw = activity in the aqueous
phase [cpm]. These experiments were performed six times independently.
Determination of the stability of the ligands in human serum. The heterobivalent ligands
(22–26) as well as the monomeric reference compounds (27 and 28) were radiolabeled with 68Ga as
described before and 125 μL of the product solution were added to 500 μL of human serum and
incubated at 37 ◦C. At defined time-points of 5, 15, 30, 60 and 90 min, aliquots of 75 μL of the mixture
were added to 75 μL of ethanol and the precipitation of serum proteins was enhanced by ice-cooling
for 2 min. After centrifugation, supernatant and precipitate were measured for radioactivity and the
supernatant was analyzed by analytical radio-HPLC. These experiments were performed thrice.
Cell culture. All cell lines were grown in suitable culture medium at 37 ◦C in a humidified CO2
(5%) atmosphere. The human breast cancer cell lines T-47D, MDA-MB-231 and MCF-7 were grown in
Dulbecco’s Modified Eagle Medium (DMEM), supplemented with 10% (v/v) fetal calf serum (FCS)
and 1% (v/v) L-Glutamine. For a high expression of the NPY(Y1) receptor on T-47D cells, the medium
for this cell line was further supplemented with 0.15% (w/v) β-estradiol. The BT-474 and PC-3 cell
lines were grown in RPMI-1640 medium, also supplemented with 10% (v/v) fetal calf serum (FCS) and
1% (v/v) L-Glutamine.
Internalization studies. Cells (T-47D, MDA-MB-231, MCF-7, BT-474 and PC-3, 1.5 × 106 cells
per well) were seeded into 6-well plates and incubated overnight at 37 ◦C in a humidified CO2
(5%) atmosphere. The next day, the medium was removed and the cells were washed twice
with the respective medium without supplements (ice-cold, 1 mL) and incubated with 3.7–4.0 kBq
(0.37–4.0 pmol) of the respective 68Ga-radiolabeled ligand [68Ga]22−[68Ga]26, [68Ga]27 or [68Ga]28
(in 1.5 mL medium, containing 0.5% (w/v) BSA) for defined time-points of 1, 2, 3 or 4 h at 37 ◦C in a
humidified CO2 (5%) atmosphere. A 1000-fold excess of the respective peptide (3 or 4) was used for
blocking to determine the non-specific cell uptake. At each time point, the medium was removed and
the cells were washed twice with the respective medium without supplements (ice-cold, 1 mL). Cells
were treated twice with 1 mL glycine buffer (ice-cold, 50 mM glycine, 100 mM NaCl, pH 2.8) for 5 min
at room temperature, followed by 2 mL NaOH solution (1 M) for 10 min at 37 ◦C. The supernatants
were collected and the radioactivity measured in a gamma counter. The internalized and surface
bound activity was expressed as percentage of measured to total added activity. Each data point was
generated thrice in triplicates.
These internalization studies were performed accordingly on T-47D, MCF-7, BT-474 and
PC-3 (negative control) cells with 125I-PYY (PerkinElmer, molar activity 81.4 GBq/μmol, 0.3 kBq,
0.0032 pmol). The cells were incubated for 1 h with the radioligand and additional blocking experiments
were performed using a 1000-fold excess of 4, 28 and 24.
In vivo experiments. All animal experiments were performed in compliance with the German
animal protection laws and protocols of the local committee (Regierungspräsidium Karlsruhe,
approval number: 35-9185.81/G-206/15). 20, six week old female immunodeficient Fox Chase
SCID (CB17/Icr-Prkdcscid/IcrIcoCrl) mice with an average weight of 20 g were subcutaneously
implanted with 17β-estradiol pellets (0.36 mg/60 days). 4 days later, the tumors were induced
by subcutaneous inoculation of 5 × 106 T-47D cells into the left flank of the approval number s. After
induction, the tumors were allowed to grow for 8–10 weeks and reached a diameter of about 0.5 cm.
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For imaging, the animals were anaesthetized with isoflurane and injected with 5.5–8.0 MBq of the
respective radioligand ([68Ga]24, [68Ga]24a or [68Ga]24b) into the lateral tail vein. Dynamic PET
images were acquired over 90 min and CT images were obtained within further 30 min. After the
end of the diagnostic scan, the animals were sacrificed, the organs were collected and measured in
a gamma-counter.
The dynamic PET images were reconstructed using the Albira Suite Reconstructor (Bruker)
with an iterative dynamic reconstruction with 12 iterations using an 2D-Maximum-Likelihood
Expectation-Maximization (MLEM) algorithm and a cubic image voxel size of 0.5 mm after scatter
and decay correction. Data were divided into time frames from 1 to 10 min (10 × 1 min, 10 × 2 min,
6 × 5 min and 3 × 10 min) for the assessment of temporal changes in regional tracer accumulation.
The CT images were obtained at 45 kVp, with currents of 0.4 mA (high dose, good resolution).
Acquisitions of 400 projections were taken and a 250 μm isotropic voxel size image was reconstructed
via filtered back projection. The reconstructed PET data were manually fused with the CT images
using PMOD 3.6.1.1. and analyzed. Volumes of interest (VOIs) were defined for the quantification
of tracer accumulation in heart, liver, kidneys, tumor, and muscle. The results for each VOI were
calculated as SUV (kBq/cm3) averaged for each time frame.
4. Conclusions
We were able to show that is chemically and radiochemically feasible to synthesize radiolabeled
heterobivalent peptides consisting of a GRPR- and a NPY(Y1)R-affine peptide on symmetrically
branched scaffolds, resulting in bispecific heterobivalent peptidic PET radiotracers. The compounds
demonstrated high stabilities in human serum, hydrophilicities comparable to the monomeric lead
peptides and high GRPR-mediated tumor cell uptakes in vitro.
The performed in vivo imaging and ex vivo biodistribution studies indicated a contribution
of both peptides of the evaluated HBPL to overall in vivo tumor uptake, showing the feasibility of
the general concept to develop GRPR- and NPY(Y1)R-bispecific PET radiotracers with regard to an
improved and more sensitive tumor visualization of human breast cancer.
Nevertheless, the results also show that further work is required to obtain GRPR- and
NPY(Y1)R-bispecific imaging agents being useful for clinical application due to the high kidney
and liver accumulation of the agents developed so far.
Supplementary Materials: Supporting material for this article, comprising the syntheses of compounds 7–11 and
12–16, the results of the logD determinations, radio-HPLC chromatograms and serum stability data, results of
in vitro cell uptake studies and ex vivo biodistribution data is available online at http://www.mdpi.com/1424-
8247/11/3/65/s1.
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Abstract: Several studies showed that [11C]ABP688 binding is altered following drug-induced
perturbation of glutamate levels in brains of humans, non-human primates and rats. We evaluated
whether the fluorinated derivative [18F]PSS232 can be used to assess metabotropic glutamate receptor
5 (mGluR5) availability in rats after pharmacological challenge with ketamine, known to increase
glutamate, or ceftriaxone, known to decrease glutamate. In vitro autoradiography was performed on
rat brain slices with [18F]PSS232 to prove direct competition of the drugs for mGluR5. One group
of rats were challenged with a bolus injection of either vehicle, racemic ketamine, S-ketamine or
ceftriaxone followed by positron emission tomography PET imaging with [18F]PSS232. The other
group received an infusion of the drugs during the PET scan. Distribution volume ratios (DVRs) were
calculated using a reference tissue model. In vitro autoradiography showed no direct competition of
the drugs with [18F]PSS232 for the allosteric binding site of mGluR5. DVRs of [18F]PSS232 binding
in vivo did not change in any brain region neither after bolus injection nor after infusion. We conclude
that [18F]PSS232 has utility for measuring mGluR5 density or occupancy of the allosteric site in vivo,
but it cannot be used to measure in vivo fluctuations of glutamate levels in the rat brain.
Keywords: glutamate; metabotropic glutamate receptor subtype 5; [18F]PSS232; ketamine;
ceftriaxone; positron emission tomography; allosteric modulator; MMPEP; ABP688
1. Introduction
Glutamate is the principle excitatory neurotransmitter in the nervous system, which elicits
its action on ionotropic (N-methyl-D-aspartate receptor (NMDA), Kainate, α-amino-3-hydroxy
-5-methyl-4-isoxazolepropionic acid receptor (AMPA)) and metabotropic (mGluR) receptors, especially
in the mammalian brain [1]. Ionotropic receptors form ion channels and exhibit a fast relay.
Metabotropic receptors are G protein-coupled, acting through a second messenger and produce
stimuli that are more prolonged. Since glutamate is not degraded in the synaptic cleft, two major
astrocytic transporters, the glutamate transporter-1 (GLT-1, EAAT2) and the glutamate aspartate
transporter (GLAST, EAAT1), remove glutamate and provide the regulation to orchestrate receptor
excitability [2]. Glutamate works not only as a point-to-point transmitter, but also through
spill-over synaptic crosstalk between synapses in which summation of glutamate released from
a neighboring synapse creates extrasynaptic signaling [3]. A disruption of these fine-tuning
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mechanisms can cause excitotoxicity, which is a driving force in the pathophysiology of various
neuropsychological disorders. An important role of the glutamatergic system has been established
in depression [4], schizophrenia [5], Parkinson’s disease [6], Alzheimer’s disease [7] and drug
addiction [8]. Due to the involvement of the glutamatergic system in a large array of diseases,
intense efforts have been made in recent years to visualize acute fluctuations in endogenous glutamate
levels. Positron emission tomography (PET) using the highly selective allosteric antagonist of mGluR5,
3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone-O-(11)C-methyl-oxime ([11C]ABP688) [9], has been
used to measure in vivo receptor availability and fluctuations of endogenous glutamate. Several studies
have shown that [11C]ABP688 binding is altered following drug-induced perturbation of glutamate
levels in humans [10–12], baboons [13], rhesus monkeys [14] and rats [15]. In a pharmacological
challenge study by Wyckhuys et al. [16], N-acetylcysteine (NAc), a compound which facilitates the
activity of the cysteine–glutamate antiporter and indirectly increases extrasynaptic glutamate levels [17]
did not affect the in vivo binding of [11C]ABP688 in the rat brain. In another pharmacological challenge
study, Zimmer et al. [15] used the drug ceftriaxone, a potent GLT-1 activator [18], which induces a
decrease in extracellular glutamate levels. Ceftriaxone selectively increases the expression of glial
GLT-1 and protects neurons against ischemia via upregulation of GLT-1 following increased uptake
of glutamate. This leads to diminished excitotoxicity of glutamate and protection of neurons against
ischemia [19]. In their publication, Zimmer et al. reported an increase in [11C]ABP688 binding potential
in the thalamic ventral anterior nucleus of the rat brain, however, the global binding potential (whole
brain) was not changed under baseline and ceftriaxone challenge. No information was provided on
any other rat brain compartment besides the thalamic ventral anterior nucleus.
We here present our study assessing the feasibility of using the novel 18F-labelled mGluR5
antagonist [18F]PSS232 [20] to measure in vivo fluctuation of endogenous glutamate levels in the rat
brain by PET imaging. The results of this study should potentially shed more light on the utility of
[18F]PSS232 for measuring mGluR5 availability after drug-induced perturbation of glutamate levels in
the rat brain. We already reported on the kinetics of [18F]PSS232 in the rat brain and established the
model-independent area-under-the-curve ratio method for robust quantification of PET results [21].
Given the contradictory results obtained in rats using [11C]ABP688, we applied two different
pharmacological challenges of altering glutamate levels. We used (i) subanesthetic doses of ketamine,
an NMDA receptor antagonist known to increase glutamate release [22,23] and (ii) the GLT-1 activator
ceftriaxone, known to reduce glutamate levels. Furthermore, we compared the effects of racemic
and S-ketamine on mGluR5 availability since a number of studies have suggested a two-fold higher
potency for S-ketamine compared to racemic or R-ketamine [24–26]. Finally, in contrast to previous
studies that used bolus injections to modulate glutamate release, we compared the effect of bolus
injection and infusion of the three drugs.
2. Results
2.1. In Vitro Effects of Racemic Ketamine, S-Ketamine or Ceftriaxone on [18F]PSS232 Binding
To exclude direct binding of either racemic ketamine, S-ketamine or ceftriaxone to mGluR5,
we performed in vitro autoradiography using rat brain slices. Figure 1 shows [18F]PSS232 binding to
mGluR5-rich regions such as the striatum, hippocampus, cortex, cortex cingulate and bulbus olfactorius.
The cerebellum with low mGluR5 density showed less [18F]PSS232 binding. This binding pattern
was not altered when the brain slices were co-incubated with either racemic ketamine, S-ketamine or
ceftriaxone compared to the vehicle. This result indicates that there is no direct interference of these
pharmaceuticals with the binding site of [18F]PSS232 to mGluR5. In addition, after co-incubation of rat
brain slices with L-glutamate, we found no competition between L-glutamate and [18F]PSS232 binding
to mGluR5. As expected, the binding of [18F]PSS232 was abolished upon co-incubation with the two
mGluR5 antagonists, MMPEP and ABP688.
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Figure 1. Representative in vitro autoradiograms of a rat brain incubated with 1 nM [18F]PSS232
solution supplemented with vehicle (0.9% NaCl), racemic ketamine, S-ketamine, ceftriaxone,
L-glutamate, MMPEP ((2-[2-(3-methoxyphenyl)ethynyl]-6-methylpyridine hydrochloride) or ABP688
((Z)-N-methoxy-3-[2-(6-methylpyridin-2-yl)ethynyl]-cyclohex-2-en-1-imine) (each 1 μM). [18F]PSS232
binding was strong to bulbus olfactorius (Bo), cortex (Cx), cortex cingulate (Cc), striatum (St) and
hippocampus (Hi). Moderate binding was observed to thalamus (Th) and midbrain (Mi) and low
binding to cerebellum (Cb). Color bar indicates low and high binding. Hematoxylin/eosin (HE)
staining shows rat brain morphology. Scale bar: 5 mm.
2.2. In Vivo Effects of Racemic Ketamine, S-Ketamine or Ceftriaxone on [18F]PSS232 Binding
To measure ketamine- or ceftriaxone-induced changes in mGluR5 availability as an index of
glutamate release, we used [18F]PSS232 PET imaging applying a bolus injection protocol. In Figure 2a,
the mGluR5 distribution volume ratios (DVRs) for selected brain regions are depicted. For all three
drugs, the highest mGluR5 DRVs were found in the striatum (2.6 ± 0.03) followed by the hippocampus
(2.2 ± 0.04), cortex cingulate (2.2 ± 0.04) and cortex (2.1 ± 0.06). Global mGluR5 DVR for the
three drugs, racemic ketamine, S-ketamine and ceftriaxone, did not change and was similar for the
whole brain (1.7 ± 0.03). We found no significant between-group differences after bolus injections.
Based on human studies with [11C]ABP688 that reported reduced mGluR5 availability after infusion
of ketamine [10,12], we adjusted our study protocol and infused ketamine or ceftriaxone after an
initial bolus injection. Figure 2b shows the DVRs for different brain regions and the whole brain after
the different challenges, which, however, did not significantly differ from each other. Similar to the
bolus protocol, mGluR5 DVRs were highest in the striatum (2.6 ± 0.02) followed by the hippocampus
(2.1 ± 0.08), cortex cingulate (2.2 ± 0.05) and cortex (2.0 ± 0.05). Global mGluR5 DVR (1.7 ± 0.01) was
not affected by the different challenges and intergroup differences were also not significant. Figure 3a
shows parametric DVR images of the rat brain using bolus and infusion protocols. There were no
differences in [18F]PSS232 binding in either ketamine- or ceftriaxone-induced glutamate fluctuations
or injection protocols. Figure 3b shows the brain regions-of-interest defined to calculate the DVRs.
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Figure 2. Influence of (a) bolus injection or (b) infusion of vehicle (0.9% NaCl), racemic ketamine,
S-ketamine and ceftriaxone on [18F]PSS232 distribution volume ratios (DVRs) in different rat brain
regions. Number of animals as depicted. SD, standard deviations.
 
Figure 3. (a) illustration of averaged [18F]PSS232 brain uptake as mGluR5 distribution volume ratios
(DVRs) after vehicle (0.9% NaCl; n = 4), racemic ketamine (n = 4), S-ketamine (n = 4) and ceftriaxone
(n = 4) challenge. PET images were derived after bolus injection (left) or infusion (right) and presented
in axial, sagittal and coronal planes. St, striatum; Cx, cortex; Cb, cerebellum; Hi, hippocampus; Th,
thalamus; (b) definition of brain regions-of-interest on PET images in horizontal (coronal), sagittal and
vertical (axial) sections. Locations in mm are distance to the Bregma. The quantitative regions-of-interest
analysis is shown in Figure 2.
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In order to demonstrate reversibility of binding of [18F]PSS232 in vivo, displacement studies,
using MMPEP and ABP688, which were applied 40 min after [18F]PSS232 injection, were performed.
The results showed a rapid wash-out of radioactivity from mGluR5-rich brain regions (Figure 4a).
Striatal radioactivity values decreased shortly after MMPEP or ABP688 administration to the cerebellar
level and remained low (Figure 4b).
Figure 4. In vivo displacement study of [18F]PSS232 with either vehicle (n = 1; 1:1 PEG200/aqua
ad inject), 1 mg/kg MMPEP (n = 1) or 1 mg/kg ABP688 (n = 1) at 40 min post radiotracer
injection. (a) [18F]PSS232 PET images of rat brains averaged from 0–40 and 41–70 min after
radiotracer injection. PET images are presented in axial, sagittal and coronal planes. St, striatum;
Cb, cerebellum; (b) time–activity curves for [18F]PSS232 in the mGluR5-rich striatum and mGluR5-low
cerebellum. Dashed line at 40 min represents the time point of injection of the vehicle, MMPEP
((2-[2-(3-methoxyphenyl)ethynyl]-6-methylpyridine hydrochloride) or ABP688 ((Z)-N-methoxy-3
-[2-(6-methylpyridin-2-yl)ethynyl]-cyclohex-2-en-1-imine). SUV, standardized uptake values.
3. Discussion
The goal of this study was to investigate whether [18F]PSS232 can be used to image glutamate
fluctuations as was, to some extent, reported for [11C]ABP688. [18F]PSS232 is a fluorinated derivative of
[11C]ABP688, which binds to the same site in the transmembrane domain of mGluR5 as [11C]ABP688.
In our experimental setup, we induced glutamate increase by injection of ketamine and glutamate
decrease by activating GLT-1 with ceftriaxone. Several publications report significant changes in
endogenous extraneuronal glutamate levels by ketamine and ceftriaxone [12,15,22]. In our study,
we used ketamine dosages (25 mg/kg bolus, 0.6 mg/kg/h infusion) known to be high enough to
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increase extraneuronal glutamate levels, as measured in vivo with microdialysis [12,22]. Ketamine
increases glutamate directly by influencing mGluR5 functional status and through the antagonism of
NMDA receptors. Furthermore, mGluR5 and NMDA receptors functionally interact and mutually
potentiate their responses [27,28]. The dosage of the bolus-injected ceftriaxone (200 mg/kg) used in
this study was also reported to be high enough to decrease glutamate levels, at least in the thalamic
ventral anterior nucleus of the rat brain by micro-PET and microdialysis [15]. Changes in glutamate
levels after infusion of ceftriaxone have not been reported yet. Although GLT-1 and mGluR5 are
expressed in almost all brain regions, splice variants or differential expression of GLT-1 may explain the
distinct activation by ceftriaxone. Our experiments demonstrated that the mGluR5-specific radiotracer,
[18F]PSS232, was not able to detect changes in endogenous glutamate levels induced by ketamine or
ceftriaxone in the rat brain in vivo. Our in vitro autoradiography results showed that neither ketamine
nor ceftriaxone or glutamate itself competed with [18F]PSS232 for binding to mGluR5. However,
the allosteric antagonists MMPEP and unlabeled ABP688 reduced [18F]PSS232 binding in vitro and
in vivo. The in vivo displacement studies confirmed that [18F]PSS232 binds to the allosteric site of
mGluR5. Our in vivo findings indicate that the altered levels of endogenous glutamate did not alter
the capacity of [18F]PSS232 to bind to mGluR5 in the rat brain. We hypothesized that changes in
endogenous glutamate would lead to conformational changes of mGluR5 resulting in an increased or
decreased affinity of [18F]PSS232. However, our results indicated no affinity shift of [18F]PSS232 to
mGluR5 in vivo. The binding of [18F]PSS232 to the allosteric site instead of the orthosteric binding
site of mGluR5 might be dependent on the tertiary and quaternary receptor conformations [29].
Oligomeric and heteromeric forms of mGluR5 might influence the availability of the allosteric
site [30,31]. Furthermore, changes of in vivo glutamate levels might alter mGluR5 conformational
states, which were, however, not supported by our findings. On the other hand, affinity shift in
receptor–radioligand interactions was described for dopamine D2 receptors, where amphetamine
challenge altered the binding of a D2 PET radioligand [32,33].
To the best of our knowledge, this is the first study reporting on the potential of [18F]PSS232
to image glutamate fluctuations. In contrast to our results, a recent study in rats indicated that
[11C]ABP688 was able to visualize acute fluctuation in endogenous glutamate levels after challenge
with ceftriaxone [15]. Ceftriaxone administration increased [11C]ABP688 binding potential in the
thalamic ventral anterior nucleus bilaterally, but not in the frontal cortex. The authors have, so far,
no explanation why this thalamic region was the first to be affected by ceftriaxone and suggested
further investigations. We investigated the thalamic area but found no changes in mGluR5 DVRs after
vehicle, ceftriaxone or ketamine administration. To date, no publication is available that has reported on
ketamine-induced glutamate fluctuations and consequent alterations in mGluR5 availability using PET
imaging in the rat brain. Most of the ketamine challenges were performed in humans demonstrating a
rapid and large (20%) reduction in [11C]ABP688 binding after ketamine infusion in healthy humans [10].
The ketamine-induced decrease in [11C]ABP688 binding was explained by a reduction in mGluR5
availability due to internalization. This internalization might be in response to glutamate release or a
glutamate-induced conformational change in the receptor that reduces the likelihood of radioligand
binding at the allosteric site. Other approaches to increase endogenous glutamate have been made
with NAc in rats, rhesus monkeys and baboons. In baboons, NAc decreased [11C]ABP688 binding
potential, which may be the result of an affinity shift in the binding to the allosteric site [13]. In rats [16]
and rhesus monkeys [14], the binding of [11C]ABP688 was not affected after NAc challenge. In the
rat study, the authors applied the NMDA receptor antagonist MK-801, which has a similar action as
ketamine, and found no changes in [11C]ABP688 binding [16]. Although the authors used a different
pharmacological approach, their results are in line with our findings. Discrepancies among the different
studies could be species differences and variations in the methodology.
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4. Materials and Methods
4.1. Animals
All procedures were performed according the Guide to the Care and Use of Experimental
Animals of the Swiss legislation on animal welfare. All procedures fulfilled the ARRIVE guidelines
on reporting animal experiments and complied with the commonly-accepted ‘3Rs’. The protocols
for pharmacological administration and PET imaging were approved by the Veterinary Office of the
Canton Zurich, Switzerland (permit number: ZH017/2015). Male Wistar (Crl:WI) rats were purchased
from Charles River (Sulzfeld, Germany) and their body weights were between 350 g and 420 g at the
time of the experiments. Rats were kept in a room with controlled temperature (21 ◦C) under a 12-h
light/12-h dark cycle, with ad libitum access to food and water.
4.2. Radiosynthesis and Pharmaceuticals
The radiosynthesis of [18F]PSS232 was conducted as described previously [20]. The mean
molar radioactivity at end of synthesis was 95.3 ± 6.2 GBq/μmol. Racemic ketamine hydrochloride
was obtained from LGC (MM0144.00) (Teddington, UK), S-ketamine hydrochloride from Cayman
Chemical (CAY-9001961) (Ann Arbor, MI, USA), ceftriaxone from Sigma Aldrich (C5793) (St. Louis,
MO, USA), L-glutamate from Sigma Aldrich (128430), and 0.9% NaCl from B.Braun (Melsungen,
Germany). MMPEP (2-[2-(3-methoxyphenyl)ethynyl]-6-methylpyridine hydrochloride) and ABP688
((Z)-N-methoxy-3-[2-(6-methylpyridin-2-yl)ethynyl]-cyclohex-2-en-1-imine) were produced in-house.
For in vivo administration, both forms of ketamine were dissolved in aqua ad inject and ceftriaxone in
0.9% NaCl. MMPEP and ABP688 were dissolved in 1:1 PEG200/aqua ad inject. Isoflurane (Isocare,
Animalcare, York, UK) was used as an anesthetic agent. Scheme 1 shows the chemical structures of
[18F]PSS232, ABP688 and MMPEP.
Scheme 1. Chemical structures of the mGluR5 radiotracer [18F]PSS232 and mGluR5 antagonists
ABP688 ((Z)-N-methoxy-3-[2-(6-methylpyridin-2-yl)ethynyl]-cyclohex-2-en-1-imine) and MMPEP
((2-[2-(3-methoxyphenyl)ethynyl]-6-methylpyridine hydrochloride).
4.3. In Vitro Autoradiography
Coronal Wistar rat brain sections (10 μm) were cut on a cryostat (CryoStar NX50, Thermo
Scientific, Waltham, MA, USA) and mounted on glass slides (Superfrost Plus, Thermo Scientific).
Consecutive sections were thawed on ice for 10 min before pre-incubation in HEPES/BSA-buffer
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid/bovine serum albumin) (30 mM HEPES, 1.2 mM
MgCl2, 110 mM NaCl, 2.5 mM CaCl2, 5 mM KCl, pH 7.4, 0.1% BSA) at 4 ◦C for another 10 min. Excess
solution was carefully removed and tissue slices were incubated with 1 nM [18F]PSS232 supplemented
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with either vehicle (0.9% NaCl), 1 μM racemic ketamine, 1 μM S-ketamine, 1 μM ceftriaxone, 1 μM
L-glutamate, 1 μM mGluR5 antagonist MMPEP or 1 μM mGluR5 antagonist ABP688. After incubation
for 40 min at room temperature in a wet chamber, the slices were washed in ice cold HEPES/BSA-buffer
for 5 min, twice in HEPES-buffer for 2 min each and finally dipped twice in distilled water. Dried slices
were exposed to a phosphor imager plate (BAS-MS 2025, Fuji, Dielsdorf, Switzerland) for 15 min and
the plate was scanned in a BAS-5000 reader (Fuji). A consecutive section was stained with hematoxylin
(Gill No. 1, Sigma) and eosin (Eosin Y, Sigma) (HE) and digitalized by a slide scanner (Pannoramic 250,
Sysmex, Horgen, Switzerland) to obtain brain morphology.
4.4. In Vivo PET Imaging
In vivo positron emission tomography/computed tomography (PET/CT) scans were performed
with a calibrated Super Argus scanner (Sedecal, Madrid, Spain). Rats were anesthetized with isoflurane
(2% isoflurane at 0.4 L/min oxygen:air (1:1) flow). Respiratory rate and temperature were controlled
during the whole scan period (SA Instruments, Inc., Stony Brook, NY, USA). Rats were placed in a
prone position and the brain was positioned in the center of the field of view. All intravenous (i.v.)
injections were conducted via tail vein.
4.5. Bolus and Infusion Protocol
For the bolus injection protocol (Figure 5a), rats were injected with either 0.5 mL/kg vehicle i.v.
(0.9% NaCl; n = 4), 25 mg/kg racemic ketamine (n = 4) intraperitoneal (i.p.), 25 mg/kg S-ketamine (n = 4)
i.p. or 200 mg/kg ceftriaxone (n = 4) i.v. at 30 min before i.v. injection of [18F]PSS232 (28.0 ± 2.1 MBq,
3.3 ± 2.0 nmol/kg, 87.8 ± 9.8 GBq/μmol). A short CT scout preceded the PET acquisition that lasted
for 60 min and was followed by a CT scan to obtain anatomical orientation.
 
Figure 5. Glutamate challenge study design. (a) bolus protocol: anesthetized rats were injected
either with 0.5 mL/kg vehicle intravenously (0.9% NaCl i.v.), 25 mg/kg racemic or S-ketamine
intraperitoneally (i.p.) or 200 mg/kg ceftriaxone i.v. at 20 min before a short computed tomography
(CT scout) or 30 min before injection of [18F]PSS232 i.v., respectively. Positron emission tomography
(PET) scans lasted for 60 min followed by CT scan; (b) infusion protocol: anesthetized rats received a
short CT scout and were injected i.v. with either 0.5 mL/kg vehicle (0.9% NaCl), 0.3 mg/kg racemic or
S-ketamine or 200 mg/kg ceftriaxone. Administration of [18F]PSS232 i.v. preceded the infusion of either
0.6 mL/kg/h vehicle (0.9% NaCl), 0.6 mg/kg/h racemic or S-ketamine or 400 mg/kg/h ceftriaxone.
PET acquisition and infusion lasted for 60 min followed by a CT scan.
91
Pharmaceuticals 2018, 11, 83
For the infusion protocol (Figure 5b), rats received a short CT scout and were injected i.v. with
either 0.5 mL/kg vehicle (0.9% NaCl; n = 4), 0.3 mg/kg racemic ketamine (n = 4), 0.3 mg/kg S-ketamine
(n = 4) or 200 mg/kg ceftriaxone (n = 4). Administration of [18F]PSS232 i.v. (28.5 ± 3.2 MBq,
3.6 ± 2.4 nmol/kg, 95.2 ± 7.8 GBq/μmol) preceded the infusion of either 0.6 mL/kg/h vehicle
(0.9% NaCl), 0.6 mg/kg/h racemic ketamine, 0.6 mg/kg/h S-ketamine or 400 mg/kg/h ceftriaxone.
PET acquisition lasted for 60 min followed by a CT scan. At the end of the scans, rats were euthanized.
4.6. In Vivo Displacement Study
For displacement studies of [18F]PSS232 from mGluR5 binding sites either 1 mL/kg vehicle (1:1
PEG200/aqua ad inject), 1 mg/kg MMPEP or 1 mg/kg ABP688 was i.v. injected at 40 min after
[18F]PSS232 i.v. injection (30.1 ± 3.2 MBq, 3.0 ± 1.9 nmol/kg, 103.6 ± 4.8 GBq/μmol). We chose this
relatively late time point to guarantee radiotracer equilibration in the brain. The total duration of the
PET scan was 70 min followed by a CT scan.
4.7. Image Data Reconstruction, Analysis and Calculation of Distribution Volume Ratios (DVRs) as Well as
Standardized Uptake Values (SUVs)
PET data were reconstructed in user-defined time frames with a voxel size of 0.3875 × 0.3875 ×
0.775 mm3 by two-dimensional-ordered subsets expectation maximization (2D-OSEM). Random and
single but no attenuation correction was applied. Image files were analyzed with PMOD 3.8 software
(PMOD Technologies Ltd., Zurich, Switzerland). For calculation of DVRs in regions-of-interest, specific
brain regions were defined on the bases of the rat MRI T2 template (provided with PMOD software)
(Figure 3b). Given that hardly any specific binding was found in rat cerebellum, this brain region was
used as a reference region. DVRs were calculated from areas-under-the-curve as described recently [21].
Individual DVR images were calculated voxel-wise with the PXMod module of PMOD by means of
the implemented reference Logan model and the cerebellum as reference region. Individual DVR
images of the 4 animals per group were combined and averaged with the View module of PMOD.
For calculation of the time–activity curves for striatum and cerebellum, both regions were defined
on the rat MRI T2 template. The tissue radioactivity values of both brain regions were decay-corrected
and normalized to the injected radioactivity and body weight resulting in SUVs.
4.8. Statistical Analysis
Differences in mean values were evaluated by one-way analysis of variance (ANOVA) tests,
followed by corrections for multiple testing (Bonferroni) using GraphPad Prism 6.0 software
(GraphPad, La Jolla, CA, USA). A p-value < 0.05 was considered significant.
5. Conclusions
The present study verified that [18F]PSS232 binds to delineated structures in the rat brain; however,
[18F]PSS232 does not seem to be a valuable tool for the in vivo assessment of acute endogenous
glutamate fluctuations. Neither increased glutamate levels after ketamine challenge with changes in
the functional status of mGluR5 through inhibition of the NMDA receptor nor decreased glutamate
levels after challenge with GLT-1 activator ceftriaxone had any effect on the binding of [18F]PSS232 to
mGluR5. Whether [18F]PSS232 will show similar effects in humans as demonstrated for [11C]ABP688
remains to be validated in future clinical studies.
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Abstract: Positron emission tomography (PET) imaging of Colony Stimulating Factor 1 Receptor
(CSF1R) is a new strategy for quantifying both neuroinflammation and inflammation in the
periphery since CSF1R is expressed on microglia and macrophages. AZ683 has high affinity
for CSF1R (Ki = 8 nM; IC50 = 6 nM) and >250-fold selectivity over 95 other kinases. In this
paper, we report the radiosynthesis of [11C]AZ683 and initial evaluation of its use in CSF1R PET.
[11C]AZ683 was synthesized by 11C-methylation of the desmethyl precursor with [11C]MeOTf in
3.0% non-corrected activity yield (based upon [11C]MeOTf), >99% radiochemical purity and high
molar activity. Preliminary PET imaging with [11C]AZ683 revealed low brain uptake in rodents and
nonhuman primates, suggesting that imaging neuroinflammation could be challenging but that the
radiopharmaceutical could still be useful for peripheral imaging of inflammation.
Keywords: neuroinflammation; microglia; carbon-11; radiochemistry; positron emission tomography
1. Introduction
Colony Stimulating Factor 1 Receptor (CSF1R, M-CSF, or cFMS) is a class III receptor tyrosine
kinase [1] that regulates immune response by controlling the survival and activity of macrophages
and macrophage-like cells [2]. Aberrant activity of CSF1R, or its endogenous ligands (CSF1 and
IL-34), plays a role in many disorders that have an immune/inflammatory component [3]. Specifically,
chronic inflammation caused by increased activity of macrophages due to increased CSF1R response is
present in many autoimmune disorders such as rheumatoid arthritis, inflammatory bowel disease, and
autoimmune nephritis, among others [4,5]. The contribution of CSF1R to symptomatic Alzheimer’s
Disease (AD) is also well known, due in part to its proliferative effects on microglia, which are
associated with neuroinflammation, a hallmark clinical symptom of AD [6,7]. A mechanism for CSF1R
involvement in inter-neuronal transmission of pathogenic tau protein by microglia was also recently
elucidated [8]. Involvement of CSF1R in certain types of cancers, such as gliomas, also correlates with
poor disease prognosis, as proliferation of CSF1R-controlled tumor-associated macrophages (TAMs)
correlates with tumor angiogenesis and metastasis [4,9–11].
Consequently, CSF1R inhibitors (both small molecules and biologics) have been proposed as
a means of controlling inflammation in this multitude of diseases and disorders via macrophage
depletion/regulation [12]. Many CSF1R inhibitors, including some that are kinase-specific, can be
found in both academic and patent literature [4,5,13], and several have proceeded to clinical trials for
the treatment of RA [14] and various types of cancer [11]. However, not all macrophage populations
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are CSF1R-sensitive, necessitating that CSF1R involvement must be positively identified prior to the
start of treatment. As CSF1R is a cell surface receptor, its upregulation is only present at the site of
inflammation. Although blood biomarkers can be used to directly measure CSF1R involvement in
certain diseases, such as lymphoma [11], methods of determining CSF1R involvement and quantifying
CSF1R levels at loci not directly connected to the central circulatory system is difficult, particularly in
the CNS, and employs either indirect means (i.e., measurement of CSF1 levels as a proxy for CSF1R [14])
or invasive procedures (i.e., immunohistochemistry using a biopsy sample or surgically excised
tissue [15,16]). In fact, despite the implication of irregular CSF1R levels in numerous diseases [4],
quantitative information on expression levels in disease is generally lacking from the literature. In
part this is because CSF1R levels are constantly changing as, for example, macrophages are produced
and/or cleared, but also because there is currently an unmet need for a non-invasive method that
can positively identify and quantify CSF1R involvement in disease. This goal can be readily achieved
with positron emission tomography (PET) imaging, wherein a CSF1R-selective radiolabeled ligand
(radiopharmaceutical) would be used to detect changes in activity, expression levels, and localization of
CSF1R in a minimally-invasive manner. Furthermore, a brain-penetrant CSF1R-selective PET imaging
agent could be used to selectively image microglia, as they are the only cells in the brain that express
CSF1R under normal conditions [17]. Microglia associate with amyloid beta plaques in the brain [18],
and are implicated in pathological tau transmission [8] and neuroinflammation [6,7], both of which are
important in the progression of neurodegenerative disorders.
The current method of choice for imaging macrophages/microglia is by targeting the translocator
protein 18 kDa (TSPO). However, TSPO is not an ideal imaging target since it is expressed in various
tissue types (in addition to immune cells). Moreover, a single nucleotide polymorphism (SNP) in the
TSPO gene has been identified that leads to considerable variability in its expression levels between
patients and, consequently, variability in the corresponding PET data [19]. Therefore, a CSF1R imaging
agent selective for microglia is of considerable interest for using PET both to quantify CSF1R and as a
surrogate biomarker for neuroinflammation (and peripheral inflammation).
Radiopharmaceuticals used in PET imaging are often structural analogs of existing pharmaceutical
agents that have been labeled with a positron-emitting radionuclide such as 11C, 18F or 124I. As
such, the radiopharmaceutical can be expected to possess the same pharmacokinetic properties as
its nonradioactive counterpart and behave accordingly in vivo. Fortunately, lead identification for
CSF1R PET radiopharmaceutical development is relatively straightforward because recent interest in
developing CSF1R inhibitors has led to hundreds of active compounds, several of which have also been
translated into clinical trials (see Figure 1 for several leads) [4,5,13]. PET imaging agents for CSF1R
have been reported [20,21], but none have seen widespread use to date. One is a mixed inhibitor of both
CSF1R and tropomyosin receptor kinases B and C (Trk B/C) [20], while the second ([11C]JHU11744)
has shown promise in preliminary evaluation in rodent models of AD and neuroinflammation [21].
PET imaging of CSF1R therefore remains underdeveloped and herein we attempt to address this
issue through development of [11C]AZ683, a new radiopharmaceutical for CSF1R. AZ683 (Figure 1)
was selected because it has >250-fold selectivity for CSF1R over 95 other kinases, low plasma protein
binding, a good pharmacokinetic (PK) profile, and both fluorine and N-methyl moieties which are
potential sites for radiolabeling with 18F or 11C, respectively [22–24]. Moreover, AZ683 has low
nanomolar affinity for CSF1R (Ki = 8 nM; IC50 = 6 nM), making it ideal for PET studies which typically
utilize nanomoles-picomoles of radiotracer, and the cLogP of the neutral (uncharged) compound is
3.1 which suggests that it should cross the BBB. Since N-methylation of the desmethyl precursor with
[11C]MeI (or [11C]MeOTf) was envisioned to be simpler than 18F-labeling of this scaffold, the synthesis
and carbon-11 radiolabeling of [11C]AZ683 was undertaken for initial evaluation and is described
herein. We also report preliminary evaluation of the radiotracer as a CSF1R imaging agent in rodent
and non-human primate PET imaging studies.
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Figure 1. Potential lead compounds for CSF1R radiopharmaceutical development (proposed radiolabeling
sites are shown in red).
2. Results and Discussion
2.1. Synthesis of Reference Standard and Precursor
AZ683 reference standard 6a and N-desmethyl precursor 7 were synthesized via modified
literature procedures in five and six steps, respectively (Scheme 1) [23]. Both syntheses diverged
from a common intermediate 4. This common intermediate was synthesized via condensation of
4-bromo-3-ethoxyaniline (1) with diethylethoxymethylenemalonate to yield 2. This was followed
by cyclization/chlorination with POCl3 and tetrabutylammonium chloride to form chloroquinoline
3. A subsequent SNAr reaction with 2,4-difluoroaniline yielded intermediate 4. Buchwald–Hartwig
cross-coupling was then used to couple either N-Boc piperazine or N-methylpiperazine with 4, yielding
intermediates 5a and 5b for the reference standard and precursor, respectively. Amidation of the ethyl
ester of 5 was performed using formamide/NaOEt to generate reference standard 6a and N-Boc
protected precursor 6b. Final deprotection of the Boc group of 6b with trimethylsilyl chloride in
methanol furnished precursor 7. Precursor 7 and reference standard 6a were readily separable on
analytical and semipreparative Phenomenex Luna C18 columns using a 30% ethanolic eluent buffered
with sodium phosphate at a pH of 6.6 (see Materials and Methods for details).
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Scheme 1. Synthesis of precursor and reference standard for [11C]AZ683. Reagents and conditions:
(i) diethylethoxymethylenemalonate, K2CO3, MeCN, 70 ◦C (71%); (ii) POCl3, TBACl, toluene, 130 ◦C
(17%); (iii) 2,4-difluoroaniline, 20% AcOH, EtOH, 80 ◦C (66%); (iv) 1–5 mol % Pd2(dba)3, BINAP,
Cs2CO3, toluene, 100 ◦C (5a: 54%; 5b: 45%); (v) formamide, NaOEt, EtOH/THF, reflux (6a: 32%; 6b:
30%); (vi) TMSCl, MeOH, room temp (100% from 6b).
2.2. Radiosynthesis of [11C]AZ683
Radiolabeling of [11C]AZ683 was accomplished by treating precursor 7 with [11C]MeOTf
(Scheme 2). The labeling reaction was automated using a TRACERLab FXC-pro synthesis module
and our standard carbon-11 procedures [25]. Following radiolabeling, [11C]AZ683 was purified within
the synthesis module via semipreparative HPLC and formulated for injection (0.9% saline solution
containing 10% ethanol) using a Waters C18 1cc vac cartridge to trap/release the product. This resulted
in an overall non-decay corrected activity yield of 1125 ± 229 MBq (3.0% based upon 37 GBq of
[11C]MeOTf), radiochemical purity >99%, and molar activity of 153 ± 38 GBq/μmol (n = 4), confirming
doses were suitable for preclinical evaluation.
 
Scheme 2. Radiosynthesis of [11C]AZ683. Reagents and conditions: (i) [11C]MeOTF, DMF, rt, 3 min
(3.0% activity yield).
2.3. Preclinical PET Imaging
Initial evaluation of the imaging properties of [11C]AZ683 was undertaken in female
Sprague–Dawley rat. [11C]AZ683 was administered via intravenous tail vein injection and rodent
brain imaging was conducted for 60 min. To our surprise, [11C]AZ683 showed very little brain uptake
but did show high uptake and retention in the pituitary and thyroid glands (Figure 2, left). Although
both glands are known for expression of CSF1R protein (thyroid) and CSF1R RNA (thyroid and
pituitary) [26], we assume the very high uptake is more likely indicative of non-specific binding
associated with the lipophilic nature of the compound (Table 1). Since inter-species differences are
sometimes apparent between rodents and non-human primates due to the higher metabolic rate in
rodents and differing BBB efflux systems, imaging in rhesus macaque brain was also performed. The
primate imaging results largely mirrored the rat data, with fairly poor brain influx during the early
frames, followed by almost complete washout and little brain retention in a normal brain (Figure 2,
right). There was some retention in the central region of the brain that was likely ventricular uptake
and, as before, the pituitary gland could be observed in frame and showed a much greater degree
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of uptake than brain. Overall though, brain uptake in monkey was higher than in rat and there was
perhaps some focal uptake in the monkey cerebellum (standardized uptake value (SUV) ~0.3–0.4 at
late time points). Given that the cerebellum is an area of known CSF1R expression in humans [26], and
CSF1R function is thought to be conserved between vertebrates [27], this signal could correspond to
CSF1R, presumably associated with microglia found in the monkey cerebellum [28]. However, this will
need to be confirmed in future in vitro experiments with primate brain sections. Target receptor density
of CSF1R could ostensibly be low in a non-diseased control animal and would explain poor brain
retention, but again normal CSF1R levels are challenging to quantify in vivo as they are transient and
expected to fluctuate with the turnover of macrophages and microglia. However, low receptor density
would not limit first pass brain influx and efflux which was also quite low. Overall these PET imaging
data suggest imaging CSF1R associated with neuroinflammation using [11C]AZ683 may be challenging,
but that uptake in monkey could be sufficient to observe accumulation in a brain inflammation model.
There is literature precedent for TSPO radiotracers with low brain uptake being used to successfully
image inflammation in rat models [29,30]. Moreover, the present studies do not rule out labeling the
scaffold with a longer-lived PET radionuclide (e.g., 18F or 124I) and using a prolonged infusion protocol
so that sufficient radiotracer accumulates at sites of inflammation. [11C]AZ683 could also possibly be
used for imaging of peripheral CSF1R to evaluate its role in inflammation outside of the brain.
Given that [11C]AZ683 possesses properties mostly consistent with BBB permeability
(Table 1) [23,31,32], the lack of brain uptake was unexpected and the reasons for it are unclear. It is
possible that [11C]AZ683 is a substrate for an efflux transporter on the BBB and since, for example,
P-glycoprotein transporter (P-gp) expression is higher in rodents than monkeys (and humans) [33],
this could explain the 2–3-fold higher uptake of the radiotracer observed in monkey brain. Given the
differences in type and expression levels of efflux transporters between species, monkeys are better for
predicting the role of P-gp in limiting brain penetration of drugs in humans [33]. However, as we take a
conservative view towards primate safety, methods to determine whether efflux activity is responsible
for the low brain uptake of [11C]AZ683 (e.g., cyclosporin A blockade of the P-gp transporter [34])
have not been pursued at this time. Alternatively, in this case, cLogP estimates (Table 1) may not be a
good indicator of BBB permeability. [11C]AZ683 has multiple groups containing nitrogen and oxygen
atoms which are ionizable, corresponding to multiple pKa values (Figure 3 [32]). We do not expect
the primary amide to limit BBB permeability since we conduct brain imaging with other primary
amide-containing radiopharmaceuticals such as [11C]LY2795050 [35]. Understanding the relationship
between cLogP of charged species as a function of pH is complicated [31], but it is likely that AZ683
is charged at physiological pH and this could be the reason for poor brain uptake. The oxygen and
nitrogen atoms in question also participate in hydrogen bonding, and cLogP—the total number of
oxygen and nitrogen atoms in a drug molecule (N + O) offers information about logBBB. If cLogP—(N
+ O) >0, logBBB is likely to be positive and the drug has a good probability of entering the CNS [31].
In the case of AZ863, cLogP—(N + O) = −4, suggesting the number of oxygen and nitrogen atoms
may be too high for good CNS penetration. All of these issues should be considered in the design of
next generation CSF1R radiopharmaceuticals going forward.
Table 1. Properties of [11C]AZ683 compared to a typical CNS drug.
Property Preferred Value for Successful CNS Drugs [31] [11C]AZ683 [23,32]
Activity Low nM Ki = 8 nM; IC50 = 6 nM
cLogP <5 (Lipinski’s Ro5 [29])<2.7 (optimized [29]) 3.1
tPSA 60–70 Å2 83 Å2
Molecular weight ≤450 g/mol 441 g/mol
H-bond donors ≤3 2
H-bond acceptors ≤7 6
Rotatable bonds <8 8
Metabolic stability T1/2 > 3.1 h 2.1 h
Solubility >60 μg/mL 128 μg/mL
pKa 7.5–10.5 6.5–7.5
cLogP—(N + O) >0 −4
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Figure 2. Summed rodent (left) and primate (right) PET images of [11C]AZ683 (0–60 min after injection
of the radiotracer) and associated time–radioactivity curves (SUV = standardized uptake value).
Figure 3. Multiple pKa values for AZ683 [32].
3. Materials and Methods
3.1. Synthesis
3.1.1. General Considerations
All the chemicals were purchased from commercially available suppliers and used without
purification. Automated flash chromatography was performed with Biotage Isolera Prime system.
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High-performance liquid chromatography (HPLC) was performed using a Shimadzu LC-2010A HT
system. 1H NMR spectra were acquired using a Varian 400 apparatus (400 MHz) in CDCl3 or CD3OD. δ
are reported in ppm relative to tetramethylsilane (δ = 0), J are given in Hz. Mass spectra were measured
on an Agilent Technologies (Santa Clara CA, USA) Q-TOF HPLC-MS or Micromass (Manchester, UK)
VG 70-250-S Magnetic sector mass spectrometer employing the electrospray ionization (ESI) method.
3.1.2. Compounds Synthesized
Diethyl 2-(((4-bromo-3-ethoxyphenyl)amino)methylene)malonate (2). To a solution mixture of
4-bromo-3-ethoxyaniline hydrochloride (1) (0.66 g, 3 mmol) and K2CO3 (1.68 g, 12.2 mmol) in MeCN
(30 mL) was added diethyl-ethoxymethylene malonate (620 μL, 3 mmol). The reaction was heated to
reflux and allowed to stir for 36 h, at which time it was cooled and vacuum filtrated through celite to
remove potassium carbonate. The filtrate was purified by flash chromatography using a hexane-EtOAc
gradient to yield 2 (0.84 g, 71%). 1H-NMR (400 MHz, CDCl3) δ 11.00 (d, J = 13.5 Hz, 1H), 8.45 (d,
J = 13.5 Hz, 1H), 7.49 (d, J = 8.5 Hz, 1H), 6.63 (d, J = 8.5 Hz, 1H), 6.59 (d, J = 2.4 Hz, 1H), 4.33–4.22 (m,
4H), 4.09 (q, J = 7.0 Hz, 2H), 1.49 (t, J = 7.0 Hz, 3H), 1.38–1.31 (m, 6H). [M + H]+: Expected 386.0598,
Found 386.0604.
Ethyl 6-bromo-4-chloro-7-ethoxyquinoline-3-carboxylate (3). Compound 2 (0.84 g, 2.2 mmol) was dissolved
in dry Toluene (2.5 mL). Tert-Butyl ammonium chloride (TBACl: 1.94 g, 7 mmol) was added, followed
by POCl3 (2 mL, 22 mmol) while stirring at room temperature for 5 min. The reaction mixture was
then heated to reflux and stirred for 68 h. After this time the reaction was cooled, diluted with DCM
(30 mL) and quenched with water (30 mL). The aq. layer was extracted with further DCM (30 mL) and
the combined organic fractions were washed with brine (60 mL), dried (Na2SO4) and concentrated.
The crude material was purified by flash chromatography using a hexane/EtOAc gradient to yield 3
(0.15 g, 17%). 1H-NMR (400 MHz, CDCl3) δ 9.16 (s, 1H), 8.61 (s, 1H), 7.42 (s, 1H), 4.48 (q, J = 7.2 Hz,
2H), 4.28 (dd, J = 14.1, 7.0 Hz, 2H), 1.58 (t, J = 7.0 Hz, 3H), 1.45 (t, J = 7.2 Hz, 3H). [M + H]+: Expected
357.9840, Found 359.9820. Cl-37 accounts for difference in expected value.
Ethyl 6-bromo-4-((2,4-difluorophenyl)amino)-7-ethoxyquinoline-3-carboxylate (4). Compound 3 (0.15 g,
0.41 mmol) was dissolved in ethanol (10 mL). 20 mol % acetic acid (4.7 μL, 0.082 mmol) was added
followed by 2,4-difluoroaniline (46 μL, 0.45 mmol, 1.1 eq.). The reaction was heated to reflux and
stirred for 24 h. After this time the reaction was cooled and Et3N (100 μL) was added to neutralize
acetic acid. The crude reaction mixture was purified by flash chromatography to yield title compound
4 (0.11 g, 66%). 1H-NMR (400 MHz, CDCl3) δ 10.30 (s, 1H), 9.19 (s, 1H), 7.73 (s, 1H), 7.03 (s, 1H),
6.97–6.94 (m, 1H), 6.94–6.92 (m, 1H), 6.84 (t, J = 8.3 Hz, 1H), 4.43 (q, J = 7.1 Hz, 2H), 4.23 (q, J = 7.0 Hz,
2H), 1.53 (t, J = 7.0 Hz, 3H), 1.45 (t, J = 7.1 Hz, 3H). [M + H]+: Expected 451.0463, Found 451.0463.
Ethyl 4-((2,4-difluorophenyl)amino)-7-ethoxy-6-(4-methylpiperazin-1-yl)quinoline-3-carboxylate (5a).
Compound 3 (113 mg, 0.251 mmol) was dissolved in dry toluene (10 mL). To this solution,
1-methylpiperizine (33.4 μL, 0.301 mmol, 1.2 eq.) was added. This solution was aspirated with a
syringe and added to a mixture of 2.5 mol % Pd2(dba)3 (5.75 mg, 0.007 mmol), 2.5 mol % BINAP
(3.9 mg, 0.007 mmol) and 1.6 eq. of Cs2CO3 (0.13 g, 0.402 mmol) under Ar. The reaction was heated to
100◦C and stirred for 60 h. After this time the reaction was cooled and quenched with satd. KHCO3
(20 mL). The organic layer was washed with water (50 mL) and the water was extracted twice with
EtOAc. The organic layers were combined, washed with brine (60 mL), concentrated and dried
(Na2SO4). The residue was purified by flash chromatography using an EtOAc/MeOH gradient to
yield compound 5a (64 mg, 54%). 1H-NMR (400 MHz, CDCl3) δ 10.14 (s, 1H), 9.11 (s, 1H), 7.32 (s,
1H), 7.26 (s, 1H), 7.00–6.90 (m, 1H), 6.89 (s, 1H), 6.75 (t, J = 8.4 Hz, 1H), 4.42 (q, J = 7.1 Hz, 2H), 4.21 (q,
J = 6.9 Hz, 2H), 2.83 (m, 4H), 2.55 (m, 4H), 2.30 (s, 3H), 1.51 (t, J = 6.9 Hz, 3H), 1.48–1.44 (m, 3H). [M +
H]+: Expected 471.2202, Found 471.2202.
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Ethyl 6-(4-(tert-butoxycarbonyl)piperazin-1-yl)-4-((2,4-difluorophenyl)amino)-7-ethoxyquinoline -3-carboxylate
(5b). The same procedure described for the synthesis of 5a was also used to prepare 5b (61 mg, 44.5%).
1H-NMR (400 MHz, CDCl3) δ 10.08 (s, 1H), 9.12 (s, 1H), 7.30 (s, 1H), 6.96–6.88 (m, 2H), 6.86 (s, 1H),
6.75 (t, J = 8.2 Hz, 1H), 4.43 (q, J = 7.1 Hz, 3H), 4.21 (q, J = 7.0 Hz, 2H), 3.53–3.45 (m, 4H), 2.75–2.67 (m,
4H), 1.52 (t, J = 7.0 Hz, 3H), 1.47 (s, 9H), 1.44 (d, J = 7.1 Hz, 3H). [M + H]+: Expected 557.2571, Found
557.2571.
4-((2.,4-Difluorophenyl)amino)-7-ethoxy-6-(4-methylpiperazin-1-yl)quinoline-3-carboxamide (AZ683
Reference Standard 6a). Compound 5a (53 mg, 0.113 mmol) was dissolved in THF (0.1 mL) and
formamide (22.4 μL, 0.563 mmol, 5 eq.) was added. To this solution, a 21% wt solution of NaOEt in
EtOH (231 μL, 0.563 mmol, 5 eq.) was added. The reaction was heated to reflux and stirred for 16 h,
after which time it was cooled and quenched with NH4Cl (53 mg, 1 mmol). The reaction mixture was
concentrated onto silica and purified by flash chromatography using an EtOAc/MeOH gradient to
yield compound 6a (16 mg, 32%). 1H-NMR (400 MHz, CD3OD) δ 8.78 (s, 1H), 7.27 (s, 1H), 7.16–7.06
(m, 3H), 6.95 (t, J = 8.6 Hz, 1H), 4.25 (q, J = 6.9 Hz, 3H), 3.10 (m, 4H), 2.73 (m, 4H), 1.96 (s, 3H), 1.51 (t,
J = 6.9 Hz, 3H). [M + H]+: Expected 442.2049, Found 442.2048.
tert-Butyl 4-(3-carbamoyl-4-((2,4-difluorophenyl)amino)-7-ethoxyquinolin-6-yl)piperazine-1-carboxylate (6b).
The same procedure described for the synthesis of 6a was used to prepare 6b (18 mg, 30%). 1H-NMR
(400 MHz, CDCl3) δ 10.44 (s, 1H), 8.76 (s, 1H), 7.27 (s, 1H), 6.94–6.88 (m, 2H), 6.87 (s, 1H), 6.74 (t,
J = 8.3 Hz, 1H), 6.21 (br. s, 1H), 4.20 (q, J = 6.9 Hz, 2H), 3.48–3.47 (m, 4H), 2.73–2.71 (m, 4H), 1.51 (t,
J = 6.9 Hz, 3H), 1.47 (s, 9H). [M + H]+: Expected 528.2417, Found 528.2419.
4-((2,4-Difluorophenyl)amino)-7-ethoxy-6-(piperazin-1-yl)quinoline-3-carboxamide (7). Compound 6b
(18 mg, 0.034 mmol) was dissolved in dry MeOH (5 mL) and cooled to -78 ◦C for 5 min. Trimethylsilyl
chloride (TMS-Cl, 43.3 μL, 0.341 mmol, 10 eq.) was added and the reaction was allowed to warm
up to room temperature and was stirred until deprotection was complete as determined by TLC
(~25 h). The reaction was quenched with water and concentrated to remove solvent and excess TMS-Cl.
The concentrate was re-dissolved in MeOH and re-concentrated two more times to ensure complete
removal of TMS-Cl. The product was further dried in a vacuum desiccator to yield compound 7 (15 mg,
100%). 1H-NMR (400 MHz, CD3OD) δ 8.80 (s, 1H), 7.56–7.50 (m, 1H), 7.38 (s, 1H), 7.34 (s, 1H), 7.26–7.18
(m, 1H), 7.14 (t, J = 8.4 Hz, 1H), 4.33 (q, J = 7.0 Hz, 2H), 3.39–3.33 (m, 4H), 3.22–3.20 (m, 4H), 1.55 (t,
J = 7.0 Hz, 3H). [M + H]+: Expected 428.1893, Found 428.1892.
3.2. Radiochemistry
3.2.1. General Considerations
All the chemicals (except for reference standard 6a and precursor 7 noted above) were purchased
from commercially available suppliers and used without purification: sodium chloride, 0.9% USP
and Sterile Water for Injection, USP were purchased from Hospira; Dehydrated Alcohol for Injection,
USP was obtained from Akorn Inc. (Lake Forest IL, USA) HPLC was performed using a Shimadzu
(Kyoto, Japan) LC-2010A HT system equipped with a Bioscan B-FC-1000 radiation detector, and HPLC
columns were acquired from Phenomenex (Torrance CA, USA). Other synthesis components were
obtained as follows: sterile filters were acquired from MilliporeSigma (Burlington MA, USA); C18 Vac
1cc Sep-Paks were purchased from Waters Corporation (Milford MA, USA); Sep-Paks were flushed
with 5 mL of ethanol followed by 10 mL of sterile water prior to use.
3.2.2. Radiosynthesis of [11C]AZ683
[11C]CO2 was produced with a General Electric Healthcare (GE, Uppsala, Sweden) PETTrace
cyclotron via the 14N(p,α)11C reaction. High purity N2 (g) containing 0.5% O2 was irradiated at
40 μA for 30 min to generate [11C]CO2 (~111 GBq), which was delivered to a GE TRACERLab FXC-Pro
synthesis module and converted to [11C]MeOTf (~37 GBq) as previously described [25]. [11C]MeOTf
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was bubbled at 15 mL/min through a solution of precursor 7 (1 mg) in DMF (100 μL) at room
temperature for 3 min. Following radiolabeling, the reaction mixture was diluted with HPLC mobile
phase and purified by semipreparative HPLC (column: Phenomenex Luna C18, 10μ, 10 × 250 mm;
mobile phase: 27% ethanol, 10 mM Na2HPO4, pH = 5.75; flow rate: 5 mL/min; see Figure 4 for a
representative semipreparative HPLC trace). The peak corresponding to [11C]AZ683 (tR ~12–14 min)
was collected, diluted in water (50 mL), and the resulting solution was passed through a Waters C18 1cc
vac cartridge to trap the product. [11C]AZ683 was eluted from the cartridge with ethanol (1 mL) and
diluted with 0.9% saline solution (9 mL) to provide the formulated product in 10% EtOH. The dose was
passed through a 0.22 μm sterile filter into a sterile dose vial. The overall non-decay corrected activity
yield of [11C]AZ683 was 1125 ± 229 MBq (3.0% based upon 37 GBq of [11C]MeOTf) and quality control
testing (see below) confirmed radiochemical purity >99%, and molar activity of 153 ± 38 GBq/μmol
(n = 4), confirming doses were suitable for preclinical evaluation.
Figure 4. Typical semi-preparative HPLC trace for [11C]AZ683.
3.2.3. Quality Control Testing of [11C]AZ683
Visual inspection
Doses were visually examined and required to be clear, colorless, and free of particulate matter.
Dose pH
The pH of the doses was determined by applying a small amount of the dose to pH-indicator
strips and determined by visual comparison to the scale provided. pH needs to be between 4.5 and 7.5,
and the pH of each [11C]AZ683 dose synthesized in this study was 5.0.
Analytical HPLC
Analytical HPLC was performed using a Shimadzu LC-2010A HT system equipped with a Bioscan
B-FC-1000 radiation detector (column: Phenomenex Luna C18, 5μ, 4.6 × 150 mm; mobile phase: 27%
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ethanol, 10 mM Na2HPO4, pH: 5.75; flow rate: 0.75 mL/min). Analysis confirmed radiochemical
purity >99% (tR of [11C]AZ683 ~6 min; see Figure 5 for a typical analytical HPLC trace) and coinjection
with unlabeled reference standard 6a confirmed radiochemical identity (see Figure 6 for a coinjection
HPLC trace).
 
Figure 5. Analytical HPLC trace for formulated [11C]AZ683 dose.
 
Figure 6. Analytical HPLC trace for formulated [11C]AZ683 dose co-injected with AZ683 reference
standard 6a.
3.3. Preclinical PET Imaging
3.3.1. General Considerations
Rodent and primate imaging studies were performed at the University of Michigan (UM) using
a Concorde (CTI-Concorde, Knoxville TN, USA) MicroPET P4 scanner. The University of Michigan
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is accredited by the Council on Accreditation of the Association for Assessment and Accreditation
of Laboratory Animal Care (AAALAC International, Frederick MD, USA) and imaging studies were
conducted in accordance with the standards set by the Institutional Animal Care and Use Committee
(IACUC) at the University of Michigan (PRO00008103: Biodistribution and Pharmacokinetics of
Radiolabeled Compounds; Approval date: 1/16/2018).
3.3.2. Animal Husbandry and Housing
Husbandry and housing for rodents and primates is provided by the University Laboratory for
Animal Medicine (ULAM) at UM, and animal facilities are in compliance with the regulations defined
by the US Department of Agriculture (USDA).
Monkeys: The University of Michigan PET Center has maintained 2 rhesus macaques for
~15 years and the monkeys are individually housed in adjacent steel cages (83.3 cm high × 152.4 cm
wide × 78.8 cm deep) equipped with foraging boxes. They are currently housed in adjacent cages as
repeated attempts to socially house them in the same cage have been unsuccessful due to aggressive
incompatibility. Cages are metal and do contain gridded floors for radiation safety reasons (radioactive
waste is contained to the gridded floor and is easier to clean). Temperature and humidity are carefully
controlled, and the monkeys are kept on a 12 h light/12 h dark schedule. Monkeys are fed Lab Fiber
Plus Monkey Diet (PMI Nutrition Intl. LLC, Shoreview MN, USA) that is supplemented with fresh fruit
and vegetables daily. Water and enrichment toys (manipulanda and food-based treats) are available
continuously in the home cage.
Rodents: Rats are housed in Allentown #3 micro ventilated cages (27 cm wide × 49 cm deep
× 27 cm high, floor area 923 Sq cm) with animal housing densities set by ULAM and the Guide for
the Care and Use of Laboratory Animals. Housing is located on ventilated racks with continuous
water and air supply exchange. All animals are provided with LabDiet 5LOD as well as enrichment
materials, and are on a light schedule of 12 h light/12 h dark.
3.3.3. Rodent Imaging Protocol
Rodent imaging studies were done using a female Sprague–Dawley rat (weight = 237 g, n = 1).
The rat was anesthetized (isoflurane), intubated, and positioned in the PET scanner. Following a
transmission scan, the animal was injected (via intravenous (i.v.) tail vein injection) with [11C]AZ683
(14.8 MBq) as a bolus over 1 min, and the brain imaged for 60 min (5 × 1 min frames-2 × 2.5 min
frames-2 × 5 min frames-4 × 10 min frames).
3.3.4. Primate Imaging Protocol
Primate imaging studies were done using a mature female rhesus monkey (weight = 9.4 kg, n = 1).
The animal was anesthetized in the home cage with ketamine and transported to the PET imaging
suite. The monkey was intubated for mechanical ventilation, and anesthesia was continued with
isoflurane. Anesthesia was maintained throughout the duration of the PET scan. A venous catheter
was inserted into one hind limb and the monkey was placed on the PET gantry with its head secured to
prevent motion artifacts. Following a transmission scan, the animal was injected i.v. with [11C]AZ683
(145.0 MBq) as a bolus over 1 min, and the brain imaged for 60 min (5 × 2 min frames-4 × 5 min
frames-3 × 10 min frames).
3.3.5. PET Image Analysis
Emission data were corrected for attenuation and scatter, and reconstructed using the 3D
maximum a priori (3D MAP) method. By using a summed image, regions of interest (ROI) were drawn
on multiple planes, and the volumetric ROIs were then applied to the full dynamic data set to generate
time-radioactivity curves.
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4. Conclusions
In conclusion, we have developed a radiosynthesis of [11C]AZ683 for PET imaging of CSF1R and
neuroinflammation that provides doses suitable for preclinical use. However, preliminary preclinical
PET imaging in rodents and nonhuman primates revealed low brain uptake of [11C]AZ683. Overall,
these PET imaging data suggest imaging CSF1R associated with neuroinflammation using [11C]AZ683
could be challenging and emphasize that high affinity, good selectivity, and appropriate drug-like
properties do not guarantee that a compound will make a good radiopharmaceutical for in vivo
brain PET. Nevertheless, uptake in monkey could be sufficient to observe accumulation in a brain
inflammation model. These studies also do not rule out labeling the scaffold with a longer-lived
PET radionuclide (e.g., 18F or 124I) and using a prolonged infusion protocol to ensure that sufficient
radiotracer accumulates at sites of inflammation for imaging and quantitation of CSF1R. [11C]AZ683
could potentially also be used for imaging of peripheral CSF1R to evaluate its role in inflammation
outside the brain. Future evaluation in animal models of inflammation appears warranted.
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Abstract: Parkinson’s disease (PD) is a neurodegenerative disease characterized by the loss of
dopaminergic neurons in the substantia nigra pars compacta, leading to alteration of the integrity of
dopaminergic transporters (DATs). In recent years, some radiopharmaceuticals have been used in
the clinic to evaluate the integrity of DATs. These include tropane derivatives such as radiolabeled
β-CIT and FP-CIT with iodine-123 (123I), and TRODAT-1 with metastable technetium-99 (99mTc).
Radiolabeling of β-CIT with radioactive iodine is based on electrophilic radioiodination using
oxidizing agents, such as Chloramine T or Iodo-Gen®. For the first time, the present work performed
a comparative study of the radiolabeling of β-CIT with iodine-131 (131I), using either Chloramine T or
Iodo-Gen® as oxidizing agents, in order to improve the radiolabeling process of β-CIT and to choose
the most advantageous oxidizing agent to be used in nuclear medicine. Both radiolabeling methods
were similar and resulted in high radiochemical yield (> 95%), with suitable 131I-β-CIT stability up to
72 h. Although Chloramine T is a strong oxidizing agent, it was as effective as Iodo-Gen® for β-CIT
radiolabeling with 131I, with the advantage of briefer reaction time and solubility in aqueous medium.
Keywords: Chloramine T; electrophilic radioiodination; iodine-131; Iodo-Gen®; oxidizing agent;
β-CIT.
1. Introduction
Dopamine transporters (DATs) are transmembrane proteins present on the presynaptic membrane
of dopaminergic neurons, playing an important role in the regulation of intensity and duration of
dopaminergic transmission [1,2].
The pathophysiology of Parkinson’s disease (PD) is characterized by progressive loss of
dopaminergic neurons in the substantia nigra pars compacta (SNpc), leading to a denervation of
the nigrostriatal tract that emits its terminal projections to the putamen and caudate nucleus with
significant reduction of dopamine and, consequently, loss of DAT integrity [3–5].
Since it is a chronic and progressive disease, it is very important to perform an early diagnosis
based on clinical evaluation then confirmed by imaging techniques. The clinical relevance of DAT
integrity evaluation by diagnostic imaging techniques, such as single photon emission computed
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tomography (SPECT) and positron emission tomography (PET), are based on the differentiation
between degenerative parkinsonism and other conditions not associated with dopamine loss,
such as essential tremor, drug-induced parkinsonism, vascular parkinsonism, and psychogenic
parkinsonism [6,7].
DAT-SPECT radiopharmaceuticals available for clinical use are all tropane derivatives:
(i) β-CIT (2β-carbomethoxy-3β-(4-iodophenyl)tropane) and FP-CIT (N-3-fluoropropyl-
2β-carbomethoxy-3β-(4-iodophenyl)nortropane) radiolabeled with iodine-123
(123I).; (ii) TRODAT-1 ([2-[[2-[[[3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3.2
0.1]oct-2-yl]methyl](2-mercaptoethyl)amino]ethyl]amino]ethanethiolato(3-)-N2,N2’,S2,S2’]oxo-[1R-(exo-
exo)]) radiolabeled with metastable technetium-99 (99mTc) [6,8,9].
β-CIT is a molecule that has been studied since the 90s [10]. Due to its binding affinity
to presynaptic DATs, radioisotope-labeled β-CIT can differentiate PD from essential tremor with
a sensibility of 95% and a specificity of 93% [8]. The proposed mechanism of β-CIT interaction with
presynaptic DATs involves electrostatic interactions or hydrogen bonds [11]. In nuclear medicine,
123I-β-CIT is a diagnostic agent for SPECT imaging used both in the initial phase (in individuals with
uncertain diagnosis) and in the follow-up of PD [12].
The radiolabeling of molecules, including β-CIT, with radioactive iodine (123I, 124I, 125I
or 131I) is frequently based on electrophilic aromatic substitution using several oxidizing
agents such as Chloramine T (N-chloro-p-toluenesulfonamide sodium salt), Iodo-Gen®
(1,3,4,6-tetrachloro-3α,6β-diphenylglycouril), lactoperoxidase, and the solid-state variants as
pre-coated Iodo-Gen® tubes, Iodo-Beads®, or Enzymobeads®. The most commonly used are
Chloramine T and Iodo-Gen®, at room temperature [13–16].
Chloramine T has been used since 1962 [17]. It is a strong oxidizing agent, demanding
shorter reaction periods, and is soluble in aqueous solutions [15,18]. On the other hand, Iodo-Gen®
is a moderate oxidizing agent, requiring longer reaction times, and is insoluble under aqueous
conditions [19,20].
To the best of our knowledge, until now there have been no comparative studies between these
two oxidizing agents in β-CIT radiolabeling with radioactive iodine. Therefore, the present study aims
to evaluate the electrophilic radioiodination of β-CIT with iodine-131 (131I), due to its 8.04 d half-life,
using either Chloramine T trihydrate or Iodo-Gen®, in order to compare the radiolabeling efficiency
and compound stability.
The importance of this work is based on the improvement of the radiolabeling process of β-CIT
with radioactive iodine through the choice of the most advantageous oxidizing agent. This study
may result in high quality radiopharmaceuticals labeled with 123I for use in nuclear medicine and,
consequently, higher quality SPECT images of the DATs.
2. Results and Discussion
The electrophilic radioiodination of β-CIT, using the precursor trimethylstannyl-β-CIT
(TMS-β-CIT), was performed using either Chloramine T or Iodo-Gen® as an oxidizing agent (Figure 1).
The final product, 131I-β-CIT, was purified by solid-phase extraction (SPE) using Sep-Pak® C18.
Radiochemical purity was evaluated by both ascendant chromatography and reversed phase-high
performance liquid chromatography (RP-HPLC).
Ascendant chromatography was performed on thin-layer chromatography on silica gel (TLC-SG;
Al) strips using 95% acetonitrile (ACN) as an eluent (Figure 2). Results are summarized in Table 1.
In this chromatographic system, Na131I migrates with the solvent front (Rf = 0.9−1.0) and 131I-β-CIT
remains in the origin (Rf = 0.1−0.3). Radiochemical yield was over 95% for both radiolabeling methods.
SPE purification did not significantly improve the radiochemical purity; however, this procedure is
recommended in order to remove iodate ions (IO3−), which are not detected by this chromatographic
system. In general, radiopharmaceuticals must present high radiochemical purity level (>90%).
Therefore, this comparative study showed that both radiolabeling procedures, using either Chloramine
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T or Iodo-Gen® as an oxidizing agent, yielded 131I-β-CIT with suitable radiochemical features, and
that no significant differences were observed between radiolabeling methods (Table 1).
Figure 1. Simplified scheme of the electrophilic radioiodination of β-CIT.
Figure 2. TLC-chromatograms: (A) 131I-β-CIT (Rf = 0.1−0.3) and (B) Na131I (Rf = 0.9−1.0).





Chloramine T 97.40 ± 1.17 98.48 ± 0.63
Iodo-Gen® 97.81 ± 0.99 98.24 ± 0.76
Values are expressed as mean ± SD (n = 9). No significant differences were observed for 131I-β-CIT obtained by
both radiolabeling methods (p > 0.05).
The radiochemical purity of 131I-β-CIT was also evaluated by RP-HPLC analysis (Figure 3) in
order to confirm ascendant chromatographic data. The unlabeled precursor TMS-β-CIT was analyzed
and presented a retention time (RT) of 6.68 min (Figure 3A). Free Na131I was also evaluated, showing
a different chromatographic profile (RT = 1.16 min) when compared to unlabeled precursor TMS-β-CIT
(Figure 3B). The final product, 131I-β-CIT, obtained by both radiolabeling methods, using either
Chloramine T or Iodo-Gen® as an oxidizing agent, showed high radiochemical purity (Figure 3C,D).
Therefore, RP-HPLC analyses were in accordance with TLC-SG data, confirming that both radiolabeling
methods yield 131I-β-CIT with high radiochemical purity and similar chromatographic profiles.
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Figure 3. RP-HPLC chromatograms of (A) unlabeled precursor TMS-β-CIT, (B) Na131I, and (C, D)
131I-β-CIT obtained by both radiolabeling methods.
The stability of 131I-β-CIT was analyzed by ascendant chromatography (Figure 4). The final
product was stable up to 72 h. Although slight statistical differences in the stability were observed
between both radiolabeling methods, radiochemical purity maintained over 94%, regardless of the
storage way, at room temperature or at 2−8 ◦C (Figure 4A, B). It is important to consider that these small
variations in stability in reaction medium should not affect the application of 131I-β-CIT. Moreover,
131I-β-CIT serum stability was also evaluated, and data showed high stability (>94%) up to 24 h, with
no significant statistical differences between the radiolabeling methods (Figure 4C).
The partition coefficient (P) of 131I-β-CIT was determined at room temperature by the ratio
between n-octanol and 0.9% NaCl. For both radioiodination processes, data showed P tending to the
hydrophobic range (Table 2). The hydrophobicity of 131I-β-CIT was also evaluated by the determination
of the percentage of serum protein binding (SPB), incubating 131I-β-CIT with serum at 37 ◦C for 30 min.
The results showed approximately 45% of SPB in both cases (Table 2).
The physicochemical features of the final product are in agreement, once P tending to the
hydrophobic range relates to high SPB [21]. Furthermore, these data are consistent with the intended
131I-β-CIT clinical application, as a radiotracer for measuring presynaptic DAT density in order to
provide information on the integrity of these terminals [12]. Therefore, 131I-β-CIT must cross the
blood−brain barrier, which is easier for lipophilic molecules. In addition, it has been reported that
45−85% of SPB is related to higher uptake by the brain [22].
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Figure 4. Evaluation of 131I-β-CIT stability. Values are expressed as mean ± SD [(A) and (B): n = 9;
(C): n = 3]. Asterisks indicate significant differences (*p < 0.05; ***p < 0.001).
Table 2. Partition coefficient and serum protein binding of 131I-β-CIT.
Partition coefficient(P) Chloramine T 0.12 ± 0.02
Iodo-Gen® 0.13 ± 0.02
Serum protein binding (SPB) Chloramine T 47.44 ± 1.31%
Iodo-Gen® 44.99 ± 3.06%
Values are expressed as mean ± SD (n = 5). No significant differences were observed for 131I-β-CIT obtained by
both radiolabeling methods (p > 0.05).
113
Pharmaceuticals 2019, 12, 25
3. Materials and Methods
3.1. Electrophilic Radioiodination of β-CIT and SPE Purification
The electrophilic radioiodination of β-CIT was performed using either Chloramine T or Iodo-Gen®
as an oxidizing agent followed by SPE purification according to previous methods [14,15,23–25], with
some modifications. The precursor TMS-β-CIT was purchased from ABX Advanced Biochemical
Compounds GmbH (Radeberg, Germany).
For the Chloramine T method, an aliquot of Na131I solution (7.4−14.8 MBq) was added to a vial
containing the precursor TMS-β-CIT (0.12 μmol/50 μL EtOH). Next, 10 μL of Chloramine T trihydrate
solution (1.5 mg.mL−1) and 4 μL of HCl solution (0.1 mol.L−1) were added. The mixture (pH = 3.0−3.5)
was kept at room temperature for 3 min and the reaction was quenched with 40 μL of NaOH solution
(0.01 mol.L−1). The final pH was 6.0−6.5.
For the Iodo-Gen® method, an aliquot of Na131I solution (37.0−44.4 MBq) was added to a vial
containing the precursor TMS-β-CIT (0.12 μmol/50 μL EtOH). Next, 37.5 μL of Iodo-Gen® solution
(6.2 mg.mL−1) and 75 μL of H3PO4 solution (0.1 mol.L−) were added. The mixture (pH = 3.0−3.5) was
kept at room temperature for 15 min and the reaction was quenched with 20 μL of NaOH solution
(0.1 mol.L−1). The final pH was 6.0−6.5.
After each radiolabeling method, the final product (131I-β-CIT) was purified by SPE using
Sep-Pak® C18, preconditioned with EtOH (5 mL) and 0.9% NaCl (5 mL). Free 131I was removed
in 0.9% NaCl (5 mL) and 131I-β-CIT was eluted by EtOH (2 mL).
3.2. Radiochemical Purity Analysis
Radiochemical purity was evaluated by ascendant chromatography (n = 9) and RP-HPLC.
Ascendant chromatography was performed by TLC-SG (Al) strips (Merck) using 95% ACN as
an eluent. The radioactivity was determined with an AR-2000 radio-TLC Imaging Scanner (Eckert &
Ziegler, Germany).
RP-HPLC analyses were performed on a 1290 Infinity II UHPLC system (Agilent Technologies,
Santa Clara, CA, USA) equipped with a radioactivity detector (Eckert & Ziegler, Germany) and Open
Lab ECM data system (Agilent Technologies, Santa Clara, CA, USA). The analytical column was
a Phenomenex Kinetex® Reversed Phase C18 (100 mm × 3 mm; 2.6 μm) maintained at 30 ◦C. Mobile
phase A was 0.1% (v:v) TFA in water. Mobile phase B was 0.1% (v:v) TFA in MeOH. The gradient of
mobile phase B was: 10% (0.0−1.0 min); 10−90% (1.0−8.0 min); 90% (8.0−10.5 min); and 90−10%
(10.5−12.0 min). The flow rate was 0.8 mL.min−1 and the UV detector was set at 284 nm.
3.3. Stability Studies
The stability of 131I-β-CIT, stored at room temperature and at 2−8 ◦C, was evaluated at 0.5, 1, 2,
24, 48, and 72 h (n = 9). Beyond that, the serum stability of 131I-β-CIT, incubated at 37 ◦C under slight
agitation (500 rpm), was evaluated at 1, 2, and 24 h (n = 3). In both cases, the stability of 131I-β-CIT
was analyzed by ascendant chromatography, as described in the previous section.
3.4. Partition Coefficient
An aliquot of purified 131I-β-CIT (50 μL) was added in a mixture of n-octanol and 0.9% NaCl
(1:1) and submitted to agitation (n = 5). The mixture was centrifuged (825 g; 3 min). Aliquots of 100
μL of both aqueous and organic phases were collected, and their radioactivities were measured with
a 2480 automatic gamma counter Wizard2™ 3” (PerkinElmer, Waltham, MA, USA).
3.5. Serum Protein Binding
An aliquot of 131I-β-CIT (25 μL) was added to 475 μL of serum and incubated at 37 ◦C for 30 min
(n = 5). Post-incubation, serum proteins were precipitated with 500 μL of 10% trichloroacetic acid
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and the content was centrifuged (825 g; 10 min; 3x). Pellets’ and supernatants’ radioactivities were
measured with a 2480 automatic gamma counter Wizard2™ 3” (PerkinElmer, Waltham, MA, USA).
4. Conclusions
In summary, the data demonstrated that both radiolabeling methods, using either Chloramine
T or Iodo-Gen® as an oxidizing agent, yield 131I-β-CIT with similar radiochemical parameters.
Although Chloramine T induces harder reaction conditions when compared to Iodo-Gen®, the results
showed that it is possible to use Chloramine T instead of Iodo-Gen® without compromising the
radiolabeling result and the final product stability, provided that the physicochemical parameters of
each radiolabeling process are respected (pH, reaction time, temperature). Furthermore, it is important
to highlight that Chloramine T is a water-soluble reagent with strong oxidizing properties requiring
a briefer reaction time, simplifying the process in nuclear medicine. Therefore, this comparative study
presents the possibility of alternating between Iodo-Gen® and Chloramine T in the radiolabeling
process of β-CIT with 123/131I, depending on the availability and costs of the oxidizing agents,
without changing the integrity of the final product, used for SPECT imaging diagnosis of PD in
nuclear medicine.
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Abstract: Introduction: Benzotriazine-1,4-dioxides (BTDOs) such as tirapazamine (TPZ) and
its derivatives act as radiosensitizers of hypoxic tissues. The benzotriazine-1-monoxide
(BTMO) metabolite (SR 4317, TPZMO) of TPZ also has radiosensitizing properties, and via
unknown mechanisms, is a potent enhancer of the radiosensitizing effects of TPZ. Unlike their
2-nitroimidazole radiosensitizer counterparts, radiolabeled benzotriazine oxides have not been
used as radiopharmaceuticals for diagnostic imaging or molecular radiotherapy (MRT) of hypoxia.
The radioiodination chemistry for preparing model radioiodinated BTDOs and BTMOs is now
reported. Hypothesis: Radioiodinated 3-(2-iodoethoxyethyl)-amino-1,2,4- benzotriazine-1,4-dioxide
(I-EOE-TPZ), a novel bioisosteric analogue of TPZ, and 3-(2-iodoethoxyethyl)-amino-1,2,4-
benzotriazine-1-oxide (I-EOE-TPZMO), its monoxide analogue, are candidates for in vivo and in vitro
investigations of biochemical mechanisms in pathologies that develop hypoxic microenvironments.
In theory, both radiotracers can be prepared from the same precursors. Methods: Radioiodination
procedures were based on classical nucleophilic [131I]iodide substitution on Tos-EOE-TPZ (P1) and by
[131I]iodide exchange on I-EOE-TPZ (P2). Reaction parameters, including temperature, reaction time,
solvent and the influence of pivalic acid on products’ formation and the corresponding radiochemical
yields (RCY) were investigated. Results: The [131I]iodide labeling reactions invariably led to the
synthesis of both products, but with careful manipulation of conditions the preferred product could
be recovered as the major product. Radioiodide exchange on P2 in ACN at 80 ± 5 ◦C for 30 min
afforded the highest RCY, 89%, of [131I]I-EOE-TPZ, which upon solid phase purification on an alumina
cartridge gave 60% yield of the product with over 97% of radiochemical purity. Similarly, radioiodide
exchange on P2 in ACN at 50 ± 5 ◦C for 30 min with pivalic acid afforded the highest yield, 92%,
of [131I]I-EOE-TPZMO exclusively with no trace of [131I]I-EOE-TPZ. In both cases, extended reaction
times and/or elevated temperatures resulted in the formation of at least two additional radioactive
reaction products. Conclusions: Radioiodination of P1 and P2 with [131I]iodide leads to the facile
formation of [131I]I-EOE-TPZMO. At 80 ◦C and short reaction times, the facile reduction of the
N-4-oxide moiety was minimized to afford acceptable radiochemical yields of [131I]I-EOE-TPZ from
either precursor. Regeneration of [131I]I-EOE-TPZ from [131I]I-EOE-TPZMO is impractical after
reaction work-up.
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1. Introduction
Solid tumors frequently demonstrate rapid growth and aberrant vasculature, leading to
microenvironmental deficiencies of oxygen (hypoxia), nutrients and therapeutic drugs. Tumor hypoxia
is an early event and an independent risk factor for progression of all types of cancers. Hypoxic
tumors are relatively more resistant than oxygenated tumors to killing by ionizing radiation
during conventional radiotherapy, and recurrent cancers may be metastatically aggressive. Clearly,
identification of hypoxic microenvironments and more effective cancer management based on
assessments of their hypoxic stature is central to effective treatment [1–5]. In vivo imaging
offers insights into the detection and management of tumor hypoxia [6–10] and, of the imaging
modalities available, nuclear imaging is both effective and widely available. Radiolabeled azomycin
(2-nitroimidazole) derivatives are the most studied and used radiopharmaceuticals for hypoxia
imaging [11–13].
Like the nitroimidazoles, 1,2,4-benzotriazines (BTDOs such as 1,2,4-benzotriazine-3-amino-1,4-
dioxide (tirapazamine, TPZ) and its derivatives are bioactivated via a single electron reduction that
is reversible in the presence of oxygen [14]. TPZ was synthesized as a potential antimicrobial agent
in 1957 [15,16], and the rediscovery of TPZ and its monoxide homologue (TPZMO; SR 4317) as
radiosensitizers [17,18] opened the door to hypoxic radiosensitization by bioreductivately-activated
BTDOs that offer an alternative mechanism to that of the nitroimidazoles [19–22]. Radiolabeled BTDOs
and BTMOs for hypoxia imaging or radiotherapy appear unreported to date.
A recent publication on the synthesis of 3-(2-iodoethoxyethyl)-amino-1,2,4-benzotriazine-
1,4-dioxide (I-EOE-TPZ) and 3-(2-iodoethoxyethyl)-amino-1,2,4-benzotriazine-1-monoxide
(I-EOE-TPZMO) reports that the in vitro toxicity and radiosensitizing potency of I-EOE-TPZ
were similar to that of TPZ [23]. These investigations into the radiosyntheses of [131I]I-EOE-TPZ
and its monoxide homologue, [131I]I-EOE-TPZMO, represent the next step in the evaluation of these
compounds as radiotheranostic pharmaceuticals. The chemical structures of TPZ, Tos-EOE-TPZ,
the precursor for nucleophilic radioiodination (P1), and I-EOE-TPZ, the precursor for isotope exchange
radiolabeling (P2), and I-EOE-TPZMO are depicted in Figure 1.
 
Figure 1. Structures of TPZ (tirapazamine), P1 (Tos-EOE-TPZ; X = tosyl), P2 (I-EOE-TPZ; X = I = 127I),
and [131I]I-EOE-TPZMO.
2. Results
[131I]I-EOE-TPZ and [131I]I-EOE-TPZMO, the desired products, were both identified in reaction
mixtures following nucleophilic substitution of the tosylate precursor (P1) by [131I]iodide, and upon
halogen isotope exchange between [131I]iodide and non-radioactive precursor I-EOE-TPZ (P2).
Radiochemical yields were strongly dependent upon reaction conditions.
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2.1. Nucleophilic Radioiodination of P1
Nucleophilic reactions on P1, irrespective of reaction duration, in either DMF or ACN at 22 ◦C
and at 60 ◦C demonstrated no formation of either [131I]I-EOE-TPZ or [131I]I-EOE-TPZMO, with only
unreacted [131I]iodide detected by RTLC (Table 1). However, reaction for 60 min at higher temperatures
(80 ◦C and 100 ◦C) in ACN afforded both products. Using DMF as a solvent at these (higher)
temperatures also led to the formation of *I-EOE-TPZ, albeit in lower yields. Radioiodination at
80 ◦C for 60 min in ACN appeared to be the best condition for synthesizing [131I]I-EOE-TPZ (RCY
48.5%; entry 3 Table 1) via nucleophilic substitution of precursor P1; at 100 ◦C, this reaction favored
production of [131I]I-EOE-TPZMO (RCY 50.2%; entry 4 Table 1). Reaction conditions and product
yields are given in Table 1 and typical radiochromatograms for 80 and 100 ◦C are shown in Figure 2
(A and B).
Table 1. Radioiodination of precursor Tos-EOE-TPZ (P1) via nucleophilic substitution of tosyl by
[131I]iodide.
Solvent Temp (◦C) Time (min) [
131I]I-EOE-TPZ
% of Total [131I]
[131I]I-EOE-TPZMO
% of Total [131I]
ACN 22 30 and 60 0, 0 0, 0
ACN 60 30 and 60 0, 0 17.2, 31.2
ACN 80 60 48.5 20.7
ACN 100 60 10.1 50.2

















Figure 2. RTLC of the reaction mixture post-nucleophilic radioiodination of P1 by [131I]iodide in ACN
after 60 min at 100 ◦C (A) and at 80 ◦C (B).
2.2. Isotope Exchange Radioiodination of P2
Radioiodination of I-EOE-TPZ (P2) by [131I]iodide was monitored under a range of reaction
conditions. The first attempt, using the conditions applied to nucleophilic labelling (P1) in DMF at
22 ◦C, showed a high yield of [131I]I-EOE-TPZMO and no [131I]I-EOE-TPZ at 30 min, and a small yield
of [131I]I-EOE-TPZ (18%) at 1 h; both radiochromatograms revealed a complex mixture of the desired
products, radioiodide and at least two unknown radioiodinated by-products (Figure 3 and Table 2).
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Figure 3. RTLC of the reaction mixture following [131I]iodide exchange on P2 at 22 ◦C.
[131I]I-EOE-TPZMO is the main product by 30 min (A), [131I]I-EOE-TPZ is evident in low radiochemical
yield (18%) at 60 min (B).









% of Total [131I]
[131I]I-EOE-TPZMO
% of Total [131I]
DMF 22 30, 60 0 0, 18 72.7, 54.3
ACN 22 30, 60 0 0, 0 34.7, 7.5
ACN 80 30 0 89 6.9
ACN 50 30, 60 3.5 0, 7.7 92.4, 66
ACN 22 30, 60, 90 3.5 3.2, 3.5, 3 54, 50, 48.7
EtOH/ACN 22 30, 60, 90 3.5 0, 0, 0 43, 42.4, 42.2
Exchange radioiodination of P2 was conducted in ACN at 50 ◦C in the presence of pivalic acid for
30 min. Under these conditions, RTLC showed the highest yield, 92.4%, of [131I]I-EOE-TPZMO but with
no [131I]I-EOE-TPZ (Figure 4A). At 60 min, a third radioactive compound at Rf 0.75, running just behind
[131I]I-EOE-TPZMO, was apparent in the RTLC as well as a trace evidence, 7.7%, of [131I]I-EOE-TPZ
(Figure 4B).
Figure 4. RTLC of the post-labelling exchange reaction mixture using precursor P2 in ACN and pivalic
acid after 30 min (A) and 60 min (B) at 50 ◦C.
To determine if pivalic acid was responsible for promoting the formation of the peak at Rf 0.75 at
the higher temperature (i.e., 50 ◦C), radioiodination was performed at a room temperature (22 ◦C) after
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30, 60 and 90 min in ACN. The RTLCs showed an increased appearance in by-products at Rf 0.35 and
0.75 (Figure 5). A room temperature experiment using pivalic acid in a protic solvent (ACN/ETOH
mixture) yielded similar (no improvement) results, but with lower peak resolution (not shown).
Figure 5. RTLC of the exchange reaction mixture using precursor P2 and pivalic acid in ACN after
30 min (A) and 90 min (B) at 22 ◦C.
Radioiodine exchange on precursor P2 in ACN at 80 ◦C for 30 min provided the highest
radiochemical yield of [131I]I-EOE-TPZ (89%; Table 2). Subsequent solid phase purification on an
alumina cartilage afforded [131I]I-EOE-TPZ in radiochemical yields of 60% with over 97% radiochemical
purity and a trace of [131I]I-EOE-TPZMO (Figure 6).
Figure 6. (A) The RTLC of the exchange-labeled [131I]I-EOE-TPZ (P2) reaction mixture in ACN, 30 min
after reacting at 80 ◦C with sodium [131I]iodide. (B) The RTLC of (A) after purification through a
neutral alumina cartridge.
3. Discussion
The radiosynthesis of [131I]I-EOE-TPZ by nucleophilic radioiodination of the corresponding
tosylate, Tos-EOE-TPZ, was associated with the production of a second hypoxia-selective
radiosensitizer, [131I]I-EOE-TPZMO. In fact, minimizing the production of this radiolabeled
1-monoxide was a major challenge to preparing the radiolabeled, fully oxidized, 1,4-dioxide, analogue.
There is precedence to the formation of the 1-monoxide in the literature, both as SR 4317, an
analogue of TPZ [16,24], and as a product of TPZ metabolism [25,26]. The synthetic chemistry of the
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X-EOE-TPZ series similarly involved the production of the corresponding X-EOE-TPZMO 1-oxides [23].
Unfortunately, up-oxidation of the monoxides to their 1,4-dioxides was difficult or even unachievable,
thereby squelching the idea of simply using the highly efficient production of [131I]I-EOE-TPZMO
(by either halogen exchange or nucleophilic substitution) and then simply oxidizing the monoxide to
[131I]I-EOE-TPZ.
The unanticipated, but facile reduction of I-EOE-TPZ by (radio)iodide in both exchange labelling
and nucleophilic substitution procedures appears to lie in the ease of oxidizing iodide to iodonium
species. Iodide may first serve as the single electron donor, giving rise to the BTDO radical
intermediate, and also provide the second electron to form the monoxide. Examples of functional
group reductions via iodide salts include amine N-oxides [27], isoxazolodines [28], sulfoxides [29] and
graphene oxide [30] and others [31] Plausible mechanisms have been proffered for the bioreduction of
TPZ [24–26] to its 1-monoxide, and these may apply when iodide is the initial electron donor.
Although it seems unlikely that pivalic acid directly affects the initial single electron reduction
in this scheme, facilitation of radioiodide/halogen exchange radiolabeling by pivalic acid is well
established in the radiopharmaceutical literature [32] In the current case, it is possible that pivalic
acid skews the equilibrium between the protonated and non-protonated radical in the aprotic solvent,
an effect that may not influence formation of the reduced monoxide, but that leads to the formation
of other reductive intermediates as well. The latter postulate is supported by the prominence of two
new radioactive by-products in the pivalic acid isotope exchange reactions, products that are also
prominent in the nucleophilic substitution reactions at 100 ◦C and when the reaction is carried out in
a protic (ACN-ethanol) solvent. A plausible mechanism for the facile conversion of I-EOE-TPZ and
Tos-EOE-TPZ to [131I]I-EOE-TPZMO, is presented in Scheme 1.
 
Scheme 1. A proposed model for the formation of [131I]I-EOE-TPZMO by [131I]iodide during isotope
exchange with I-EOE-TPZ and nucleophilic substitution on Tos-EOE-TPZ. This model is based in part
on a model proposed by Siim et al. for TPZ metabolism [26].
4. Experimental
4.1. Materials
Precursors P1 and P2 were synthesized as reported [23] Anhydrous EtOH, sterile water for
injection (SWFI) and 0.9% bacteriostatic saline were purchased from commercial suppliers. All solvents
(ethyl acetate [EtOAc], acetonitrile [ACN] and dimethylformamide [DMF] were reagent grade,
purchased from commercial suppliers, and used without further purification. Sodium [131I]iodide was
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purchased by the Edmonton Radiopharmacy Center from NTP Radioisotopes (Pretoria, South Africa),
and was provided to us at no cost for experimental development. Reacti-V-vials (4 mL; reactivial) were
purchased from Wheaton, Millville, NJ, USA, while disposable sterile items (syringes and needles of
various size, vent needles, product vials [Hollister, 20 mL], GS filters [22 μm pore; Millipore, Cork,
Ireland], neutral alumina cartridges [Waters, Milford, MS, USA]) were purchased from respective
suppliers. Progress of reactions, and radiochemical purity of final products were monitored on silica
gel pre-coated glass TLC plates (2.5 × 7.5 cm; Whatman). RadioTLC (RTLC) plates were scanned using
a Bioscan TLC scanner (Eckert & Ziegler, Berlin, Germany). Specific quality control tests that included
confirming radionuclidic identity by determining the half-life by counting a sample of purified product
(from optimized synthesis batch) in a counting well and checking pH of purified product solution
using pH test strips. The authentic reference standards, I-EOE-TPZ and I-EOE-TPZMO monoxide that
were co-spotted, were visible as red (Rf 0.45 ± 0.05) and yellow (Rf 0.85± 0.05) spots, respectively.
4.2. Methods
4.2.1. Nucleophilic Radioiodination of Tos-EOE-TPZ (Precursor P1)
It started by mixing a solution of P1 (100 μg/100 μL) in the selected solvent and adding this to
the reactivial containing [131I]iodide (nominally 37 kBq). After radiometry, the vial was placed on a
pre-heated block and radioiodination was performed for the specified time. The reaction vial was
removed, cooled to room temperature, and then aliquots were taken for RTLC. Data are presented in
Table 1.
4.2.2. Halogen Isotope Exchange Radioiodination of I-EOE-TPZ (Precursor P2)
The procedure was based on the procedure used for synthesizing P2.23 P2 (100 μg), pre-dissolved
in an appropriate reaction solvent (100 μL), was added to the reaction v-vial containing sodium
[131I]iodide (nominally 37 kBq). The vial was capped and the radioactivity measured. Reaction
vials that required heating were placed on a heating block (50 or 80 ◦C). Progress of reactions was
monitored using radioTLC and co-chromatography with authentic reference standards. Reaction
times, temperatures and product yields for exchange radiolabeling are given in Table 2. In reactions
where pivalic acid was used, a solution of P2 (100 μg) in acetonitrile (100 μL) was added to pivalic acid
(3.5 mg), the solution was gently swirled and then transferred to a reactivial containing [131I]iodide.
4.3. Cartridge-Based Purification
Once the labeling process was complete, the reaction vial was cooled in an ice-bath. Acetonitrile
(10 μL) was added to the reaction vial, the vial was gently swirled to dissolve the mixture and the
contents were diluted with additional SWFI (10 mL) and then the entire solution was withdrawn into a
20 mL syringe. After removing the syringe needle, the syringe barrel was attached to a Waters alumina
cartridge (preconditioned by USP-grade ethanol [10 mL], followed by sterile water [10 mL]) fitted with
a filter (Millex GS, Millipore, Cork, Ireland) and needle assembly that was connected to a vented 20 mL
sterile product vial. Contents of the needle were slowly pushed through the cartridge to recover the
purified products.
5. Conclusions
Two approaches to radiolabel I-EOE-TPZ are reported. Both methods, isotope exchange and
nucleophilic substitution, produce two compounds of interest, [131I]I-EOE-TPZ and [131I]I-EOE-
TPZMO, their relative proportions being dependent on reaction conditions. [131I]I-EOE-TPZMO
was obtained almost exclusively in high yield from P2 via isotope radioiodination in ACN and pivalic
acid after 30 min at 50 ◦C. Whereas the highest yield of [131I]I-EOE-TPZ was obtained from P1 via
halogen isotope exchange radioiodination in ACN and no pivalic acid after 60 min at 80 ◦C. A simple
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solid phase extraction process, a methodology that is preferred in clinical settings, was developed and
used to purify and isolate [131I]I-EOE-TPZ in 45%–60% radiochemical yield and >97% purity.
This is the first report of developing bioreductively-activated, radiohalogenated BTDO and BTMO
molecules for assessing focal hypoxia. Preclinical evaluations of these radiotracers are in progress in
animal models of tumor hypoxia.
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Abstract: Background: New approaches based on the receptor-targeted molecular interaction have
been recently developed with the aim to investigate specific probes for sentinel lymph nodes.
In particular, the mannose receptors expressed by lymph node macrophages became an attractive
target and different multifunctional mannose derivate ligands for the labeling with 99mTc have been
developed. In this study, we report the synthesis of a specific class of dextran-based, macromolecular,
multifunctional ligands specially designed for labeling with the highly stable [99mTc≡N]2+ core.
Methods: The ligands have been obtained by appending to a macromolecular dextran scaffold
pendant arms bearing a chelating moiety for the metallic group and a mannosyl residue for allowing
the interaction of the resulting macromolecular 99mTc conjugate with specific receptors on the
external membrane of macrophages. Two different chelating systems have been selected, S-methyl
dithiocarbazate [H2N-NH-C(=S)SCH3=HDTCZ] and a sequence of two cysteine residues, that in
combination with a monophosphine coligand, are able to bind the [99mTc≡N]2+ core. Conclusions:
High-specific-activity labeling has been obtained by simple mixing and heating of the [99mTc≡N]2+
group with the new mannose-dextran derivatives.
Keywords: sentinel lymph node; dextran; mannose; 99mTc-radiopharmaceuticals
1. Introduction
The sentinel lymph node (SLN) is defined as the first lymph node that receives lymphatic drainage
as well as metastatic cells from the primary tumor sites. An accurate identification and characterization
of SLNs is very important as it helps the physician to decide the extension of surgery, the tumor staging,
and the development of an appropriate treatment plan.
Sentinel lymph node detection (SLND) is a radionuclide-based technique for imaging regional
lymph node drainage systems, performed by injecting small radiolabeled particles (20 to 500 nm).
This technique has become the standard of care in breast cancer [1,2] and melanoma [3,4], and is
increasingly being applied to other solid cancers with high metastatic potential in lymph nodes,
such as oral and oropharyngeal squamous cell carcinoma [5].
The most frequently used radiopharmaceuticals for SLND are 99mTc-labelled colloidal particles.
However, they are characterized by nonideal properties [6–8]; in particular, their uptake mechanism is
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driven by passive diffusion and show slow clearance rate from the injection site or low residence time
in the SLN [9–12]. From the clinical point of view, an ideal tracer must combine persistent retention in
the SLN, low distal lymph node accumulation, fast clearance rate from the injection site, safe radiation
exposure level, and lack of toxicity.
New approaches based on the receptor-targeted molecular interaction have been developed with
the aim to investigate specific probes for SLN. In particular, the mannose receptors expressed by
lymph node macrophages became an attractive target [13,14], and multifunctional mannose-derivate
ligands have been studied for the labeling with 99mTc [8,11,12]. A multifunctional ligand is commonly
depicted as a molecular moiety being sufficiently large in size to accommodate a number of
different chemical groups performing specific chemical and biological functions. Dextran provides
a convenient macromolecular scaffold for hosting a relatively large number of functional groups
and it has been recently employed to develop the 99mTc radiopharmaceutical (Lymphoseek®)
for SLND [15]. The basic design of this new agent involves appending at various positions of the
dextran structure a number of diethylenetriaminepentaacetic acid (DTPA) groups for the chelation
of the metal together with a number of mannose residues for recognition by specific receptors on
the macrophage’s membrane. A strong limitation of this approach comes from the fact that DTPA
is not considered an optimal chelating system for 99mTc and, as a consequence, the stability of
the resulting conjugate macromolecular complex is poor. Furthermore, the technetium chemistry
with DTPA is not well defined and some controversy about the nature of the complex formed
with this metal exists [16]. Recently, aiming to provide more stable and chemically well-defined
target-specific 99mTc complexes for SLND, 99mTc-tricarbonyl technology has been applied to label
mannosylated-dextran conjugates in combination with pyrazolyldiamine chelator that selectively
react with the fac-[99mTc(CO)3(H2O)3]+ metal fragment [11]. According to the mannosylated-dextran
conjugates strategy, ‘4 + 1’ mannosylated-dextran Tc(III) mixed-ligand complexes have been
also reported [17].
Based on the dextran derivatives functionalized with mannose units’ principle, we report in
this work the design, the synthesis, and the characterization of a specific class of dextran-mannose
multifunctional ligands specially designed for binding to [99mTcN]2+ group. The coordination
chemistry of this metallic synthon is very well established [18–20] and can be efficiently manipulated
by a careful selection of the coordinating atoms type bound to the [99mTcN]2+ group.
The compound S-methyl dithiocarbazate [H2N-NH-C(=S)SCH3=HDTCZ] has been selected
as the first chelating system to be investigated in the production of a multifunctional ligand for
SLND based on 99mTc nitrido chemistry. DTCZ strongly binds to the [99mTc≡N]2+ core, through the
neutral thiocarbonyl sulfur atom and the deprotonated terminal amine nitrogen atom, forming both
mono- and bis-substituted complexes [21,22]. Thus, the synthesis of this ligand is described in the
following sections.
Another convenient chelating system for the [99mTc≡N]2+ core is provided by the so-called ‘3 + 1’
method. This approach stems from the finding that the coordination arrangement composed by
a tridentate π-donor ligand, having [S−, N, S−] as a set of donor atoms, and a monodentate π-acceptor
monophosphine ligand (PR3) usually exhibits a high stability when bound to a [99mTc≡N]2+ group in
a square pyramidal geometry. A very convenient tridentate [S−, N, S−] chelating system is provided
by the simple combinations of two terminal cysteine aminoacids (Cys-Cys). The schematic structure of
of ‘3 + 1’ 99mTc nitrido complexes with the Cys-Cys chelating system is illustrated in Figure 1.
In the following, the preparation and stability studies of 99mTc-radiopharmaceuticals containing
mannose-dextran derivatives are described.
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Figure 1. Structure of ‘3 + 1’ 99mTc nitrido complexes with the Cys-Cys chelating system.
2. Results and Discussion
2.1. Design of a Dextran-Mannose Multifunctional Ligand for Coordination to the [99mTc≡N]2+ Core
A chemical approach, usually employed for attaching different functional groups to a dextran
scaffold, consists of hanging them at different positions of the polymeric chain. We used here
a simplified strategy that allowed a more careful control of the number of functional groups introduced
into the final macromolecule. This approach is schematically illustrated in Figure 2. As mentioned
above, two functional groups are required for obtaining a new 99mTc nitrido agent for SLND, namely
a suitable chelating group and a mannosyl residue. Each group was placed at one terminus of a linear
chain of atoms that was also equipped with a reactive group (W) in its central position (Figure 2a).
In turn, this latter group was reacted with another suitable reactive moiety, previously attached
to the dextran scaffold, thus forming a stable linkage (click chemistry) (Figure 2b). Through this





Figure 2. Schematic drawing of a multifunctional fragment with a reactive group (W) (a) for binding to
dextran (b).
2.2. Synthesis of Dextran-Mannosyl Multifunctional Ligands for the [99mTc≡N]2+ Core
As mentioned above, the overall synthetic strategy employed here involved the preliminary
preparation of a linear trifunctional fragment bearing a mannose residue at one terminus, a chelating
group for the [99mTc≡N]2+ core at the other terminus, and a reactive alkyne or sulfide group placed
almost in the center of the linear chain (W in Figure 2a). These fragments were subsequently linked to
the dextran backbone using three different procedures: (a) Thiol-ene chemistry [23]; (b) azide-alkyne
Huysgen cycloaddition (click chemistry) [24], and (c) amide condensation. Specifically, the allyl-dextran
(1), the azido-dextran (2), and cysteine-dextran derivative (3) (Figure 3) were used with thiolene
condensation, click chemistry, and amide bond formation, respectively.
Figure 3. Dextran derivatives used in the synthesis of the new dextran-mannose multifunctional ligands.
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2.2.1. Synthesis of Dextran Derivatives
The commercially available dextran with average molecular weight 10,000 Da was reacted
with allyl bromide, sodium hydroxide, and sodium borohydride to obtain the dextran derivative 1.
The product was purified by repeated precipitation with ethanol and dried under vacuum to achieve
a constant weight. The final loading of dextran polymer was achieved by comparison of 1H-NMR
spectra. In particular, the chemical shift and the integral value of anomeric protons (nonsubstituted
and substituted dextran) at 4.96 ppm and 5.13 ppm were reported to the allylic proton at 5.96 ppm.
The loading was about 18 allylic groups for every polymeric unit (18 allyl moiety for 55 monomeric
sugar in the dextran); see Figure 4. As shown by the NMR spectra of allyl dextran, only one compound
was reported. As suggested by Pirmettis and coworkers [12], and in agreement with our analytical data,
position 2 of dextran was the most accessible, probably for steric reasons. In our experience, no other
positions were touched by the alkyl group using allyl bromide and sodium hydroxide as reagents.
Figure 4. 1H-NMR spectra of dextran (left) and allyl dextran (right).
Compound 1 was then treated with the azido-thioglicol amide at 50 ◦C in the presence of
ammonium persulfate to obtain the corresponding thiol-ene adduct 2 (Figure 5). The same procedure
was adopted for the reaction with the Fmoc-cysteine ethyl ester to obtain compound 1a that was
directly deprotected to obtain the free amine compound 3.
Figure 5. Synthesis of dextran derivatives.
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2.2.2. Synthesis of a Dextran-DTCZ Multifunctional Ligand
A preliminary synthesis of a dextran-DTCZ derivative was carried out according to the reaction
scheme depicted in Figure 6. HDTCZ was firstly functionalized with an alkyne moiety (4) and then
linked to azido-dextran (2) by click chemistry. Preliminary labeling of the resulting ligand (5) was
carried out in physiological solution by simple mixing with the [99mTc≡N]2+ intermediate prepared by
reaction of [99mTc][TcO4]− with succinic dihydrazide (SDH) in the presence of Sn2+ ions. Although the
labeling yield was >90%, it was found that 5 was highly unstable also in the solid state. In particular,
after freeze-drying, the labelling yield dropped to 50%, thus indicating that the DTCZ group was
partially removed from the dextran scaffold by the lyophilization process. Because of these difficulties,
this type of dextran derivative for SLND was abandoned and the mechanism of DTCZ decomposition
has not been deepened.
Figure 6. Schematic drawing of the synthesis of dextran-DTCZ (5).
2.3. Synthesis of 2-(2,3,4,6-tetra-O-acetyl-β-D-mannopyranosyl)-Acetic Acid
The novel 2-(2,3,4,6-tetra-O-acetyl-β-D-mannopyranosyl)-acetic acid 8 was synthesized by
oxidation of the corresponding β-D-mannopyranosyl acetaldehyde 7, which in turn was prepared from
the isomeric α-aldehyde 6 [25] by a previously optimized anomerization procedure [26]. It is worth
noting that the challenging mannosyl derivative 8, that is a β-C-mannoside, was suitably designed
to display a metabolically stable carbon–carbon anomeric linkage between the sugar moiety and
the carboxylic functionality, thus preventing the corresponding glycoconjugates from chemical and
enzymatic degradation (deglycosylation) in vivo [27]. Accordingly, the α-mannosyl acetaldehyde 6
was dissolved in MeOH and treated with L-proline organocatalyst (30 mol%), which promoted the
anomeric process to the corresponding β-aldehyde 7 with the aid of microwave (MW) dielectric heating
(constant power at 13 W for 3 h). The target β-mannosyl aldehyde 2 (thermodynamic product) was
duly isolated in pure form by column chromatography (75% yield) and then subjected to a standard
oxidation procedure with sodium chlorite [28] to give the corresponding acid 8 in almost quantitative
yield (Figure 7).
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Figure 7. Synthesis of 2-(2,3,4,6-tetra-O-acetyl-β-D-mannopyranosyl)-acetic acid 8.
2.4. Synthesis of a Dextran-Mannose-CysCys Multifunctional Ligand
A pair of multifunctional mannosylated CysCys ligands 9 and 10, (Figure 8a) suitable for the
labeling through the 3 + 1 method, was obtained using the reactions depicted in Figure 8b.
As a first step, the two linear pseudopeptides 9 and 10 were produced following the procedures
illustrated in Figure 8b. Essentially, these compounds have the same basic structural features given by
a terminal mannose group and a terminal combination of two cysteine aminoacids, but differ from the
reactive group positioned approximately at the center of the linear pseudopeptide chain. In particular,
9 carries an alkyne group that is replaced by a carboxylic group in 10. Pseudopeptide 9 was then
linked to the dextran derivatives 2 through click chemistry reaction. Instead, pseudopeptide 10 was
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(b) 
Figure 8. Structure (a) and synthesis (b) of mannosyl-CysCys ligands.
Figure 9. Synthesis and structure of dextran-mannosyl-CysCys ligands 18 and 19.
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2.5. Preparation of 99mTcN-“3 + 1” Labeled Dextran-Mannose Derivates
The resulting multifunctional ligands 18 and 19 (Figure 9) were labeled with the [99mTc≡N]2+
core by applying the 3 + 1 approach, as shown in Figure 10. The monophosphine PCN (tris-cyanoethyl
phosphane) was employed as ancillary ligand. Labeling yields were >95% (Figure 11a,b), and the
resulting complexes exhibited a prolonged stability (>6 h) in physiological solution.
The formulation developed to prepare the 99mTcN-“3+1” labeled dextran-mannose compound
contains 0.1 mg of dextran-derivate, about half of that involved in the Lymphoseek® formulation
(0.250 mg). Therefore, even if this dextran-derivate could have hypersensitivity effect, still to be
verified, it is reasonable to assume that the reactions by patients to dextran in our formulation could
be smaller than with Lymphoseek®. Further studies must be performed on this topic.






















Figure 11. HPLC chromatograms of [99mTc≡N(18)PCN] (a) and [99mTc≡N(19)PCN] (b) complexes.
2.5.1. Stability Studies
The in vitro stability of 99mTc-complexes was evaluated by monitoring radiochemical purity (RCP)
at different time points (15, 30, 60, 120 min) by high-performance liquid chromatography (HPLC).
After preparation, 100 μL of the selected radioactive compound were incubated at 37 ◦C with 900 μL
of saline or, alternatively, rat serum. No significant variation of RCP was observed in both conditions.
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2.5.2. Cysteine and Glutathione (GSH) Challenge
An aliquot of freshly prepared aqueous solution of L-cysteine or GSH (50 μL, 10.0 mM) was
placed in a test tube containing phosphate buffer (250 μL, 0.2 M, pH = 7.4), water (100 μL), and the
appropriate 99mTc-complex (100 μL). The mixture was incubated at 37 ◦C for 2 h. A blank experiment
was carried out using an equal volume of saline. Aliquots of the resulting solutions were withdrawn
at 15, 30, 60, 120 min after incubation and analyzed by HPLC chromatography. The complexes were
found to be inert toward transchelation by cysteine and GSH.
3. Materials and Methods
3.1. General
Dextran with average molecular weight 10,000 Da, succinic dihydrazide [SDH=H2N–NH–
(O=)C–(CH2)2–C(=O)–NH–NH2], sodium dihydrogen phosphate monohydrate (NaH2PO4·H2O),
disodium hydrogen phosphate heptahydrate (Na2HPO4·7H2O), SnCl2·2H2O, tris(2-cyanoethyl)phosphine
[PCN=P(CH2CH2CN)3], γ-hydroxypropylcyclodextrin, L-cysteine, and glutathione (GSH) were obtained
from Sigma Aldrich, Milan, Italy.
Technetium-99m, as Na[99mTcO4] in physiological solution, was obtained from a Drytec™
99Mo/99mTc generator (GE Healthcare, Belfast, UK).
The infrared spectra (IR) (PerkinElmer, Waltham, Massachusetts, US) were recorded with
FT-Perkin Elmer Spectrum 100 using a universal ATR crystal Zr/Se Diamond Bounces 1, serial number
14031; 1H-NMR spectra were recorded on a Varian 400 NMR instrument (Varian Inc., Palo Alto,
CA, USA); the chemical shift (δ) is expressed in ppm.
3.1.1. Synthesis of 1
Sodium hydroxide (NaOH, 0.5 g, 12.5 mmol) and sodium borohydride (NaBH4, 20.0 mg,
0.53 mmol) were added to a stirred solution of dextran (average molecular weight = 10,000 Daltons)
(2.0 g, 0.2 mmol) in water. Allyl bromide (BrCH2CH=CH2, 3.5 g, 30 mmol) was then added to this
solution at 40 ◦C. The mixture was stirred at 60 ◦C for 3 h and then neutralized with acetic acid.
The product was purified by repeated precipitation with ethanol and dried under vacuum to achieve
a constant weight. The final loading of dextran polymer was achieved by comparison of 1H-NMR
spectra. In particular, the chemical shift and the integral value of anomeric protons (nonsubstituted
and substituted dextran) at 4.96 ppm and 5.13 ppm were reported to the allylic proton at 5.96 ppm.
The loading was about 18 allylic groups for every polymeric unit (18 allyl moiety for 55 monomeric
sugar in the dextran).
3.1.2. Synthesis of Thioglycol Amide
Sodium azide (NaN3, 3.34 g, 51.38 mmol) was added to a stirred solution of 2-chloro-ethylamine
hydrochloride (H2NCH2CH2Cl, 2.0 g, 17.39 mmol) in water, and the reaction solution was heated at
80 ◦C for 15 h. After cooling the reaction at 0 ◦C, KOH pellets were added until pH = 14. The aqueous
solution was extracted 3 times with diethyl ether (30 mL each), and the resulting organic phase was
separated, dried, and concentrated under vacuum to obtain the corresponding amino-azide compound
H2NCH2CH2N3 (caution: explosive compound).
This compound was successively used to prepare the corresponding thioazide using the following
procedure. The amino-azide (H2NCH2CH2N3, 0.33 g, 3.8 mmol), WSC (0.42 g, 2.19 mmol), and HOBt
(0.18 g, 2.19 mmol) were added to a stirred solution of thioglicolic acid (0.33 g, 1.99 mmol) in DMF
at 0 ◦C. The reaction mixture was stirred at room temperature for 24 h and then concentrated under
vacuum and diluted with ethyl acetate. The organic phase was washed with a citric acid solution
(10% in water, 30 mL), NaHCO3 (5% in water, 30 mL), and Brine (30 mL). The organic phase was dried
and concentrated to dryness to obtain the thiozide.
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1H NMR (400 MHz, Chloroform-d) δ 6.64 (bs, 1H), 3.59–3.54 (m, 1H), 3.36–3.31 (m, 4H), 3.29–3.23
(m, 2H).
13C NMR (100 MHz, Chloroform-d) δ 171.60, 49.84, 41.37, 32.75.
The allyl dextran (1) (80.0 mg) and the thioazide HSCH2C(=O)NHCH2CH2N3 (86.0 mg,
0.53 mmol) were dissolved in a mixture of water and THF(1:1). Ammonium persulfate (80.0 mg,
0.35 mmol) was added in one pot and the mixture was then heated at 50 ◦C for 2 h. After evaporation
of the solvent under vacuum, the resulting product (2) was purified by gel filtration using a Sephadex
G25 PD 10 column using water as eluent.
As depicted in Figure 12, the infrared spectra of azido dextran showed the classical absorption
peak at 2101 cm−1.
Figure 12. IR spectra of azido dextran after purification procedure.
3.1.3. Synthesis of 3
The dextran moiety 3 was prepared according to literature methods [29]. The Fmoc-Cys-OEt
group was attached to the allyl moiety using ammonium persulfate in water. In order to evaluate
the derivatization loading of allyl-dextrane, we performed, in a small part of the product, a Fmoc
deprotection and titration [30]; this analysis allowed us to determine the final loading of dextran in
0.20 mmol/g. The deprotection of Fmoc residue from the cysteine with DMF/20% piperidine yielded
the free amine product 3.
3.1.4. Synthesis of 4
To a stirred solution of HDTCZ (2.0 g, 14.68 mmol) in anhydrous THF (60 mL), DIPEA (2.84
g, 22.02 mmol) and propargyl chloroformate (2.61 g, 22.02 mmol) were added at 0 ◦C. The reaction
was stirred at room temperature for 4 h and then quenched with a saturated solution of ammonium
chloride to afford compound 4.
1H NMR (400 MHz, Chloroform-d) δ 8.01 (bs, 1H), 4.85 (s, 2H), 2.61 (m, 4H).
3.1.5. Synthesis of 5
Compound 4 (5.3 mg, 3.69 × 10−4 mmol), sodium ascorbate (0.8 mg, 4.059 × 10−5 mmol),
and CuSO4 (0.01 mg, 4.059 × 10−6 mmol) were added to a stirred solution of compound 2 (5.69 mg,
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approximately 4.06 × 10−4 mmol) in water (3.0 mL). The solution was stirred at room temperature for
12 h and then concentrated under vacuum to yield compound 5.
3.1.6. Synthesis of 2-(2,3,4,6-Tetra-O-acetyl-β-D-Mannopyranosyl)-Acetaldehyde (7)
A 0.5–2.0 mL process vial was filled with the α-mannosyl aldehyde 6 (150 mg, 0.40 mmol)
and MeOH (1.5 mL). The resulting solution was cooled to 0 ◦C, and then L-proline (14 mg, 0.12 mmol)
was added in one portion. The vial was sealed with the Teflon septum and aluminium crimp by using
an appropriate crimping tool. The mixture was then vigorously stirred at 0 ◦C for 1 h, then the vial was
placed in its correct position in the Biotage Initiator cavity where irradiation at constant power (13 W)
was performed for 3 h with simultaneous cooling of the vial (internal temperature ≈60 ◦C) by means
of pressurized air (4 bar). After the full irradiation sequence was completed, the vial was cooled to
room temperature and then opened. The mixture was diluted with AcOEt (80 mL) and washed with
saturated NaHCO3 (2 × 15 mL) and brine (2 × 5 mL). The organic phase was dried (Na2SO4), filtered,
and concentrated to give crude β-mannosyl aldehyde 7 (β/α ratio 10:1). Flash column chromatography
with 1:1 cyclohexane-AcOEt (containing 20% of CH2Cl2 and 1% of MeOH) afforded pure 7 (112 mg,
75%) as a white amorphous solid. 1H NMR: δ = 9.75 (dd, 1 H, J = 0.5 Hz, J = 1.5 Hz, CHO), 5.36 (dd, 1 H,
J = 0.5 Hz, J = 3.0 Hz, H-2′), 5.24 (dd, 1 H, J = 9.0 Hz, J = 9.2 Hz, H-4′), 5.12 (dd, 1 H, J = 3.0 Hz,
J = 9.2 Hz, H-3′), 4.30–4.20 and 4.18–4.06 (2 m, 3 H, H-1′, 2 h-6′), 3.72 (ddd, 1 H, J = 2.5 Hz, J = 6.0 Hz,
J = 9.0 Hz, H-5′), 2.77 (ddd, 1 H, J = 1.5 Hz, J = 7.5 Hz, J = 17.0 Hz, H-2a), 2.54 (ddd, 1 h, J = 0.5 Hz,
J = 4.5 Hz, J = 17.0 Hz, H-2b), 2.20, 2.10, 2.05, and 1.98 (4 s, 12 H, 4 Me). ESI MS (374): 397 (M + Na+).
3.1.7. Synthesis of 2-(2,3,4,6-Tetra-O-Acetyl-β-D-Mannopyranosyl)-Acetic Acid (8)
A mixture of β-aldehyde 7 (112 mg, 0.30 mmol), sodium chlorite (271 mg, 3.00 mmol), sodium
dihydrogen phosphate monohydrate (311 mg, 2.25 mmol), 2-methyl-2-butene (1.2 mL), t-BuOH
(5.5 mL), and H2O (2.1 mL) was stirred at room temperature for 4 h and then diluted with CH2Cl2
(15 mL) and H2O (5 mL). The organic layer was separated and the aqueous layer was extracted with
CH2Cl2 (3 × 10 mL) then acidified (pH 2) with 5% HCl and extracted again with CH2Cl2 (3 × 10 mL).
The combined organic phases were dried (Na2SO4), filtered, and concentrated to give the β-mannosyl
acetic acid 8 (111 mg, 95%) at least 95% pure as established by 1H NMR analysis. 1H NMR: δ = 5.40
(dd, 1 h, J = 0.5 Hz, J = 3.0 Hz, H-2′), 5.24 (dd, 1 H, J = 9.0 Hz, J = 9.2 Hz, H-4′), 5.11 (dd, 1 H, J = 3.0 Hz,
J = 9.2 Hz, H-3′), 4.27 (dd, 1 H, J = 5.5 Hz, J = 12.0 Hz, H-6′a), 4.14 (ddd, 1 H, J = 0.5 Hz, J = 5.0 Hz,
J = 7.5 Hz, H-1′), 4.10 (dd, 1 H, J = 3.0 Hz, J = 12.0 Hz, H-6′b), 3.70 (ddd, 1 H, J = 3.0 Hz, J = 5.5 Hz,
J = 9.0 Hz, H-5′), 2.68 (dd, 1 H, J = 7.5 Hz, J = 17.0 Hz, H-2a), 2.50 (dd, 1 H, J = 5.0 Hz, J = 17.0 Hz,
H-2b), 2.20, 2.08, 2.04, and 1.98 (4 s, 12 H, 4 Me). ESI MS (390): 413 (M + Na+).
3.1.8. Synthesis of Pseudopeptide 9
Fmoc-Rink amide resin (0.69 mmol/g, 0.2 g) was treated with piperidine [20% in
N,N-dimethylformamide (DMF)] and linked with Fmoc-aa-OH (4.0 equiv) by using
[O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate] (HATU, 4.0 equiv)
as a coupling reagent. The coupling reaction was continued for 1 h and then piperidine (20% in DMF)
was used to remove the Fmoc group at every step. The peptide resin was washed with methanol
and dried in vacuum to yield the protected peptide-resin. This resin was treated with a mixture
of trifluoroacetic acid (TFA)/H2O/Et3Si (9:0.5:0.5) for 1 h at room temperature. After filtration of
the resin, the solvent was concentrated in vacuum and the residue triturated under diethyl ether.
The crude linear peptide was purified by preparative reversed-phase HPLC to yield a white powder
after lyophilization. Further purification was obtained by preparative reversed-phase HPLC using
a Water Delta Prep 4000 system equipped with a Waters PrepLC 40-mm Assembly C18 column
(30 × 4 cm, 300 A, 15 mm spherical particle size column). The column was perfused at a flow rate of
40 mL min−1 with solvent A (5% v/v acetonitrile in 0.1% aqueous TFA) and a linear gradient from 0 to
50% of solvent B (80% v/v acetonitrile in 0.1% aqueous TFA) over a period of 25 min. Analytical HPLC
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was performed on a Beckman 125 instrument fitted with an Alltech C18 column (4.6 × 150 mm, 5 mm
particle size) and equipped with a Beckman 168 diode array detector. Analytical purity and retention
time (tR) of 9 were determined using the solvent system A + B as specified above, at a flow rate of
1.0 mL min−1, and using a linear gradient ranging from 5 to 40% B over 25 min. Molecular weight of 9
was measured by ESI-MS analysis using a Micromass ZMD 2000 mass spectrometer.
HPLC: Rt 10.60 min; ESI MS (812): 813.3 (M + H+).
3.1.9. Synthesis of Pseudopeptide 10
Peptide 10 was obtained through a Fmoc-chemistry solid phase peptide synthesis using a Rink
amide resin to elongate the peptide backbone starting from the C terminal (Cys). The pseudopeptide
was cleaved from the resin using a mixture of TFA/water and triethylsilane.
HPLC: Rt 9.98 min; ESI MS (846): 847.6 (M + H+).
3.1.10. Synthesis of 18
To a stirred solution of compound 2 (5.69 mg, approximately 4.06 × 10−4 mmol) in water (3.0 mL)
was added 9 (6.0 mg, 3.69 × 10−4 mmol), sodium ascorbate (0.8 mg, 4.059 × 10−5 mmol), and CuSO4
(0.01 mg, 4.059 × 10−6 mmol). The solution was stirred at room temperature for 12 h and then
concentrated under vacuum to yield compound 18. As depicted in Figure 13, the IR spectra showed
the disappearance of azide peak (at 2097 cm−1) and the appearance of a new broad signal at 1652 cm−1
that could be assigned to carbonyl stretching of peptide amide moiety.
HPLC: Rt = 14.30 min.
 
Figure 13. Comparison of IR spectra before and after click reaction.
3.1.11. Synthesis of 19
Using a classical peptide chemistry condensation, pseudopeptide 10 (6 mg, 0.00709 mmol) was
condensed with dextran moiety 3 (40 mg, loading 0.2 mmol/g, 0.00788 mmol), using as coupling
agents WSC (1.5 mg, 0.007799 mmol) and HOBt (1.2 mg, 0.007799 mmol).
HPLC: Rt = 14.30 min.
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3.2. Preparation of 99mTcN-“3 + 1” Labeled Dextran-Mannose Derivate
Freshly generator-eluted Na[99mTcO4] (100 MBq, 0.9 mL) was added to a nitrogen-purged vial
containing 1.0 mg of succinic dihydrazide (SDH) and 0.1 mg of SnCl2. The vial was kept at room
temperature for 15 min to yield the [99mTcN]2+ group. The appropriate dextran-mannose derivate
(0.1 mg dissolved in 0.5 mL of saline) and tris(2-cyanoethyl) phosphine (PCN, 0.5 mg dissolved in
a saline solution containing 2.0 mg of γ-hydroxypropylcyclodextrin) were freshly prepared and then
simultaneously added to the reaction vial containing the radioactive Tc-99m nitrido intermediate.
The resulting mixture was heated at 80 ◦C for 15 min. The radiochemical yield, as determined by
radio-HPLC chromatography, ranged from 95 to 98%.
3.3. Chromatography
The RCP of the final Tc-99m compounds was determined by HPLC performed on a Beckman
System Gold Instrument equipped with a programmable solvent Module 126, scanning detector
Module 166, and a radioisotope detector Module 170. Chromatographic analyses were carried out on
a reversed-phase Agilent precolumn Zorbax 300SB-C18 (4.6 × 12.5 mm) and a reversed-phase Agilent
column Zorbax 300SB-C18 (4.6 × 250 mm) using the following conditions. Mobile phase: A = water
containing 0.1% TFA, B = acetonitrile containing 0.1% TFA; gradient: 0 min, B = 0%; 0–25 min, B = 100%;
25–30 min, B = 100%; 30–35 min, B = 0%; flow rate: 1.0 mL/min.
4. Conclusions
A new particular of mannosyl-dextran-derived multifunctional ligands, potentially useful for
sentinel node detection, has been reported. These multifunctional ligands have been specifically
designed to accommodate, in a controlled way, the same number of functional groups, each performing
a specific chemical or biological function on the selected position on the dextran scaffold.
Click reactions, as well as standard amide condensation, allowing the use of modular building
blocks, have proven to be very efficient for building up the multifunctional ligands, containing
a chelating system specifically chosen to label the [99mTcN]2+. We have found no differences between
in vitro stability of the 99mTcN-“3+1” labeled dextran-mannose derivate obtained through the different
chemical procedures. However, further in vivo investigations should be performed to confirm
our results.
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Abstract: Irradiation of salivary glands remains the main dose-limiting side effect of
therapeutic PSMA-inhibitors, especially when using alpha emitters. Thus, further advances in
radiopharmaceutical design and therapy strategies are needed to reduce salivary gland uptake,
thereby allowing the administration of higher doses and potentially resulting in improved response
rates and better tumor control. As the uptake mechanism remains unknown, this work investigates the
salivary gland uptake of [177Lu]Lu-PSMA-617 by autoradiography studies on pig salivary gland tissue
and on PSMA-overexpressing LNCaP cell membrane pellets. Displacement studies were performed
with non-labeled PSMA-617 and 2-PMPA, respectively. The uptake of [177Lu]Lu-PSMA-617 in
glandular areas was determined to be partly PSMA-specific, with a high non-specific uptake fraction.
The study emphasizes that [177Lu]Lu-PSMA-617 accumulation in pig salivary glands can be attributed
to a combination of both specific and non-specific uptake mechanisms. The observation is of high
impact for future design of novel radiopharmaceuticals addressing the dose-limiting salivary gland
irradiation of current alpha endoradiotherapy in prostate cancer.
Keywords: PSMA-617; salivary gland uptake; prostate cancer; endoradiotherapy
1. Introduction
The therapy of metastatic, hormone-refractory prostate cancer poses a major clinical challenge.
Treatment options are limited, rendering new developments and advances in therapy strategies of
high clinical interest. The development of radioactive labeled prostate-specific membrane antigen
(PSMA)-inhibitors suitable for endoradiotherapy has enabled a promising new form of therapy
for metastatic, hormone-refractory prostate cancer. In particular, PSMA represents an attractive
target structure and proved suitable for highly sensitive and specific nuclear medicine imaging and
therapy as it is overexpressed in almost all prostate carcinomas with markedly increased levels in
metastases [1–5]. Physiological expression has been shown to be significantly lower, and is limited
to a few organs [1,6]. Clinical experience with PSMA-targeting positron emission tomography (PET),
especially with [68Ga]Ga-PSMA-11 [7–14], in patients with recurrent prostate cancer show that lesions
can be detected in almost all patients, in some cases with very low PSA levels. These findings often
have a high impact on further therapeutic strategies [11,12].
When used therapeutically, radiation dose to organs with physiological PSMA expression might
be dose-limiting and can thus minimize the therapeutic success of radiolabeled PSMA-inhibitors.
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In particular, renal and salivary gland uptake can be of concern, which, in the case of a therapeutic
application, gives rise to relevant organ doses and possible side effects. With the development of
PSMA-617 showing an improved and fast kidney excretion, a highly promising compound is already
being clinically investigated for endoradiotherapy of prostate cancer with 177Lu or 225Ac [15–17].
In a first-in-man study with [225Ac]Ac-PSMA-617, two patients with advanced disease showed
complete remission as confirmed by drop in PSA below the detection limit and a radiologic response
in [68Ga]Ga-PSMA-11-PET. Alpha therapy did not result in hematologic toxicity or renal impairment.
Nevertheless, strong accumulation of PSMA ligands in salivary glands was described in numerous
papers, leading to considerable side effects. The salivary glands are significantly and partially
irreversibly damaged, in particular during alpha therapy with 225Ac with a mean radiation dose
of approximately 2.3 Sv/MBq compared to 0.7 Sv/MBq for kidneys and 0.05 Sv/MBq for bone
marrow [18]. The resulting xerostomia leads to a significant impairment of the patients’ quality of
life and thus represents a dose-limiting side effect for therapeutic use of radiolabeled small molecule
PSMA-inhibitors. In contrast, PSMA-targeting antibodies such as J591 labeled with 177Lu show no
significant uptake in salivary glands. Unfortunately, myelotoxicity appears caused by longer blood
circulation of antibodies, making them unsuitable for PSMA-directed alpha therapy [19,20]. On the
other hand, a reduction of the dose-limiting salivary gland uptake of small molecule PSMA-inhibitors
has not yet been achieved by specific molecular design. Besides many rather non successful
approaches towards reduction of salivary gland uptake such as local cooling or lemon juice [21,22],
Baum et al. reported a 64% decrease in [68Ga]Ga-PSMA-11 uptake after multifocal, ultrasound-guided
injections of botulinum toxin A in a parotid gland [23]. Although first approaches resulted in
reduced salivary gland uptake of PSMA-targeting radioligands, the exact mechanisms of tracer
accumulation, especially the ratio of specific to non-specific uptake in salivary glands, are not yet
sufficiently understood. Salivary glands are known to physiologically express PSMA, which results
in a PSMA-specific uptake of small molecule PSMA-inhibitors [24]. However, the detected strong
salivary gland uptake of PSMA-inhibitors in clinical studies does not correlate with the rather low
physiological PSMA-expression in that tissue. This is underlined by the fact that other physiologically
PSMA-expressing organs like intestine, spleen and kidney show similar or even lower radiation doses
after endoradiotherapy compared to salivary glands [18,25,26].
Therefore, the present study investigates the salivary gland uptake of [177Lu]Lu-PSMA-617 by
autoradiography enabling visualization and quantification of tissue radioligand distribution. Therefore,
specific and non-specific uptake of [177Lu]Lu-PSMA-617 were analyzed on pig salivary gland, as a
close human homologue, in comparison to LNCaP membrane pellets expressing human PSMA as a
positive control. This study gives a further insight into the salivary gland uptake of small molecule
PSMA-inhibitors, which is crucial for the future development of novel PSMA-inhibitors with reduced
salivary gland toxicity in endoradiotherapy of prostate cancer.
2. Results
2.1. Radiolabeling of PSMA-617
Radiolabeling of PSMA-617 with 177Lu resulted in high radiochemical yields > 95%. Thus, the output
of labeling reactions was directly diluted with the appropriate buffer for further use in subsequent
experiments (Radiochemical purity > 95%). The molar activity amounted to 48 GBq/μmol.
2.2. PSMA-Specific Binding and Saturation Analysis of [177Lu]Lu-PSMA-617 on Pig Salivary Gland Tissue
and LNCaP Membrane Pellets
The regional distribution of glandular areas could be visualized on 10 μm pig cryosections
of salivary gland tissue after H&E staining (Figure 1A). In particular, glandular areas showed a
high enrichment of [177Lu]Lu-PSMA-617 (Figure 1B). Additional blocking with 2-PMPA, a highly
potent PSMA-inhibitor, resulted in a reduced uptake of radioligand in the glandular areas, whereby a
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relevant amount of non-specific bound [177Lu]Lu-PSMA-617 was still detectable with autoradiography
(Figure 1C).
Figure 1. Salivary gland tissue cryosections (pig, 10 μm). Arrows indicate glandular areas.
(A) H&E staining; autoradiography after incubation for 1.5 h at ambient temperature with 80 nM
[177Lu]Lu-PSMA-617 showing total binding (B) and additional incubation with 80 μM 2-PMPA (highly
potent PSMA-inhibitor) indicating non-specific binding (C).
For the saturation binding studies, LNCaP membrane pellets were used as a human PSMA expressing
positive control. [177Lu]Lu-PSMA-617 revealed a Kd value in the low nanomolar range to both, pig salivary
gland tissue (1.1 ± 0.2 nM) and LNCaP membrane pellets (2.0 ± 0.3 nM) (Figure 2, Table 1).
Figure 2. Saturation binding curve (specific binding) of [177Lu]Lu-PSMA-617 to pig salivary gland
cryosections. Sections were incubated with 10 different concentrations of [177Lu]Lu-PSMA-617
(0.2–80 nM) for 1.5 h at ambient temperature. Autoradiography was performed with a Cyclone
Plus Phosphorimager after an exposure time of 24 h.
Besides the specific binding of [177Lu]Lu-PSMA-617, non-specific uptake in salivary gland tissue
accompanied by a reduced Bmax value of 0.01 ± 0.0006 fmol/mm2 was notably high as compared to
LNCaP membrane pellets (4.9 ± 0.5 fmol/mm2). Non-specific binding was determined at the presence
of a 1000-fold excess of 2-PMPA, indicating a lower PSMA density and higher non-specific uptake in
salivary gland tissue in contrast to PSMA overexpressing LNCaP membranes (Table 1).
Table 1. Binding affinity of [177Lu]Lu-PSMA-617 and receptor density of PSMA on LNCaP membrane
pellets and pig salivary gland tissue.
Specimen Kd [nM] Receptor Density (PSMA) Bmax [fmol/mm2]
LNCaP membrane pellets (human, PSMA+) 2.0 ± 0.3 4.9 ± 0.5
Salivary gland tissue (pig) 1.1 ± 0.2 0.01 ± 0.0006
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2.3. Competitive Binding Analysis of PSMA-617
In competitive binding studies, PSMA-617 revealed high binding affinities in the low nanomolar
range using the non-labeled precursor PSMA-617 as a competitor (Figure 3). The IC50 value on LNCaP
membrane pellets was determined to be 2.7 ± 0.1 nM and on pig salivary gland tissue 6.0 ± 0.1 nM.
Furthermore, a high non-specific uptake fraction in pig salivary gland tissue was detected, whereas
LNCaP cell membrane pellets showed only negligible non-specific uptake (Figure 3).
Figure 3. Competitive binding studies of PSMA-617 on LNCaP membrane pellets and pig salivary
gland tissue. 6 nM radioligand ([177Lu]Lu-PSMA-617) were incubated with increasing concentrations
(0.1 nM–100 μM) of PSMA-617 (unlabeled) as competitor for 1.5 h at ambient room temperature.
Autoradiography was performed with a Cyclone Plus Phosphorimager after an exposure time of 48 h.
3. Discussion
Endoradiotherapy of metastatic, hormone-refractory prostate cancer with small molecule
PSMA-inhibitors represents a promising approach in the clinical challenging treatment regimen
of those patients. In particular, endoradiotherapy with the small molecule PSMA-inhibitor PSMA-617
labeled with alpha emitters was reported to have the potential of complete remission in advanced
stage prostate cancer patients [27]. Due to the high linear energy transfer of alpha emitters, critical
doses are achieved in accumulating tissue. Besides a highly specific uptake in tumor tissue, rapid
excretion of radiopharmaceuticals from non-target tissue is therefore crucial for a successful therapy
and to minimize potential dose-limiting side effects. Kratochwil et al. reported the salivary gland
toxicity to be the severe and the dose-limiting side effect during endoradiotherapy with 225Ac-labeled
PSMA-617 strongly reducing the patient’s quality of life and limiting therapy success [18].
Thus, further advances in radiopharmaceutical design and therapy strategies are needed to reduce
salivary gland uptake, thereby allowing the administration of higher doses potentially resulting in
improved response rates and better tumor control. However, the molecular mechanism underlying the
salivary gland accumulation of those radiopharmaceuticals still remains unknown. Several studies
indicate that the uptake is potentially caused by a combination of non-specific and PSMA-specific
uptake, whereby the exact ratio of specific to non-specific uptake is still undefined [23,28,29].
Therefore, the present study focused on the salivary gland uptake of PSMA-617 analyzed by
autoradiography enabling an insight to binding characteristics. Pig salivary gland tissue was chosen
as an easily accessible human homologue model representing the healthy organ. Glandular areas
could be identified by H&E-staining allowing clear delimitation from surrounding tissue for precise
quantification. As a PSMA-positive reference, cell membranes derived from LNCaP cells were analyzed,
which are a well-established PSMA-expressing androgen-sensitive human prostate model. Saturation
binding studies demonstrated that the uptake of [177Lu]Lu-PSMA-617 on pig salivary gland tissue is
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PSMA-specific, although a remarkably high proportion of non-specific uptake was noted. The 2-PMPA
blocked uptake increased linear in dependence to the radioligand concentration on pig salivary
gland tissue indicating a typical characteristic of non-specific binding. In contrast, LNCaP membrane
pellets only showed a negligible non-specific bound fraction. Furthermore, the remarkably low
Bmax value detected in the saturation binding study indicates a low PSMA density on pig salivary
gland tissue as compared to tumor cell membranes. This confirms that pig salivary gland tissue as
a physiologically PSMA expressing tissue has a low PSMA density. As expected and in line with
theoretical considerations, the binding affinity of PSMA-617 is not affected by the differences in
PSMA densities. The Kd values of [177Lu]Lu-PSMA-617 were observed to be in the low nanomolar
range on both species, matching well with previously published binding affinities of PSMA-617 (Ki:
2.34 ± 2.94 nM on LNCaP cells) [16]. The findings of the saturation binding study were confirmed
with a competitive experimental design also revealing high binding affinities for PSMA-617 in the
low nanomolar range on both tested species comparable to previously published binding data [16].
The respective competitive binding curves showed differences with regard to the bottom plateau
representing non-specific binding. In contrast to LNCaP cell membrane pellets, a high non-specific
bound fraction of PSMA-617 was observed again on salivary gland tissue samples. Both experimental
set ups confirmed the previously published binding affinities of PSMA-617 on the tested species as well,
however they were accompanied by a high non-specific bound fraction on pig salivary gland tissue.
The high amount of non-specific tracer uptake determined in this study might contribute to
the phenomenon of strong salivary gland uptake of PSMA-inhibitors in clinical studies, which does
not correlate with the rather low physiological PSMA-expression in that tissue [24]. In particular,
non-specifically bound PSMA-617 was found to be located in glandular areas. Due to high blood
supply, salivary glands are likely to enrich systemically applied pharmaceuticals. Ionic charges and
molecular weight might also play an important role in non-specific radiotracer uptake.
Further studies should focus on the rational design of chemically modified derivatives of clinically
used PSMA-inhibitors in order to reduce the salivary gland uptake. In that context, concepts related
to the non-specific uptake should be taken into account as well to improve the endoradiotherapy of
prostate cancer. A more rapid elimination of the radiopharmaceutical from salivary gland tissue would
avoid severe side effects and subsequently allow the administration of higher doses to better control
the disease.
4. Material and Methods
All commercially obtained chemicals were best grade and purchased from common suppliers.
[177Lu]LuCl3 was purchased from ITG (Munich, Germany). PSMA-617 and 2-Phosphonomethyl
pentanedioic acid (2-PMPA) were purchased from ABX (Radeberg, Germany). All reagents used in cell
culture were purchased from Gibco©.
4.1. Radiolabeling of PSMA-617 with 177Lu
The γ- and β-emitter [177Lu]LuCl3 (ITG, Munich), with a t1/2 of 6.7 days was used for the
autoradiography studies. Radiolabeling was performed by adding 13 μL [177Lu]LuCl3 (~30–37 MBq)
in 0.4 mM HCl, 7 μL of diluted peptide (0.1 mM solution of PSMA-617 in nanopure H2O) to 230 μL
ammonium-acetate buffer (0.5 M, pH 5.4). The reaction mixture was incubated at 95◦C for 30 min.
After quality control by HPLC one equivalent of natLu3+ (0.7 μL) was added and the mixture was
incubated under the same reaction conditions. The radiochemical yield (RCY) was determined using
high performance liquid chromatography (RP-HPLC; Chromolith RP-18e, 100 × 4.6 mm; Merck,
Darmstadt, Germany). Analytical HPLC runs were performed using an Agilent 1200 series (Agilent
Technologies, Santa Clara, CA, USA) equipped with a γ-detector. HPLC runs were performed using a
linear gradient of A (0.1% trifluoroacetic acid (TFA) in water) to B (0.1% TFA in acetonitrile) (gradient:
5% B to 80% B in 15 min) at a flow rate of 2 mL/min.
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4.2. Quantitative In Vitro Autoradiography with [177Lu]Lu-PSMA-617
Pig salivary gland tissue was obtained from Prof. Dr. Mehrabi, University Hospital Heidelberg in
cooperation with DKFZ, Heidelberg. Tissue was immediately frozen after surgical removal on dry-ice
and stored at −80 ◦C in order to block further biological processes including protein degradation and
tissue hardening.
The LNCaP membrane pellets were collected by washing LNCaP cells twice with ice-cold 0.05 M
Tris-HCl (pH 7.4) in a first step. Afterwards the cells were scraped into ice-cold 0.05 M Tris-HCl (pH
7.4), collected by centrifugation, and homogenized using a Polytron PT1200E (Kinematica AG, Luzern,
Switzerland) in the same buffer. After centrifugation at 120× g for 5 min at 4 ◦C, the supernatant was
collected and centrifuged again at 48.000× g for 30 min at 4 ◦C. The resulting pellet was re-suspended
in ice-cold Tris-HCl, transferred into a microfuge tube, and centrifuged at 20.000× g for 15 min at 4 ◦C.
After withdrawal of the supernatant, the membrane pellet was stored at −80 ◦C.
Tissue and membrane pellets were embedded in Tissue Tek (Tissue-Tek O.C.T., Sakura Finetek
Europe B.V). Cryosections of 10 μm were prepared using a cryomicrotome (CM 1950, Leica
Microsystems, Wetzlar, Germany) and mounted onto microscope slides (SuperFrost plus, Langenbrinck,
Germany). Afterwards mounted sections were stored at least one day to improve adhesion of the
tissue to the slide at −20 ◦C until quantitative in vitro autoradiography.
Autoradiographic images were analyzed with a Cyclone Plus Phosphorimager (Perkin Elmer)
and data analysis was performed with OptiQuant data processing software Version 5.0, Microsoft
Excel and GraphPad Prism Version 5.01.
4.3. Saturation Binding Assay
For the determination of the dissociation constant (Kd) and maximum binding capacity (Bmax)
cryosections of salivary gland tissue (pig) and LNCaP membrane pellets were prepared for quantitative
in vitro autoradiography as described above.
Consecutive cryosections (20 per saturation binding assay) were incubated with 10 different
concentrations of [177Lu]Lu-PSMA-617, one section to measure total binding and one section for
non-specific binding, respectively. Samples were covered with 200 μL incubation solution containing
increasing concentrations of [177Lu]Lu-PSMA-617 (0.2–80 nM) in 170 mM Tris-HCl buffer (pH 7.4) with
1% bovine serum albumin (BSA), bacitracin (40 μg/mL) and MgCl2 (5 mM) to inhibit endogenous
proteases. Non-specific binding was determined at the presence of 2-PMPA at a final concentration of
80 μM. Sections were incubated for 1.5 h at ambient temperature. Thereafter sections were washed
twice for 5 min in ice-cold 170 mM Tris-HCl buffer (pH 7.4) containing 0.25% BSA and once in ice-cold
170 mM Tris-HCl buffer (pH 7.4). Finally, sections were dipped in distilled water to remove buffer
salts and dried rapidly under a stream of cool dry air. The sections were placed on a multisensitive
storage phosphor screen for exposure in dedicated lead shielded cassettes. Exposure time for sufficient
screen saturation was 10 min for LNCaP membrane pellets and 24 h for pig salivary gland tissue
with the same experiment conditions. For data analysis the Phosphor Imager software (OptiQuant)
expresses the radioactivity signal of the probes in digital light units per square millimeter (DLU/mm2).
The intensity of the light from the retained energy is proportional to the amount of activity in the
sample. As a standard, aliquots (2 μL) of the radioligand concentrations were spotted on ITLC paper
(Polygram®SilG, Machery-Nagel, Düren, Germany) and co-exposed with the samples. From the
known specific activity of the radioligand stock solution, the corresponding relative concentration
(fmol/mm2) of the receptor was calculated. Regions of interests (ROIs) were drawn in the particular
experiments to receive DLU/mm2 values. The dissociation constant (Kd) and maximum binding
capacity (Bmax) were analyzed and calculated by nonlinear regression using GraphPad Prism.
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4.4. Competitive Binding Assay
In order to determine the potency (IC50) of PSMA-617 on salivary gland tissue (pig) and LNCaP
membranes, a competitive binding assay was performed. Therefore, non-labeled compound PSMA-617
was tested with [177Lu]Lu-PSMA-617 as radioligand. For experiments, five adjacent cryosections were
analyzed. Samples were covered with 200 μL incubation solution with increasing concentrations of the
competitor ranging from 0.1 nM–1 μM in the presence of 6 nM radioligand. Sections were incubated
for 1.5 h at ambient temperature, and were subsequently washed twice for 5 min in ice-cold 170 mM
Tris-HCl buffer (pH 7.4) containing 0.25% BSA and once in ice-cold 170 mM Tris-HCl buffer (pH 7.4).
Afterwards, sections were dipped in distilled water to remove buffer salts and dried rapidly under a
stream of cool dry air. Autoradiography was performed as described in the section above. Exposure
time for sufficient screen saturation was 48 h for all samples. Regions of interests (ROIs) were drawn
using Phosphor Imager software (OptiQuant), which calculated the intensity units in each region as
the fraction of activity in the region with the highest activity. IC50 values were analyzed by nonlinear
regression using GraphPad Prism.
4.5. Statistical Aspects
All experiments were performed at least in triplicate. Quantitative data were expressed as mean ± SD.
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Abstract: Girentuximab (cG250) targets carbonic anhydrase IX (CAIX), a protein which is expressed
on the surface of most renal cancer cells (RCCs). cG250 labeled with 177Lu has been used in clinical
trials for radioimmunotherapy (RIT) of RCCs. In this work, an extensive characterization of the
immunoconjugates allowed optimization of the labeling conditions with 177Lu while maintaining
immunoreactivity of cG250, which was then investigated in in vitro and in vivo experiments. cG250
was conjugated with S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid
(DOTA(SCN)) by using incubation times between 30 and 90 min and characterized by mass
spectrometry. Immunoconjugates with five to ten DOTA(SCN) molecules per cG250 molecule
were obtained. Conjugates with ratios less than six DOTA(SCN)/cG250 had higher in vitro antigen
affinity, both pre- and postlabeling with 177Lu. Radiochemical stability increased, in the presence of
sodium ascorbate, which prevents radiolysis. The immunoreactivity of the radiolabeled cG250 tested
by specific binding to SK-RC-52 cells decreased when the DOTA content per conjugate increased.
The in vivo tumor uptake was < 10% ID/g and independent of the total amount of protein in the
range between 5 and 100 μg cG250 per animal. Low tumor uptake was found to be due to significant
necrotic areas and heterogeneous CAIX expression. In addition, low vascularity indicated relatively
poor accessibility of the CAIX target.
Keywords: carbonic anhydrase IX; girentuximab; renal cell carcinomas; 177Lu-radiopharmaceuticals;
radioimmunotherapy
1. Introduction
Targeted therapy with monoclonal antibodies (mAbs) carrying radioisotopes
(radioimmunotherapy, RIT) has become a powerful tool in nuclear medicine, because of highly
selective small molecules and targeted internal radiotherapy; it is currently being increasingly
applied in the treatment of a growing number of malignant diseases [1–8]. Additionally, imaging
Pharmaceuticals 2018, 11, 132; doi:10.3390/ph11040132 www.mdpi.com/journal/pharmaceuticals150
Pharmaceuticals 2018, 11, 132
studies with gamma emitting isotopes open the possibility of translational investigation of
dosimetry [9]. The effectiveness of RIT depends on a number of factors related to the Ab such as the
specificity and affinity as well as the immunoreactivity, stability and blood clearance of the resulting
radioimmunoconjugate [10,11]. Three radiolabeled mAbs—two murine, 90Y-ibritumomab tiuxetan
(Zevalin; Biogen Idec) and 131I-tositumomab (Bexxar; Corixa/GSK), and one chimeric, 131I-ch-TNT
(Shanghai Medipharm Biotech)—have been approved for non-Hodgkin’s lymphoma (NHL) or lung
cancer, but only a minority of anticancer mAbs currently in the clinics, are radioimmunoconjugates [12].
A suitable therapeutic window exists, only when RIT leads to a sufficient deposition of radioactivity in
the tumor and, at the same time, acceptably low doses to healthy organs and tissues. Clinical studies
revealed the limitations of radioimmunoconjugates as cancer therapeutics (for example, mAbs did not
deliver effective radiation doses, especially to solid tumor sites [13], complex chemistry was often
required for conjugation, and there were potentially toxic effects on normal tissues). In addition,
in solid large tumors, accumulation of radioactivity by RIT is negatively influenced by slow diffusion
properties of large molecules when interstitial fluid pressure is high and perfusion and vascular
permeability are heterogeneous [10,14]. Furthermore, antigen expression can be reduced due to the
presence of necrotic areas in those tumors, leading to a reduction of the radionuclide uptake.
Reaching cancer cells within solid tumors by mAbs, follows slower kinetics, compared to small
molecules, such as peptides. Thus, long circulation times require therapeutic radionuclides with
relatively long half-lives and with high stability of the radioimmune-conjugation. The released
energy from the radiometal can also induce radiolysis and degradation of the protein, and thus loss
of specificity. The formation of free radicals can be attenuated with the addition of quenching reagents
like human serum albumin (HSA), gentisic acid, ascorbic acid, and other antiradicals [15]. β− emitting
radionuclides are currently prevalent in RIT since they have shown particular efficacy against a larger
number of diseases. Radionuclides such as 131I, 90Y, 188Re, and 177Lu have been used extensively
for the RIT of neoplastic lesions [3,16–18]. 177Lu is increasingly being used as a potent radionuclide
for use in in vivo therapy because of its favorable decay characteristics. It decays by the emission of
beta particles with maximum energies of 497 keV (78.6%), 384 keV (9.1%), and 176 keV (12.2%) to
stable 177Hf [19] allowing delivery of therapeutic doses to the tumor and minimal doses to healthy
tissues (i.e., low renal toxicity). The β-emission energy of 177Lu (βmean = 166 keV) is lower than for
other radionuclides commonly used for therapy such as 131I (βmean = 191 keV), 90Y (βmean = 699 keV),
or 188Re (βmean = 770 KeV). In addition, the emission of gamma rays of 113 keV (6.4%) and 208 keV
(11%) with relatively low abundances, provides advantages that allow simultaneous scintigraphic
studies, which help to monitor proper in vivo localization of the injected radiopharmaceutical and to
perform dosimetric evaluations. Another important aspect for consideration is the relatively long t1/2
of 177Lu (6.73 days), which provides logistical advantages that facilitate its supply to locations far from
reactors. The relatively long t1/2 also favors this nuclide for use in RIT [20].
An essential criterion for successful targeted radiotherapy with 177Lu depends on the choice of
the proper bifunctional chelator (BFC). 177Lu is a bone-seeking element [14], its premature release and
accumulation in the bone can lead to dose-limiting bone marrow toxicity. A number of acyclic and
cyclic ligand systems have already been investigated for the labeling of mAb (full-length and fragments)
with 177Lu [21–23]. Macrocyclic BFCs such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
(DOTA) are of particular interest for the use of lanthanides in RIT because they are very well organized
structures, enabling the formation of metal complexes, with a high thermodynamic stability and slow
decomposition kinetics [22,24–26].
During the preparation of conjugated mAbs and the radiolabeling process, the protein might
suffer some modifications, resulting in the loss of target recognition [27–29]. First, binding affinity
to target and nontarget tissue might be affected during the immunoconjugation step, because the
amino acids or peptides involved in the recognition of the antigen can be occupied by the BFC [11].
Amino acids with side chains amenable to modifications are found in all regions of Abs. Therefore,
modification methods are not site-specific and there is no control over which amino acids are modified.
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First, immunoconjugates with modifications in the binding structures result in decreased efficacy of
the targeting system [30–32]. Second, the sensitivity of Abs to heating and extreme pH values during
the labeling process. The labeling reaction with DOTA and its analogues is very slow and largely
depends on the conditions at which it is performed, which includes DOTA-mAb concentration, reaction
temperature, time, pH, buffer used and its concentration, and the presence of metal ions such as Zn2+
and Fe3+. In order to achieve a good radiolabeling yield it is necessary to increase the temperature
(>50 ◦C). The released energy from the radiometal might induce radiolysis and degradation of the
protein, and thus loss of the specificity of the mAb to reach the target. The formed free radicals
during the labeling can be attenuated with the addition of quenching reagents like HSA, gentisic acid,
ascorbic acid, and others antiradicals [15].
Girentuximab (cG250) is a chimeric mAb reactive to the protein carbonic anhydrase IX (CAIX),
a transmembrane glycoprotein with an intracellular enzymatic domain, which is overexpressed in
hypoxic cells [33–35]. This antigen CAIX is also expressed on a variety of other solid tumors, including
cervical, bladder, colon, and non-small cell lung cancer. Immunohistochemical (IHC) analysis of renal
tumors showed homogeneous expression of CAIX in the vast majority (>80%) of primary renal cell
carcinomas (RCCs) and about 70% of metastatic RCC lesions [36–39]. In most of the RCCs constitutive
CAIX expression is common due to the presence of von Hippel Lindau mutation leading to a hypoxia
inducible factor 1 alpha (HIF-1a), without expression in normal kidney tissue [34,36,38–42]. Therefore,
CAIX is a promising target for renal cancer and other hypoxic tumors. A clinical trial failed to show a
benefit of native cG250 in adjuvant treatment after surgery on the RCCs [43]. However, the patient
collective showed a better overall prognosis than expected, which points to a lack of tumor cells
that were available for targeting. Safety and tolerability of the antibody was demonstrated. Clinical
and preclinical attempts have been made to use cG250 as carrier molecules for radioisotopes [44,45].
Therefore, there are many ongoing experiments in the therapeutic area. The first clinical trial for
therapy was carried out with [131I]-girentuximab but the results were not as positive as expected.
The widely used beta emitting isotope 177Lu (t1/2 = 6.7 days, 497 keV end-point energy) has also been
investigated in preclinical and clinical studies treating metastasized RCCs [2,46–48].
Here, a detailed evaluation of the parameters affecting conjugation of
S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid (p-SCN-Bn-DOTA) to
girentuximab by the isothiocyanate group was conducted [49]. In order to characterize the conjugated
cG250 the modification sites and the number of BFC modifications per mAb were determined by
mass spectrometry. The loss of immunoreactivity post conjugation was evaluated in cells and tumor
tissues. DOTA(SCN)-girentuximab conjugates with different BFC/mAb ratios were labeled with 177Lu
and the influence of sodium ascorbate on the radiostability was studied. A comparison between
the one-step labeling method and the two-step labeling method was another variable to consider, in
regards to the preparation of the radioconstructs. In addition, the dependence of the in vitro binding
of the radioconjugates, in vivo pharmacokinetics, tumor uptake on the mAb protein dose, and the
heterogeneity of CAIX expression was studied in xenograft mice.
2. Results
2.1. Conjugation of p-SCN-βn-DOTA to cG250
DOTA(SCN)-cG250 immunoconjugates with a range of BFC/mAb loading ratios were prepared
and purified by modulating the duration of the bioconjugation reaction times between 30 and 90 min.
Immunoconjugates were classified by their molecular weight (MW) after conjugation with DOTA(SCN):
C2 (90 min reaction time) > C3 (60 min reaction time) > C7 (30 min reaction time) detectable by size
exclusion-high performance liquid chromatography (SE-HPLC/UV) and sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) (Figure 1). For example, conjugate C2 obtained after
90 min of incubation time showed a retention time of 12.24 min compared to 15.1 min for the native
mAb; a shift of 3 min on the SE chromatograms. Likewise, conjugates C3 (12.72 min elution time)
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and C7 (13.66 min elution time) were incubated for 60 and 30 min, respectively, which correlated
with the expected increment of the MW of the conjugates after the protein conjugation with the
BFC was indicated by the left shifting of the peak on the SE-HPLC chromatogram, compared to the
native cG250 (Figure 1a). The completeness of the protein purification by filtration–centrifugation
in the conjugates was corroborated by monitoring the signal intensity within the 30 min region on
the SE-HPLC chromatogram, which corresponded to the elution time of the free BFC. The complete





Figure 1. Conjugation of cG250 with DOTA via benzylthiocyano group: (a) Size exclusion-high
performance liquid chromatography (SE-HPLC) chromatograms of different selected DOTA(SCN)-cG250
conjugates compared to the native cG250; (b) size exclusion-high performance liquid
chromatography/ultraviolet (SE-HPLC/UV) chromatograms of DOTA(SCN)-cG250 conjugates prepared
from the same batch; and (c) SDS-PAGE chromatograms of cG250-conjugates in reduced conditions.
As expected for a denaturing analytical technique, SDS-PAGE chromatogram of the
DOTA(SCN)-cG250 conjugates C2, C3, C4, C5, and C7 showed easily distinguishable bands
corresponding to the light (LC) and heavy chain (HC) of the Abs. The conjugated protein bands
of the LC and HC were, as expected, broader and shifted to higher molecular weights, when compared
to the LC and HC bands of the native mAb (Figure 1c). Using a standard (Precision Plus™ Protein
Unstained, 10–25 kDa, BioRad) the MW of the HC and LC bands of cG250 could be estimated.
The results correspond to the same order of MW (C2 (90 min) > C3 (60 min) > C7 (30 min)) obtained by
SEC chromatography.
For large-scale clinical production of immunoconjugates the reproducibility of the conjugation
process is relevant. Consistency of the conjugation process was explored by undertaking the
conjugation process in triplicate. Three conjugates (C3, C4, and C5) were prepared and purified
by using a 60 min incubation time. The retention times of conjugates C3, C4, and C5 by SE-HPLC were
similar, and the retention times of the conjugates varied by 12.64 ± 0.08% with less than 7% uncertainty
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(Figure 1b). In the case of the SDS-PAGE, the reproducibility obtained was less than 1% of uncertainty
of the MW of the HC and LC (Figure 1c). Based on the SE-HPLC and SDS-PAGE results, the conjugates
C3, C4, and C5 could be classified within the same group. The ratio of DOTA molecules per molecule
of mAb, was calculated by the difference of the MW between the conjugated and the native mAb.
The average ratio ranged from 1 to 6 in LC and from 4 to 23 in the HC based on the information from
the SDS-PAGE chromatograms; using an uncertainty of 10% of the MW estimation by SDS-PAGE
(Supplementary Table S1). Another important aspect that might influence the accuracy of the MW
determination by SDS-PAGE is the preservation of the separation conditions. Different conditions such
as the gel concentration and voltage during the protein separation would influence the migration of
proteins in the tested sample, when compared to the standard sample, changing the standard mass
calibration procedure as a consequence. In order to measure the MW with better accuracy, another
analytical tool like mass spectrometry is required.
For SE-HPLC/UV, the stability of the conjugates was evaluated based on the shift between
the retention times of the conjugates compared to the native mAb. This way, the variability of the
retention time measurements at different days was excluded. These variations of retention time
signals were observed due to the interactions of the stationary phase with the mobile phase (eluent or
sample) components. After 24 months the difference between the retention times of the conjugates
and the native monoclonal antibody were 2.91 ± 0.03, 2.51 ± 0.01, and 1.48 ± 0.03 for conjugates
C2, C3, and C7, respectively. The intensity of the peak was the same using 0.05 mg/mL as protein
concentration. The chromatogram of the conjugates showed no significant changes to peak positions
or bands in SE-HPLC chromatograms or SDS-PAGE, respectively.
2.2. Identification of DOTA Modification Sites
The conjugates were analyzed through peptide-mass mapping using tandem liquid
chromatography–mass spectrometry (LC–MS/MS). The modification sites by DOTA, were identified
by comparing the peptide-mass mapping of the conjugates with the data base of peptide masses of the
native cG250 after the digestion processes were completed with trypsin. The native cG250 sequence
coverage LC–MS/MS was 96% and 88% for LC and HC, respectively. The data obtained was used as
a control to identify the modified peptides in the conjugated protein and to calculate the occupancy
by DOTA molecules on the amino acid sequence. The peptide mapping of the DOTA(SCN)-cG250
conjugates resulted in sequence coverages from 71% to 87% for HC and from 73% to 95% for LC,
respectively. The lower coverage values were obtained in the conjugates with higher ratio DOTA(SCN)
per molecule of mAb ratios. The higher the BFC/cG250 ratios led to a higher heterogeneity of the
conjugated peptides, which resulted in decreased digestion efficiency of trypsin due to blocked trypsin
cleavage sites, resulting in longer peptide sequences and consequently reduced extraction efficiency
from the gel matrix. In order to increase the peptide sequence coverage, a second digestion process with
chymotrypsin was performed for the conjugate C2. The combined data of two different digests resulted
in almost 100% sequence coverage of both mAb subunits, HC (98.4%) and LC (98.6%). The combination
of trypsin and chymotrypsin digests successfully increased the sequence coverage of the conjugates
to 97.6% for the HC, and 92.5% for the LC. Short peptides could not be identified, which was due to
chromatographic and data analysis/processing limitations.
Figure 2 shows that the DOTA(SCN)-modified peptides sites were, as expected, mostly through
lysine amino acid residues (K and Lys), as previously described [25]. Also, DOTA modifications were
not consistently allocated to the same K residues across all replicates on the HC and LC as shown by
Figure 2a. The occupancy of K residues with DOTA(SCN) modification was calculated by MaxQuant,
using peptide intensities and search parameter settings as previously for EasyProt. DOTA conjugated
peptides were eluted at different retention times from the reversed phase chromatography column and
detected with higher charge states than the nonconjugated peptides, as expected. DOTA(SCN)-labeled
peptides eluted at different retention times from the reversed phase column than the native peptides,
due to different matrix effects at the time of elution and possibly different ionization efficacies of native
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and conjugated peptide forms. The latter is supported by the observation that DOTA-labeled peptides
were usually detected with a higher charge state than the nonlabeled peptides. We assumed that
higher ratios represent a better accessibility of DOTA to the corresponding K residue.
a b 
Figure 2. Characterization of the DOTA(SCN)-cG250 conjugates by mass spectrometry: (a) Lysine
occupancy in the LC (top) and HC of DOTA(SCN)-cG250 post trypsin in-gel digestion of the proteins
(n = 3) in conjugate C2 (90 min), C3, C4, C5 (60 min), and C7 (30 min) and (b) mass measurements by
MALDI-TOF MS of native cG250 and conjugates C3 and C7.
K-416 of the HC appears to be almost quantitatively labeled, meaning that the probability of the
conjugation of the K-416 is higher compared to the other K residues. Based on the incomplete sequence
coverage achieved by in-gel digestion LC–MS/MS using trypsin enzyme, we also have to assume
that there are K residues on peptides modified by DOTA(SCN), which could not be extracted from
the gel matrix. Furthermore, DOTA(SCN) labeling renders peptides more hydrophobic, thus making
it more difficult to extract them from the gel matrix. Therefore, nonlabeled peptides were extracted
more efficiently than labeled ones, leading to an over-representation of the nonlabeled forms. It is
well known and has been described that K is the most nucleophilic amine in proteins; however, K-416
has an additional input because it is the C-terminus of the HC of native cG250 [50,51]. The reaction
that takes place does not have steric hindrance compared with the other K residues rendering the
substitution reaction more efficient. In general, the reactivity of the N-terminal amino group is higher
because its pKa value is lower than the K. Thus, DOTA(SCN) modifications were also observed at the
amino terminus through aspartic acid amino residues (D, Asp) in the HC and LC.
2.3. Ratio of DOTA Molecules Per Molecule of Antibody
In general, when the average number of BFCs per protein (N) increases the immunoreactivity
of the obtained product decreases. It is possible to determine “N” by calculating the difference in
mass between the mass of the conjugates and the native mAb [52,53]. The mass of the conjugates
was measured by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS) (Figure 2b) and the average number of DOTA(SCN) molecules per molecule of cG250
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was then calculated. The native cG250 shows the presence of three major peaks corresponding to the
MW of 148,736.14 Da (monocharged and unconjugated mAb, [M+H]+), 74,292.94 Da (doubly charged
unconjugated mAb, [M+2H]2+), and 49,510.29 Da (triply charged unconjugated mAb, [M+3H]3+).
Furthermore, the MALDI-TOF mass spectra of the DOTA(SCN)-cG250 conjugates also showed
three peaks corresponding to the mono, doubly and triply charged conjugates species. Compared
to the spectrum of the native cG250 mAb, these spectra show a broadening of the peaks, which
indicates heterogeneity in the number and location of DOTA(SCN) molecules conjugated to the Abs,
thus confirming the results of the LC–MS analysis. The MW of the peak [M+H]+ (151,543.63 Da) is lower
for the conjugate C7 than for conjugate C3, corresponding to the results obtained by SE-HPLC/UV and
SDS-PAGE (Figure 1). The MW of the conjugates C4 and C5 were also measured. The uncertainty of
the MW by MALDI-TOF was also less than 1% in the three major peaks of conjugates C3, C4, and C5,
which were prepared in the same conditions (data not shown). These results show a similar MW
and, therefore, similar ranges of BFC/mAb ratios. The average number of DOTA(SCN) molecules per
molecule of cG250 calculated for the conjugates are summarized in Table 1. Similar BFC per Ab ratios
were obtained, by using the same conjugation method and incubation time but different mAbs [3,49].







C2 (90 min) - - 12–23 1 6–7 1
C3 (60 min) 154,187.07 8–10 3–4 1–2
C7 (30 min) 151,543.63 5–6 1–2 1–2
1 Values obtained by intact mass.
In order to know the number of conjugated molecules of BFC in the HC and LC of the mAb,
the native cG250 and conjugates were incubated with dithiothreitol (DTT) (40 mM) for 1 h before
injecting the test sample in the MALDI-TOF spectrometer. The mass spectrum of the native cG250
showed peaks which corresponded to LC and HC. The mass spectrum of the reduced conjugate C3
also showed two main peaks at 51,546.27 Da and 24,151.98 Da, which corresponded to the MW of
the HC and LC of the conjugated cG250, respectively. Those peaks were also broader compared to
the spectrum of the reduced native cG250 (Supplementary Figure S1). The average of DOTA(SCN)
moieties was found to be 1–2 and 3–4 in the LC and the HC of conjugate C3, respectively (Table 1).
The ratios were obtained per chain and were multiplied by two based on the antibody structure
matched well with the ratios obtained for the nonreduced conjugate.
It was not possible to determine the ratio of BFC molecules in the HC and LC of conjugate
C2 because it was not possible to measure the MW by MALDI-TOF, presumably due to the high
heterogeneity of the conjugate. However, it was possible to determine the ratio of BFC molecules in
the LC by intact mass using a QExactive mass spectrometer (ThermoFisher, Bremen, Germany) via a
nanospray electrospray ionization (ESI) source. The samples (the native and the conjugated cG250)
were treated with DTT to cleave the LC and HC. Very clean signals could be measured for the native
LC and HC as well as the conjugated LC, while the conjugated HC spectrum was extremely complex
and deconvolution resulted in several signals with an inherent uncertainty of being correct (data not
shown). From the LC of conjugate C2, accurate mass determination was possible, however the HC
presented challenges. The software was able to extract a few masses in the HC of the conjugate C2,
but they were less certain than in all other measurements (95% vs. 99%). Using the obtained MWs of
the native and the conjugate divided by the MW of the BFC (552.6 Da), the DOTA(SCN)/cG250 mAb
ratio ranged from 5 to 6 in the LC. For the higher intensity MW peaks (50,682.105 Da and 50,519.625 Da)
the average number of BFC ranged from 12 to 23 per mAb. Therefore, those results are not reliable
because of the intensity of the rest of the peaks (background) on the chromatogram. The range of
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values corresponded to the ones obtained by SDS-PAGE with the range of the total MW of C2 obtained
by MALDI-TOF (Table 1).
2.4. In Vitro Characterization of the Conjugates
Immunoreactivity of the conjugates was evaluated by flow cytometric and IHC analyses before
labeling the cG250 with 177Lu. An increasing extent of conjugation of the cG250 with DOTA(SCN)
moieties, correlates with a reduction in binding to CAIX on the SK-RC-52 cells compared to the native
cG250 by flow cytometry and IHC (Figure 3). Staining of the cell lines with the native variant of cG250
showed that CAIX recognition on SK-RC-52 cell line is 20 times higher than on the SK-RC-18 cell line,
which confirms the specificity of the cG250 and the suitability of these two cell lines for the remaining
studies. The results were previously validated by immunocytochemistry analysis (ICC), where the
SK-RC-52 cell line showed a strong staining intensity and cell membrane localization (Supplementary
Figure S2). However, CAIX expression was not detected in the SK-RC-18 cell line by flow cytometry






Figure 3. Immunoreactivity of DOTA(SCN)-cG250 conjugates with SK-RC-52 cells in vitro and in
tumor tissue. (a) Concentration-dependent binding of native cG250 to SK-RC-52 cells and SK-RC-18
(control), as assessed by flow cytometry. The red dashed line corresponds to the IC50. (b) Flow
cytometric assessment of CAIX recognition on SK-RC-52 cells of immunoconjugates C2 (90 min),
C3 (60 min) and C7 (30 min). (c) Flow cytometric assessment of CAIX recognition on SK-RC-52 cells
of immunoconjugates C3, C4, and C5 (60 min). (d) CAIX immunostaining in frozen SK-RC-52 tumor
samples using native cG250 mAb and immunoconjugates C2, C3, C4, C5, and C7. CAIX Abcam
(ab15086) as a positive control and Dako (P0214) as a negative control. 100 μm scale bar and
10X objective.
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Concentration-dependent experiments demonstrated an IC50 of around 0.02 μg/mL for cG250
(Figure 3a), which was used to evaluate the effect of DOTA(SCN) on the mAb recognition in subsequent
experiments. At high doses (e.g., 100 μg/mL) of protein, the geometric mean fluorescence intensity
(GMFI) values increase until the cG250 saturates all the binding sites. After conjugation of the cG250
with DOTA(SCN), a reduction in the recognition of the CAIX by the conjugates on SK-RC-52 cells
compared to the native variant was observed (Figure 3b). The loss of recognition was dependent
on the average number of conjugated DOTA(SCN) per molecule of mAb, as C2 contains more than
12–23 DOTA, C3 contains 8–10 DOTA, and C7 contains 3–5 DOTA. In order to explore if whether or not
the location of the DOTA modifications had any influence over the loss recognition by the conjugated
mAb, three different conjugates (C3, C4, and C5) with the same number of BFCs located in different
K residues were compared. As evidenced in Figure 3c, there were no differences (p > 0.05) in the
recognition between the three conjugates, indicating that their biological activity was directly related to
the ratio BFC/mAb rather than the location of the BFC molecules on the K residues. Those conjugates
were also analyzed by IHC and no significant difference between them was observed (Figure 3d).
The recognition of the conjugates to CAIX in tumor samples was another variable that was
evaluated (Figure 3d). The native cG250 was evaluated showing a staining pattern that nicely
reproduced the pattern of the commercial Ab, staining the same histological areas in frozen samples.
CAIX staining with the C7 conjugate (conjugated with the lowest level of DOTA) was the most specific
antibody without relevant background staining. The conjugate C2 showed a high background and
no specific staining, which might be due to the high number of BFCs attached to cG250. In general,
all conjugates showed the same staining pattern as the native cG250. The areas that did not express
CAIX by the native and conjugated cG250 were comparable and showed the same pattern as the
commercial Ab (Abcam), which was used as a positive control.
To evaluate possible recognition and accumulation of the radiolabeled cG250 in subsequent
animal studies, the antigen was also measured in healthy tissue which was related to the metabolism
and excretion of the large proteins. In the paraffin normal tissue samples, CAIX immunostaining,
showed strong intensity in the stomach and negative immunostaining in the rest of the organs (liver,
gallbladder, spleen, and duodenum) by Abcam Ab. However, normal tissue frozen samples were
negative for cG250 mAb and the control Abs (Supplementary Figure S3).
2.5. Radiochemical Purity and Influence of Sodium Ascorbate on the Stability In Vitro
Radioimmunoconjugates with different specific activities were obtained with >90% of
radiochemical purity (RCP) by instant thin layer chromatography (ITLC) before and after the addition
of DTPA. A slight excess of DTPA was added to the reaction mixture to complex any free 177Lu3+ ions,
which was monitored on the SE radiochromatogram. After the purification processes by SE, the typical
radiochemical yield of [177Lu]DOTA(SCN)-cG250 was 85% with radiochemical purity above 99%.
It was possible to reach highest specific activities of 9 MBq/μg with the conjugate C3. In the case of
conjugate C7 (less DOTA content), the RCP decreased when the initial activity was increased reaching
as much as 5 MBq/μg. The presence of the ionic (free 177Lu3+) impurities is explained by the low
DOTA content in this conjugate compared to the other conjugates. The average number of 177Lu atoms
chelated per mAb was 1–2 for the conjugate C3 and 0–1 for the conjugates C7 postpurification. Higher
initial activities of 177Lu were used to increase those values of specific activities of the labeled mAb,
but they resulted in lower radiochemical yields.
Stability of the radioimmunoconjugates becomes a critical issue for conjugated mAb due to their
pharmacokinetics and long circulation times. In vitro stability was studied under different conditions:
HSA 20%, human serum (HS) and phosphate-buffered saline (PBS) with and without the addition
of sodium ascorbate (NaAsc, 50 mg/mL) postpurification. Figure 4a shows a drop in the RCP of
the radioconstruct two days after labeling at 319 MBq/mL activity concentration (specific activity
was > 9 MBq/μg), even in the presence of the 50 mg/mL quenching solution. We assume that the
protein was damaged to a certain degree, due to the formation of radical ions by radiolysis during the
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labeling process. Nevertheless, radiostability of [177Lu]DOTA(SCN)-cG250 at lower specific activities
(<3 MBq/μg) and activity concentrations (<107 MBq/mL) was increased by the addition of NaAsc
(Figure 4a). The RCP was above 90% by ITLC up to 10 d postlabeling in 20% HSA and HS for the three
types of conjugates (Figure 4b).
a 
b 
Figure 4. In vitro stability of [177Lu]DOTA(SCN)-cG250 in the presence of NaAsc by TLC: (a) C3
radioconstructs at different activity concentrations without and with NaAsc respectively and (b) C2,
C3, and C7 radioconstructs (2 MBq/μg) in human serum and HSA 20% in the presence of NaAsc.
2.6. In Vitro Radioimmunoreactivity of the Conjugates Labeled with 177Lu
During the radiolabeling process, the biological activity of the protein may be compromised
and the specificity of the biomolecule to bind to CAIX antigen may therefore be reduced. Therefore,
the immunoreactivity of the radioconstructs was evaluated in vitro using the SK-RC-52 cells before
in the in vivo application. First, the specific binding to SK-RC-52 cells was measured using different
protein concentrations and as a result, a maximum of 60% binding was obtained (Figure 5a).
After adding 5 ng of carrier antibodies to 5 × 106 cells, a decrease in the percentage of binding
was observed due to the saturation of binding sites with the nonlabeled mAb. During the preparation
of the radioconstructs it was not possible to separate the labeled-mAb from the nonlabeled-mAb
using PD10 columns. Saturation of the binding sites was also observed by flow cytometric analysis
(Figure 3a) at high protein doses. In the case of the SK-RC-18 cells (negative control) the percentage of
binding and internalization was <2.0% (Figure 5a) as compared to the values for nonspecific binding
using the native cG250 at the highest studied protein concentration (data not shown).
Figure 5b shows the percentage of binding and internalization of different conjugates to positive
and negative CAIX cell lines (SK-RC-52 and SK-RC-18, respectively). The percentage of binding of
[177Lu]DOTA(SCN)-cG250 to SK-RC-52 cells ranged from 60 to 70% for conjugate C7 with a ratio of
less than six DOTA(SCN) molecules per cG250. The percentage of binding to the SK-RC-52 cell line
was significantly higher (p < 0.001) for the radioconstructs using conjugate C7 (lowest DOTA content).
The percentage of internalization of the radioconstruct was >90% of the total activity bound to the
SK-RC-52 cells (Figure 5b,c). In general, the percentage of binding and internalization decreased
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with increasing DOTA content showing the same pattern as observed in the flow cytometric analysis
(Figure 3b). Figure 5c shows no significant change (p > 0.05) in the percentage of binding and
internalization after a dilution of the radioconstructs with 20% HSA, human serum, and PBS to simulate
in vivo conditions. The percentage of binding and internalization slightly decreased using higher
specific activities of the radioconstructs (Figure 5d). Blocking studies with an excess of native cG250
revealed the specificity of the labeled cG250 by reducing binding and internalization to background
levels. In all cases, the SK-RC-18 cells were used as a negative control to correct the percentage of




Figure 5. Radioimmunoactivity in vitro of [177Lu]DOTA(SCN)-cG250 to SK-RC-52 cells (n = 3).
(a) Concentration-dependent binding of [177Lu]DOTA(SCN)-cG250 using the conjugate C3 (60 min).
(b) Recognition of radioconstructs from conjugates C2 (90 min), C3 (60 min) and C7 (30 min) to
SK-RC-52 cells by radioimmunoassay at 2 MBq/μg specific activity. (c) Radioimmunoactivity in HSA
20%, HS and PBS at 2 MBq/μg specific activity using the conjugate C3. (d) Radioimmunoactivity of
[177Lu]DOTA(SCN)-cG250 at different activity concentrations using the conjugate C3. Blocking studies
were performed with 50 μg of native cG250.
2.7. Biodistribution
The biodistribution of [177Lu]DOTA(SCN)-cG250 which was measured 48 h after the I.V.
application of 12 MBq in BALB/c nu/nu mice across a range of Ab protein mass doses
(specific activities) shows a moderate influence by the total applied protein dose (Figure 6). In vivo,
blood retention increased with higher protein doses (i.e., lower specific activity) and liver uptake
slightly declined with protein doses up to 60 μg/animal. In contrast, tumor accumulation was
not significantly influenced (p > 0.05) by total protein doses between 5 and 100 μg per animal.
Correspondingly, at higher protein doses blood circulation seemed prolonged and tumor uptake
was highest at a relatively high amount of cG250 (30 μg) per animal (Figure 6a). In addition, a higher
amount of radioactivity remained in the rest of the animal body (skin, blood, muscles, and bones) for
animals with higher administrated protein doses and the excretion process was low (Figure 6b). Longer
circulation and the remaining activity in the rest of the animal may be correlated to the saturation
of the binding sites in the target, which was observed during the blocking studies. A reduction of
tumor uptake at 24 h (p < 0.05) was observed in the animals with a previous injection of 500 μg of
native cG250 (Figure S4). The native mAb was injected shortly before the radioconjugate and CAIX
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Figure 6. Biodistribution of [177Lu]DOTA(SCN)-cG250 from conjugate C7 at 48 h using total protein
dose adjusted between 5 and 100 μg and 12 MBq per animal (n = 4). (a) Organs: tumor, blood,
spleen and liver. (b) Activity balance.
Tumor volume had more influence on tumor uptake when low protein doses were used (Figure 7).
Interestingly, for one animal bearing a small tumor (140 μg), a positive out layer was observed in
the group receiving the lowest protein dose. In case of higher doses, the %ID/g was similar across
mass doses and was independent of the tumor size (Figure 7). The effect of the tumor weight on
tumor retention has been studied in previous work, where an exponential decline of tumor uptake of
111In-DTPA-girentuximab was demonstrated [54].
 
Figure 7. Relationship between tumor uptake and tumor volume per animal of the biodistribution of
[177Lu]DOTA(SCN)-cG250 from conjugate C7 at 48 h using total protein dose adjusted between 5 and
100 μg and 12 MBq per animal (n = 4).
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The relationship of blood circulation values with the protein amount was also observed in the
biodistribution of [177Lu]DOTA(SCN)-cG250 measured 24 h and 96 h after the I.V. application of 2 MBq
(0.5 μg) and 18 MBq (5 μg) without adjusted doses (Figure 8). The animals with a 5 μg protein dose
showed a slower blood clearance until 24 h. The T/B ratio of 43.25 at 96 h was almost four times higher
than the ratio at 24 h in the animals with a 5 μg protein dose. Therefore, tumor uptake was higher in the
animal group with lower liver uptake. The decreased %ID/g in the liver with an increased protein dose
was observed independently regardless of if the protein dose was adjusted (Figures 6 and 8) [33,55].
Figure 8. Biodistribution of [177Lu]DOTA(SCN)-cG250 from conjugate C7 using a 0.5 μg (2 MBq) and a
5 μg (18 MBq) protein dose per animal (n = 4).
In order to determine the availability of the radioconstruct in blood and in vivo stability,
a metabolism analysis was performed by protein precipitation (data not shown). The percentage
of the activity was >50% in plasma showing a low complexation with blood cells. Another important
parameter is the percentage of free 177Lu activity in blood plasma relative to the intact labeled
radioconstruct. The percentage of free 177Lu was <5% at 24 h and increased to 10% at 96 h from
the release of the radiometal. Indeed, the tumor/blood (T/B) ratio increased at 96 h (0.5 μg) to 10.16
(Figure 8a) when the specific activity was <3 MBq/μg. This could indicate the importance of the
radiostability of the radioconstructs in vivo. Therefore, tumor uptake was low but in line with the
values obtained by Muselaers, C. H. (escalating doses of 111In-DTPA-G250) comparing the lower
protein dose (<5 μg) [56].
2.8. Effect of Tumor Volume, Hypoxia, and Necrosis on cG250 Tumor Retention
The accumulation of the radioactivity in the tumor is also related to the properties of the
target such as the location, size, antigen expression, and others. To study the target influence in
the radiopharmaceutical uptake and diffusion, tumor properties such as CAIX expression and the
vascularity were studied in different-sized tumors. IHC analysis of SK-RC-52 tumors (n = 20) showed
a CAIX expression depending on the tumor size and tumor growth. In general, it resulted in decreased
availability of the antigen when the tumor volume was increased. Tumors smaller than 20 mm3
(Figure 9a) and tumors larger than 200 mm3 (Figure 9c,d) usually developed necrosis after 6 weeks
of tumor growth. The extent of necrosis consequently reduces the expression of CAIX. Large tumors
(544 mm3) showed 80% necrosis (as observed by H&E stain) (Figure 9c). However, tumor volumes
smaller (161 mm3) showed mostly homogeneous patterns and a strong intensity of CAIX localized in
cell membranes of the SK-RC-52 tumors and no necrosis (Figure 9b).
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Figure 9. Evaluation of vascular density and hypoxia in FFPE from four different SK-RC-52 tumors:
(a–d) (H&E) staining; (e–h) CD31 immunostaining; and (i–l) HIF1α staining. (a) 200 μm scale bar,
5x objective. (b–d) 1000 μm scale bar, 1.5x objective; (inset) 50 μm scale bar, 20x objective.
The vascular density was determined by CD31 (a marker of endothelial cells) (Figure 9e–h).
Additionally, CD31 staining showed an average percentage of vascular density of 2.5 ± 0.5% in the
tumors, which was also independent of the tumor size and the CAIX expression. Results are in line with
the values obtained by Oosterwijk-Wakka, J.C. in 2015 [57]. Hypoxia-inducible factor 1 (HIF-1) marker,
which is a key mediator of tumor survival and adaptation to a hypoxic environment, was evaluated by
IHC [58]. IHC analysis of the SK-RC-52 tumors with different size showed the presence of HIF1α in
all nuclei from tumor cells (Figure 9i–l) but also reflects necrosis and a high heterogeneity of CAIX
expression across the tumor. These effects have a direct influence on the targeting of the mAb and
resulting radiation dose accumulation to the tumor [59].
3. Discussion
In the present study we evaluated some variables that might affect the immunoreactivity of the
cG250 during the conjugation and radiolabeling processes in comparison with the initial properties of
the native cG250. DOTA isothiocyanate modifications occurred via K residues with the formation of a
stable and strong thiourea bond (SC(NH2)2). The precision of the isothiocyanate conjugation to mAbs
via lysine residues allows for higher selectivity and control compared to the iodination reaction. Higher
levels of modification can still lead to impaired binding, and, therefore, loss of efficacy. However,
the extent of Ab modifications via BFC/mAb ratio can be controlled during the bioconjugation reaction.
The absence of DOTA(SCN) labeling in the CDR is an additional advantage of the labeling of mAb
with radiometals compared to previous studies with 131I [55]. The radioiodination of cG250 using the
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standard method Chloramine–T is performed through tyrosine amino residues (Y, Tyr), which are part
of the complementarity determining regions (CDRs) of the cG250. In in vivo studies the bond 131I-Y
amino residues might be affected due to the action mechanism of the mAb during the internalization
process into the cancer cells [60]. The use of the radiometals is a tool more suitable for RIT of RCC [2].
However, the occupancy of the K in the neighborhood of the CDRs can compromise the biological
activity of conjugates and limit the effectiveness of the therapy. The higher the number of DOTA(SCN)
attached to K residues in the mAb sequence, the more heterogeneity the conjugate has and the more
difficult it is to characterize. For example, conjugate C2 (90 min) was impossible to measure the MW
and calculate then the BFC/mAb ratio by mass spectrometry.
The effectiveness of RIT depends on a number of factors and processes. Some factors relate to
the specificity, affinity, and immunoreactivity of the mAb postconjugation and post-radiolabeling.
The in vitro evaluation of the immunoreactivity of the conjugates showed that the conjugates with
the lowest DOTA content have a better recognition of the CAIX compared to conjugates with higher
DOTA content using the native cG250 as a reference. Meanwhile, conjugates with the same BFC/mAb
ratio showed similar percentage of binding to the CAIX antigen in SK-RC-52 cells and tumor samples,
which was observed by flow cytometry and immunohistochemistry. The immunoreactivity of the
DOTA(SCN)-cG250 conjugates seemed mainly determined by the average number of the BFC attached
to the mAb. Also, the introduction of multiple BFC modifications might enhance blood clearance
and thus the deterioration of pharmacokinetic properties occurred [29]. Another critical point for the
use of radiolabeled mAbs is stability and immunoreactivity after the labeling or chelation with the
radiometal. The radiochemical yield of DOTA(SCN) conjugates at room temperature in general,
is very low; but offers advantages over heating most importantly, such as the preservation of
the protein. To complete the radiolabeling (RCP > 90%) without loss of immunoreactivity of the
radiolabeled Abs, longer reaction times (90 min) and elevated temperatures (below 42 ◦C) were used.
We were able to label DOTA(SCN)-cG250 conjugates with 177Lu obtaining RCP > 95% for each
conjugate (different BFC/mAb ratios). Compared to a two-step method the ratio of 177Lu to mAb
was orders of magnitude higher. As the effectiveness of the RIT also depends on the accumulation
of radioactivity at the tumor site, the specific activity of the radioconstruct might play a determining
role in accessible tumor sites such as circulating tumor cells and tumor cell clusters. With prevention
of radiolysis it was possible to keep the stability in vitro in physiological conditions for specific
activities < 3 MBq/μg (<107 MBq/mL) by adding sodium ascorbate to the formulation after labeling.
In general, the immunoreactivity of the radiolabeled cG250 to the specific binding of SK-RC-52 cells
decreased when the DOTA content per conjugates was high. The internalization and accumulation of
the radionuclide into the target is an important parameter in RIT [24], and does not seem significantly
influenced by the increment of DOTA modifications. However, the percentage of internalization to the
SK-RC-52 cells was not significantly different (p > 0.05) between conjugate C3 (8–10 BFCs/mAb ratio)
and conjugate C7 (5–6 BFCs/mAb ratio).
The biodistribution of [177Lu]DOTA(SCN)-cG250 in Balb/c nu/nu mice with subcutaneous
SK-RC-52 showed more than 20% ID/g in the liver and less than 10% ID/g in the tumor, independent
of the protein dose which ranged from 5 to 100 μg. Both lower as well as higher tumor uptakes were
observed when increasing the protein dose. The blood clearance appeared generally slightly faster
with lower amounts of protein. Typically, the therapeutic index between the tumor effect and systemic
toxicity is determined by accumulation and retention within tumor tissue on one side and blood
circulation on the other. Due to the possibility of slow accumulation and further internalization into
the tumor tissue, long blood circulation might enhance both tumor accumulation and systemic toxicity.
Thus, a complex in vivo interaction between pharmacokinetic (PK) properties of the radioconstruct
and tissue properties of the tumor exist. For smaller molecules like 99mTc-(HE)3-ZCAIX:1 the influence
on PK on tumor uptake is generally less pronounced [61]. At very low protein amounts (0.5 μg
girentuximab/animal) rapid clearing from blood was observed, which results in a shorter time of
availability of the radioimmunoconjugate for internalization into the tumors and correspondingly very
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low tumor uptake. At high mAb doses oversaturation of binding sites occurs and tumor uptake is
obviously maximized mainly by the possibility of long diffusion into the tumor and by resaturation
of recycled antigens after internalization. Although higher specific activities are very feasible,
the lowest amount of cG250 showing acceptable PK was 5 to 30 μg/animal. This resulted in typical
tumor accumulation of 10% ID/g in tumors with higher uptake in small and homogenous tumors.
This compares well to tumor uptake of F(ab’)2 fragments in head and neck squamous cell carcinomas
(HNSCC) xenografts of 1 to 4% ID/g [45]. Nevertheless, tumor accumulation is highly influenced
by the heterogeneity of tumor microstructure. However, at much lower protein doses, the PK might
be an obstacle when the radiolabeled Ab is rapidly cleared from the blood and distributed to organs
like the liver and spleen. Thus, PK of [177Lu]DOTA(SCN)-cG250 (3 MBq/μg) was influenced by the
applied total protein dose, whereby at low amounts of mAb rapid clearance from blood by to liver and
spleen occurred.
For disseminated small tumors, including single cancer cells, diffusion is less important than
saturation of antigens. This is particularly true for systemic disease-spreads where tumor cells and
tumor cell clusters are distributed through the body. Here, a high ratio between radioactivity and the
amount of protein carrier mAbs might be beneficial. When binding occurs in relation to the circulation
time, it is plausible to measure a relationship between tumor accumulation and tumor size. However,
if oversaturation occurs, such a relationship declines when binding sites stay saturated over the blood
clearance time. Subsequently, the expected inverse relationship between tumor size and tumor uptake
was not observed at protein doses of 60 and 100 μg per mouse. This indicates that protein amounts
above 60 μg will not be optimal for binding, in particular, for small tumors and single cells. To target
subclinical tumor manifestations—either single cells or small tumor cell clusters—replacement of a beta
emitting isotope by long lived alpha emitting isotopes might be promising [4,5,62,63]. Furthermore,
the effect of longer blood circulation with a higher protein amount is evident with a higher inverse
relationship between the tumor size and tumor targeting for animals receiving 5 μg, over animals
receiving only 0.5 μg cG250 without adjusting for specific activity. Therefore, future development of
targeting smaller tumor clusters without the observed tendency to necrosis and heterogeneity might
include alpha emitting isotopes like Actinium-225.
Other factors related to the target or antigen such as density, location, and heterogeneity of
expression of tumor-associated antigen within tumors will affect the therapeutic efficacy of RIT, as will
physiological factors such as the tumor vascularity, blood flow, and permeability [10,59]. Consistent
with decreased vessel density, elevated intratumoral pressure, and the presence of necrotic areas,
large tumors only display a very low uptake. A minimum value of tumor–antigen density is a
prerequisite for mAb/ADC efficacy [11]. In view of tumor properties influencing radiopharmaceutical
uptake and diffusion, great heterogeneity with regards to the occurrence of necrosis and expression of
CAIX was detected. Those properties were studied in different sized-tumors and resulted in decreased
availability of the antigen when the tumor volume was large. In addition, the poor vascularization
could influence the reachability of the target and thus the tumor uptake.
We show that, the transportation of therapeutic activities to the tumor tissue by cG250 was
influenced by several factors. Thus, an optimization of the radiolabeling and BFC/mAb ratio along
with an optimized protein dose is important to be able to preferentially target small and homogeneous
CAIX expressing tumors. An inverse relationship between the tumor volume and tumor uptake
was found. Tumors smaller than 20 mm3 and larger than 200 mm3 mostly developed necrosis
after six weeks of tumor growth. In addition, after four weeks of tumor growth variation in the
tumor volume increased because the growth of the tumor size among the animals was very different.
This resulted in dispersed %ID/g values in the animal experiments and resulted in the interpretation
of the results being difficult. Heterogeneous expression of the CAIX antigen and necrosis resulted in
lower tumor uptake. In particular, large tumor sizes are not ideal targets. However, investigations
targeting small tumor cell clusters are typically not directly possible, due to the difficulties of detection
within the organism. Therefore, we conclude that specific activities of 2–10 MBq/ug and antibody
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amounts of 5–30 μg per mouse are optimal to investigate [177Lu]cG250-mediated therapies regarding
differently accessible target cells and to optimize repeated application schemes.
4. Materials and Methods
4.1. Preparation of cG250 Conjugates
cG250 was provided by the company Wilex (Munich, Germany). Isothiocyanate-benzyl-DOTA
(p-SCN-βn-DOTA) was purchased from Macrocyclics (Dallas, TX). cG250 (5 mg) was mixed with
p-SCN-Bn-DOTA (2.5 mg) in 50 μL of sodium bicarbonate buffer (1 M NaHCO3) following the
previously described protocol [49]. The mixture was incubated at 37 ◦C for 30, 60, and 90 min
using a thermomixer to obtain conjugates with different BFC molar ratios per molecule of mAb.
The mixture was purified by filtration–centrifugation using a Millipore centrifugal device YM-10
(10,000 MW cut off, Millipore). The sample was centrifuged (4000 g × 5 min) at 4 ◦C to remove the
unreacted BFC and buffer exchange the conjugation into a saline solution (NaCl 0.9%) using five
volumes of NaCl 0.9%. Postpurification, the samples were transferred to Eppendorf vials (2 mL)
previously weighted and labeled C2 (90 min), C3–C5 (60 min), and C7 (30 min). The concentration of
the conjugates were determined by ultraviolet spectroscopy (UV) using 1.4 mL/mg/cm as extinction
coefficient (Nanovue-GE Healthcare Life Sciences).
The purified fraction was analyzed by SE-HPLC/UV using a G3000 column (7.5 × 300 mm, 10 μm,
Waters). The samples were prepared in triplicate for each of the conjugates (0.05 μg/mL) and measured
at 280 nm with a flow rate of 0.5 mL/L of 0.9% NaCl (Dionex, P680 HPLC pump, UVD1704 detector).
The spectra were evaluated by the software Chromeleon from Dionex (Chromeleon 6.8 SR13 Build
3967 Version). The native cG250 was used as a reference in all cases. The elution time of the peaks of
the conjugate were compared with the native cG250.
The conjugates were also analyzed by electrophoresis SDS-PAGE using 10% gel. The native cG250
and conjugated samples were incubated with a sample buffer (0.125 M Tris-HCl pH 6.8, 4% (w/v) SDS,
10% (v/v) glycerol, 0.01% bromophenol blue, 40 mM DTT) and heated at 95 ◦C for 5 min following
the protocol by Laemmli [64]. The electrophoresis was run at a constant voltage of 100 mV (Hoefer
SE250 Mini-Vertical gel Electrophoresis unit, USA). The visualization of the light chain (LC) and heavy
chain (HC) bands were performed by Coomassie blue G-250 al 0.05% (Merck) blue-stained [65] and
analyzed with ChemiDoc XL Imager (Bio Rad) by Image Lab Software 5.2.1 (Bio Rad). Precision Plus™
Protein Unstained (10–25 kDa, BioRad) was used as a MW marker.
4.2. Characterization by Mass Spectrometry
Prior to the mass spectrometric identification by LC–MS/MS, HC, and LC bands were excised and
in-gel digested to generate the peptides as previously described [66]. Extracted peptides were loaded
onto a precolumn (PepMap C18, 5 μm, 300 A, 300 μm × 15 mm length) at a flow rate of 20 μL/min
with solvent A (0.1% formic acid in water/acetonitrile 98:2) with an Ultimate-3000 (ThermoFisher,
Reinach, Switzerland), thereafter eluted in back flush mode onto the analytical nanocolumn (C18, 5 μm,
300A, 0.075 mm i.d., × 150 mm length) using an acetonitrile gradient of 5 to 40% of solvent B (0.1%
formic acid in water/acetonitrile 4.9:95) in 40 min at a flow rate of 400 nL/min. The column effluent
was directly coupled to a Fusion LUMOS mass spectrometer (ThermoFischer, Bremen; Germany) via a
nanospray ESI source. Data was acquired in data-dependent mode with precursor ion scans recorded
in the Orbitrap at a resolution of 120,000 (at m/z = 250), which is parallel to the top speed of the
fragment spectra of the most intense precursor ions in the linear trap, for a maximum cycle time of 3 s.
Peptides were fragmented in parallel by high-energy collision and electron transfer.
The fragment spectra acquired by LC–MS/MS were converted to a mascot generic file format
(mgf) by ProteomeDiscoverer 2.0 (ThermoFisher Scientific) and interpreted with Easyprot (version 2.3)
searching against the SwissProt human protein sequence database (version 2014_01) including
the sequence of native cG250 using fixed modification of carbamidomethylation on cysteine
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(Cys, C), variable modifications of oxidation on methionine (Met, M), deamidation on glutamine
(Gln, Q)/asparagine(Asn, N), and DOTA on K residues and on protein N-Terminus, respectively.
A forward + reversed sequence database search was used to estimate the false discovery rate.
Parent and fragment mass tolerances were set to 10 ppm and 0.4 Da, respectively. Protein identifications
were only accepted, when two unique peptides fulfilling the 1% false discovery rate (FDR) criteria
were identified. Furthermore, the occupancy of K residues with DOTA modification were calculated
by MaxQuant (version 1.5.0.0) using peptide intensities and the search parameter settings as used for
EasyProt. Mass spectrometry sequencing data was acquired at the Proteomics and Mass Spectrometry
Core Facility, Department for Biomedical Research (DBMR), University of Bern, Switzerland.
The determination of the MW and the average number of BFC groups attached to each mAb
molecule was performed by MALDI-TOF-MS. Samples were injected on an Autoflex III Smartbeam
instrument (Bruker Daltonics, Bremen, Germany). An analysis was performed in the linear mode
with a positive polarity, and a mass range of 200 kDa. Conjugated cG250 solution was diluted (1:10)
with saturated α-cyano-4-hydroxycinnamic acid (CHCA, MW 189.04 Da) solution. Data acquisition
and processing was performed by flexAnalysis software (Built 75, version 3.3). MALDI-TOF mass
spectra data was obtained at the mass spectrometry group, Department of Chemistry and Biochemistry,
University of Bern, Switzerland.
4.3. Cell Culture
The human kidney carcinoma cell lines, SK-RC-52 and SK-RC-18, were kindly provided by
Dr. Weis-Garcia from Memorial Sloan Kettering Cancer Centre (MSKCC, New York, USA). SK-RC-52
is a CAIX-expressing human RCC cell line derived from mediastinum and SK-RC-18 is derived from
lymph node cells, negative for CAIX [39]. The cells were cultured in RPMI medium (Life Technologies)
supplemented with 10% fetal calf serum (FCS), 100 IU/ml of penicillin and 100 μg/ mL of streptomycin
at 37 ◦C in a humidified atmosphere with 5% CO2.
4.4. Flow Cytometric Analysis
The Abs were briefly diluted in 100 μL of fluorescence-activated cell sorting (FACS) buffer
(Dulbecco’s phosphate buffered saline with 0.2% bovine serum albumin, BSA) in concentrations
ranging from 3 ng/mL to 100 μg/mL, or as otherwise indicated. The mAb dilutions were mixed with
105 cells and incubated for 60 min at 37 ◦C. Subsequently, the cells were washed three times with a
FACS buffer and incubated with a R-Phycoerythrin AffiniPure F(ab’)2 Fragment Goat Anti-Human
IgG + IgM (H + L) (Jackson Immunoresearch) for 30 min at 4 ◦C in the dark. Next, the samples were
washed and resuspended in the FACS buffer for analysis. An IgG1 from myeloma (Sigma) was used as
an isotype control to define the threshold of the background staining. The analysis was carried out
on a FACSVerse (BD Biosciences, San Jose, CA, USA). The data was analyzed by FlowJo (Tree Star,
Ashland, OR, USA). The flow cytometry analysis was performed at the Institute of Pharmacology
(PKI), University of Bern, Switzerland.
4.5. Radiolabeling, Quality Control, and Radiostability
DOTA(SCN)-cG250 conjugates were labeled with 177Lu (>500 GBq/mg, IDB Holland) in an
ammonium acetate buffer, pH 5.5–6.5, at 37 ◦C for 90 min as described previously [49]. All solutions
used for the labeling were prepared with metal-free water and filtered using 0.22 μm filters (Millipore).
Conjugates with different specific activities were obtained by labeling 100 μg of protein with 177Lu
activities (0.05 M HCl) from 0.1 to 3 GBq. The reaction was stopped after 90 minutes by adding
diethylene triamine pentaacetic acid (DTPA, 10 mM) and incubation at 37 ◦C for another 30 min.
The radioconstructs were purified by size exclusion (SE) using a PD 10 column and 1% HSA in PBS.
ITLC was performed using a silica gel (SG 1.5 × 10 cm, Varian) as stationary phase and 20 mM of
DTPA as a mobile phase (Raytest, MiniGita Firm, ver. 1.10). The chromatograms were evaluated by
Gina Star TLC software (ver. 5.0.1 Rel 2). Purified radioconstructs were diluted with human serum,
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20% of HSA and PBS in order to simulate in vivo conditions. The stability of the radioconstructs at
different specific activities was studied in the presence or absence of sodium ascorbate at 37 ◦C.
4.6. Radioactivity Binding Assay
The binding assay was performed in triplicate using 200 μL of SK-RC-52 and SK-RC-18 cells. As a
control, nonspecific binding was carried out incubating 500 μg of the native cG250 with the SK-RC-52
cell for 5 min before the addition of the radioconstruct. The radiocontructs were diluted in HSA/PBS
to 5 × 10−2 μg/mL and 10 μL of the radiolabeled mAb was added to the cells and incubated at 37 ◦C
for 1 h. After incubation, the cell pellets were washed twice with 1% HSA/PBS, centrifuged (400× g,
5 min) and measured by an automatic gamma counter (WIZARD2, PerkinElmer). The pellets were
then treated with a stripping buffer (0.1 M CH3COOH, 0.15 M NaCl, PBS, pH = 3) to determine the
percentage of internalization.
4.7. Animals
3 × 106 SK-RC-52 cells in 100 μL PBS were injected subcutaneously into the right flank
of 6–8 week old male BALB/c nu/nu mice (Janvier, le Genest-Saint-Isle, FR). Two different
dimensions (length and width) of tumor size were measured at least twice a week with a caliper.
The tumor volume was calculated using the equation: V = (π/6)*(higher diameter)*(lower diameter)2.
All animal experiments were performed in accordance with German law and guidelines for care
and use of laboratory animals. The experiments were approved by the competent authority
(Landesuntersuchungsamt Rheinland-Pfalz, Germany; according to §8 Abs. 1 Tierschutzgesetz;
permission no. 23177-07/G15-1-033).
4.8. Immunohistochemical Analysis (IHC)
Tissue samples of the stomach, liver, gallbladder, spleen, and tumor were collected and divided
into two parts. One part of the tissue sample was fixed in a formaldehyde solution at 4% and
embedded in paraffin (FFPE). The other remaining tissue sample was embedded in OCT (Tissue-Tek®)
and frozen at −80 ◦C. The samples were transported to the Translational Research Unit (TRU)
at the Pathology Institute, University of Bern, Switzerland to perform the immunohistochemical
analysis (IHC). The samples were cut to 3 μm thickness and IHC analysis was carried out in the
automated system BOND RX (Leica Biosystems, Newcastle, UK). FFPE sections were deparaffinized
and rehydrated in a dewax solution (Leica Biosystems) and the antigen was retrieved by heating in a
citrate buffer solution (pH = 6.5) at 95 ◦C for 20 min. Endogenous peroxidase activity was blocked with
a H2O2 solution for 4 min. Carbonic anhydrase rabbit polyclonal Ab (Abcam, ab15086) was incubated
at 1:1500 dilution for 30 min at room temperature. This Ab was used to validate the native and
conjugated cG250. Hypoxia-inducible factor 1 (HIF-1) rabbit polyclonal Ab (Genetex, GTX127309) was
diluted at 1:1000 and incubated for 30 min to confirm the hypoxia conditions into the tumor. The CD31
rabbit polyclonal Ab, (Abcam, ab28364) was diluted at a 1:30 dilution and incubated for 2 h to detect
the endothelial cells from blood vessels to show extent of vascularization of the tumors. The frozen
samples were fixed in acetone for 15 min at −20 ◦C and then air-dried. The samples were incubated
with native and conjugated cG250 at a 1:1000 dilution for 30 min and subsequently the secondary
rabbit anti-human Ab (Dako, P0214) was used at a 1:400 dilution for 15 min. As a negative control,
the same tissue samples were incubated in parallel with only a secondary rabbit anti-human Ab.
All the samples were visualized with the Bond Polymer Refine Kit with 3-3′-Diaminobenzidine-DAB
as the chromogen (Leica Biosystems). The samples were then counterstained with hematoxylin and
mounted in Aquatex (Merck, Darmstadt, Germany). Finally, all slides were scanned and photographed in
a Pannoramic P250 scanner (3DHistech, Hungary). By using ImageJ, the vascular density through CD31
expression was quantified for each tumor sample as a percentage of the CD31-positive microvessel area
to the total tumor area (CD31 area/total tumor area) as previously described [67].
168
Pharmaceuticals 2018, 11, 132
4.9. Biodistribution
After 4 to 6 weeks of tumor growth, groups of four mice were injected intravenously (I.V.) via the
tail vein with 12 MBq of [177Lu]DOTA(SCN)-cG250 with adjusted protein doses with native cG250
from 5 to 100 μg. The animals were sacrificed at 48 h post injection and the organs were collected.
To determine differences in pharmacokinetics and its influence on tumor uptake at very low protein
doses (n, groups of four animals were injected with 0.5 μg (2 MBq) and 5 μg (18 MBq) at a fixed
specific activity of 3 MBq/μg and biodistribution was determined after 24 h and 96 h. Blood samples
were collected, mixed with a 100 μL heparin solution to avoid coagulation, weighed, and the activity
measured with a gamma counter. After the addition of 500 μL of PBS, the blood was centrifuged
at 7500 rpm for 5 min to separate blood cells and plasma. The plasma fractions were weighed and
measured with a gamma counter. Proteins were precipitated by adding 500 μL of acetonitrile and
separated by centrifugation at 7500 rpm for 5 min. The supernatants were weighed followed by the
determination of the activity with a gamma counter. The percentage of radioactivity in the blood cell
was calculated by subtracting the activities of the supernatant from the activity of the whole blood.
In all the experiments the percentage of incorporated doses (%ID/g) was calculated by the weight of
the organs and the measurements by gamma counter (WIZARD2, PerkinElmer).
4.10. Statistical Analysis
All statistical analyses were performed using the program GraphPad Prism (version 6.0).
The one-way ANOVA was used for the comparison between the conjugates by FACS, and radioactivity
curves and blocking in vivo experiments. Two-way ANOVA was used to compare the groups at
different specific activities and different stability conditions. Differences were considered to be
statistically significant at a level of p < 0.05. The %ID/g in the biodistribution studies were presented
with the average of the same group of animals and their standard deviation.
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BSA bovine serum albumin
CAIX carbonic anhydrase IX
cG250 monoclonal antibody anti-CAIX, girentuximab
Cys, C cysteine amino residues
CDR complementarity-determining regions
CHCA hydroxycinnamic acid
CD31 cluster of differentiation 31, endotelial cells marker
DOTA tetraxetan or 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid
DOTA(SCN) p-SCN-Bn-DOTA or S-2-(4-Isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid
DTPA pentetic acid or diethylenetriaminepentaacetic acid
DTT dithiothreitol
DCB Department of Chemistry and Biochemistry, University of Bern, Switzerland




FDR false discovery rate
FFPE formalin-fixed paraffin-embedded
FACS fluorescence-activated cell sorting applied in flow cytometry
FCS fetal calf serum
FT Fourier transform
Fac formic acid
Gln, Q glutamine amino residues
HC heavy chain of immunoglobulin
HIF-1 hypoxia-inducible factor 1
HSA human serum albumin
HS human serum
HNSCC head and neck squamous cell carcinomas (HNSCC)
h hour
HPLC high-performance liquid chromatography
Ig immunoglobulin
IC50 concentration of an inhibitor where the response (or binding) is reduced by half
IHC immunohistochemistry
ICC immunocytochemistry
ITLC instant thin layer chromatography
ID injected dose
i.v. intravenously
LET linear energy transfer
LC light chain of immunoglobulin
LC liquid chromatography
Lys, K lysine amino residues
LRC Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen PSI, Switzerland
mAb monoclonal antibody
MBq megabecquerel
Met, M methionine amino residues
MALDI matrix assisted laser desorption/ionization–mass spectrometry
MS mass spectrometry
MW molecular weight or mass
mgf mascot generic file format
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NHS N-hydroxysuccinimide
OCT optimum cutting temperature
PKM pharmacokinetic modifying linker
PK pharmacokinetics
PET positron emission tomography
PBS phosphate buffer saline
ppm parts per million (chemical shift)
PSI Paul Scherrer Institute, Villigen PSI, Switzerland
PKI Institute of Pharmacology, University of Bern, Switzerland
RIT radioimmunotherapy
RCCs renal cell carcinomas
RCP radiochemical purity
Rf retardation factor
RPMI Roswell Park Memorial Institute medium
RPM revolutions per minute
SEC size exclusion chromatography




Tyr,Y tyrosine amino residues
TOF time of flight
TFA trifluoroacetic acid
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Abstract: The tracer [11C]meta-Hydroxyephedrine ([11C]mHED) is one of the most applied PET
tracers for cardiac imaging, whose radiosynthesis was already reported in 1990. While not stated
in the literature, separation difficulties and an adequate formulation of the product are well known
challenges in its production. Furthermore, the precursor (metaraminol) is also a substrate for
the norepinephrine transporter, and can therefore affect the image quality. This study aims at
optimizing the synthetic process of [11C]mHED and investigating the effect of the apparent molar
activity (sum of mHED and metaraminol) in patients and animals. The main optimization was the
improved separation through reverse phase-HPLC by a step gradient and subsequent retention of
the product on a weakly-cationic ion exchange cartridge. The μPET/μCT was conducted in ten rats
(ischemic model) and the apparent molar activity was correlated to the VOI- and SUV-ratio of the
myocardium/intra-ventricular blood pool. Moreover, nine long-term heart transplanted and five
Morbus Fabry patients underwent PET and MRI imaging for detection of changes in the sympathetic
innervation. In summary, the fully-automated synthesis and optimized purification method of
[11C]mHED is easily applicable and reproducible. Moreover, it was shown that the administered
apparent molar activities had a negligible effect on the imaging quality.
Keywords: [11C]meta-hydroxyephedrine; radiosynthesis; separation; apparent molar activity
1. Introduction
The world health organization (WHO) estimates that almost 18 million people die of
cardiovascular diseases (CVD) each year. Moreover, from the year 2000 onwards, it has been reported
that CVDs have become the number one cause of death worldwide [1,2]. Therefore, there is a high
Pharmaceuticals 2019, 12, 12; doi:10.3390/ph12010012 www.mdpi.com/journal/pharmaceuticals176
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demand for a reliable imaging technique enabling the investigation of CVDs. One of the most frequently
used positron emission tomography (PET) tracers in this regard is [11C]meta-hydroxyephedrine
([11C]mHED), also known as 3-[(1R,2S)-1-hydroxy-2-([11C]methylamino)propyl]phenol, a false
transmitter agent and a norepinephrine transporter (NET) substrate [3,4]. It has been described
that [11C]mHED underlies the uptake-1 pathway of NET from the synaptic cleft to the cytoplasm
of the sympathetic nerve terminal. Advantages of [11C]mHED are the metabolic resistance against
the enzymes MAO (monoamine oxidase) and COMT (catechol-O-methyltransferase), and in contrast
to endogenous ligands, the high selectivity towards uptake-1, the low non-specific binding to the
myocardium, the fast pharmacokinetics, as well as a continuous release and re-uptake by sympathetic
nerves [5,6]. Thus, the combination of these biochemical properties, together with a fast and reliable
automated radiosynthesis, allows PET acquisition duration of at least one hour, despite the short
half-life of carbon-11 (20 min). Additionally, flow dependent effects can be examined when combined
with a [13N]NH3 scan or duplex sonography [7]. In more recent studies, [11C]mHED has also been used
to image the white-to-brown fat conversion, and it was shown that cold-induced BAT thermogenesis is
controlled by the sympathetic nervous system [8,9]. Besides, [11C]mHED might be utilized in oncology
for the diagnosis of adrenal tumors and metastasis [10,11].
The first [11C]mHED radiosynthesis was described in 1990 by Rosenspire et al. [4], which is
still the most cited concerning radiosynthesis. Since then, only a few publications have dealt with
the optimization of the radiosynthetic procedure. These studies focused mainly on automation and
optimization, in terms of time efficiency and radiochemical yields. Indeed, producers of [11C]mHED
know about the difficulties of HPLC separation and purification via solid-phase extraction, caused
by the strong pH sensitivity of mHED. Nevertheless, this phenomenon has not been published.
Furthermore, none of those investigations focused on the improvement of the molar activity or the
reduction of the residual precursor concentration [3,5,12,13]. In fact, a blocking study demonstrated
that the [11C]mHED precursor, metaraminol (meta-hydroxynorephedrine), can affect the image quality
through displacement of the tracer itself. Consequently, the amount of residual metaraminol plays a
major role in this matter. Besides the probability of triggering a pharmacological effect at high doses,
both metaraminol and mHED are substrates for NET, and can therefore cause dose-dependent loss
of image quality [14]. Thus, there is a necessity to include the sum of precursor and cold product
concentrations (apparent molar activity) in the quality control criteria.
2. Results
2.1. Radiosynthesis of [11C]mHED
The radiosynthesis of [11C]mHED was set up on a GE Tracerlab FX C Pro and was performed fully
automated. The methylation of metaraminol was highly reproducible in a mixture of DMF:DMSO
as solvent, leading to a stable radiochemical yield of around 2–3 GBq. This yield was sufficient
for 2–3 animals or at least 1 patient dose per production. The most common reason for a failed
synthesis was the irregular reversed phase-high performance liquid chromatography (RP-HPLC)
separation of metaraminol and [11C]mHED before radiosynthetic optimization. Changing the RP-HPLC
purification to the buffer free step gradient led to a significantly more stable separation and improved
reproducibility. Overall (see Table 1), 51 syntheses were performed with the reliable RP-HPLC set-up;
out of these 51 syntheses 26 were used for pre-clinical and clinical studies, ten were incomplete
production files or failed synthesis and were subsequently excluded. Fifteen radiosyntheses were
solely performed for the purpose of experimentation with different conditions or testing the system.
None of the failed syntheses was caused by separation problems.
For calculation of the molar activity, a calibration curve in the range of 0.1–5 μg/mL was prepared
and the UV-Vis-signal was measured at 275 and 220 nm, respectively. For both wavelengths R2 was
>0.99, whereas the slope was steeper at 220 nm, indicating a better sensitivity.
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2.2. μPET/μCT Imaging
The administered dose was 5 ± 8 μg/kg bodyweight for metaraminol and 2 ± 4 μg/kg for
mHED, with an absolute mass dose of 2.3 ± 3.1 μg (sum of precursor and product), in a range of 0.1 to
9.5 μg (Table 2). No dose effects were visible in rats (Figure 1). Neither the correlation between the
myocardium/intra-ventricular blood pool ratio and the molar activity, nor with the apparent molar
activity or the sum of residual precursor and formed mHED showed any significance (p-value in all
cases > 0.05).
Table 2. Overview on the applied mass concentrations of the precursor metaraminol and mHED as well
as applied mass per bodyweight (BW). None of the patients received more than 0.1 μg/kg bodyweight
of metaraminol and mHED, with a maximal administrated mass dose of 12 μg metaraminol and 4.6 μg
mHED, respectively.
[11C]mHED Metaraminol mHED
Patients [μg/applied volume] [μg/kg BW] [μg/applied volume] [μg/kg BW]
Morbus Fabry (n = 5) 5.2 ± 3.3 0.06 ± 0.05 1.6 ± 1.3 0.02 ± 0.02
HTX (n = 9) 5.5 ± 3.8 0.1 ± 0.1 2.1 ± 1.5 0.02 ± 0.02
Animals (n = 11) 1.8 ± 2.9 4.9 ± 8.4 0.8 ± 1.8 1.8 ± 3.8
Figure 1. Correlation of the myocardium/intra-ventricular blood pool ratio and the molar activity,
the mass of residual precursor and non-labelled mHED, as well as the sum of both.
For representative PET images see Figure 2 below. The ratios of myocardium/intra ventricular
blood pool (Myo/ivBP) ranged between 3.1 and 6.3 for all animals. Infarcted areas are clearly definable
within all applied masses.
Figure 2. Representative cardiac images in short axis orientation of rat hearts (infarct model) with
different applied mass doses of metaraminol and mHED. The sum of metaraminol and mHED is shown
beneath the respective image.
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2.3. PET/MRI Imaging
No correlation was found between the myocardium/intra-ventricular blood pool ratio and
the molar activity, or the overall mass of injected metaraminol and mHED (p-values ranged from
0.1 to 1) in Morbus Fabry patients (Figure 3). The same was true for the relation between the
myocardium/mediastinum ratio and the mass or molar activity of the respective compound. Even
expanding the analysis to ratios based on the SUVmean did not lead to any correlation (data not
illustrated). Only one of the five imaged Morbus Fabry patients showed a pathological finding.
Excluding this patient from the correlation causes no changes in significance.
Figure 3. Correlation of the myocardium/intra-ventricular blood pool ratio (left) and correlation
between the myocardium/mediastinum ratio (right) and the molar activity, the mass of residual
precursor and non-labelled mHED, as well as the sum of both (Morbus Fabry patients).
The ratio of myocardium/intra ventricular blood pool (Myo/ivBP), calculated from SUVmean
values, were in all cases 4 (ratio range for SUVmax: 3 to 4). The myocardium/mediastinum ratio
(Myo/Med) varies between 7 and 13 for the calculation, with SUVmax and SUVmean (Figure 4).
Figure 4. Cardiac images (short axis orientation) of Morbus Fabry patients with different applied mass
doses of metaraminol and mHED. The sum of metaraminol and mHED is shown beneath the respective
image. The patient with abnormality of sympathetic innervation was excluded in the figure, showing a
Myo/Med ratio of <4 with an applied mass dose of 4.5 μg.
The correlations using the SUVmean for the heart transplantation patients (HTX) showed again no
significance for the Myo/ivBP (p-values between 0.3 and 0.6), as well as for the Myo/Med (p-values
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range from 0.4 to 0.6) ratios (data not illustrated). Moreover, no relationship was found using the
ratios calculated with SUVmax values for the Myo/ivBP and Myo/Med versus the molar activity or
the respective injected mass, or the sum of both compounds (p-value > 0.2, Figure 5).
Figure 5. Correlation of the myocardium/intra-ventricular blood pool ratio (left) and correlation
between the myocardium/mediastinum ratio (right) and the molar activity, the mass of residual
precursor and non-labelled mHED, as well as the sum of both (heart transplantation (HTX) patients).
3. Discussion
In general, [11C]mHED is a cardiac PET tracer with excellent pharmacokinetic properties, and can
be used for diverse clinical issues like imaging of cardiac diseases, white-to-brown fat conversion, and
oncology. The radiosynthesis is highly robust, as already reported in literature. Since the retention of
mHED is strongly affected by minor variations in pH or salt concentration, a major challenge of the
[11C]mHED radiosynthesis is the separation and purification from the precursor, side products, and
the used methylation agent ([11C]CH3I or [11C]MeOTf). None of the published separation methods
using semi-preparative RP-HPLC were reproducible or (long-term) repeatable in our laboratories
(see Figure 6).
Figure 6. Overview on the radiosynthesis optimization, including the challenges and establishments
during the first 44 syntheses and the stable separation process of the last 51 syntheses.
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Changes in the separation efficiency occur even by necessary maintenance changes, such as
renewing the column of a similar type. Almost 40 syntheses had to be performed to establish long-term
stable conditions, and twelve out of these 40 syntheses were used to determine the purification potency
via solid phase extraction (SPE). Here, different SPE cartridges were tested (XAD-4, C-18 or SCX),
which showed either none or very strong retention of [11C]mHED. The product purification was
achieved by removal of the mobile phase via a weakly-cationic ion exchange cartridge, and it was
formulated in 3 mL of physiological saline.
The described synthesis procedure is now consistent and has been reproducible for over 50
preparations. None of the fail syntheses was due to poor separation or purification problems. The major
achievement of this optimized procedure is the buffer free mobile phase and the utilization of the pH
sensitivity of [11C]mHED to elute quickly from the RP-18 column caused by protonation.
Compared to previously published [11C]mHED productions, our method led to a reduced
synthesis time, higher molar activities, and the apparent molar activity was discussed for the very first
time (see Table 3). However, further comparison of the radiochemical yields or starting activities were
not possible, due to insufficient information within the previously published radiosyntheses [5,12,15].
The overall administered doses for patients and animals was calculated in μg/kg bodyweight for
metaraminol and mHED and correlated to the myocardium/intraventricular blood pool. To investigate
the perfusion effect, a [13N]NH3 scan was performed upfront to the [11C]mHED imaging. However,
neither patients nor animals suffered from pharmacological effects, nor any loss in imaging quality
could be confirmed. The intra-individual variations and the progress of denervation had a higher
impact on [11C]mHED accumulation than the apparent and molar activity. A limit of 50 nmol/kg
(8.4 μg/kg) for metaraminol was stated to avoid effect on the imaging quality based solely on blocking
studies, and the overall amount of metaraminol and mHED was not taken into account [14]. On the
other hand, different doses of mHED were applied with constant concentrations of metaraminol in a
recently published study. A washout or decreased time activity curve was observed from an applied
concentration of 10 μg/kg bodyweight mHED [16]. The IC50 value of mHED towards NET drug
inhibition was reported as 0.42 μM (competitive inhibition) by Foley at al. [17]. However, in PET
studies, target binding affinities are required in the low nanomolar range to avoid competition to
endogenous ligands. Therefore, the imaging mechanism of [11C]mHED is subject to long tissue life
caused by several reuptake cycles, metabolic resistance, and rapid pharmacokinetics (Myo/ivBP ratio
up to 5 after 10 min) [6,17]. With our new synthesis method, this limiting concentration was never
reached, and by the correlation we could prove that higher doses of metaraminol, mHED, or the sum
of both are necessary for observing impact on the image quality. Therefore, we could confirm that our
administered amounts are too low for any effect on image quality or to trigger pharmacological effects.
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4. Material and Methods
4.1. Radiosynthesis
The [11C]CO2 was produced within a GE PETtrace cyclotron (General Electric Medical System,
Uppsala, Sweden) by a 14N(p,α)11C nuclear reaction under irradiation of a gas target filled with N2
(+1% O2) (Air Liquide Austria, GmbH, Schwechat, Austria). The conversion of [11C]CO2 to [11C]CH3I
was performed in the GE Tracerlab FX C Pro synthesizer. Therefore, the cyclotron production of
[11C]CO2 was terminated at desired target activities between 67–127 GBq using a current of 45 μA for
~30 min, and the activity was trapped upon delivery on a molecular sieve (4 Å) within the synthesizer.
Subsequently, [11C]CO2 was converted into [11C]CH4 by a Ni-catalyzed reduction with H2 at 400 ◦C.
The [11C]CH3I was produced using gas phase conversion, as described in a previous study [18].
In short, the resulting [11C]CH4 was reacted with sublimated iodine at 738 ◦C in a recirculating process
for 5 min to give [11C]CH3I. The produced [11C]CH3I was trapped on-line on a Porapak® N column and
finally released by heating the trap to 190 ◦C. The [11C]CH3OTf was prepared on-line at the passage
of [11C]CH3I through a silver triflate column (containing 300 mg impregnated graphitized carbon),
pre-heated to 200 ◦C, at a flow rate of 40 mL/min. The [11C]CH3OTf was trapped in a glass reactor
containing 1 mg metaraminol in 500 μL of a DMF:DMSO mixture (4/1 %v/v) and heated to 75 ◦C for
2 min (Figure 7). After the reaction time, the reactor was cooled to 35 ◦C and the reaction was quenched
by adding 1 mL of RP-HPLC solvent (mobile phase A). The entire volume of the crude mixture was
automatically transferred to a semi-preparative RP-HPLC column (see section semi-preparative scale
purification). The [11C]mHED peak was collected in a round-bottom flask containing 10 mL of distilled
water to increase the volume for subsequent solid-phase extraction, which was performed using a
weakly-cationic ion exchange cartridge (Sep-Pak Accell Plus Short Cartridge, Waters [WAT020550]).
After rinsing the cartridge with 10 mL water for complete removal of residual acetonitrile from the
HPLC solvent, the pure product was eluted with 3 mL of 0.9% saline and filter sterilized (0.22 μm)
under aseptic conditions (laminar air flow hot cell, class A).
Figure 7. Reaction scheme of the radiosynthesis of [11C]mHED.
4.2. Semi-Preparative Purification
Purification of the crude mixture was performed using a semi-preparative RP-HPLC (Supelcosil
TMLC-ABZ+Plus, 5 μm, 250 × 10 mm (Supelco®, Bellefonte, PA, USA)) with a step gradient method.
For the step gradient, two solvents were used: solvent A consisted of acetonitrile and water (58/42),
and solvent B of a mixture of acetonitrile/water (50/50) mixture, which has been acidified (~pH 3, 0.1%
H3PO4). The column was conditioned with solvent A, at a flow rate of 6 mL/min for injection, and
then the flow was raised immediately to 8 mL/min. After the elution of [11C]CH3OTf, non-converted
[11C]CH3I, precursor, as well as the DMF/DMSO mixture (approx. 6 min.), the mobile phase was
switched to solvent mixture B. Subsequently, the [11C]mHED could be eluted with a retention time
of 8–10 min (see Figure 8). After the completion of the RP-HPLC separation (after around 12 min),
the mobile phase was set back to 100% solvent A to elongate column separation stability and lifespan,
as long-time storage under acidic conditions should be avoided.
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Figure 8. Typical chromatogram of the semi-preparative RP-HPLC purification of the crude mixture:
The [11C]mHED elutes after 9.5 min from the C-18 RP column after using a step gradient, as illustrated
at the top of the graphic. Solvent A consists of an acetonitrile:water mixture (58:42) and solvent B is a
mixture of acetonitrile and acidified water (50:50; 0.004% H3PO4, conc).
4.3. Quality Control
Radiochemical and chemical purities were assessed using analytical radio- and UV/Vis-RP-HPLC.
Identity of [11C]mHED was confirmed by co-injection with the respective reference standard. In detail,
an Agilent 1260 system (Agilent Technologies GmbH; Santa Clara, CA, USA) equipped with a
quaternary pump (G1311B), a multi wavelength UV-detector (G1365D) set to 220 and 275 nm (reference
wavelength 450 nm), a NaI (Tl) detector from Berthold Technologies (Bad Wildbad, Germany), and
GINA Star controlling software (Elysia-Raytest; Straubenhardt, Germany) were used. As the stationary
phase, an analytical RP-HPLC column, X-Bridge BEH Shield RP-18, 4.6 × 50 mm, 2.5 μm, 130 Å (Waters
GmbH) was used [19]. Precursor and mHED concentrations were determined, and subsequently,
the molar activity was calculated. The concentrations of the calibration curve were in the range
of 0.1–5.0 μg/mL with R2 = 0.996 ± 0.002 (see Figure 9). The limit of detection for mHED was
0.22 μg/mL (220 nm) and 0.27 μg/mL (275 nm), and 0.23 μg/mL (220 nm) and 0.32 μg/mL (275 nm) for
metaraminol. Sterility, absence of endotoxins, pH, osmolality, and residual solvents were determined
by standard procedures routinely performed at the PET Centre of the Vienna General Hospital/Medical
University of Vienna, and following similar monographs to the European Pharmacopoeia.
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Figure 9. Calibration curve for metaraminol and mHED. Concentrations were chosen in the range of
0.1–5 μg/mL.
4.4. Animal Preparation
All procedures and protocols involving animals were conducted in compliance with and approval
by the Institutional Animal Care and Use Committee of the Medical University of Vienna, Austria,
as well as by the Austrian Ministry of Science, Research, and Economy (ZI. 1413/115-97/98 2014/2015).
The manuscript adheres to the Directive European law (2010/63/EU) and to the ARRIVE guidelines
for reporting animal experiments.
4.5. Imaging of μPET/μCT
In vivo imaging experiments were conducted with a small animal-cone beam-computed
tomography (μCT) and positron emission tomography (μPET) scanner (Siemens Inveon Multimodal
μSPECT/μCT, dedicated μPET; Siemens Medical Solutions, Knoxville, TN, USA). Twelve to fourteen
weeks old male Sprague Dawley rats (HIM:OFA, Himberg, Austria) underwent the scans 14–15 days
after chirurgical intervention (myocardial infarction model), weighing 373 ± 45 g (n = 11), and were
kept under controlled laboratory conditions (22 ± 1 ◦C; 12 h light/dark cycle), with food and water
access ad libitum. Rats were anesthetized (1.5–2.0% isoflurane vaporized in oxygen 1.0–1.5 L/min)
and positioned in the center of the field of view (FOV). Physiological parameters and the depth of
anesthesia were constantly monitored and adapted throughout the experiment. All animals received
[11C]mHED in 100% physiological saline (78 ± 12 MBq, molar activity: 211 ± 152 GBq/μmol (range:
38–446 GBq/μmol)). Once the radiotracer was administered through the lateral tail vein, μPET data
acquisition took 30 min to allow tracer kinetics to attain full equilibrium. Three-dimensional static
sinograms were generated from the list files, which were further reconstructed by an OSEM-3D/MAP
algorithm (4 OSEM and 18 MAP iterations). All μPET data were corrected for attenuation, scatter,
and decay. The image matrix was 256 × 256 pixels in the transversal plane. The μCT data were
acquired within a full rotation and 360 projections with a FOV of 100 × 100 mm2. Furthermore, 80 kV,
500 μA, and 200 ms exposure time were used for the protocol settings. CT raw data was reconstructed
with a Feldkamp algorithm, including ramp filtration and beam-hardening correction, resulting in a
final image matrix of 1024 × 1024 pixels in the transversal plane. Data pre- and post-processing was
performed by means of PMOD 3.8 (PMOD Technologies Ltd., Zurich, Switzerland). A 3D Gaussian
filter with kernel size 1 mm × 1 mm × 1 mm was applied to the μPET data and a 2 × 2 × 2 reduction
to the matrix was performed for the μCT data, in order to prevent excessive computing time. Rigid
multimodal registration was performed to align both image datasets. A delineation of the volumes of
interest (VOI), namely myocardium and intra-ventricular blood pool, was performed. We defined a
good image quality, by the differentiability of myocardium and blood, respectively. Therefore, the ratio
between myocardium/intra-ventricular blood pool was calculated. All animal data were excluded
from the correlation when there was an incomplete data set available, due to technical problems or
vitality of the animals.
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4.6. PET/MRI Imaging
Institutional review board approval was gained for this prospective pilot study (IRB No.:
2301/2016 and 1562/2018). All patients gave written an informed consent prior to study inclusion.
Patients were allowed to eat until 4 hours prior to the examination, but were asked to abstain from
caffeine intake for 36 hours prior to PET/MRI imaging. None of the patients received medication
that interferes with the presynaptic sympathetic nervous system (e.g., antidepressants, clonidine, etc.),
beta-, or alpha blockade. All PET/MRI examinations (frames: 6 × 30 s, 2 × 60, 2 × 150, 2 × 300,
2 × 600) were conducted on a simultaneous PET/MR system (Biograph mMR; Siemens, Erlangen,
Germany) according to a study published in 2013 [20]. Patients were positioned head first and supine.
An ECG device was used for cardiac triggering. The [11C]mHED was injected through a venous
cannula. A 40 min dynamic PET acquisition was performed for all patients.
All Morbus Fabry patients (n = 5) received [11C]mHED as well as [13N]NH3 for perfusion
monitoring. Applied [11C]mHED activities were 320 ± 47 MBq, with molar activities of 155 ± 85
GBq/μmol (range: 61–279) formulated in 0.9% saline solution, and further diluted with saline to a
standard volume of 17 mL. For the heart transplanted patients (HTX), the tracer formulation and scan
procedure were the same, with applied activities of 470 ± 102 MBq (128 ± 148 GBq/μmol). From
ten overall HTX patients, one had to be excluded due to a shorter scanning time. The myocardium/
intra-ventricular blood pool ratio was calculated according to Bonfiglioli et al. [5].
4.7. Statistical Analysis
All data is shown as mean ± standard deviation, if not stated otherwise. The limit of detection
was calculated according to ICH guidelines, and was defined as LOD = (3 × σ)/slope.
All ratios were correlated with the absolute applied concentration of mHED and metaraminol,
the apparent and molar activity (pearson correlation, two-tailed p-value, and a confidence interval
of 95%), and the p-values were determined using GraphPadPrism 6.01 (GraphPad Software 7825 Fay
Avenue, Suite 230 La Jolla, CA 92037, USA).
5. Conclusions
Due to the optimized synthesis procedure of [11C]mHED, the overall synthesis time was reduced
as well as the amount of the precursor metaraminol and mHED, and consequently a higher molar
activity. Indeed, the beneficial feature is the buffer free RP-HPLC assay and the formulation
through a weakly-cationic ion exchange cartridge. Therefore, a highly reproducible and repeatable,
fully-automated radiosynthetic procedure could be developed. Furthermore, it was shown that
the administrated molar and apparent activities are distinctly lower, and therefore no effect on the
imaging quality was observed using this separation and purification method. Therefore, this robust
production procedure is appropriate for preclinical as well as clinical studies without showing blocking
or pharmacological effects in patients or animals.
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Abstract: The tropomyosin receptor kinases family (TrkA, TrkB, and TrkC) supports neuronal growth,
survival, and differentiation during development, adult life, and aging. TrkA/B/C downregulation
is a prominent hallmark of various neurological disorders including Alzheimer’s disease (AD).
Abnormally expressed or overexpressed full-length or oncogenic fusion TrkA/B/C proteins were
shown to drive tumorigenesis in a variety of neurogenic and non-neurogenic human cancers and are
currently the focus of intensive clinical research. Neurologic and oncologic studies of the spatiotemporal
alterations in TrkA/B/C expression and density and the determination of target engagement of emerging
antineoplastic clinical inhibitors in normal and diseased tissue are crucially needed but have remained
largely unexplored due to the lack of suitable non-invasive probes. Here, we review the recent
development of carbon-11- and fluorine-18-labeled positron emission tomography (PET) radioligands
based on specifically designed small molecule kinase catalytic domain-binding inhibitors of TrkA/B/C.
Basic developments in medicinal chemistry, radiolabeling and translational PET imaging in multiple
species including humans are highlighted.
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1. Introduction
Tropomyosin receptor kinases (TrkA, TrkB, and TrkC) are transmembrane glycoproteins encoded
by genes NTRK1–3, respectively. These kinases encompass extracellular domains (ECD) interacting
specifically with endogenous neurotrophins as well as highly homologous intracellular tyrosine kinase
domains (Figure 1A). Nerve growth factor (NGF) binds to TrkA, brain-derived neurotrophic factor (BDNF),
neurothrophin-3 (NT-3), and neurotrophin-4 (NT-4) to TrkB, and NT-3 to TrkC [1–3]. Full length TrkB
is a 140-kD transmembrane spanning protein, with an extracellular ligand-binding domain containing
two cysteine clusters, leucine-rich repeats, and two immunogloblulin-like domains [4]. The intracellular
domain encodes a tyrosine kinase domain that when activated transphosphorylates monomers of the
TrkB dimer. When transphosphorylated, the Trks engage and phosphorylate their major substrates Shc,
Phospholipase C γ1 (PLC-γ 1), and Fibroblast Growth Factor Receptor Substrate 2 (FRS2/SNT1) [5].
The TrkB locus also encodes four variants generated by alternative splicing, of which the most abundant
is the 90-kD truncated TrkB.t1 isoform that lacks the kinase domain [6]. Trk signaling occurs primarily
through Ras/Mitogen-Activated Protein Kinase 1 (MAPK1), Phosphoinositide-3-Kinase (PI3-K)/Akt
and PLC-γ1 [4,7–9] and plays central roles in mediating neuronal survival and differentiation in the
embryonic, postnatal, and mature peripheral (PNS) and central nervous system (CNS) [2,3]. Within the
CNS, reduced expression, as well as abnormal and impaired signaling of Trk receptors, are associated
with a plethora of neuropathologies, including ischemic brain injury, schizophrenia, Rett syndrome,
depression, Parkinson’s disease (PD), and Alzheimer’s disease (AD) [10–16]. In AD, evidence from ex
vivo experiments accumulated over the last two decades demonstrates reductions in full length catalytic
TrkB/C receptor densities as well as a decline in TrkB/C neurotrophin signaling [17]. Direct evidence for
the involvement of alterations in BDNF/TrkB signalling in AD is supported by studies indicating that
TrkB levels are profoundly decreased in the hippocampus, frontal and temporal cortex of patients with
Alzheimer’s [18], although apparently not in the parietal cortex [19]. Furthermore, progressive loss of TrkA,
B, and C in basal forebrain cholinergic nuclei is well correlated with the clinical progression of AD [20].
Treatment with agonists of the BDNF/TrkB system of transgenic mouse models of AD increases dendritic
spines in the hippocampus and cortex, inhibits neuronal apoptosis and neurodegeneration, and improves
spatial memory performance [21–25]. These findings support the use of agents that activate BDNF/TrkB
for treating AD [26]. Yet, the in vivo relevance or the spatiotemporal evolution of such changes, as well
as the relationships which may exist with known neuropathological hallmarks of neurodegeneration
such as plaque deposition and neurofibrillary tangle (NFTs) aggregation in AD—both of which can be
visualized using diagnostic positron emission tomography (PET)—are unresolved questions. The potential
importance of perturbations of Trk expression, activity and signalling in neurodegeneration hence raises
the question of whether these molecular targets can in turn be imaged in vivo and non-invasively using
PET. Another potential application for Trk-targeted radioligands stems from the renewed and rapidly
growing interest in anti-Trk therapy for cancer. Indeed, important advances in recent years have been made
in the treatment of patients with NTRK fusion-positive cancers in basket trials using pan-Trk inhibitors [27].
In parallel, remarkable progress has also been achieved in the development of selective pan-Trk and
TrkA subtype-selective tyrosine kinase inhibitors (TKIs). NTRK fusions are found at low frequency in
a number of common cancers and at a relatively high frequency in rare neoplasms—amounting to about
1500–5000 patients with NTRK fusions-positive diseases per year in the United States. Current clinical
trials assessing NTRK fusion-positive patients inherently rely on tumour biopsy (which may not be
always achievable) followed by next generation sequencing or fluorescence in situ hybridization for
fusion detection. The use of Trk-targeted PET imaging in early clinical stages to assess receptor occupancy,
dosing regimen, and NTRK fusion-positive status, or to monitor treatment response in place of sequential
191
Pharmaceuticals 2019, 12, 7
tumour biopsy may be both achievable and desirable—as previously done with other molecular targeted
TKI therapies [28].
Figure 1. Detailed and representative domains of normally expressed and aberrantly expressed
oncogenic tropomyosin receptor kinase (Trk) proteins from NTRK fusions (TKI: tyrosine kinase inhibitor).
(A) Structure overview of the representative full TrkA receptor (D1–D5: domain 1–5; C1/3: cysteine
cluster 1/3; LRR: leucine-rich repeat; Ig-1/2: immunoglobulin domain 1/2, TM: transmembrane
domain). (B) Schematic representation of diverse Trk proteins and domains, including Trk splice
variants and Trk fusion proteins. Dimerization and trans-autophosphorylation of Trk kinase domains
leads to the activation of the downstream signaling pathways, including MAPK1, PI3-K/Akt and
PLC-γ1 (DD: dimerization domain).
Until very recently, suitable imaging lead compounds or quantifiable non-invasive techniques
to measure spatiotemporal fluctuations of TrkA/B/C levels have been unavailable. To address this,
we undertook in 2014 the task of identifying structural determinants which would enable TrkA/B/C
PET imaging. To this end, we developed structurally diverse Trk radiotracers and inhibitor libraries
with various levels of potency and kinome selectivity, both from type I and type II inhibitor classes,
and exploited diverse radiochemical approaches using carbon-11 and fluorine-18. While our primary
objective has been non-oncological neuroimaging in the context of neurodegeneration and most
results gathered thus far aimed at meeting this objective, we recognize that with the recent clinical
oncological breakthrough in Trk inhibitor therapy comes a clear need for reliable and non-invasive
assessment of Trk status in cancer therapy trials. In this short review, we describe the rational design
and development of first-in-class Trk-targeted TKI PET radiotracers and delineate imaging validation
obtained with these molecular probes to date.
2. The Development of Trk Radioligands for PET Imaging
2.1. Binding Site Considerations
PET radionuclides decay by emission of a positron, which in turn annihilates with a nearby
electron, generating two gamma rays of 511 keV (conversion of the positron’s and electron’s mass into
energy). These two gamma rays, emitted in the opposite directions, can then be detected by an outside
PET camera, revealing the position of the annihilation events with sufficient spatial resolution (from
submillimeter to millimeter in preclinical and clinical settings respectively). Under the assumption of
a sufficient tissue target receptor concentration (Bmax), an ideal radiotracer, in this context, needs to meet
certain criteria which include: (1) high radioligand concentration in the tissue of interest, (2) radiotracer
equilibrium conditions are reached, (3) lack of interfering radiometabolites and (4) high on-target selectivity.
Beyond requiring careful studies of possible radiometabolites, this also highlights the importance of
targeting suitable domains of a molecular target. This is especially relevant in the case of Trk where
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various isoforms, splice variants or fusions proteins may be co-expressed within a single tissue in
different clinical contexts. For example, in addition to the full length TrkA/B/C, a number of truncated
isoforms lacking the intracellular kinase domain have been characterized for TrkB (Figure 1B). Within the
brain, the protein expression levels of the truncated isoforms of TrkB present (TrkB.T1 and TrkB.T2) far
exceed that of full length TrkB [29]. A radiotracer binding the TrkB extracellular domain (ECD) would
consequently map the sum of all TrkB receptors in the brain including the truncated isoforms which as
yet have no known reported association with neurodegeneration or as oncogenic drivers. A PET signal
originating from such a radiotracer would fail to differentiate catalytically-incompetent truncated from
full-length kinase domain-containing receptors and would be unable to engage targets which lack cognate
ectodomains such as the many NTRK fusion proteins which are of prime clinical interest (Figure 1B).
More pragmatically, another reason to avoid targeting ECDs of Trk for imaging stems from the lack
of suitable compounds. Indeed, while the study of nonprotein Trk ECD-binding compounds largely
predates the advent of Trk-targeted TKIs, very limited progress has been achieved due to the inherently
challenging druggability of the ectodomains compared to the kinase domains of TrkA/B/C and the poor
drug-like properties of such compounds. These limitations have been exemplified by our imaging study of
radiolabeled 7,8-dihydroxyflavone (7,8-DHF) [30]. This work was based on the initial report by Jang et al.
suggesting that 7,8-DHF binds with high affinity to the ECD of TrkB and exhibits agonistic activity in
neurons [31]. From this initial work, other more active flavones were described including fluorinated
analogs which caught our attention as potential starting points for 18F-PET tracer development [32,33].
Yet, using synthesized or commercially available described flavones we were unable to reproduce any
basic biochemical effects in cells (unpublished data). In line with our findings, Boltaev et al. more recently
unambiguously demonstrated the lack of direct interaction or TrkB-driven effect of such compounds [34].
In addition, we observed poor in vivo profiles in rats when investigating the radiolabeled isotopologs
of these compounds for imaging (including 2-(4-[18F]fluorophenyl)-7,8-dihydroxy-4H-chromen-4-one).
Preclinical imaging revealed low-radioactivity overall brain uptake with a maximum standard uptake
value (SUV) of 0.64 (whole brain) followed by fast elimination from the brain. These radioligands
also were rapidly eliminated from the plasma compartment by hepatic metabolism with an estimated
plasma half-life under 4 min suggesting a fast and extensive phase II metabolism and suggesting overall
poor druglike properties, as it is known for hydroxyflavones more generally [35,36]. Interestingly,
in vitro autoradiography with rat brains revealed apparent specific and BDNF-competitive binding
reminiscent of 125I-BDNF binding topology. Yet, we surmise that this binding/blocking effect may have
been a consequence of covalent reactivity to nucleophilic cysteines or other non-selective thiol-based
reactivity as previously described for pan assay interference flavonoids [37]. Compared to putative ECD
binding compounds, inhibitors targeting the ATP binding site of the cytoplasmic Trk kinase domains
have been well characterized both functionally and structurally and have been reported alongside
detailed crystallographic data enabling derivatization [38]. Targeting the kinase domains however comes
with the challenge of selectivity, firstly within the kinome and secondly from within the Trk kinase
family itself (TrkA, TrkB and TrkC)—TrkA/B/C display 72–78% and 95–100% sequence identity in
their kinase domain and ATP binding sites, respectively. We have strived to detail kinome selectivity
using comprehensive kinase screening whenever possible. With the exception of a few compounds,
all radiolabeled inhibitors display pan-Trk activities. Yet, owing to the high expression levels of TrkB/C in
the CNS compared to TrkA [39–43], and given that the PET signal is driven by target density and ligand
affinity, it is to be expected that CNS PET using pan-Trk radioligands will nevertheless detect nearly
exclusively TrkB/C-based signal. Another important note pertains to the fact that Trk kinases can adopt
both DFG-in (active, targeted by type-I inhibitors) and DFG-out (inactive, targeted by type-II inhibitors)
conformations (Figure 2). Conformational changes upon DFG triad rearrangement allow for the access of
a deep pocket which can be occupied favorably by lipophilic moieties (Figure 2B,C). Type II Trk inhibitors
targeting DFG-out conformation thus also present longer residence times compared to type-I inhibitors.
To study potential benefits from each binding modes, we have developed both type-I and II radioligands.
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The following paragraphs give an account on our Trk radiotracer development program in chronological
order progressing towards first in human PET imaging from preclinical research.
Figure 2. Trk kinase domain. (A) Overlap of TrkA, TrkB, and TrkC kinase domain (inactive
conformations, PDB ID: 4F0I, 4ASZ, 3V5Q). (B,C) Views of the conformational differences between
“Asp-Phe-Gly” DFG-in and DFG-out TrkB. The Phe residues of the DFG triad are shown in spheres
(PDB ID: 4AT3, 4AT5).
2.1.1. The 4-Aza-2-oxindole Radioligands
PET tracers for neuroimaging have significantly higher chances of achieving high specific binding
in brain when displaying certain physicochemical properties. Parameters such as rapid Blood Brain
Barrier (BBB) permeation and neuron cell penetration as well as low non-specific binding are mostly
determined by the compound’s lipophilicity (represented as clogD 7.4 value, assuming passive diffusion
through the cell membrane), reduced susceptibility to active efflux, molecular weight (<350 Da),
favorable neuroreceptor binding potential (BP = Bmax/Kd >10), topological surface area (TSPA) of
30–80 Å2, and hydrogen bond donor ability (HBD) of >1. These general factors as well as specific
properties tend to characterize successful neuroimaging PET tracers [44–47]. With these parameters
in mind, we first opted for an inhibitor belonging to the family of 3-arylideneindolin-2-one Trk
inhibitors. The 4-aza-2-oxindole inhibitor GW441756 [48] was screened as a compound favorably
fulfilling the above mentioned requirements of a potentially successful candidate for brain imaging and
was consequently labeled with carbon-11 to provide the radioactive isotopolog for autoradiography
and PET imaging (half maximal inhibitory concentration (IC50); TrkA = 29.6 nM, TrkB = 6.7 nM,
and TrkC = 4.6 nM, Figure 3) [49]. Even though the radiolabeling was straightforward and high
yielding, the targeted Z isomer, which based on molecular modeling was found to be the active isomer,
could not be obtained in pure form after purification of the crude radiolabeling solution. An E/Z 1:1
mixture was isolated under all conducted labeling conditions as a result of rapid in situ isomerisation
either during the radiosynthesis or during the HPLC purification procedure, reducing the amount
of high affinity Trk tracer Z-[11C]GW441756 by 50%. The inevitable contamination of the E-isomer
with Z-[11C]GW441756 significantly compromised the merit of this tracer as a potential Trk PET
imaging agent, not only from an imaging quality perspective (50% of the PET signal will be the
result of the non-specific binding of the Z-isomer) but also from a clinical translational point of view.
Autoradiography of the mixed isomers on coronal rat brain sections revealed a displaceable binding
in accordance with the ubiquitous distribution of all TrkB/C subtypes. The in vivo evaluation of
[11C]GW441756 was performed in Sprague–Dawley rats to evaluate BBB penetration and in vivo
biodistribution. In baseline scans the tracer rapidly entered the brain peaking at a SUV of 2 after 30 s,
after which the compound was rapidly eliminated from the brain over 30 min. Tracer distribution was
uniform in accordance with ubiquitous TrkB/C expression in the rodent brain. A blocking study using
unlabeled GW441756 pre-treatment was inconclusive as to whether the tracer specifically engages the
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CNS TrkB/C in vivo, however specific binding was indicated from blocking significant lung uptake of
the tracer which may be linked to TrkB specific binding in pulmonary tissue [50]. An 18F derivative
bearing an 18F-fluoroethyl group at the 5-hydroxy moiety of a new GW441756 derivative, although
being highly selective over other kinases and displaying generally favorable in vitro properties (low
IC50 values in the nanomolar range for all Trk subtypes), showed unexpected susceptibility towards
CYP450 metabolism in vitro in contrast to the original GW441756. These findings were corroborated by
rapid formation of brain penetrating metabolites and no observable blocking upon pre-treatment with
non-radioactive GW441756 in an animal PET experiment in rats. It can be concluded from our data that
radioligands for pan-Trk imaging with PET, derived from the 3-indolydene 4-aza-2-oxindole scaffold
despite being selective and highly potent inhibitors of Trk, do most probably not lend themselves
towards PET tracer development and clinical translation. The main reason is the inevitable presence
of the low affinity E-isomer of [11C]GW441756 due to the rapid reaching of a photostationary state,
a physicochemical reality that most definitely is not limited to GW441756 but rather extends to
all structurally similar derivatives. However, both tracers displayed high specific binding in TrkB
expressing neuroblastoma tumour sections in vitro providing a proof of principle of the utility of such
radioligands for oncological imaging.
 
Figure 3. Chemical structures of early Trk-targeted positron emission tomography (PET) radioligands.
2.1.2. 2,4-Diaminopyridmidine and Quinazoline-Based Radioligands
In order to explore the effect of targeting the DFG-out Trk kinase conformation, especially with regard to
kinetics [51], we also developed type II radiolabeled inhibitors. In general, type II Trk inhibitors tend to possess
mostly elongated structural features, higher molecular weight and HBD count than type-I inhibitors, which
may be detrimental for BBB permeation but inconsequential in the context of peripheral imaging. So far we
have developed two distinct type-II radiolabeled inhibitors belonging to the class of 2,4-diaminopyridines [52]
and quinazoline [53] (Figure 3). Analyses of large kinase inhibitor sets identified GW2580, an orally active
dual Trk/colony-stimulating factor-1 receptor (CSF-1R) inhibitor (Kd; CSF-1R = 2 nM, TrkA = 630 nM,
TrkB = 36 nM, and TrkC = 120 nM), as one of the most kinome selective inhibitors known [54]. Based on this
attribute, and the overall promising preclinical ADME (absorption, distribution, metabolism, and excretion) of
this inhibitor, we undertook to identify a radioligand based on this scaffold. We rationalized that since CSF-1R
is highly expressed in tumour-infiltrating macrophages, such compounds may be useful in cancer imaging
beyond Trk. We synthesized fluorinated derivatives and performed labelling of the most promising lead,
5-(4-((4-[18F]fluorobenzyl)oxy)-3-methoxybenzyl)pyrimidine-2,4-diamine ([18F]3, Figure 3). While inhibitor
[18F]3 maintained the excellent kinome selectivity of GW2580, its radiosynthesis was challenging and relied on
the synthesis of the prosthetic group 4-[18F]fluorobenzyl bromide [55] followed by subsequent reaction with
a phenolic labeling precursor. The multistep procedure only produced low radiochemical yields (RCYs) of
[18F]3. This technical shortcoming precluded this tracer from its translation into a clinical setting and only most
recent efforts applying Cu-mediated late stage fluorination techniques provided this tracer in high RCYs and
high molar activities suitable for human PET scanning (unpublished). More recently, the quinazoline-based
type II pan-Trk inhibitor [18F]QMICF ([18F]4) was developed (Figure 3) [53]. Starting from the corresponding
racemic quinazoline-based dual FLT3/TrkB inhibitor, a structure–activity relationship study demonstrated
that the (R)-enantiomer was primarily responsible for Trk inhibition [56]. To conserve optimal target
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interaction with the Trk receptor, the position of fluorine introduction was carefully consolidated through
molecular modeling. Only one particular position, namely the allosteric pocket fragment, proved adaptable
towards structural modifications with the least detrimental effect on binding interaction. We replaced
the isopropyl moiety connected in 4-position to a structurally flexible benzene moiety in the original
inhibitor with a 2-fluoro ethyl group to facilitate an easy introduction of 18F− via common nucleophilic
substitution of a corresponding mesyl derivative. This modification led to an about 10-fold potency reduction
but also favorably abrogated FLT3 activity. Kinases profiling of inhibitor 4 revealed excellent selectivity
and a Calcein-AM assay in P-gp overexpressing MDCKII cells confirmed only low interaction with P-gp.
Radiotracer [18F]QMICF could be straightforwardly synthesized from the corresponding mesyl precursor
in RCYs of 18% in one step. The compound is currently being evaluated for Trk brain imaging and tumor
imaging in TrkA-TPM3 (IC50 = 162 nM) overexpressing colon carcinoma KM12 mice tumor xenografts and
other neoplasms bearing diverse NTKR fusions.
2.1.3. Imidazo[1,2-b]pyridazine-Based Radioligands
In 2014, when we started the syntheses of imidazo[1,2-b]pyridazine-based radioligands, it was
demonstrated that NTRK fusion were actionable drivers in human cancers, however only a few non
selective Trk inhibitors had been used in a therapeutic approach. The Trk inhibitor landscape was however
rapidly moving from exploratory tool inhibitor (such as GW441756) to more relevant drug leads and
there was a clear trend in preclinical work and patent literature towards what has now become one of the
most explored chemotypes, specifically imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine-based
inhibitors (Figure 4). Cognizant of this trend, and expecting that scaffolds selected for clinical oncological
studies should display overall excellent druglike properties which could in turn be advantageous for
achieving brain and peripheral imaging using PET, we reoriented our effort towards inhibitors of
these classes. We found that in comparison to all potential radiotracers described above, the type I
pan-Trk inhibitors sharing the (2-pyrrolidin-1-yl)imidazo[1,2-b]pyridazine structural motif (Figure 5),
share exceptionally high affinities to all three Trk subtype receptors orders of magnitude higher than
any other inhibitor described so far.57 Based on extensive molecular docking studies, a comprehensive
PET-oriented library of imidazo[1,2-b]pyridazine-based compounds (bearing positions amenable for
labeling using carbon-11 and/or fluorine-18) was reported in 2015 [57]. All new pan-Trk inhibitors were
subjected to a [γ-33P]ATP-based enzymatic assay to assess activities towards the different Trk subtypes.
Remarkably, eight inhibitors from this library displayed <200 pM potency against TrkB/C and were
initially regarded as potential candidates for radiotracer development. Two structures, (±)-IPMICF6 and
(±)-IPMICF10 (Figure 5) lent themselves towards an easy introduction of 18F via simple nucleophilic
substitution and were translated into the corresponding 18F-radiotracers. Both compounds displayed
favorable in vitro activity and kinome selectivity. Their 18F labeling was straightforward and yielded
the corresponding radiotracers in 3% and 8% RCY, respectively. In autoradiography experiments,
both compounds were conclusively apt to topologically map the known brain distribution (cortex,
striatum, thalamus and cerebellum) of TrkB/C receptors in coronal rat brain sections in accordance
with mRNA and protein levels. In an important follow up study, one inhibitor from the reported
imidazo[1,2-b]pyridazine-based library, IPMICF16, was chosen for radiotracer translation based on the
alignment of favorable physicochemical properties (as described above) and optimal pharmacological
parameters [58]. Pan-Trk inhibitor IPMICF16’s structure is geared towards simple 11C-methylation
radiolabeling. In order to confirm that (R)-IPMICF16 was the more active and hence more suitable
enantiomer for radiotracer development, as expected based on crystal structure and docking analyses,
both the R and S isomers were synthesized and evaluated. Non-radioactive (R)-IPMICF16 displayed IC50s
of 4.0, 0.2 and 0.1 nM for human TrkA, TrkB, and TrkC, respectively and inhibitory constants (Ki) of 2.80,
0.05 and 0.021 nM for TrkA, TrkB, and TrkC, respectively (200,000–500,000-fold over Km ATP for all Trks).
The S-enantiomer was significantly less potent which is in line with our docking studies. Interestingly,
this study showed that (R)-IPMICF16 constitutes a rare example where an ATP-competitive Trk inhibitor
displays intra-Trk sub-type selectivity. With regard to TrkA, (R)-IPMICF16 showed 56-fold and 133-fold
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higher selectivity for TrkB and TrkC, respectively. It was further asserted that the compound shows high
selectivity towards TrkB/C over >99% of the testable human kinome (369 targets). The radiosynthesis of
[11C]-(R)-IPMICF16 was routinely achieved using the corresponding desmethyl-precursor and radioactive
[11C]methyl iodide (or alternatively [11C]methyl triflate) in >10% RCYs. Soon thereafter, the robust
synthesis was set up according to good manufacturing practices and regulations at four different
production sites where [11C]-(R)-IPMICF16 was evaluated in mice, rats, non-human primates, and finally
in one healthy human subject (Figure 6).
 
Figure 4. Chemical structures of selected clinical Trk inhibitors.
Figure 5. Chemical structures of preclinical imidazo[1,2b]pyridazine-based Trk-targeted PET radioligands.
Figure 6. Chemical structures of clinical imidazo[1,2b]pyridazine-based Trk-targeted PET radioligands.
Despite partial elimination of [11C]-(R)-IPMICF16 from the rat brain due to active efflux
transporters in rodents (P-gp and breast cancer resistance protein) as demonstrated in double knockout
Mdr1a/b-Bcrp mice, SUV after 60-min scan time was still 0.4. The brain TrkB/C specific binding of
[11C]-(R)-IPMICF16 in vivo was unambiguously demonstrated by pharmacological challenge with
the clinical pan-Trk inhibitor entrectinib. Up to 88% of the radioactivity signal could be blocked after
intraperitoneal injection of entrectinib, albeit high blocking doses (350 mg/kg) were required due to the
documented low brain uptake of this inhibitor. Encouraged by these promising data, an evaluation of
[11C]-(R)-IPMICF16 was performed in non-human primates (NHP). In comparison to rodents, the brain
kinetics in NHP was significantly slower with a continuously increasing radioactivity signal in the
brain devoid of an observable washout throughout the entire 60 min PET scan. Regional analysis
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confirmed a heterogenous radioactivity distribution following Trk rich grey matter with highest uptake
in thalamus (SUV 0.8). Radioactivity uptake in white matter was comparatively low, as expected and
in accordance with low level Trk expression. Although the efflux kinetic profiles of [11C]-(R)-IPMICF16
was notable in rodents, data from NHP PET imaging indicated interspecies differences and suggested
that efflux may not be a liability in higher species. Hence, it was decided to move the tracer forward
towards human in vivo translation. This decision was further motivated by the demonstration that
in vitro [11C]-(R)-IPMICF16 autoradiography was sufficiently sensitive to reproduce the known and
significant region-specific hippocampal TrkB/C density reduction found in AD brains (compared to
age-matched controls). All radioactivity signals in brain tissues (controls and AD) were blockable
using a structurally unrelated pan-Trk inhibitor proving specificity of the observed uptake as a result
of TrkB/C receptor engagement. Taken together, these preclinical data justified moving towards
a first-in-human tracer evaluation with PET.
Injection of [11C]-(R)-IPMICF16 into a 41-year-old healthy male subject led to brain uptake of
the radiotracer which was rapid, with a peak SUV in the thalamus of 1.5 after 25 s post injection,
very similar to what was observed in NHP. After reaching equilibrium, the SUV in one of the highest
Trk tissues, the thalamus, remained 0.7 after 60 min with low observable washout. In accordance with
non-human primate PET data, the radioactivity distribution in human matched the topography of
the Trk disposition in grey matter with lowest SUVs in TrkB/C low white matter regions (Figure 7).
The overall distribution aligned affirmatively with the known Trk distribution from ex vivo studies
with highest uptake in the thalamus, followed by cerebellum and cortex. No adverse effects were
observed after the injection of [11C]-(R)-IPMICF16.
 
Figure 7. Upper row: PET/T1MP-RAGE MRT in vivo overlay images of [11C]-(R)-12 in a human
subject with high SUVs in TrkB/C rich compartments such as thalamus, followed by cerebellum
and cortical grey matter and low uptake in Trk devoid white matter areas; Bottom row: In vivo PET
images of [18F]-(R)-13 (high Am of 245 GBq/μmol) in rhesus monkey brain matching the expected
TrkB/C distribution.
Owing to the detailed structure-activity study conducted in the first phase of this project,
we intended to modify the structure of [11C]-(R)-IPMICF16 to enable labeling with fluorine-18 based
on the recently introduced Cu catalysed late stage fluorination of non-activated aromatic boronic
esters [59–61]. Despite several shortcomings such as the inevitable side formation of protodeboronation
side products, consequently contaminating the 18F-labeled target molecule and therefore significantly
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reducing the effective molar activity (Am) (the 18F and H substitution product have very similar
physicochemical as well as pharmacodynamics properties), the Cu-catalyzed 18F fluorination of
boronic esters and the introduction of mesityl aryl iodonium salts as labeling precursors can be easily
regarded as being among the most important developments of modern 18F-radiochemistry [62,63].
[11C]-(R)-IPMICF16 originally bore a methoxy group directly adjacent to the fluorine atom at the
aromatic amide fragment (Figure 6) which was identified as one contributor for the overall P-gp liability
observed. That methoxy group was removed resulting in a pan-Trk inhibitor with further improved
subtype selectivity but slightly reduced affinity for TrkB/C to reach binding equilibrium faster than
[11C]-(R)-IPMICF16. The efflux of the corresponding fluorinated inhibitor was also noticeably reduced
in cells. This radiotracer, called [18F]TRACK (the R isomer), was conveniently obtained in one step
via Cu mediated radio-fluorination of a corresponding boronic ester precursor (the Bpin derivative)
in satisfactory RCYs for further translation [64]. During the 18F-fluorination, the protodeboronation
product was formed which reduced the effective Am to a low value of 15 GBq/μmol, an order
of magnitude below what was expected. After extensive screening, this problem could be solved
by employing a pentafluorophenyl (PFP) HPLC column for tracer purification—which constitutes
currently the standard method used to achieve separation [65]. The column material showed improved
stationary phase affinity interaction with the fluorinated TRACK tracer over standard octadecylsilane
reversed phase, leading to a base-line separation of [18F]TRACK from all impurities—including the
protodeboronation side product. This improved the Am to >100 GBq/μmol. In vivo evaluation in
rhesus monkey confirmed uptake of [18F]TRACK in TrkB/C-rich regions with SUVs in the grey matter
ranging from 0.9 for the cerebellum, 0.8 for the thalamus, and 0.6 for the cortex (Figure 7). White matter
uptake was comparably low (0.2 SUV). The brain kinetics of [18F]TRACK were significantly different
than what has been observed for [11C]-(R)-IPMICF16, displaying characteristics of a more reversibly
binding radiotracer. Injections of [18F]TRACK of varying Am (low, medium and high) into the same
monkey illustrated the paramount importance of high Am for Trk PET imaging. The PET signal was
obviously reduced in cases of sub-optimal Am. [18F]TRACK is currently evaluated in human healthy
controls and first in human PET data will be reported in due course. First obtained results with
[18F]TRACK in a healthy human volunteer are in line with the data obtained with [11C]-(R)-IPMICF16
in terms of PET image quality and ease of production (unpublished).
3. Conclusions
The analysis, investigation and quantification of Trk receptors in neurodegenerative diseases and
cancer is currently limited to ex vivo post-mortem analysis or invasive methods. While these kinases
constitute important molecular targets which can be visualized using non-invasive PET imaging,
Trk PET imaging is still in its infancy. Whether prototypical radioligands such as [11C]-(R)-IPMICF16
and [18F]TRACK, which display moderate brain uptake in humans, will be suitable for clinical
neuroimaging and can provide reliable CNS TrkB/C measurements or adequately detect reductions
in receptor density remain to be established. While tracers with higher brain penetration, volume of
distribution (VT) values or binding potentials are desirable for temporally and spatially assessing Trk
expression in conditions such as AD, the current tracers could certainly be beneficial in cases where Trk
is overexpressed such as in numerous human cancers, both in the periphery and CNS. Further research
is currently aimed at identifying structural determinants improving overall brain uptake of current
type I and II tracers, including cyclic derivatives such as LOXO 195 and derivatives thereof.
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